[	O
Long	O
term	O
observation	O
in	O
effects	O
of	O
potassium	O
and	O
calcium	O
supplementation	O
on	O
arterial	Physical
blood	Physical
pressure	Physical
and	O
sodium	Physical
metabolism	Physical
in	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effects	O
of	O
potassium	O
and	O
calcium	O
supplementation	O
in	O
table	O
salt	O
on	O
reduction	O
of	O
arterial	Physical
blood	Physical
pressure	Physical
and	O
sodium	Physical
metabolism	Physical
in	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
.	O

METHODS	O
A	O
single	O
blind	O
placebo-controlled	O
trial	O
was	O
carried	O
out	O
for	O
two	O
years	O
in	O
220	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
,	O
aged	O
18	O
-	O
22	O
years	O
,	O
who	O
were	O
randomly	O
divided	O
into	O
supplementary	O
group	O
(	O
n	O
=	O
110	O
)	O
and	O
control	O
group	O
(	O
n	O
=	O
110	O
)	O
.	O

Each	O
of	O
the	O
subjects	O
in	O
the	O
supplementary	O
group	O
and	O
their	O
family	O
members	O
was	O
given	O
10	O
mmol	O
of	O
potassium	O
and	O
10	O
mmol	O
of	O
calcium	O
mixed	O
in	O
their	O
table	O
salt	O
daily	O
for	O
24	O
months	O
.	O

RESULTS	O
Night	Physical
urinary	Physical
sodium	Physical
and	O
potassium	Physical
excretion	Physical
increased	O
(	O
urinary	O
Na	O
(	O
+	O
)	O
,	O
P	O
<	O
0.05	O
;	O
urinary	O
K	O
(	O
+	O
)	O
,	O
P	O
<	O
0.01	O
)	O
and	O
blood	Physical
pressure	Physical
lowered	O
by	O
5.3	O
mm	O
Hg/1.8	O
mm	O
Hg	O
in	O
average	O
from	O
the	O
baseline	O
in	O
the	O
supplementary	O
group	O
two	O
years	O
after	O
potassium	O
and	O
calcium	O
supplementation	O
,	O
as	O
compared	O
with	O
that	O
in	O
the	O
control	O
group	O
increased	O
by	O
(	O
1.3/1.7	O
)	O
mm	O
Hg	O
.	O

CONCLUSIONS	O
Adequate	O
supplement	O
of	O
potassium	O
and	O
calcium	O
in	O
daily	O
table	O
salt	O
intake	O
was	O
an	O
effective	O
way	O
to	O
prevent	O
form	O
hypertension	Physical
and	O
could	O
promote	O
their	O
urinary	Physical
sodium	Physical
excretion	Physical
and	O
reduction	Physical
of	Physical
arterial	Physical
blood	Physical
pressure	Physical
in	O
adolescents	O
with	O
higher	O
blood	O
pressure	O
.	O

Comparison	O
of	O
the	O
time	Others
required	Others
to	O
administer	O
three	O
different	O
fluke	O
and	O
worm	O
combination	O
products	O
to	O
commercial	O
beef	O
cattle	O
at	O
housing	O
.	O

Larger	O
livestock	O
units	O
,	O
a	O
decline	O
in	O
the	O
farm	O
labor	O
force	O
,	O
animal	O
welfare	O
concerns	O
,	O
and	O
a	O
trend	O
toward	O
more	O
selective	O
use	O
of	O
drugs	O
have	O
increased	O
the	O
focus	O
on	O
animal	O
handling	O
,	O
time	O
management	O
,	O
convenience	O
,	O
and	O
compliance	O
in	O
administering	O
veterinary	O
therapeutics	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
quantify	Others
and	O
compare	Others
the	Others
time	Others
needed	Others
to	Others
treat	Others
commercial	Others
beef	Others
cattle	Others
with	O
three	O
fluke	O
and	O
worm	O
combination	O
products	O
with	O
different	O
administration	O
profiles	O
.	O

Young	O
beef	O
cattle	O
(	O
n	O
=	O
270	O
)	O
weighing	O
approximately	O
400	O
kg	O
were	O
allocated	O
to	O
batches	O
of	O
five	O
,	O
which	O
were	O
randomly	O
assigned	O
to	O
receive	O
ivermectin	O
+	O
clorsulon	O
injection	O
,	O
ivermectin	O
+	O
closantel	O
injection	O
,	O
or	O
levamisole	O
+	O
triclabendazole	O
oral	O
drench	O
.	O

The	O
mean	Others
time	Others
needed	Others
to	O
administer	O
ivermectin	O
+	O
clorsulon	O
(	O
single	O
injection	O
)	O
to	O
five	O
cattle	O
was	O
31	O
seconds	O
,	O
which	O
was	O
significantly	O
less	O
than	O
the	O
100	O
seconds	O
needed	O
for	O
ivermectin	O
+	O
closantel	O
(	O
two	O
injections	O
)	O
and	O
the	O
126	O
seconds	O
needed	O
for	O
levamisole	O
+	O
triclabendazole	O
(	O
P	O
<	O
.001	O
)	O
.	O

Such	O
quantitative	O
data	O
can	O
allow	O
for	O
better	O
planning	O
and	O
selection	O
of	O
parasiticide	O
treatment	O
approaches	O
at	O
the	O
farm	O
level	O
.	O

Does	O
temporary	O
clamping	O
of	O
drains	O
following	O
knee	O
arthroplasty	O
reduce	O
blood	O
loss	O
?	O
A	O
randomised	O
controlled	O
trial	O
.	O

In	O
a	O
randomised	O
,	O
blinded	O
study	O
76	O
patients	O
undergoing	O
primary	O
total	O
knee	O
arthroplasty	O
were	O
assigned	O
to	O
either	O
immediate	O
drain	O
opening	O
(	O
n	O
=	O
45	O
)	O
or	O
drains	O
opened	O
at	O
2	O
h	O
(	O
n	O
=	O
31	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
groups	O
for	O
the	O
volume	Physical
of	Physical
drained	Physical
blood	Physical
,	O
transfusion	Others
requirements	Others
,	O
knee	Physical
motion	Physical
or	O
wound	Physical
status	Physical
.	O

The	O
authors	O
conclude	O
that	O
the	O
practice	O
of	O
clamping	O
drains	O
has	O
no	O
benefit	O
in	O
routine	O
knee	O
arthroplasty	O
.	O

However	O
,	O
when	O
faced	O
with	O
immediate	O
brisk	O
blood	Physical
loss	Physical
,	O
the	O
results	O
suggest	O
that	O
drains	O
can	O
be	O
clamped	O
without	O
any	O
excess	O
morbidity	Adverseeffect
.	O

0.1	O
%	O
bupivacaine	O
does	O
not	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
infusion	O
after	O
major	O
abdominal	O
surgery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Although	O
local	O
anesthesia	O
has	O
been	O
demonstrated	O
to	O
potentiate	O
spinal	O
morphine	O
analgesia	O
in	O
animal	O
studies	O
,	O
results	O
comparing	O
epidural	O
local	O
anesthesia/opioid	O
mixtures	O
with	O
opioid	O
alone	O
are	O
contradictory	O
in	O
clinical	O
studies	O
.	O

The	O
hypothesis	O
was	O
that	O
,	O
although	O
the	O
concentration	O
of	O
bupivacaine	O
(	O
0.1	O
%	O
)	O
was	O
low	O
to	O
minimize	O
its	O
adverse	O
effects	O
,	O
if	O
the	O
infusion	O
rate	O
of	O
a	O
fentanyl/bupivacaine	O
solution	O
was	O
closely	O
adjusted	O
according	O
to	O
need	O
,	O
the	O
presence	O
bupivacaine	O
would	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
.	O

METHODS	O
Forty	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
fentanyl	O
(	O
10	O
micrograms/mL	O
)	O
or	O
a	O
fentanyl/bupivacaine	O
(	O
0.1	O
%	O
)	O
mixture	O
epidurally	O
corresponding	O
to	O
the	O
dermatome	O
of	O
the	O
surgical	O
incision	O
in	O
a	O
double-blind	O
fashion	O
for	O
the	O
first	O
18	O
hours	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
infusion	O
was	O
titrated	O
for	O
each	O
patient	O
to	O
the	O
rate	O
required	O
for	O
pain	O
relief	O
during	O
forced	O
inspiration	O
(	O
pain	O
score	O
<	O
or	O
=	O
2	O
,	O
maximum	O
10	O
)	O
.	O

Pain	O
scores	O
,	O
the	O
fentanyl	O
doses	O
required	O
,	O
plasma	O
concentrations	O
of	O
fentanyl	O
at	O
18	O
hours	O
,	O
and	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	Adverseeffect
effects	Adverseeffect
were	O
recorded	O
.	O

RESULTS	O
Patients	O
reported	O
similar	O
median	Pain
pain	Pain
scores	Pain
and	O
were	O
equally	O
satisfied	O
with	O
pain	Pain
relief	Pain
in	O
both	O
groups	O
.	O

The	O
mean	Others
required	Others
post-operative	Others
fentanyl	Others
infusion	Others
rate	Others
(	O
57.7	O
+/-	O
19.5	O
micrograms/h	O
)	O
and	O
the	O
plasma	Physical
concentrations	Physical
(	O
0.84	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl	O
group	O
were	O
comparable	O
to	O
the	O
infusion	Others
rate	Others
(	O
54.4	O
+/-	O
19.2	O
micrograms/h	O
)	O
and	O
the	O
plasma	Physical
concentrations	Physical
(	O
0.86	O
+/-	O
0.36	O
ng/mL	O
)	O
in	O
the	O
fentanyl/bupivacaine	O
group	O
.	O

Respiratory	Physical
and	Physical
cardiovascular	Physical
functions	Physical
were	O
preserved	O
,	O
and	O
the	O
incidence	Physical
of	Physical
nausea	Adverseeffect
,	Physical
pruritus	Adverseeffect
,	Physical
and	Physical
periods	Adverseeffect
of	Adverseeffect
drowsiness	Adverseeffect
or	Adverseeffect
sleep	Adverseeffect
were	O
similar	O
in	O
both	O
groups	O
.	O

CONCLUSIONS	O
In	O
low	O
concentrations	O
(	O
0.1	O
%	O
)	O
,	O
bupivacaine	O
did	O
not	O
reduce	O
the	O
titrated	O
dose	O
of	O
epidural	O
fentanyl	O
required	O
for	O
adequate	O
pain	O
relief	O
during	O
forced	O
inspiration	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
incidence	O
and	O
severity	O
of	O
adverse	O
effects	O
were	O
also	O
comparable	O
whether	O
or	O
not	O
low-dose	O
bupivacaine	O
infusion	O
was	O
used	O
.	O

Comparison	O
of	O
the	O
effect	O
of	O
gonadotropin-releasing	O
hormone	O
analog	O
(	O
Diphereline	O
)	O
and	O
Cabergoline	O
(	O
Dostinex	O
)	O
treatment	O
on	O
uterine	O
myoma	O
regression	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effect	O
of	O
cabergoline	O
(	O
Dostinex	O
,	O
a	O
dopamine	O
agonist	O
)	O
on	O
the	O
myoma	O
growth	O
compared	O
to	O
Diphereline	O
(	O
a	O
gonadotropin-releasing	O
hormone	O
agonist	O
)	O
.	O

METHODS	O
This	O
study	O
took	O
place	O
in	O
the	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
of	O
Tabriz	O
University	O
of	O
Medical	O
Sciences	O
,	O
Tabriz	O
,	O
Iran	O
from	O
July	O
2004	O
to	O
December	O
2005	O
.	O

Fifty	O
women	O
with	O
uterine	O
myoma	O
,	O
who	O
met	O
the	O
criteria	O
of	O
the	O
study	O
thoroughly	O
,	O
were	O
randomly	O
allocated	O
into	O
2	O
equal	O
groups	O
to	O
take	O
either	O
Diphereline	O
or	O
Cabergoline	O
.	O

The	O
first	O
Group	O
took	O
3.75	O
mg	O
of	O
Diphereline	O
4	O
times	O
every	O
28	O
days	O
and	O
the	O
second	O
group	O
took	O
0.5	O
mg	O
of	O
Cabergoline	O
once	O
a	O
week	O
for	O
6	O
weeks	O
.	O

RESULTS	O
The	O
Cabergoline	O
was	O
well	Others
tolerated	Others
and	O
fewer	Adverseeffect
adverse	Adverseeffect
effects	Adverseeffect
were	O
noted	O
.	O

The	O
tumor	Physical
regressed	Physical
significantly	O
and	O
volume	Physical
reduction	Physical
rate	Physical
of	Physical
individual	Physical
tumor	Physical
nodule	Physical
varied	O
from	O
46-53	O
%	O
.	O

The	O
gonadotropin	O
releasing	O
hormone	O
agonist	O
group	O
all	O
responded	O
to	O
the	O
treatment	O
,	O
and	O
volume	O
reduction	O
rate	O
of	O
the	O
individual	O
tumor	O
nodule	O
varied	O
from	O
21-97	O
%	O
.	O

The	O
extent	O
of	O
tumor	Physical
shrinkage	Physical
was	O
positively	O
correlated	O
to	O
the	O
number	Physical
of	Physical
nodules	Physical
(	O
p=0.881	O
,	O
p	O
<	O
0.005	O
and	O
0.701	O
,	O
p	O
<	O
0.005	O
)	O
.	O

CONCLUSION	O
In	O
light	O
of	O
therapeutic	O
efficacy	O
and	O
few	O
adverse	O
effects	O
,	O
the	O
dopamine	O
agonists	O
may	O
hold	O
promise	O
as	O
novel	O
treatment	O
modalities	O
for	O
leiomyoma	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
determine	O
the	O
optimal	O
strategy	O
for	O
the	O
treatment	O
of	O
leiomyoma	O
through	O
these	O
agents	O
.	O

Controlled	O
clinical	O
trial	O
of	O
IV	O
cyclophosphamide	O
versus	O
IV	O
methylprednisolone	O
in	O
severe	O
neurological	O
manifestations	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

BACKGROUND	O
Severe	O
neurological	O
involvement	O
in	O
systemic	O
lupus	O
erythematosus	O
(	O
NPSLE	O
)	O
is	O
one	O
of	O
the	O
most	O
dreadful	O
complications	O
of	O
the	O
disease	O
.	O

OBJECTIVE	O
To	O
identify	O
the	O
best	O
drug	O
,	O
dose	O
,	O
and	O
treatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
The	O
study	O
was	O
a	O
controlled	O
clinical	O
trial	O
at	O
two	O
tertiary	O
care	O
centres	O
of	O
patients	O
with	O
SLE	O
according	O
to	O
the	O
ACR	O
criteria	O
,	O
with	O
incident	O
(	O
no	O
more	O
than	O
15	O
days	O
)	O
onset	O
of	O
severe	O
NP	O
manifestations	O
such	O
as	O
seizures	O
,	O
optic	O
neuritis	O
,	O
peripheral	O
or	O
cranial	O
neuropathy	O
,	O
coma	O
,	O
brainstem	O
disease	O
,	O
or	O
transverse	O
myelitis	O
.	O

Induction	O
treatment	O
with	O
3	O
g	O
of	O
IV	O
methylprednisolone	O
(	O
MP	O
)	O
followed	O
by	O
either	O
IV	O
monthly	O
cyclophosphamide	O
(	O
Cy	O
)	O
versus	O
IV	O
MP	O
bimonthly	O
every	O
4	O
months	O
for	O
1	O
year	O
and	O
then	O
IV	O
Cy	O
or	O
IV	O
MP	O
every	O
3	O
months	O
for	O
another	O
year	O
.	O

The	O
primary	O
end	O
point	O
was	O
response	Physical
to	Physical
treatment	Physical
:	O
at	O
least	O
20	Physical
%	Physical
improvement	Physical
from	Physical
basal	Physical
conditions	Physical
on	O
clinical	Physical
,	Physical
laboratory	Physical
,	Physical
or	Physical
specific	Physical
neurological	Physical
testing	Physical
variables	Physical
.	O

RESULTS	O
Overall	O
,	O
a	O
response	Physical
rate	Physical
of	O
75	O
%	O
was	O
observed	O
.	O

Of	O
the	O
32	O
patients	O
studied	O
,	O
18/19	O
receiving	O
Cy	O
and	O
7/13	O
receiving	O
MP	O
responded	O
to	O
treatment	O
(	O
p	O
<	O
0.03	O
)	O
.	O

CONCLUSIONS	O
Cy	O
seems	O
to	O
be	O
more	O
effective	Others
than	O
MP	O
in	O
the	O
treatment	O
of	O
acute	O
,	O
severe	O
NPSLE	O
.	O

Co-administration	O
of	O
pethidine	O
and	O
clonidine	O
:	O
a	O
spinal	O
anaesthetic	O
technique	O
for	O
total	O
hip	O
replacement	O
.	O

Co-administration	O
of	O
pethidine	O
0.75	O
mg	O
kg-1	O
and	O
clonidine	O
75	O
micrograms	O
intrathecally	O
provided	O
good	O
intraoperative	O
anaesthesia	O
for	O
total	O
hip	O
replacement	O
,	O
similar	O
to	O
that	O
obtained	O
using	O
0.5	O
%	O
isobaric	O
bupivacaine	O
.	O

Sensory	O
and	O
motor	O
block	O
were	O
of	O
shorter	O
duration	O
than	O
that	O
after	O
0.5	O
%	O
isobaric	O
bupivacaine	O
and	O
0.5	O
%	O
isobaric	O
bupivacaine	O
with	O
morphine	O
0.5	O
mg	O
(	O
P	O
<	O
0.001	O
sensory	O
block	O
,	O
P	O
<	O
0.001	O
motor	O
block	O
)	O
.	O

Postoperative	Others
morphine	Others
consumption	Others
,	O
measured	O
using	O
a	O
patient-controlled	O
system	O
,	O
was	O
similar	O
to	O
that	O
in	O
patients	O
in	O
the	O
bupivacaine	O
only	O
group	O
(	O
pethidine-clonidine	O
:	O
median	O
39	O
mg/24	O
h	O
;	O
bupivacaine	O
:	O
median	O
34	O
mg/24	O
h	O
)	O
but	O
greater	O
than	O
that	O
in	O
the	O
bupivacaine-morphine	O
group	O
(	O
median	O
8	O
mg/24	O
h	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Visual	Pain
analogue	Pain
pain	Pain
scores	Pain
after	O
operation	O
were	O
similar	O
to	O
those	O
with	O
bupivacaine	O
alone	O
at	O
all	O
but	O
one	O
of	O
the	O
recording	O
times	O
but	O
were	O
greater	O
than	O
those	O
in	O
patients	O
who	O
received	O
bupivacaine	O
and	O
morphine	O
at	O
4	O
,	O
6	O
and	O
10	O
h	O
after	O
operation	O
(	O
P	O
<	O
0.001	O
,	O
P	O
<	O
0.04	O
,	O
P	O
<	O
0.02	O
)	O
.	O

The	O
combination	O
did	O
not	O
offer	O
any	O
major	O
advantage	O
over	O
conventional	O
agents	O
.	O

18F-FDG	O
PET/CT	O
for	O
early	O
prediction	O
of	O
response	O
to	O
neoadjuvant	O
lapatinib	O
,	O
trastuzumab	O
,	O
and	O
their	O
combination	O
in	O
HER2-positive	O
breast	O
cancer	O
:	O
results	O
from	O
Neo-ALTTO	O
.	O

UNLABELLED	O
Molecular	O
imaging	O
receives	O
increased	O
attention	O
for	O
selecting	O
patients	O
who	O
will	O
benefit	O
from	O
targeted	O
anticancer	O
therapies	O
.	O

Neo-ALTTO	O
(	O
Neoadjuvant	O
Lapatinib	O
and/or	O
Trastuzumab	O
Treatment	O
Optimisation	O
)	O
enrolled	O
455	O
women	O
with	O
invasive	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
-positive	O
breast	O
cancer	O
and	O
compared	O
rates	O
of	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
to	O
neoadjuvant	O
lapatinib	O
,	O
trastuzumab	O
,	O
and	O
their	O
combination	O
.	O

Each	O
anti-HER2	O
therapy	O
was	O
given	O
alone	O
for	O
6	O
wk	O
,	O
followed	O
by	O
12	O
wk	O
of	O
the	O
same	O
therapy	O
plus	O
weekly	O
paclitaxel	O
.	O

The	O
early	O
metabolic	Physical
effects	Physical
of	O
the	O
anti-HER2	O
therapies	O
on	O
the	O
primary	O
tumors	O
and	O
their	O
predictive	O
values	O
for	O
pCR	O
were	O
assessed	O
in	O
a	O
subset	O
of	O
patients	O
.	O

METHODS	O
Eighty-six	O
patients	O
underwent	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
at	O
baseline	O
and	O
weeks	O
2	O
and	O
6	O
of	O
anti-HER2	O
treatment	O
.	O

An	O
imaging	O
core	O
laboratory	O
provided	O
central	O
validation	O
,	O
and	O
2	O
independent	O
reviewers	O
,	O
masked	O
to	O
assigned	O
treatment	O
arm	O
and	O
clinical	O
outcomes	O
,	O
performed	O
consensus	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
readings	O
.	O

Maximum	O
standardized	Physical
uptake	Physical
value	Physical
(	Physical
SUVmax	Physical
)	Physical
reductions	Physical
from	Physical
baseline	Physical
were	O
used	O
to	O
measure	O
metabolic	O
response	O
.	O

RESULTS	O
Seventy-seven	O
of	O
the	O
86	O
enrolled	O
patients	O
presented	O
an	O
evaluable	O
baseline	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
scan	O
;	O
of	O
these	O
,	O
68	O
and	O
66	O
were	O
evaluable	O
at	O
weeks	O
2	O
and	O
6	O
,	O
respectively	O
.	O

Metabolic	Physical
responses	Physical
in	O
the	O
primary	O
tumors	O
were	O
evident	O
after	O
2	O
wk	O
of	O
targeted	O
therapy	O
and	O
correlated	O
highly	O
with	O
metabolic	O
responses	O
at	O
week	O
6	O
(	O
R	O
(	O
2	O
)	O
=	O
0.81	O
)	O
.	O

pCRs	O
were	O
associated	O
with	O
greater	O
SUVmax	O
reductions	O
at	O
both	O
time	O
points	O
.	O

Mean	O
SUVmax	O
reductions	O
for	O
pCR	O
and	O
non-pCR	O
,	O
respectively	O
,	O
were	O
54.3	O
%	O
versus	O
32.8	O
%	O
at	O
week	O
2	O
(	O
P	O
=	O
0.02	O
)	O
and	O
61.5	O
%	O
versus	O
34.1	O
%	O
at	O
week	O
6	O
(	O
P	O
=	O
0.02	O
)	O
.	O

(	Physical
18	Physical
)	Physical
F-FDG	Physical
PET/CT	Physical
metabolic	Physical
response	Physical
rates	Physical
at	O
weeks	O
2	O
and	O
6	O
were	O
71.6	O
%	O
and	O
60	O
%	O
,	O
respectively	O
using	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
criteria	O
;	O
pCR	O
rates	O
were	O
twice	O
as	O
high	O
for	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
responders	O
than	O
nonresponders	O
(	O
week	O
2	O
:	O
42	O
%	O
vs.	O
21	O
%	O
,	O
P	O
=	O
0.12	O
;	O
week	O
6	O
:	O
44	O
%	O
vs.	O
19	O
%	O
,	O
P	O
=	O
0.05	O
)	O
.	O

CONCLUSION	O
Early	O
metabolic	O
assessment	O
using	O
(	O
18	O
)	O
F-FDG	O
PET/CT	O
can	O
identify	O
patients	O
with	O
an	O
increased	O
likelihood	O
of	O
pCR	O
after	O
neoadjuvant	O
trastuzumab	O
,	O
lapatinib	O
,	O
or	O
their	O
combination	O
when	O
given	O
with	O
chemotherapy	O
.	O

Comparison	O
of	O
rectal	O
midazolam	O
and	O
diazepam	O
for	O
premedication	O
in	O
pediatric	O
dental	O
patients	O
.	O

Rectally	O
administered	O
midazolam	O
(	O
0.35	O
mg/kg	O
)	O
and	O
diazepam	O
(	O
0.70	O
mg/kg	O
)	O
were	O
compared	O
with	O
each	O
other	O
and	O
with	O
placebo	O
for	O
preanesthetic	O
medication	O
in	O
children	O
undergoing	O
dental	O
extractions	O
.	O

All	O
rectal	O
medications	O
were	O
very	O
well	O
accepted	O
,	O
but	O
mask	Mental
acceptance	Mental
,	O
improvement	O
in	O
anxiety	Mental
,	O
and	O
sedation	Mental
were	O
best	O
in	O
the	O
midazolam	O
group	O
.	O

Improvement	O
in	O
anxiety	Mental
and	O
sedation	Mental
were	O
significantly	O
better	O
in	O
the	O
two	O
drug	O
groups	O
than	O
in	O
those	O
patients	O
who	O
had	O
received	O
placebo	O
.	O

Thirty	O
minutes	O
after	O
rectal	O
administration	O
of	O
midazolam	O
,	O
patients	O
showed	O
a	O
decrease	O
in	O
both	O
systolic	Physical
and	Physical
diastolic	Physical
blood	Physical
pressure	Physical
and	O
heart	Physical
rate	Physical
.	O

Although	O
these	O
decreases	O
differed	O
significantly	O
from	O
the	O
premedication	O
values	O
,	O
they	O
were	O
probably	O
of	O
little	O
clinical	O
importance	O
.	O

Only	O
minor	Adverseeffect
adverse	Adverseeffect
effects	Adverseeffect
were	O
observed	O
in	O
this	O
study	O
.	O

Overall	O
rectally	O
administered	O
midazolam	O
appeared	O
to	O
be	O
somewhat	O
more	O
efficacious	O
than	O
diazepam	O
.	O

The	O
dipeptidyl	O
peptidase-4	O
inhibitor	O
PHX1149	O
improves	O
blood	Physical
glucose	Physical
control	Physical
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

AIM	O
To	O
determine	O
the	O
efficacy	Others
and	O
tolerability	Others
of	O
PHX1149	O
,	O
a	O
novel	O
dipeptidyl	O
peptidase-4	O
(	O
DPP4	O
)	O
inhibitor	O
,	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

METHODS	O
This	O
is	O
a	O
multicentre	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
4-week	O
study	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
with	O
suboptimal	O
metabolic	O
control	O
.	O

Patients	O
with	O
a	O
baseline	O
haemoglobin	O
A	O
(	O
1c	O
)	O
(	O
HbA	O
(	O
1c	O
)	O
)	O
of	O
7.3	O
to	O
11.0	O
%	O
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
once-daily	O
oral	O
therapy	O
with	O
either	O
PHX1149	O
(	O
100	O
,	O
200	O
or	O
400	O
mg	O
)	O
or	O
placebo	O
;	O
patients	O
were	O
on	O
a	O
constant	O
background	O
therapy	O
of	O
either	O
metformin	O
alone	O
or	O
metformin	O
plus	O
a	O
glitazone	O
.	O

RESULTS	O
Treatment	O
with	O
100	O
,	O
200	O
or	O
400	O
mg	O
of	O
PHX1149	O
significantly	O
decreased	O
postprandial	Physical
glucose	Physical
area	Physical
under	Physical
the	Physical
curve	Physical
AUC	Physical
(	Physical
0-2	Physical
h	O
)	O
by	O
approximately	O
20	O
%	O
(	O
+0.11	O
+/-	O
0.50	O
,	O
-2.08	O
+/-	O
0.51	O
,	O
-1.73	O
+/-	O
0.49	O
and	O
-1.88	O
+/-	O
0.48	O
mmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.002	O
,	O
0.008	O
and	O
0.004	O
vs.	O
placebo	O
)	O
.	O

Postprandial	Physical
AUC	Physical
(	Physical
0-2	Physical
h	Physical
)	Physical
of	Physical
intact	Physical
glucagon-like	Physical
peptide-1	Physical
,	O
the	O
principal	O
mediator	O
of	O
the	O
biological	O
effects	O
of	O
DPP4	O
inhibitors	O
,	O
was	O
increased	O
by	O
3.90	O
+/-	O
2.83	O
,	O
11.63	O
+/-	O
2.86	O
,	O
16.42	O
+/-	O
2.72	O
and	O
15.75	O
+/-	O
2.71	O
pmol/l	O
x	O
h	O
,	O
respectively	O
,	O
for	O
placebo	O
and	O
100	O
,	O
200	O
and	O
400	O
mg	O
(	O
p	O
=	O
0.053	O
,	O
0.001	O
and	O
0.002	O
vs.	O
placebo	O
)	O
.	O

Mean	Physical
HbA	Physical
(	Physical
1c	Physical
)	Physical
was	O
lower	O
in	O
all	O
dose	O
groups	O
;	O
the	O
placebo-corrected	O
change	O
in	O
the	O
groups	O
receiving	O
400	O
mg	O
PHX1149	O
was	O
-0.28	O
%	O
(	O
p	O
=	O
0.02	O
)	O
.	O

DPP4	Physical
inhibition	Physical
on	O
day	O
28	O
was	O
53	O
,	O
73	O
and	O
78	O
%	O
at	O
24	O
h	O
postdose	O
in	O
the	O
groups	O
receiving	O
100	O
,	O
200	O
and	O
400	O
mg	O
PHX1149	O
,	O
respectively	O
.	O

There	O
were	O
no	O
differences	O
in	O
adverse	Adverseeffect
events	Adverseeffect
between	O
PHX1149-treated	O
and	O
placebo	O
subjects	O
.	O

CONCLUSIONS	O
Addition	O
of	O
the	O
DPP4	O
inhibitor	O
PHX1149	O
to	O
a	O
stable	O
regimen	O
of	O
metformin	O
or	O
metformin	O
plus	O
a	O
glitazone	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
was	O
well	Others
tolerated	Others
and	O
improved	O
blood	Physical
glucose	Physical
control	Physical
.	O

Ten-year	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
prognosis	O
after	O
infarction	O
.	O

Department	O
of	O
Veterans	O
Affairs	O
Cooperative	O
Study	O
of	O
Coronary	O
Artery	O
Bypass	O
Surgery	O
.	O

BACKGROUND	O
The	O
10-year	O
incidence	O
of	O
myocardial	O
infarction	O
(	O
fatal	O
and	O
nonfatal	O
)	O
and	O
the	O
prognosis	O
after	O
infarction	O
were	O
evaluated	O
in	O
686	O
patients	O
with	O
stable	O
angina	O
who	O
were	O
randomly	O
assigned	O
to	O
medical	O
or	O
surgical	O
treatment	O
in	O
the	O
Veterans	O
Administration	O
Cooperative	O
Study	O
of	O
Coronary	O
Artery	O
Bypass	O
Surgery	O
.	O

METHODS	O
AND	O
RESULTS	O
Myocardial	O
infarction	O
was	O
defined	O
by	O
either	O
new	O
Q	O
wave	O
findings	O
or	O
clinical	O
symptoms	O
compatible	O
with	O
myocardial	O
infarction	O
accompanied	O
by	O
serum	O
enzyme	O
elevations	O
with	O
or	O
without	O
electrocardiographic	O
findings	O
.	O

Treatment	O
comparisons	O
were	O
made	O
according	O
to	O
original	O
treatment	O
assignment	O
;	O
35	O
%	O
of	O
the	O
medical	O
cohort	O
had	O
bypass	O
surgery	O
during	O
the	O
10-year	O
follow-up	O
period	O
.	O

The	O
overall	Physical
cumulative	Physical
infarction	Physical
rate	Physical
was	O
somewhat	O
higher	O
in	O
patients	O
assigned	O
to	O
surgery	O
(	O
36	O
%	O
)	O
than	O
in	O
medical	O
patients	O
(	O
31	O
%	O
)	O
(	O
p	O
=	O
0.13	O
)	O
due	O
to	O
perioperative	O
infarctions	O
(	O
13	O
%	O
)	O
and	O
an	O
accelerated	Physical
infarction	Physical
rate	Physical
after	O
the	O
fifth	O
year	O
of	O
follow-up	O
(	O
average	O
,	O
2.4	O
%	O
/yr	O
in	O
the	O
surgical	O
group	O
versus	O
1.4	O
%	O
/yr	O
in	O
the	O
medical	O
group	O
)	O
.	O

The	O
10-year	Mortality
cumulative	Mortality
incidence	Mortality
of	Mortality
death	Mortality
or	Adverseeffect
myocardial	Physical
infarction	Physical
was	O
also	O
higher	O
in	O
surgical	O
(	O
54	O
%	O
)	O
than	O
in	O
medical	O
(	O
49	O
%	O
)	O
patients	O
(	O
p	O
=	O
0.20	O
)	O
.	O

According	O
to	O
the	O
Cox	O
model	O
,	O
the	O
estimated	Mortality
risk	Mortality
of	Mortality
death	Mortality
after	Mortality
infarction	Mortality
was	O
59	O
%	O
lower	O
in	O
surgical	O
than	O
in	O
medical	O
patients	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

The	O
reduction	O
in	O
postinfarction	Mortality
mortality	Mortality
with	O
surgery	O
was	O
most	O
striking	O
in	O
the	O
first	O
month	O
after	O
the	O
event	O
:	O
99	O
%	O
in	O
the	O
first	O
month	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
and	O
49	O
%	O
subsequently	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

The	O
estimated	O
risk	Mortality
of	Mortality
death	Mortality
in	Mortality
the	Mortality
absence	Mortality
of	Mortality
infarction	Mortality
was	O
nearly	O
identical	O
regardless	O
of	O
treatment	O
(	O
p	O
=	O
0.75	O
)	O
.	O

Exclusion	O
of	O
perioperative	O
infarctions	O
did	O
not	O
alter	O
the	O
findings	O
.	O

CONCLUSIONS	O
Although	O
surgery	O
does	O
not	O
reduce	O
the	O
incidence	O
of	O
myocardial	Physical
infarction	Physical
overall	O
,	O
it	O
does	O
reduce	O
the	O
risk	O
of	O
mortality	Mortality
after	O
infarction	O
,	O
particularly	O
in	O
the	O
first	O
30	O
days	O
after	O
the	O
event	O
(	O
fatal	O
infarctions	O
)	O
.	O

Junctional	Physical
ectopic	Physical
tachycardia	Physical
after	O
congenital	O
heart	O
surgery	O
in	O
the	O
current	O
surgical	O
era	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
postoperative	Physical
junctional	Physical
ectopic	Physical
tachycardia	Physical
(	Physical
JET	Physical
)	Physical
in	O
a	O
modern	O
cohort	O
of	O
pediatric	O
patients	O
,	O
evaluate	O
possible	O
risk	Physical
factors	Physical
for	Physical
JET	Physical
,	O
and	O
examine	O
the	O
effects	Physical
of	Physical
JET	Physical
on	O
postoperative	Physical
morbidity	Physical
and	O
mortality	Mortality
.	O

JET	O
is	O
common	O
after	O
congenital	O
heart	O
surgery	O
.	O

JET-related	O
mortality	O
has	O
been	O
a	O
rare	O
event	O
at	O
our	O
center	O
,	O
which	O
is	O
different	O
from	O
previous	O
reports	O
.	O

We	O
reviewed	O
records	O
for	O
pediatric	O
patients	O
who	O
had	O
postoperative	O
arrhythmias	O
between	O
January	O
2006	O
and	O
June	O
2010	O
at	O
a	O
large	O
tertiary-care	O
children	O
's	O
hospital	O
.	O

We	O
performed	O
a	O
matched	O
case-control	O
study	O
to	O
identify	O
risk	O
factors	O
for	O
JET	O
and	O
a	O
matched-cohort	O
study	O
to	O
compare	O
outcomes	O
between	O
patients	O
and	O
controls	O
.	O

Whenever	O
possible	O
,	O
each	O
JET	O
case	O
was	O
randomly	O
matched	O
to	O
two	O
controls	O
on	O
the	O
basis	O
of	O
lesion	O
,	O
repair	O
,	O
and	O
surgical	O
period	O
.	O

We	O
identified	O
54	O
patients	O
with	O
JET	O
(	O
incidence	O
=	O
1.4	O
%	O
)	O
.	O

After	O
multivariate	O
logistic	O
regression	O
analysis	O
,	O
low	Physical
operative	Physical
weight	Physical
,	O
cardiopulmonary	Physical
bypass	Physical
(	Physical
CPB	Physical
)	Physical
duration	Physical
>	O
100	O
min	O
,	O
and	O
immediate	Physical
postoperative	Physical
serum	Physical
lactic	Physical
acid	Physical
level	Physical
>	O
20	O
mg/dl	O
were	O
associated	O
with	O
increased	O
odds	O
of	O
developing	O
JET	O
.	O

Patients	O
with	O
JET	O
had	O
longer	O
mechanical	Physical
ventilation	Physical
time	Physical
,	O
cardiac	Others
intensive	Others
care	Others
unit	Others
(	Others
CICU	Others
)	Others
stay	Others
,	O
and	O
hospital	Others
stay	Others
.	O

There	O
was	O
only	O
one	O
death	Mortality
in	O
JET	O
group	O
(	O
1.8	O
%	O
)	O
with	O
no	O
significant	O
difference	O
compared	O
with	O
the	O
control	O
group	O
.	O

JET	O
remains	O
a	O
relatively	O
common	O
postoperative	Physical
arrhythmia	Physical
,	O
but	O
it	O
is	O
less	O
frequent	O
than	O
previously	O
reported	O
.	O

JET	O
occurs	O
more	O
commonly	O
in	O
smaller	O
patients	O
with	O
longer	O
CPB	O
runs	O
and	O
significant	O
postoperative	Physical
lactic	Physical
acidosis	Physical
levels	Physical
.	O

Mortality	Mortality
associated	O
with	O
JET	O
is	O
lower	O
than	O
historically	O
reported	O
,	O
but	O
morbidity	Physical
remains	O
high	O
.	O

Effect	O
of	O
cigarette	O
smoking	O
on	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	O
smokers	O
:	O
a	O
crossover	O
study	O
using	O
the	O
13C-octanoic	O
acid	O
breath	O
test	O
.	O

BACKGROUND	O
Cigarette	O
smoking	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
peptic	O
ulcer	O
and	O
gastroesophageal	O
reflux	O
disease	O
.	O

Gastric	O
emptying	O
disorders	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
these	O
upper	O
gastrointestinal	O
diseases	O
.	O

Thus	O
,	O
studies	O
examining	O
a	O
link	O
between	O
smoking	O
and	O
gastric	O
emptying	O
disorders	O
have	O
clinical	O
relevance	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
effect	Physical
of	Physical
smoking	Physical
on	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	O
smokers	O
.	O

METHODS	O
The	O
(	O
13	O
)	O
C-octanoic	O
acid	Physical
breath	Physical
test	Physical
was	O
performed	O
in	O
eight	O
male	O
habitual	O
smokers	O
on	O
two	O
randomized	O
occasions	O
(	O
either	O
sham	O
smoking	O
or	O
actively	O
smoking	O
)	O
.	O

The	O
time	O
vs	O
(	O
13	O
)	O
CO	O
(	O
2	O
)	O
excretion	Physical
rate	Physical
curve	Physical
was	O
mathematically	O
fitted	O
to	O
a	O
conventional	O
formula	O
of	O
y	O
(	O
t	O
)	O
=	O
m*k*beta*e	O
(	O
-k*t	O
)	O
*	O
(	O
1	O
-	O
e	O
(	O
-k*t	O
)	O
)	O
(	O
beta-1	O
)	O
,	O
and	O
the	O
parameters	Others
of	Others
k	Others
and	Others
beta	Others
were	O
determined	O
:	O
under	O
the	O
crossover	O
protocol	O
,	O
a	O
larger	O
(	O
smaller	O
)	O
beta	O
indicates	O
slower	Physical
(	Physical
faster	Physical
)	Physical
emptying	Physical
in	O
the	O
early	O
phase	O
,	O
and	O
a	O
larger	O
(	O
smaller	O
)	O
k	O
indicates	O
faster	O
(	O
slower	O
)	O
emptying	O
in	O
the	O
later	O
phase	O
.	O

The	O
half	Physical
(	Physical
13	Physical
)	Physical
CO	Physical
(	Physical
2	Physical
)	Physical
excretion	Physical
time	Physical
(	O
t	O
(	O
1/2b	O
)	O
=	O
-	O
[	O
ln	O
(	O
1	O
-	O
2	O
(	O
-1/beta	O
)	O
)	O
]	O
/k	O
)	O
and	O
the	O
time	Physical
of	Physical
maximal	Physical
(	Physical
13	Physical
)	Physical
CO	Physical
(	Physical
2	Physical
)	Physical
excretion	Physical
rate	Physical
(	Physical
t	Physical
(	Physical
max	Physical
)	Physical
=	O
[	O
lnbeta	O
]	O
/k	O
)	O
were	O
also	O
calculated	O
.	O

Between	O
the	O
two	O
occasions	O
,	O
k	O
,	O
beta	O
,	O
t	O
(	O
1/2b	O
)	O
,	O
and	O
t	O
(	O
max	O
)	O
were	O
compared	O
by	O
the	O
Wilcoxon	O
signed-rank	O
test	O
.	O

RESULTS	O
After	O
smoking	O
,	O
k	O
was	O
significantly	O
increased	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
beta	Others
,	Others
t	Others
(	Others
1/2	Others
)	Others
,	Others
and	Others
t	Others
(	Others
max	Others
)	Others
between	O
the	O
two	O
occasions	O
.	O

CONCLUSIONS	O
The	O
increase	Others
in	Others
k	Others
suggests	O
the	O
acceleration	O
of	O
gastric	O
emptying	O
in	O
the	O
later	O
phase	O
.	O

For	O
the	O
first	O
time	O
,	O
this	O
study	O
has	O
revealed	O
that	O
acute	O
smoking	O
speeds	O
the	O
gastric	O
emptying	O
of	O
solids	O
in	O
Japanese	O
habitual	O
smokers	O
.	O

Long	O
pediatric	O
colonoscope	O
versus	O
intermediate	O
length	O
adult	O
colonoscope	O
for	O
colonoscopy	O
.	O

BACKGROUND	O
Controversy	O
exists	O
on	O
how	O
the	O
length	O
and	O
diameter	O
of	O
colonoscopes	O
affect	O
the	O
quality	Others
of	Others
colonoscopy	Others
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
a	O
long	O
pediatric	O
colonoscope	O
with	O
an	O
intermediate	O
length	O
adult	O
colonoscope	O
with	O
regards	O
to	O
completion	Others
rate	Others
and	O
cecal	Others
intubation	Others
time	Others
.	O

Whether	O
either	O
scope	O
may	O
be	O
more	O
efficient	Others
in	O
any	O
subgroups	O
was	O
also	O
investigated	O
.	O

METHODS	O
Asymptomatic	O
patients	O
admitted	O
to	O
the	O
physical	O
check-up	O
department	O
of	O
Buddhist	O
Dalin	O
Tzu	O
Chi	O
General	O
Hospital	O
were	O
included	O
.	O

A	O
single	O
endoscopist	O
performed	O
all	O
of	O
the	O
colonoscopic	O
examinations	O
under	O
sedation	O
.	O

Consecutive	O
patients	O
were	O
randomized	O
to	O
undergo	O
colonoscopy	O
with	O
either	O
intermediate	O
length	O
adult	O
colonoscope	O
(	O
CF-240I	O
)	O
or	O
long	O
pediatric	O
colonoscope	O
(	O
PCF-240L	O
)	O
.	O

The	O
success	Others
rate	Others
and	O
time	Others
required	Others
to	Others
reach	Others
cecum	Others
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

RESULTS	O
Between	O
April	O
2005	O
and	O
February	O
2006	O
,	O
a	O
total	O
of	O
918	O
patients	O
were	O
enrolled	O
.	O

Incomplete	Others
colonoscopy	Others
occurred	O
in	O
21	O
(	O
2.3	O
%	O
)	O
cases	O
(	O
14	O
in	O
the	O
CF-240I	O
group	O
and	O
seven	O
in	O
the	O
PCF-240L	O
group	O
,	O
P	O
>	O
0.1	O
)	O
.	O

The	O
overall	Others
cecal	Others
mean	Others
insertion	Others
time	Others
was	O
6.00	O
+/-	O
3.66	O
min	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
CF-240I	O
and	O
PCF	O
240L	O
groups	O
with	O
regard	O
to	O
the	O
cecal	Others
intubation	Others
rate	Others
(	O
96.9	O
%	O
vs	O
98.5	O
%	O
,	O
P	O
=	O
0.18	O
)	O
,	O
the	O
need	O
for	O
abdominal	Others
pressure	Others
(	O
71.7	O
%	O
vs	O
73.4	O
%	O
,	O
P	O
=	O
0.55	O
)	O
and	O
change	Others
of	Others
position	Others
(	O
13.5	O
%	O
vs	O
11.5	O
%	O
,	O
P	O
=	O
0.37	O
)	O
.	O

However	O
,	O
the	O
cecal	Others
intubation	Others
time	Others
was	O
shorter	O
in	O
the	O
CF-240I	O
group	O
(	O
5.75	O
+/-	O
3.18	O
vs	O
6.26	O
+/-	O
3.30	O
min	O
,	O
P	O
=	O
0.02	O
)	O
.	O

Subgroup	O
analysis	O
by	O
sex	O
,	O
age	O
,	O
and	O
body	O
mass	O
index	O
showed	O
comparable	O
outcomes	O
between	O
the	O
two	O
groups	O
except	O
that	O
the	O
cecal	Others
intubation	Others
times	Others
were	O
significantly	O
shorter	O
in	O
the	O
CF-240I	O
group	O
when	O
only	O
men	O
(	O
4.78	O
+/-	O
2.57	O
vs	O
5.50	O
+/-	O
2.93	O
min	O
,	O
P	O
<	O
0.01	O
)	O
or	O
those	O
younger	O
than	O
50	O
years	O
(	O
5.50	O
+/-	O
2.90	O
vs	O
6.25	O
+/-	O
3.68	O
min	O
,	O
P	O
=	O
0.02	O
)	O
were	O
considered	O
.	O

CONCLUSION	O
Cecal	Others
intubation	Others
time	Others
is	O
shorter	O
in	O
patients	O
examined	O
with	O
an	O
intermediate	O
length	O
adult	O
colonoscope	O
,	O
mainly	O
in	O
the	O
subgroups	O
of	O
men	O
and	O
those	O
younger	O
than	O
50	O
years	O
of	O
age	O
.	O

Direct	O
trocar	O
insertion	O
vs.	O
Verres	O
needle	O
use	O
for	O
laparoscopic	O
sterilization	O
.	O

A	O
randomized	O
,	O
prospective	O
trial	O
was	O
designed	O
to	O
compare	O
direct	O
trocar	O
insertion	O
with	O
prior	O
peritoneal	O
insufflation	O
with	O
a	O
Verres	O
needle	O
for	O
laparoscopic	O
tubal	O
sterilization	O
.	O

Direct	O
trocar	O
insertion	O
resulted	O
in	O
fewer	O
instrument	Others
insertions	Others
(	O
21.8	O
%	O
vs.	O
7.8	O
%	O
)	O
and	O
use	O
of	O
smaller	Others
volumes	Others
of	Others
CO2	Others
(	O
2.67	O
vs.	O
2.32	O
L	O
)	O
.	O

Direct	O
trocar	O
use	O
resulted	O
in	O
a	O
decrease	O
in	O
operating	Others
time	Others
from	O
9	O
minutes	O
,	O
40	O
seconds	O
in	O
the	O
needle	O
group	O
to	O
7	O
minutes	O
,	O
30	O
seconds	O
in	O
the	O
trocar	O
group	O
.	O

Minor	Adverseeffect
omental	Adverseeffect
injuries	Adverseeffect
occurred	O
in	O
a	O
small	O
percentage	O
of	O
each	O
group	O
,	O
while	O
serious	O
complications	O
occurred	O
once	O
in	O
each	O
group	O
.	O

Psychoeducational	O
group	O
intervention	O
for	O
wives	O
of	O
men	O
with	O
prostate	O
cancer	O
.	O

OBJECTIVE	O
The	O
effects	O
of	O
a	O
6-week	O
psychoeducational	O
group	O
intervention	O
on	O
the	O
distress	O
,	O
coping	O
,	O
personal	O
growth	O
,	O
and	O
marital	O
communication	O
of	O
wives	O
of	O
men	O
diagnosed	O
with	O
prostate	O
cancer	O
were	O
evaluated	O
using	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
Sixty	O
wives	O
completed	O
measures	O
prior	O
to	O
random	O
assignment	O
to	O
either	O
the	O
psychoeducational	O
group	O
intervention	O
or	O
a	O
no-treatment	O
control	O
group	O
,	O
and	O
1	O
month	O
after	O
completion	O
of	O
the	O
group	O
.	O

RESULTS	O
No	O
differences	O
with	O
regard	O
to	O
wives	O
'	O
general	Mental
distress	Mental
or	Mental
cancer-specific	Mental
distress	Mental
were	O
noted	O
.	O

In	O
comparison	O
with	O
the	O
control	O
group	O
,	O
participants	O
receiving	O
the	O
intervention	O
perceived	O
that	O
having	O
a	O
spouse	O
with	O
prostate	O
cancer	O
had	O
made	O
positive	O
contributions	O
to	O
their	O
lives	O
,	O
reported	O
gains	O
in	O
the	O
use	O
of	O
positive	Mental
reappraisal	Mental
coping	Mental
and	O
reductions	O
in	O
denial	Mental
coping	Mental
.	Mental

CONCLUSION	O
Although	O
the	O
psychoeducational	O
intervention	O
did	O
not	O
result	O
in	O
changes	O
in	O
psychological	Mental
distress	Mental
,	O
improvements	O
in	O
adaptive	Mental
coping	Mental
and	Mental
indicators	Mental
of	Mental
psychological	Mental
growth	Mental
were	O
found	O
.	O

The	O
utility	O
of	O
group	O
interventions	O
for	O
spouses	O
of	O
men	O
with	O
prostate	O
cancer	O
is	O
discussed	O
.	O

[	O
Effect	O
of	O
liu	O
wei	O
di	O
huang	O
or	O
jin	O
gui	O
shen	O
qi	O
decoction	O
as	O
on	O
adjuvant	O
treatment	O
in	O
small	O
cell	O
lung	O
cancer	O
]	O
.	O

Eighty-three	O
patients	O
with	O
small	O
cell	O
lung	O
cancer	O
were	O
randomized	O
with	O
or	O
without	O
using	O
a	O
traditional	O
Chinese	O
Kidney-tonifying	O
decoction	O
(	O
Liu	O
Wei	O
Di	O
Huang	O
or	O
Jin	O
Gui	O
Shen	O
Qi	O
medicinal	O
decoction	O
)	O
in	O
chemotherapy	O
or	O
radiotherapy	O
courses	O
.	O

74	O
patients	O
were	O
availble	O
to	O
be	O
analysis	O
.	O

The	O
two	O
treatment	O
groups	O
were	O
well-matched	O
in	O
age	O
,	O
sex	O
,	O
stage	O
and	O
performance	O
status	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
response	Physical
rate	Physical
and	O
the	O
median	Mortality
survival	Mortality
between	O
two	O
groups	O
.	O

The	O
overall	Physical
response	Physical
rate	Physical
(	O
CR+PR	O
)	O
was	O
91.5	O
%	O
for	O
Chinese	O
herb	O
group	O
and	O
46.9	O
%	O
for	O
control	O
group	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
median	Mortality
survival	Mortality
was	O
16	O
months	O
for	O
the	O
traditional	O
Chinese	O
Kidney-tonifying	O
decoction	O
group	O
,	O
and	O
10	O
months	O
for	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Survival	Mortality
curve	Mortality
(	Mortality
Kaplan-meire	Mortality
's	Mortality
)	Mortality
of	O
the	O
Chinese	O
herb	O
group	O
was	O
better	O
than	O
that	O
of	O
the	O
control	O
group	O
.	O

10	O
patients	O
of	O
Chinese	O
herb	O
group	O
was	O
alive	O
beyond	O
more	O
than	O
2	O
years	O
.	O

Until	O
now	O
,	O
4	O
patients	O
in	O
the	O
Chinese	O
herb	O
group	O
,	O
one	O
in	O
the	O
control	O
group	O
are	O
still	O
enjoying	O
their	O
disease-free	Others
life	Others
for	O
more	O
than	O
7	O
years	O
.	O

Hematologic	Adverseeffect
toxicities	Adverseeffect
were	O
observed	O
much	O
frequently	O
in	O
the	O
patients	O
of	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0.005	O
and	O
0.01/WBC	O
and	O
BPC	O
)	O
.	O

Results	O
of	O
animal	O
experiments	O
with	O
the	O
same	O
traditional	O
medicinal	O
decoctions	O
as	O
used	O
in	O
clinic	O
have	O
showed	O
immuno-enhancement	Physical
activities	Physical
.	O

These	O
results	O
have	O
showed	O
that	O
the	O
traditional	O
Chinese	O
Kidney-tonifying	O
decoction	O
may	O
enhance	O
non-specific	O
immunology	O
activities	O
and	O
may	O
be	O
much	O
useful	O
for	O
solid	O
cancer	O
patients	O
as	O
an	O
adjuvant	O
treatment	O
.	O

Online	O
conductivity	O
monitoring	O
:	O
validation	O
and	O
usefulness	O
in	O
a	O
clinical	O
trial	O
of	O
reduced	O
dialysate	O
conductivity	O
.	O

Relatively	O
low	O
dialysate	O
conductivity	O
(	O
Cndi	O
)	O
may	O
improve	O
outcomes	O
by	O
reducing	O
the	O
overall	O
sodium	Physical
burden	Physical
in	O
dialysis	O
patients	O
.	O

Excess	O
sodium	O
removal	O
,	O
however	O
,	O
could	O
lead	O
to	O
hemodynamic	O
instability	O
.	O

We	O
performed	O
a	O
randomized	O
controlled	O
trial	O
of	O
reduction	O
of	O
Cndi	O
.	O

For	O
the	O
study	O
,	O
28	O
patients	O
were	O
randomized	O
to	O
maintenance	O
of	O
Cndi	O
at	O
13.6	O
mS/cm	O
(	O
equivalent	O
to	O
135	O
mmol/L	O
of	O
Na+	O
)	O
or	O
serial	O
reduction	O
of	O
Cndi	O
in	O
steps	O
of	O
0.2	O
mS/cm	O
,	O
guided	O
by	O
symptoms	O
and	O
blood	O
pressure	O
.	O

Sodium	O
removal	O
estimated	O
from	O
pre-	O
and	O
postplasma	O
concentrations	O
correlated	O
well	O
with	O
removal	O
measured	O
by	O
conductivity	O
monitoring	O
as	O
ionic	Physical
mass	Physical
balance	Physical
(	O
R2	O
0.66	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Of	O
the	O
16	O
patients	O
randomized	O
to	O
reduction	O
of	O
Cndi	O
,	O
6	O
achieved	O
Cndi	O
13.4	O
mS/cm	O
,	O
6	O
achieved	O
13.2	O
mS/cm	O
,	O
and	O
4	O
achieved	O
13.0	O
mS/cm	O
.	O

No	O
episodes	O
of	O
disequilibrium	O
occurred	O
.	O

Interdialytic	Physical
weight	Physical
gain	Physical
was	O
reduced	O
from	O
2.34	O
+/-	O
0.10	O
kg	O
to	O
1.57	O
+/-	O
0.11	O
kg	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Predialysis	Physical
systolic	Physical
blood	Physical
pressure	Physical
fell	O
from	O
144	O
+/-	O
3	O
mm	O
Hg	O
to	O
137	O
+/-	O
4	O
mm	O
Hg	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
reduction	Others
in	Others
convective	Physical
sodium	Physical
removal	Physical
was	O
balanced	O
by	O
an	O
increase	O
in	O
diffusive	Physical
sodium	Physical
removal	Physical
(	O
95	O
+/-	O
9	O
mmol	O
cf	O
.	O

175	O
+/-	O
14	O
mmol	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Reduction	O
in	O
Cndi	O
monitored	O
by	O
IMB	O
is	O
safe	O
and	O
practical	O
and	O
leads	O
to	O
improved	O
interdialytic	O
weight	O
gains	O
and	O
blood	O
pressure	O
control	O
,	O
while	O
avoiding	O
excessive	O
sodium	O
removal	O
.	O

Secretin	O
and	O
sleep	O
in	O
children	O
with	O
autism	O
.	O

The	O
objectives	O
of	O
this	O
pilot	O
study	O
were	O
1	O
)	O
to	O
examine	O
possible	O
effects	O
of	O
secretin	O
infusions	O
on	O
sleep-wake	O
state	O
organization	O
in	O
children	O
with	O
autism	O
,	O
and	O
2	O
)	O
to	O
assess	O
the	O
feasibility	O
of	O
home	O
recordings	O
using	O
time-lapse	O
videosomnography	O
in	O
children	O
with	O
autism	O
.	O

Participants	O
were	O
a	O
subset	O
of	O
subjects	O
from	O
two	O
double	O
blind	O
,	O
placebo-control	O
,	O
multi-center	O
clinical	O
trials	O
.	O

One	O
trial	O
,	O
the	O
UC	O
Irvine	O
study	O
,	O
assessed	O
the	O
effects	O
of	O
porcine	O
secretin	O
vs.	O
saline	O
infusions	O
on	O
children	O
's	O
behavior	Mental
,	O
language	Mental
and	O
IQ	Mental
.	O

The	O
UC	O
Davis	O
trial	O
assessed	O
the	O
effects	O
of	O
synthetic	O
human	O
secretin	O
vs.	O
saline	O
infusions	O
on	O
behavior	Mental
,	O
language	Mental
and	O
gastrointestinal	O
function	O
.	O

The	O
sleep	O
study	O
enrolled	O
some	O
of	O
the	O
children	O
from	O
each	O
of	O
the	O
two	O
trials	O
to	O
observe	O
possible	O
secretin	O
effects	O
on	O
sleep	O
.	O

To	O
examine	O
sleep	O
,	O
the	O
UC	O
Irvine	O
trial	O
used	O
the	O
Children	Mental
's	Mental
Sleep	Mental
Habits	Mental
Questionnaire	Mental
and	O
daily	Mental
sleep	Mental
diaries	Mental
,	O
whereas	O
the	O
UC	O
Davis	O
study	O
used	O
home-recorded	Others
time-lapse	Others
videosomnography	Others
.	O

Because	O
of	O
the	O
small	O
sample	O
size	O
,	O
the	O
results	O
from	O
both	O
trials	O
are	O
preliminary	O
.	O

They	O
suggest	O
that	O
secretin	O
,	O
porcine	O
or	O
synthetic	O
,	O
does	O
not	O
improve	O
sleep-wake	Mental
state	Mental
organization	Mental
dramatically	O
.	O

Hydrogen	O
peroxide	O
mouth	O
rinse	O
:	O
an	O
analgesic	O
post-tonsillectomy	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
analgesic	Others
efficacy	Others
of	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
mouth	O
rinse	O
with	O
control	O
for	O
post-tonsillectomy	Pain
pain	Pain
management	Pain
.	O

DESIGN	O
Double-blinded	O
,	O
prospective	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

PATIENTS	O
AND	O
METHODS	O
Thirty-seven	O
patients	O
from	O
5	O
to	O
14	O
years	O
old	O
undergoing	O
electrocautery	O
tonsillectomy	O
were	O
randomized	O
to	O
either	O
the	O
H2O2	O
mouth	O
rinse	O
or	O
the	O
water	O
rinse	O
(	O
control	O
)	O
group	O
.	O

For	O
14	O
days	O
,	O
patients	O
recorded	O
pain	Pain
levels	Pain
twice	Pain
daily	Pain
using	O
a	O
visual	Pain
analogue	Pain
scale	Pain
.	O

Analgesic	O
uses	O
,	O
as	O
well	O
as	O
any	O
complications	O
,	O
were	O
also	O
noted	O
by	O
the	O
patients	O
.	O

RESULTS	O
Thirty-seven	O
patients	O
completed	O
the	O
study	O
,	O
21	O
in	O
the	O
treatment	O
group	O
and	O
16	O
in	O
the	O
control	O
group	O
.	O

Mean	Pain
postoperative	Pain
days	Pain
of	Pain
pain	Pain
were	O
10.3	O
and	O
8.3	O
,	O
respectively	O
,	O
and	O
differed	O
significantly	O
(	O
p	O
=	O
.008	O
)	O
.	O

Mean	Others
postoperative	Others
days	Others
of	Others
analgesic	Others
use	O
were	O
9.0	O
and	O
6.7	O
,	O
respectively	O
,	O
and	O
differed	O
significantly	O
(	O
p	O
=	O
.005	O
)	O
.	O

Only	O
one	O
incidence	O
of	O
postoperative	Adverseeffect
hemorrhage	Adverseeffect
occurred	O
in	O
the	O
study	O
group	O
.	O

CONCLUSION	O
In	O
our	O
study	O
,	O
the	O
H2O2	O
mouth	O
rinse	O
does	O
not	O
provide	O
a	O
better	O
analgesic	Others
effect	Others
than	O
the	O
water	O
rinse	O
for	O
post-tonsillectomy	Pain
pain	Pain
relief	Pain
.	O

Niacin	O
revisited	O
.	O

A	O
randomized	O
,	O
controlled	O
trial	O
of	O
wax-matrix	O
sustained-release	O
niacin	O
in	O
hypercholesterolemia	O
.	O

Two	O
hundred	O
one	O
male	O
and	O
female	O
subjects	O
,	O
aged	O
20	O
to	O
70	O
years	O
,	O
with	O
elevated	O
low-density	O
lipoprotein	O
cholesterol	O
values	O
(	O
in	O
the	O
75th	O
to	O
95th	O
percentiles	O
)	O
,	O
participated	O
in	O
a	O
randomized	O
,	O
controlled	O
,	O
double-blind	O
study	O
using	O
a	O
new	O
form	O
of	O
niacin	O
(	O
Enduracin	O
)	O
,	O
which	O
employs	O
a	O
wax-matrix	O
vehicle	O
for	O
sustained	O
release	O
.	O

Four	O
niacin	O
treatment	O
groups	O
(	O
daily	O
doses	O
of	O
2000	O
,	O
1500	O
,	O
1250	O
,	O
and	O
1000	O
mg	O
)	O
were	O
compared	O
with	O
placebo-	O
and	O
diet-treated	O
controls	O
to	O
determine	O
side-effect	O
profile	O
and	O
optimal	O
range	O
of	O
efficacy	O
.	O

The	O
groups	O
given	O
2000	O
and	O
1500	O
mg	O
demonstrated	O
significant	O
reductions	O
in	O
values	O
of	O
low-density	Physical
lipoprotein	Physical
cholesterol	Physical
(	O
-26	O
%	O
and	O
-19.3	O
%	O
,	O
respectively	O
)	O
,	O
total	Physical
cholesterol	Physical
(	O
-18.4	O
%	O
and	O
-13.3	O
%	O
)	O
,	O
and	O
total	Physical
cholesterol-high-density	Physical
lipoprotein	Physical
cholesterol	Physical
ratio	Physical
(	O
-20.4	O
%	O
and	O
-19.4	O
%	O
)	O
when	O
compared	O
with	O
diet-	O
and	O
placebo-treated	O
controls	O
.	O

Smaller	O
improvements	O
were	O
seen	O
in	O
high-density	Physical
lipoprotein	Physical
cholesterol	Physical
and	Physical
triglyceride	Physical
levels	Physical
.	Physical

Blood	O
chemistry	O
monitoring	O
indicated	O
that	O
reduction	O
in	O
low-density	Physical
lipoprotein	Physical
cholesterol	Physical
level	Physical
strongly	O
correlated	O
with	O
an	O
increase	O
in	O
baseline	O
levels	O
of	O
some	O
enzymes	O
for	O
niacin-treated	O
subjects	O
.	O

The	O
improved	O
side-effect	O
profile	O
of	O
the	O
wax-matrix	O
form	O
of	O
niacin	O
was	O
particularly	O
notable	O
.	O

The	O
dropout	Others
rate	Others
due	O
to	O
side	Adverseeffect
effects	Adverseeffect
was	O
only	O
3.4	O
%	O
and	O
was	O
coupled	O
with	O
good	O
medication	O
compliance	O
.	O

Is	O
a	O
calculated	O
total	O
hip	O
BMD	O
of	O
clinical	Others
use	Others
?	O
The	O
diagnosis	O
of	O
osteoporosis	O
is	O
based	O
on	O
bone	O
mass	O
measurement	O
.	O

To	O
avoid	O
the	O
errors	O
associated	O
with	O
the	O
measurement	O
of	O
spinal	O
bone	O
density	O
the	O
total	O
hip	O
has	O
been	O
accepted	O
as	O
the	O
standard	O
measurement	O
site	O
.	O

This	O
information	O
is	O
not	O
available	O
for	O
many	O
early	O
measurements	O
.	O

We	O
have	O
assessed	O
whether	O
it	O
is	O
possible	O
to	O
derive	O
clinically	O
useful	O
information	O
about	O
total	O
hip	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
from	O
measurements	O
at	O
other	O
hip	O
sites	O
.	O

The	O
bone	O
mass	O
measurements	O
of	O
46	O
patients	O
participating	O
in	O
a	O
current	O
trial	O
of	O
therapy	O
for	O
osteoporosis	O
were	O
reviewed	O
.	O

The	O
total	Physical
hip	Physical
BMD	Physical
as	O
directly	O
measured	O
was	O
compared	O
with	O
that	O
obtained	O
from	O
the	O
formula	O
:	O
Total	Physical
hip	Physical
BMD	Physical
=	O
0.48	O
x	O
Neck	Physical
BMD	Physical
+	O
0.62	O
x	O
Trochanteric	Physical
BMD	Physical
+	O
0.03	O
.	O

In	O
30	O
patients	O
with	O
follow-up	O
data	O
the	O
rate	Physical
of	Physical
change	Physical
in	Physical
hip	Physical
BMD	Physical
over	O
a	O
year	O
was	O
also	O
determined	O
by	O
both	O
methods	O
.	O

In	O
the	O
pretreatment	O
state	O
there	O
was	O
good	O
agreement	O
between	O
the	O
two	O
measures	O
(	O
r2	O
=	O
0.96	O
,	O
SEE	O
0.012	O
g/cm2	O
)	O
.	O

If	O
the	O
formula	O
was	O
used	O
to	O
compute	O
a	O
change	Physical
in	Physical
total	Physical
hip	Physical
BMD	Physical
,	O
the	O
agreement	O
between	O
both	O
methods	O
remained	O
good	O
.	O

However	O
,	O
the	O
standard	O
error	O
of	O
the	O
estimate	O
of	O
the	O
change	O
represented	O
59	O
%	O
of	O
the	O
observed	O
change	O
.	O

This	O
indicates	O
that	O
the	O
error	Others
associated	Others
with	Others
this	Others
estimate	Others
is	O
too	O
great	O
to	O
allow	O
clinically	O
meaningful	O
conclusions	O
to	O
be	O
drawn	O
from	O
calculated	Physical
total	Physical
hip	Physical
BMD	Physical
.	O

We	O
conclude	O
that	O
,	O
whilst	O
it	O
may	O
be	O
possible	O
to	O
obtain	O
reasonable	O
point	O
estimates	O
of	O
total	Physical
hip	Physical
BMD	Physical
from	O
other	O
measures	O
in	O
the	O
hip	O
,	O
these	O
estimates	O
are	O
too	O
imprecise	O
to	O
allow	O
conclusions	O
about	O
change	Physical
in	Physical
BMD	Physical
to	O
be	O
made	O
.	O

Effects	Others
of	O
three	O
oral	O
analgesics	O
on	O
postoperative	O
pain	O
following	O
root	O
canal	O
preparation	O
:	O
a	O
controlled	O
clinical	O
trial	O
.	O

AIM	O
To	O
compare	O
the	O
effects	O
of	O
single	O
doses	O
of	O
three	O
oral	O
medications	O
on	O
postoperative	O
pain	Pain
following	O
instrumentation	O
of	O
root	O
canals	O
in	O
teeth	O
with	O
irreversible	O
pulpitis	O
.	O

METHODOLOGY	O
In	O
this	O
double-blind	O
clinical	O
trial	O
,	O
100	O
patients	O
who	O
had	O
anterior	O
or	O
premolar	O
teeth	O
with	O
irreversible	O
pulpitis	O
without	O
any	O
signs	O
and	O
symptoms	O
of	O
acute	O
or	O
chronic	O
apical	O
periodontitis	O
and	O
moderate	O
to	O
severe	O
pain	O
were	O
divided	O
by	O
balanced	O
block	O
random	O
allocation	O
into	O
four	O
groups	O
of	O
25	O
each	O
,	O
a	O
control	O
group	O
receiving	O
a	O
placebo	O
medication	O
,	O
and	O
three	O
experimental	O
groups	O
receiving	O
a	O
single	O
dose	O
of	O
either	O
Tramadol	O
(	O
100	O
mg	O
)	O
,	O
Novafen	O
(	O
325	O
mg	O
of	O
paracetamol	O
,	O
200	O
mg	O
ibuprofen	O
and	O
40	O
mg	O
caffeine	O
anhydrous	O
)	O
or	O
Naproxen	O
(	O
500	O
mg	O
)	O
immediately	O
after	O
the	O
first	O
appointment	O
where	O
the	O
pulp	O
was	O
removed	O
,	O
and	O
the	O
canals	O
were	O
fully	O
prepared	O
.	O

The	O
intensity	O
of	Pain
pain	Pain
was	O
scored	O
based	O
on	O
10-point	O
VAS	O
before	O
and	O
after	O
treatment	O
for	O
up	O
to	O
24	O
h	O
postoperatively	O
.	O

Data	O
were	O
submitted	O
to	O
repeated	O
analysis	O
of	O
variance	O
.	O

RESULTS	O
At	O
the	O
6	O
,	O
12	O
and	O
24	O
h	O
postoperative	O
intervals	O
after	O
drug	O
administration	O
,	O
the	O
intensity	Pain
of	Pain
pain	Pain
was	O
significantly	O
lower	O
in	O
the	O
experimental	O
groups	O
than	O
in	O
the	O
placebo	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Tramadol	O
was	O
significantly	O
less	O
effective	O
(	O
P	O
<	O
0.05	O
)	O
than	O
Naproxen	O
,	O
and	O
Novafen	O
that	O
were	O
similar	O
to	O
each	O
other	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
A	O
single	O
oral	O
dose	O
of	O
Naproxen	O
,	O
Novafen	O
and	O
Tramadol	O
taken	O
immediately	O
after	O
treatment	O
reduced	O
postoperative	O
pain	O
following	O
pulpectomy	O
and	O
root	O
canal	O
preparation	O
of	O
teeth	O
with	O
irreversible	O
pulpitis	O
.	O

Monitoring	O
tumour	O
cells	O
in	O
the	O
peripheral	O
blood	O
of	O
small	O
cell	O
lung	O
cancer	O
patients	O
.	O

BACKGROUND	O
Flow	O
cytometry	O
was	O
used	O
to	O
enumerate	O
tumour	O
cells	O
in	O
longitudinal	O
studies	O
of	O
peripheral	O
blood	O
from	O
small	O
cell	O
lung	O
cancer	O
(	O
SCLC	O
)	O
patients	O
,	O
together	O
with	O
magnetic	O
bead	O
selection	O
to	O
isolate	O
and	O
identify	O
these	O
cells	O
.	O

As	O
part	O
of	O
a	O
trial	O
,	O
11	O
patients	O
received	O
either	O
standard	O
(	O
four	O
weekly	O
)	O
chemotherapy	O
with	O
ifosfamide	O
,	O
carboplatin	O
,	O
and	O
etoposide	O
(	O
ICE	O
)	O
or	O
accelerated	O
(	O
two	O
weekly	O
)	O
ICE	O
with	O
filgrastim	O
(	O
granulocyte	O
colony-stimulating	O
factor	O
[	O
G-CSF	O
]	O
)	O
and	O
autologous	O
stem	O
cell	O
support	O
.	O

METHODS	O
Fresh	O
venous	O
blood	O
was	O
taken	O
throughout	O
treatment	O
and	O
follow-up	O
.	O

Aliquots	O
were	O
stained	O
with	O
a	O
tumour-specific	O
antibody	O
against	O
epithelial	O
tissue	O
(	O
Ber	O
EP4	O
)	O
,	O
verified	O
as	O
a	O
good	O
marker	O
of	O
SCLC	O
cells	O
by	O
immunohistochemistry	O
.	O

Matched	O
samples	O
labelled	O
with	O
Ber	O
EP4	O
were	O
separated	O
magnetically	O
by	O
adding	O
a	O
secondary	O
bead-antibody	O
conjugate	O
for	O
confirmation	O
of	O
tumour	O
cell	O
identity	O
.	O

RESULTS	O
Circulating	Physical
tumour	Physical
cells	Physical
were	O
detected	O
and	O
monitored	O
throughout	O
treatment	O
periods	O
.	O

An	O
initial	O
rise	O
in	O
circulating	Physical
cells	Physical
after	O
the	O
first	O
cycle	O
was	O
followed	O
by	O
a	O
fall	O
in	O
both	O
treatment	O
arms	O
to	O
baseline	O
levels	O
set	O
by	O
normal	O
controls	O
.	O

This	O
was	O
achieved	O
by	O
week	O
12	O
in	O
the	O
accelerated	O
treatment	O
arm	O
and	O
by	O
week	O
24	O
in	O
the	O
standard	O
arm	O
.	O

CONCLUSIONS	O
Flow	O
cytometry	O
and	O
magnetic	O
bead	O
isolation	O
can	O
be	O
used	O
to	O
identify	O
changes	O
in	O
numbers	O
of	O
circulating	O
tumour	O
cells	O
in	O
patients	O
undergoing	O
chemotherapy	O
for	O
SCLC	O
and	O
thereafter	O
during	O
follow-up	O
periods	O
.	O

Absence	O
of	O
tumour	O
cells	O
may	O
indicate	O
a	O
more	O
favourable	O
patient	O
group	O
who	O
would	O
benefit	O
from	O
a	O
more	O
intense	O
course	O
of	O
treatment	O
.	O

Effect	O
of	O
ranolazine	O
on	O
A1C	O
and	O
glucose	O
levels	O
in	O
hyperglycemic	O
patients	O
with	O
non-ST	O
elevation	O
acute	O
coronary	O
syndrome	O
.	O

OBJECTIVE	O
We	O
determined	O
the	O
relationships	O
between	O
glycemia	O
at	O
randomization	O
,	O
concurrent	O
antidiabetic	O
therapy	O
,	O
and	O
change	O
in	O
A1C	O
and	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
in	O
patients	O
with	O
diabetes	O
receiving	O
standard	O
treatment	O
for	O
diabetes	O
and	O
randomized	O
to	O
ranolazine	O
or	O
placebo	O
within	O
the	O
MERLIN-TIMI-36	O
(	O
MERLIN	O
)	O
study	O
.	O

Ranolazine	O
is	O
a	O
novel	O
first-in-class	O
drug	O
approved	O
for	O
treating	O
angina	O
pectoris	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
Randomization	O
and	O
4-month	O
glycemic	O
and	O
antidiabetes	O
drug	O
usage	O
data	O
from	O
MERLIN	O
were	O
analyzed	O
using	O
Spotfire	O
and	O
SAS	O
version	O
9.1	O
software	O
.	O

RESULTS	O
In	O
patients	O
with	O
diabetes	O
and	O
A1C	O
of	O
>	O
or=8-10	O
%	O
at	O
randomization	O
(	O
n	O
=	O
171	O
)	O
,	O
there	O
was	O
an	O
absolute	O
A1C	Physical
reduction	Physical
in	O
the	O
ranolazine	O
group	O
of	O
1.2	O
%	O
(	O
95	O
%	O
CI	O
-1.4	O
to	O
-1.0	O
)	O
,	O
and	O
the	O
placebo-adjusted	O
(	O
n	O
=	O
182	O
)	O
decrease	O
in	O
A1C	Physical
by	O
ranolazine	O
was	O
0.59	O
%	O
(	O
95	O
%	O
CI	O
-0.99	O
to	O
-0.20	O
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
patients	O
with	O
FPG	O
of	O
150-400	O
mg/dl	O
at	O
randomization	O
,	O
ranolazine	O
(	O
n	O
=	O
131	O
)	O
compared	O
with	O
placebo	O
(	O
n	O
=	O
147	O
)	O
reduced	O
FPG	O
by	O
25.7	O
mg/dl	O
(	O
95	O
%	O
CI	O
-43.3	O
to	O
-8.1	O
,	O
P	O
=	O
0.001	O
)	O
.	O

When	O
changes	O
in	O
either	O
A1C	Physical
or	O
FPG	Physical
were	O
correlated	O
to	O
A1C	O
or	O
FPG	O
at	O
randomization	O
,	O
the	O
slopes	O
were	O
significantly	O
steeper	O
for	O
ranolazine	O
than	O
placebo	O
(	O
A1C	O
,	O
P	O
=	O
0.046	O
;	O
FPG	O
,	O
P	O
<	O
0.001	O
)	O
,	O
indicating	O
that	O
lowering	O
of	O
A1C	Physical
and	O
FPG	Physical
by	O
ranolazine	O
is	O
related	O
to	O
hyperglycemia	O
at	O
randomization	O
.	O

Ranolazine	O
,	O
compared	O
with	O
placebo	O
,	O
was	O
not	O
associated	O
with	O
serious	Adverseeffect
hypoglycemic	Adverseeffect
events	Adverseeffect
,	O
associated	O
with	O
significant	O
changes	O
in	O
concurrent	O
antidiabetic	O
therapy	O
,	O
or	O
dependent	O
on	O
a	O
history	O
of	O
angina	O
.	O

CONCLUSIONS	O
Ranolazine	O
,	O
when	O
added	O
to	O
concurrent	O
antidiabetes	O
treatment	O
,	O
lowers	O
FPG	Physical
and	O
A1C	Physical
in	O
patients	O
with	O
cardiovascular	O
disease	O
and	O
poorly	O
controlled	O
diabetes	O
.	O

Pilot	O
comparison	O
between	O
potassium	O
titanyl	O
phosphate	O
laser	O
and	O
bipolar	O
radiofrequency	O
in	O
paediatric	O
tonsillectomy	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
advantages	O
and	O
disadvantages	O
of	O
potassium	O
titanyl	O
phosphate	O
laser	O
with	O
those	O
of	O
bipolar	O
radiofrequency	O
techniques	O
,	O
in	O
paediatric	O
tonsillectomy	O
.	O

STUDY	O
DESIGN	O
Prospective	O
,	O
randomised	O
,	O
clinical	O
study	O
.	O

PATIENTS	O
AND	O
METHODS	O
From	O
July	O
2004	O
to	O
April	O
2006	O
,	O
80	O
patients	O
aged	O
between	O
10	O
and	O
15	O
years	O
,	O
with	O
tonsillectomy	O
planned	O
for	O
chronic	O
tonsillitis	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Children	O
were	O
prospectively	O
randomised	O
into	O
two	O
equal	O
groups	O
:	O
potassium	O
titanyl	O
phosphate	O
laser	O
tonsillectomy	O
and	O
bipolar	O
radiofrequency	O
tonsillectomy	O
.	O

Operative	O
time	O
and	O
intra-operative	O
blood	O
loss	O
were	O
recorded	O
.	O

Patients	O
were	O
scheduled	O
for	O
follow	O
up	O
during	O
the	O
first	O
,	O
second	O
and	O
fourth	O
post-operative	O
weeks	O
.	O

They	O
were	O
asked	O
to	O
record	O
their	O
pain	O
and	O
discomfort	O
on	O
a	O
standardised	O
visual	O
analogue	O
scale	O
,	O
from	O
zero	O
(	O
no	O
pain	O
)	O
to	O
10	O
(	O
severe	O
pain	O
)	O
.	O

Post-operative	O
complications	O
were	O
also	O
recorded	O
and	O
managed	O
.	O

RESULTS	O
The	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
showed	O
a	O
slightly	O
longer	Others
operative	Others
time	Others
(	O
mean	O
12	O
minutes	O
)	O
than	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
mean	O
10	O
minutes	O
)	O
.	O

Intra-operative	Physical
blood	Physical
loss	Physical
was	O
significantly	O
less	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
(	O
mean	O
21	O
cm3	O
)	O
than	O
in	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
mean	O
30	O
cm3	O
)	O
.	O

In	O
the	O
first	O
week	O
,	O
post-operative	Pain
pain	Pain
scores	Pain
were	O
less	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
than	O
in	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
means	O
7.5	O
and	O
8.5	O
,	O
respectively	O
)	O
.	O

However	O
,	O
in	O
the	O
second	O
week	O
pain	Pain
scores	Pain
increased	O
more	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
than	O
in	O
the	O
bipolar	O
radiofrequency	O
group	O
(	O
means	O
8.5	O
and	O
6	O
,	O
respectively	O
)	O
.	O

In	O
the	O
fourth	O
week	O
,	O
both	O
groups	O
showed	O
equal	O
and	O
nearly	O
normal	O
pain	Pain
scores	Pain
.	O

No	O
case	O
of	O
reactionary	Adverseeffect
post-tonsillectomy	Adverseeffect
haemorrhage	Adverseeffect
was	O
recorded	O
in	O
either	O
group	O
.	O

Only	O
one	O
case	O
of	O
secondary	Adverseeffect
post-tonsillectomy	Adverseeffect
haemorrhage	Adverseeffect
was	O
recorded	O
,	O
in	O
the	O
potassium	O
titanyl	O
phosphate	O
laser	O
group	O
(	O
2.5	O
per	O
cent	O
)	O
,	O
managed	O
conservatively	O
.	O

CONCLUSION	O
Both	O
the	O
potassium	O
titanyl	O
phosphate	O
and	O
the	O
bipolar	O
radiofrequency	O
techniques	O
were	O
safe	Others
and	O
easy	Others
to	Others
use	Others
for	O
tonsillectomy	O
,	O
with	O
reduced	O
operative	Others
time	Others
,	O
blood	Physical
loss	Physical
and	O
complication	Adverseeffect
rates	Adverseeffect
and	O
better	O
post-operative	O
general	O
patient	O
condition	O
.	O

Potassium	O
titanyl	O
phosphate	O
laser	O
resulted	O
in	O
reduced	O
operative	Physical
bleeding	Physical
and	O
immediate	Pain
post-operative	Pain
pain	Pain
,	O
compared	O
with	O
the	O
bipolar	O
radiofrequency	O
technique	O
.	O

However	O
,	O
potassium	O
titanyl	O
phosphate	O
laser	O
required	O
slightly	O
more	O
operative	Others
time	Others
and	O
caused	O
more	O
late	Pain
post-operative	Pain
pain	Pain
than	O
the	O
bipolar	O
radiofrequency	O
technique	O
.	O

The	O
low	O
rate	O
of	O
recorded	O
complications	O
showed	O
that	O
both	O
techniques	O
cause	O
little	O
damage	O
to	O
the	O
tonsillar	O
bed	O
during	O
dissection	O
,	O
thus	O
minimising	O
complications	O
.	O

Timing	O
for	O
delivering	O
individualized	O
patient	O
education	O
intervention	O
to	O
Coronary	O
Artery	O
Bypass	O
Graft	O
patients	O
:	O
An	O
RCT	O
.	O

BACKGROUND	O
The	O
primary	O
focus	O
of	O
this	O
study	O
is	O
on	O
the	O
timing	O
of	O
the	O
delivery	O
of	O
education	O
to	O
patients	O
who	O
had	O
CABG	O
surgery	O
.	O

AIM	O
To	O
determine	O
the	O
efficacy	O
of	O
an	O
individualized	O
telephone	O
patient	O
education	O
intervention	O
,	O
delivered	O
at	O
two	O
different	O
points	O
in	O
time	O
(	O
1-2	O
days	O
pre-discharge	O
versus	O
1-2	O
days	O
post-discharge	O
)	O
in	O
enhancing	O
the	O
CABG	O
patient	O
's	O
knowledge	O
of	O
self-care	O
behaviours	O
,	O
performance	O
of	O
self-care	O
behaviours	O
,	O
and	O
symptom	O
frequency	O
.	O

METHOD	O
A	O
randomized	O
clinical	O
trial	O
that	O
included	O
a	O
convenience	O
sample	O
of	O
first	O
time	O
CABG	O
patients	O
.	O

Individuals	O
who	O
received	O
education	O
pre-discharge	O
were	O
compared	O
to	O
individuals	O
who	O
received	O
education	O
post-discharge	O
on	O
the	O
outcomes	O
.	O

RESULTS	O
Results	O
indicated	O
no	O
statistically	O
significant	O
difference	O
in	O
outcomes	Others
between	Others
the	Others
two	Others
time	Others
points	Others
.	Others

As	O
well	O
,	O
anxiety	Mental
levels	Mental
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
pre-discharge	O
group	O
than	O
the	O
post-discharge	O
group	O
.	O

CONCLUSIONS	O
The	O
individualized	O
nature	O
of	O
the	O
educational	O
intervention	O
may	O
have	O
accounted	O
for	O
non-significant	O
findings	O
reported	O
in	O
outcomes	O
between	O
the	O
two	O
time	O
points	O
.	O

PRACTICE	O
IMPLICATIONS	O
Nurses	O
may	O
consider	O
assessing	O
anxiety	Mental
levels	Mental
prior	O
to	O
delivery	O
of	O
educational	O
interventions	O
,	O
implement	O
interventions	O
aimed	O
at	O
reducing	O
anxiety	O
levels	O
,	O
and	O
provide	O
individualized	O
teaching	O
.	O

Comparative	O
efficacy	Others
and	O
safety	Others
of	O
twice	O
daily	O
fluticasone	O
propionate	O
powder	O
versus	O
placebo	O
in	O
the	O
treatment	O
of	O
moderate	O
asthma	O
.	O

BACKGROUND	O
Fluticasone	O
propionate	O
,	O
an	O
inhaled	O
corticosteroid	O
with	O
negligible	O
systemic	O
bioavailability	O
via	O
the	O
oral	O
route	O
,	O
is	O
efficacious	O
in	O
the	O
treatment	O
of	O
asthma	O
when	O
administered	O
via	O
metered-dose	O
inhaler	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	Others
and	O
safety	Others
of	O
inhaled	O
fluticasone	O
propionate	O
powder	O
in	O
patients	O
with	O
moderate	O
asthma	O
previously	O
treated	O
with	O
an	O
inhaled	O
corticosteroid	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel-group	O
,	O
multicenter	O
study	O
of	O
342	O
adolescent	O
and	O
adult	O
patients	O
with	O
moderate	O
asthma	O
[	Physical
forced	Physical
expiratory	Physical
volume	Physical
in	Physical
1	Physical
second	Physical
(	Physical
FEV1	Physical
)	Physical
between	O
50	O
%	O
and	O
80	O
%	O
of	O
predicted	O
]	O
treated	O
previously	O
by	O
beclomethasone	O
dipropionate	O
or	O
triamcinolone	O
acetonide	O
.	O

Patients	O
received	O
fluticasone	O
propionate	O
powder	O
50	O
micrograms	O
,	O
100	O
micrograms	O
,	O
250	O
micrograms	O
,	O
or	O
placebo	O
via	O
a	O
breath-actuated	O
inhalation	O
device	O
,	O
the	O
Diskhaler	O
,	O
twice	O
daily	O
for	O
12	O
weeks	O
.	O

RESULTS	O
Patients	O
in	O
the	O
fluticasone	O
propionate	O
groups	O
experienced	O
a	O
mean	Physical
increase	Physical
from	Physical
baseline	Physical
to	Physical
endpoint	Physical
in	Physical
FEV1	Physical
ranging	O
from	O
0.43	O
L	O
to	O
0.47	O
L.	O
Patients	O
in	O
the	O
placebo	O
group	O
experienced	O
a	O
mean	O
decrease	O
from	O
baseline	O
of	O
0.22	O
L	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
probability	O
of	O
patients	O
remaining	O
in	O
the	O
study	O
over	O
time	O
without	O
developing	O
signs	O
of	O
exacerbating	Physical
asthma	Physical
was	O
significantly	O
greater	O
in	O
the	O
fluticasone	O
propionate	O
groups	O
than	O
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
.001	O
)	O
.	O

Asthma	Physical
symptom	Physical
scores	Physical
,	O
supplemental	Others
rescue	Others
albuterol	Others
use	Others
,	O
and	O
number	Physical
of	Physical
nighttime	Physical
awakenings	Physical
due	Physical
to	Physical
asthma	Physical
requiring	O
treatment	O
also	O
improved	O
significantly	O
with	O
all	O
fluticasone	O
propionate	O
treatment	O
regimens	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
.001	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
at	O
endpoint	O
among	O
the	O
three	O
fluticasone	O
propionate	O
groups	O
.	O

No	O
serious	Adverseeffect
drug-related	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
occurred	O
.	O

CONCLUSIONS	O
Fluticasone	O
propionate	O
powder	O
(	O
50	O
,	O
100	O
,	O
and	O
250	O
micrograms	O
)	O
was	O
well-tolerated	Others
and	Physical
significantly	Physical
improved	Physical
lung	Physical
function	Physical
in	O
patients	O
with	O
moderate	O
asthma	O
.	O

Effectiveness	O
and	O
safety	O
of	O
the	O
Levitan	O
FPS	O
Scope?	O
for	O
tracheal	O
intubation	O
under	O
general	O
anesthesia	O
with	O
a	O
simulated	O
difficult	O
airway	O
.	O

PURPOSE	O
Studies	O
show	O
that	O
the	O
Levitan	O
FPS	O
(	O
first	O
pass	O
success	O
)	O
Scope?	O
(	O
LFS	O
)	O
is	O
analogous	O
to	O
a	O
bougie	O
in	O
simulated	O
difficult	O
airways	O
with	O
comparable	O
tracheal	O
intubation	O
success	O
rates	O
.	O

In	O
this	O
study	O
,	O
the	O
efficacy	O
and	O
safety	O
of	O
tracheal	O
intubation	O
with	O
the	O
LFS	O
was	O
compared	O
with	O
that	O
of	O
the	O
Macintosh	O
laryngoscope	O
utilizing	O
manual	O
in-line	O
stabilization	O
(	O
MILS	O
)	O
to	O
simulate	O
difficult	O
airways	O
.	O

METHODS	O
Ninety-four	O
subjects	O
successfully	O
completed	O
the	O
trial	O
.	O

Manual	O
in-line	O
stabilization	O
of	O
the	O
cervical	O
spine	O
was	O
applied	O
and	O
the	O
initial	O
laryngoscopy	O
was	O
performed	O
using	O
either	O
the	O
Macintosh	O
or	O
the	O
LFS	O
in	O
conjunction	O
with	O
the	O
Macintosh	O
.	O

Following	O
the	O
initial	O
grading	O
,	O
a	O
second	O
laryngoscopy	O
was	O
repeated	O
using	O
the	O
second	O
randomized	O
technique	O
.	O

Cormack-Lehane	O
grades	Physical
,	O
percentage	Physical
of	Physical
glottic	Physical
opening	Physical
(	Physical
POGO	Physical
)	Physical
scores	Physical
,	O
time	Others
to	Others
intubate	Others
,	O
number	Others
of	Others
intubation	Others
attempts	Others
,	O
and	O
the	Others
use	Others
of	Others
alternate	Others
techniques	Others
were	O
recorded	O
.	O

The	O
anesthesiologist	O
rated	O
the	O
subjective	O
difficulty	O
in	O
using	O
each	O
technique	O
with	O
a	O
numeric	O
rating	O
scale	O
and	O
a	O
visual	O
rating	O
scale	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
primary	O
outcome	O
good	Physical
laryngoscopic	Physical
views	Physical
(	O
Cormack-Lehane	Physical
grade	Physical
1	O
and	O
2	O
)	O
compared	O
with	O
poor	Physical
laryngoscopic	Physical
views	Physical
(	O
Cormack-Lehane	Physical
grade	Physical
3	O
and	O
4	O
)	O
between	O
the	O
LFS	O
and	O
the	O
Macintosh	O
.	O

There	O
were	O
higher	O
POGO	O
scores	O
with	O
the	O
LFS	O
compared	O
with	O
the	O
Macintosh	O
(	O
80	O
%	O
vs	O
20	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
but	O
this	O
did	O
not	O
translate	O
to	O
easier	O
intubations	O
,	O
as	O
documented	O
by	O
the	O
need	O
for	O
an	O
alternate	O
intubation	O
technique	O
or	O
time	O
to	O
intubate	O
(	O
<	O
30	O
and	O
<	O
60	O
sec	O
,	O
respectively	O
)	O
.	O

The	O
incidence	O
of	Adverseeffect
mucosal	Adverseeffect
trauma	Adverseeffect
,	Adverseeffect
sore	Adverseeffect
throat	Adverseeffect
,	Adverseeffect
and	Adverseeffect
hemodynamic	Adverseeffect
responses	Adverseeffect
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
techniques	O
.	O

CONCLUSION	O
The	O
LFS	O
in	O
conjunction	O
with	O
the	O
Macintosh	O
laryngoscope	O
does	O
not	O
improve	O
the	O
efficacy	O
or	O
safety	O
of	O
tracheal	O
intubation	O
in	O
a	O
simulated	O
difficult	O
airway	O
.	O

Genotyping	O
of	O
CYP21	O
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
sex-specific	O
gene	O
in	O
neonatal	O
screening	O
for	O
congenital	O
adrenal	O
hyperplasia	O
.	O

We	O
investigated	O
the	O
feasibility	Others
and	Others
diagnostic	Others
utility	Others
of	O
genotyping	O
9	O
CYP21	O
mutations	O
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
dimorphic	O
X-Y	O
marker	O
from	O
neonatal	O
screening	O
samples	O
.	O

Blood-impregnated	O
filter	O
papers	O
(	O
Guthrie	O
cards	O
)	O
from	O
603	O
randomly	O
chosen	O
New	O
Zealand	O
neonates	O
were	O
genotyped	O
blind	O
to	O
17-hydroxyprogesterone	O
(	O
17-OHP	O
)	O
levels	O
.	O

Another	O
50	O
samples	O
from	O
Swiss	O
and	O
North	O
American	O
infants	O
with	O
correlative	O
hormonal	O
data	O
were	O
also	O
genotyped	O
.	O

DNA	O
was	O
extracted	O
,	O
and	O
gene-specific	O
PCR	O
was	O
performed	O
.	O

CYP21	O
PCR	O
products	O
were	O
subjected	O
to	O
ligase	O
detection	O
reaction	O
,	O
simultaneously	O
analyzing	O
9	O
CYP21	O
mutations	O
;	O
PCR	O
products	O
of	O
other	O
genes	O
were	O
subjected	O
to	O
direct	O
gel	O
analysis	O
.	O

CYP21	O
genotyping	O
indicated	O
a	O
heterozygote	Physical
rate	Physical
of	O
2.8	O
%	O
for	O
classic	O
mutations	O
(	O
excluding	O
CYP21	O
deletions	O
)	O
,	O
and	O
2.0	O
%	O
for	O
nonclassic	O
mutations	O
in	O
New	O
Zealanders	O
.	O

Ten	O
full-term	O
affected	O
neonates	O
showed	O
a	O
wide	Physical
range	Physical
of	Physical
17-OHP	Physical
levels	Physical
(	O
15-1400	O
nmol/L	O
)	O
.	O

Sick	O
or	O
preterm	O
infants	O
or	O
infants	O
screened	O
on	O
the	O
first	O
day	O
of	O
life	O
with	O
high	O
17-OHP	Physical
proved	O
genetically	O
unaffected	O
.	O

Genetic	Physical
linkage	Physical
disequilibrium	Physical
was	O
found	O
between	O
two	O
CYP21	O
mutations	O
and	O
chromosome	O
6p	O
markers	O
.	O

Guthrie	O
cards	O
can	O
be	O
used	O
to	O
accurately	O
genotype	O
CYP21	Physical
and	Physical
other	Physical
relevant	Physical
markers	Physical
,	O
potentially	O
enhancing	O
the	O
specificity	Others
and	Others
sensitivity	Others
of	O
congenital	O
adrenal	O
hyperplasia	O
screening	O
.	O

CYP21	Physical
heterozygote	Physical
frequency	Physical
for	Physical
classic	Physical
mutations	Physical
is	O
higher	O
than	O
expected	O
based	O
on	O
genotype	O
compared	O
with	O
that	O
predicted	O
by	O
hormonal	O
newborn	O
screening	O
.	O

Randomized	O
trial	O
of	O
tailored	O
skin	O
cancer	O
prevention	O
for	O
children	O
:	O
the	O
Project	O
SCAPE	O
family	O
study	O
.	O

This	O
study	O
evaluated	O
a	O
tailored	O
intervention	O
to	O
promote	O
sun	O
protection	O
in	O
parents	O
and	O
their	O
children	O
,	O
hypothesizing	O
that	O
the	O
tailored	O
intervention	O
would	O
lead	O
to	O
improved	Mental
skin	Mental
cancer	Mental
prevention	Mental
behaviors	Mental
compared	O
to	O
generic	O
materials	O
.	O

Families	O
were	O
recruited	O
through	O
schools	O
and	O
community	O
centers	O
and	O
were	O
included	O
if	O
there	O
was	O
1	O
child	O
in	O
Grades	O
1-3	O
at	O
moderate	O
to	O
high	O
risk	O
for	O
skin	O
cancer	O
.	O

Participants	O
were	O
randomized	O
into	O
one	O
of	O
two	O
intervention	O
groups	O
:	O
a	O
tailored	O
intervention	O
,	O
in	O
which	O
they	O
received	O
personalized	O
skin	O
cancer	O
education	O
through	O
the	O
mail	O
;	O
or	O
a	O
control	O
group	O
who	O
received	O
generic	O
skin	O
cancer	O
information	O
materials	O
.	O

Before	O
and	O
after	O
intervention	O
,	O
parents	O
completed	O
questionnaires	O
about	O
their	O
and	O
their	O
children	O
's	O
skin	O
cancer	O
risk	O
and	O
prevention	O
knowledge	O
and	O
behaviors	O
.	O

Parents	O
also	O
completed	O
4-day	O
sun	O
exposure	O
and	O
protection	O
diaries	O
for	O
their	O
child	O
and	O
themselves	O
.	O

Tailored	O
group	O
participants	O
demonstrated	O
significantly	Mental
greater	Mental
positive	Mental
changes	Mental
in	Mental
prevention	Mental
behavior	Mental
after	O
the	O
intervention	O
,	O
including	O
children	Mental
's	Mental
use	Mental
of	Mental
sunscreen	Mental
,	Mental
shirts	Mental
,	Mental
and	Mental
hats	Mental
,	Mental
and	Mental
parents	Mental
'	Mental
use	Mental
of	Mental
shade	Mental
,	Mental
and	Mental
skin	Mental
examinations	Mental
.	Mental

Effect	O
sizes	O
were	O
small	Mental
and	Mental
perceived	Mental
benefits	Mental
and	Mental
social	Mental
norms	Mental
mediated	Mental
intervention	Mental
effects	Mental
.	Mental

Findings	O
from	O
this	O
study	O
support	O
the	O
efficacy	O
of	O
focusing	O
tailored	O
communications	O
to	O
families	O
in	O
order	O
to	O
change	O
skin	O
cancer	O
prevention	O
practices	O
in	O
young	O
children	O
.	O

PROCLAIM	O
:	O
pilot	O
study	O
to	O
examine	O
the	O
effects	O
of	O
clopidogrel	O
on	O
inflammatory	O
markers	O
in	O
patients	O
with	O
metabolic	O
syndrome	O
receiving	O
low-dose	O
aspirin	O
.	O

Metabolic	O
syndrome	O
is	O
associated	O
with	O
intravascular	O
inflammation	O
,	O
as	O
determined	O
by	O
increased	O
levels	O
of	O
inflammatory	O
biomarkers	O
and	O
an	O
increased	O
risk	O
of	O
ischemic	O
atherothrombotic	O
events	O
.	O

Evidence	O
suggests	O
that	O
atherothrombosis	O
and	O
intravascular	O
inflammation	O
share	O
predictive	O
biomarkers	O
,	O
including	O
high-sensitivity	O
C-reactive	O
protein	O
,	O
CD40	O
ligand	O
,	O
P-selectin	O
,	O
and	O
N-terminal	O
pro-brain	O
natriuretic	O
peptide	O
.	O

Patients	O
who	O
had	O
metabolic	O
syndrome	O
were	O
randomized	O
to	O
receive	O
clopidogrel	O
75	O
mg/day	O
plus	O
aspirin	O
81	O
mg/day	O
(	O
n	O
=	O
89	O
)	O
or	O
placebo	O
plus	O
aspirin	O
81	O
mg/day	O
(	O
n	O
=	O
92	O
)	O
for	O
9	O
weeks	O
to	O
assess	O
the	O
efficacy	O
of	O
each	O
treatment	O
in	O
suppression	O
of	O
inflammatory	O
markers	O
.	O

Change	O
from	O
baseline	O
in	O
the	O
levels	O
of	O
high-sensitivity	Physical
C-reactive	Physical
protein	Physical
,	O
CD40	Physical
ligand	Physical
,	O
P-selectin	Physical
,	O
and	O
N-terminal	Physical
pro-brain	Physical
natriuretic	Physical
peptide	Physical
at	O
6	O
weeks	O
was	O
assessed	O
to	O
evaluate	O
each	O
treatment	O
.	O

There	O
was	O
a	O
significant	O
difference	O
at	O
Week	O
6	O
in	O
model-adjusted	Physical
CD40-ligand	Physical
levels	Physical
in	O
favor	O
of	O
clopidogrel	O
plus	O
aspirin	O
compared	O
with	O
placebo	O
plus	O
aspirin	O
in	O
both	O
the	O
intent-to-treat	O
population	O
(	O
difference	O
between	O
least-squares	O
means	O
=	O
-186.5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-342.3	O
to	O
-30.8	O
;	O
P	O
=	O
0.02	O
)	O
and	O
the	O
per-protocol	O
population	O
(	O
P	O
=	O
0.05	O
)	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
treatment	O
arms	O
for	O
high-sensitivity	Physical
C-reactive	Physical
protein	Physical
,	O
P-selectin	Physical
,	O
and	O
N-terminal	Physical
pro-brain	Physical
natriuretic	Physical
peptide	Physical
.	O

There	O
were	O
no	O
deaths	Mortality
or	O
serious	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
in	O
either	O
treatment	O
arm	O
.	O

Data	O
from	O
this	O
study	O
suggest	O
that	O
clopidogrel	O
can	O
decrease	O
the	O
expression	Physical
of	Physical
the	Physical
CD40-ligand	Physical
biomarker	Physical
.	O

Optimization	O
of	O
acid	O
suppression	O
for	O
patients	O
with	O
peptic	O
ulcer	O
bleeding	O
:	O
an	O
intragastric	O
pH-metry	O
study	O
with	O
omeprazole	O
.	O

OBJECTIVE	O
To	O
study	O
whether	O
an	O
intravenous	O
infusion	O
dose	O
of	O
omeprazole	O
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
during	O
24	O
h	O
can	O
be	O
subsequently	O
reduced	O
with	O
maintained	O
effect	O
.	O

Second	O
,	O
to	O
study	O
the	O
effect	O
of	O
oral	O
omeprazole	O
20	O
mg	O
given	O
once	O
or	O
twice	O
daily	O
up	O
to	O
day	O
10	O
,	O
after	O
cessation	O
of	O
a	O
3-day	O
intravenous	O
infusion	O
(	O
80	O
mg	O
+	O
8	O
mg/h	O
)	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
partly	O
blinded	O
study	O
.	O

METHODS	O
Twelve	O
Helicobacter	O
pylori	O
(	O
+	O
)	O
patients	O
and	O
12	O
H.	O
pylori	O
(	O
-	O
)	O
subjects	O
were	O
included	O
.	O

In	O
part	O
I	O
the	O
patients	O
received	O
omeprazole	O
,	O
80	O
mg	O
+	O
8	O
mg/h	O
,	O
during	O
24	O
h	O
followed	O
by	O
8	O
,	O
4	O
or	O
2	O
mg/h	O
.	O

In	O
part	O
II	O
the	O
subjects	O
received	O
80	O
mg	O
+	O
8	O
mg/h	O
during	O
3	O
days	O
followed	O
by	O
20	O
mg	O
omeprazole	O
orally	O
,	O
once	O
or	O
twice	O
daily	O
until	O
day	O
10	O
.	O

Intragastric	Physical
pH	Physical
was	O
measured	O
.	O

RESULTS	O
All	O
H.	O
pylori	O
(	O
+	O
)	O
patients	O
showed	O
a	O
rapid	O
increase	O
of	O
intragastric	Physical
pH	Physical
with	Physical
a	Physical
mean	Physical
intragastric	Physical
pH	Physical
of	O
6.7	O
during	O
the	O
second	O
half	O
of	O
the	O
first	O
day	O
.	O

After	O
the	O
subsequent	O
dose	O
reduction	O
,	O
the	O
mean	Physical
pH	Physical
decreased	O
to	O
6.1-6.2	O
.	O

Patients	O
continuing	O
on	O
8	O
mg/h	O
showed	O
the	O
best	O
results	O
.	O

Likewise	O
,	O
all	O
H.	O
pylori	O
(	O
-	O
)	O
subjects	O
showed	O
a	O
rapid	O
and	O
sustained	O
reduction	O
of	O
intragastric	Physical
acidity	Physical
during	O
the	O
infusion	O
.	O

Subsequent	O
dose	O
reduction	O
to	O
20	O
mg	O
once	O
daily	O
led	O
to	O
a	O
stable	O
fraction	O
of	O
time	O
with	O
pH	O
>	O
3	O
of	O
72	O
%	O
.	O

CONCLUSIONS	O
Omeprazole	O
given	O
as	O
a	O
continuous	O
infusion	O
of	O
80	O
mg	O
+	O
8	O
mg/h	O
for	O
72	O
h	O
followed	O
by	O
omeprazole	O
20	O
mg	O
once	O
daily	O
raised	O
the	O
intragastric	Physical
pH	Physical
to	O
and	O
above	O
levels	O
alleged	O
to	O
allow	O
haemostasis	O
in	O
patients	O
with	O
peptic	O
ulcer	O
bleeding	O
and	O
subsequent	O
healing	O
of	O
the	O
ulcer	O
.	O

B-domain	O
deleted	O
recombinant	O
factor	O
VIII	O
preparations	O
are	O
bioequivalent	O
to	O
a	O
monoclonal	O
antibody	O
purified	O
plasma-derived	O
factor	O
VIII	O
concentrate	O
:	O
a	O
randomized	O
,	O
three-way	O
crossover	O
study	O
.	O

BACKGROUND	O
Deletion	O
of	O
the	O
B-domain	O
of	O
recombinant	O
blood	O
coagulation	O
factor	O
VIII	O
(	O
BDDrFVIII	O
)	O
increases	O
the	O
manufacturing	O
yield	O
of	O
the	O
product	O
but	O
does	O
not	O
impair	O
in	O
vitro	O
or	O
in	O
vivo	O
functionality	O
.	O

BDDrFVIII	O
(	O
ReFacto	O
)	O
has	O
been	O
developed	O
with	O
the	O
additional	O
benefit	O
of	O
being	O
formulated	O
without	O
human	O
albumin	O
.	O

OBJECTIVE	O
The	O
primary	O
objective	O
of	O
this	O
three-way	O
crossover-design	O
study	O
was	O
to	O
compare	O
the	O
pharmacokinetic	O
(	O
PK	O
)	O
parameters	O
of	O
two	O
BDDrFVIII	O
formulations	O
(	O
one	O
reconstituted	O
with	O
5	O
mL	O
of	O
sterile	O
water	O
,	O
the	O
other	O
reconstituted	O
with	O
4	O
mL	O
sodium	O
chloride	O
0.9	O
%	O
USP	O
)	O
with	O
those	O
of	O
a	O
plasma-derived	O
,	O
full-length	O
FVIII	O
preparation	O
(	O
Hemofil	O
M	O
)	O
in	O
patients	O
with	O
haemophilia	O
A	O
to	O
determine	O
bioequivalence	O
.	O

METHODS	O
A	O
series	O
of	O
blood	Physical
samples	Physical
were	O
collected	O
over	O
a	O
period	O
of	O
48	O
h	O
after	O
i.v	O
.	O

administration	O
of	O
each	O
of	O
the	O
FVIII	O
preparations	O
.	O

Plasma	Physical
FVIII	Physical
activity	Physical
was	O
determined	O
using	O
a	O
validated	O
chromogenic	O
substrate	O
assay	O
.	O

Plasma	Physical
FVIII	Physical
activity	Physical
vs.	O
time	Others
curves	Others
was	O
characterized	O
for	O
a	O
standard	O
set	O
of	O
PK	O
parameter	O
estimates	O
.	O

Two	O
parameter	O
estimates	O
,	O
the	O
maximum	Physical
plasma	Physical
concentration	Physical
(	Physical
Cmax	Physical
)	Physical
and	O
the	Physical
area	Physical
under	Physical
plasma	Physical
concentration	Physical
vs.	O
time	Physical
curves	Physical
(	Physical
AUCs	Physical
)	Physical
,	O
were	O
used	O
to	O
evaluate	O
bioequivalence	O
.	O

The	O
two	O
preparations	O
were	O
considered	O
bioequivalent	O
if	O
the	O
90	O
%	O
confidence	O
intervals	O
for	O
the	O
ratio	Physical
of	Physical
geometric	Physical
means	Physical
for	Physical
Cmax	Physical
and	O
AUCs	Physical
fell	O
within	O
the	O
bioequivalence	O
window	O
of	O
80	O
%	O
to	O
125	O
%	O
.	O

RESULTS/CONCLUSION	O
Results	O
show	O
that	O
each	O
BDDrFVIII	O
formulation	O
is	O
bioequivalent	Physical
to	O
Hemofil	O
M	O
and	O
the	O
two	O
formulations	O
of	O
BDDrFVIII	O
are	O
bioequivalent	O
to	O
each	O
other	O
.	O

Information	O
source	O
affects	O
peers	O
'	O
initial	O
attitudes	O
toward	O
autism	Physical
.	O

Authors	O
examined	O
the	O
effects	O
of	O
information	O
source	O
on	O
peers	O
'	O
cognitive	Mental
and	Mental
behavioral	Mental
attitudes	Mental
toward	O
an	O
unfamiliar	O
child	O
with	O
autism	O
.	O

Children	O
(	O
N=296	O
;	O
M	O
age=10.21	O
years	O
)	O
received	O
information	O
about	O
an	O
unfamiliar	O
child	O
with	O
autism	O
from	O
one	O
of	O
the	O
following	O
sources	O
:	O
(	O
a	O
)	O
videotape	O
,	O
(	O
b	O
)	O
teacher	O
,	O
(	O
c	O
)	O
hypothetical	O
mother	O
,	O
(	O
d	O
)	O
hypothetical	O
father	O
,	O
or	O
(	O
e	O
)	O
hypothetical	O
doctor	O
.	O

Interactive	O
effects	O
between	O
source	O
,	O
and	O
sex	O
and	O
grade	O
were	O
found	O
for	O
cognitive	O
and	O
behavioral	O
attitudes	O
.	O

Fifth-graders	O
reported	O
more	O
favorable	O
cognitive	Mental
and	Mental
behavioral	Mental
attitudes	Mental
when	O
information	O
was	O
provided	O
by	O
extra-familial	O
sources	O
(	O
i.e.	O
,	O
doctor	O
)	O
versus	O
parent	O
sources	O
.	O

Mother	O
yielded	O
more	O
persuasive	Mental
effects	Mental
on	Mental
behavioral	Mental
attitudes	Mental
for	O
third-graders	O
versus	O
fifth-graders	O
.	O

Attitudes	O
toward	O
autism	O
differ	O
depending	O
on	O
who	O
provides	O
information	O
about	O
the	O
disability	O
.	O

Persuasion	O
theory	O
appears	O
useful	O
to	O
guide	O
evaluation	O
of	O
educational	O
interventions	O
to	O
improve	O
attitudes	O
towards	O
autism	Mental
.	O

Implications	O
of	O
the	O
findings	O
,	O
study	O
limitations	O
,	O
and	O
recommendations	O
for	O
future	O
research	O
are	O
discussed	O
.	O

Efficacy	O
of	O
a	O
family	O
practice-based	O
lifestyle	O
intervention	O
program	O
to	O
increase	O
physical	Others
activity	Others
and	O
reduce	O
clinical	O
and	O
physiological	O
markers	O
of	O
vascular	O
health	O
in	O
patients	O
with	O
high	O
normal	O
blood	O
pressure	O
and/or	O
high	O
normal	O
blood	O
glucose	O
(	O
SNAC	O
)	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Previous	O
interventions	O
to	O
increase	O
physical	Physical
activity	Physical
and	O
reduce	O
cardiovascular	O
risk	O
factors	O
have	O
been	O
targeted	O
at	O
individuals	O
with	O
established	O
disease	O
;	O
less	O
attention	O
has	O
been	O
given	O
to	O
intervention	O
among	O
individuals	O
with	O
high	O
risk	O
for	O
disease	O
nor	O
has	O
there	O
been	O
determination	O
of	O
the	O
influence	O
of	O
setting	O
in	O
which	O
the	O
intervention	O
is	O
provided	O
.	O

In	O
particular	O
,	O
family	O
practice	O
represents	O
an	O
ideal	O
setting	O
for	O
the	O
provision	O
and	O
long-term	O
maintenance	O
of	O
lifestyle	O
interventions	O
for	O
patients	O
at	O
risk	O
(	O
ie	O
high-normal	O
blood	O
pressure	O
or	O
impaired	O
glucose	O
tolerance	O
)	O
.	O

METHODS/DESIGN	O
The	O
Staged	O
Nutrition	O
and	O
Activity	O
Counseling	O
(	O
SNAC	O
)	O
study	O
is	O
a	O
randomized	O
clustered	O
design	O
clinical	O
trial	O
that	O
will	O
investigate	O
the	O
effectiveness	O
and	O
efficacy	O
of	O
a	O
multi-component	O
lifestyle	O
intervention	O
on	O
cardiovascular	O
disease	O
risk	O
factors	O
and	O
vascular	O
function	O
in	O
patients	O
at	O
risk	O
in	O
primary	O
care	O
.	O

Patients	O
will	O
be	O
randomized	O
by	O
practice	O
to	O
either	O
a	O
standard	O
of	O
care	O
lifestyle	O
intervention	O
or	O
a	O
behaviourally-based	O
,	O
matched	O
prescriptive	O
physical	O
activity	O
and	O
diet	O
change	O
program	O
.	O

The	O
primary	O
goal	O
is	O
to	O
increase	O
physical	Others
activity	Others
and	O
improve	O
dietary	Mental
intake	Mental
according	O
to	O
Canada	O
's	O
Guides	O
to	O
Physical	Mental
Activity	Mental
Healthy	Mental
Eating	Mental
over	O
24	O
months	O
.	O

The	O
primary	O
intention	O
to	O
treat	O
analysis	O
will	O
compare	O
behavioral	O
,	O
physiological	O
and	O
metabolic	O
outcomes	O
at	O
6	O
,	O
12	O
and	O
24	O
months	O
post-randomization	O
including	O
estimation	O
of	O
incident	O
hypertension	Physical
and/or	O
diabetes	Physical
.	O

DISCUSSION	O
The	O
design	O
features	O
of	O
our	O
trial	O
,	O
and	O
the	O
practical	O
problems	O
(	O
and	O
solutions	O
)	O
associated	O
with	O
implementing	O
these	O
design	O
features	O
,	O
particularly	O
those	O
that	O
result	O
in	O
potential	O
delay	O
between	O
recruitment	O
,	O
baseline	O
data	O
collection	O
,	O
randomization	O
,	O
intervention	O
,	O
and	O
assessment	O
will	O
be	O
discussed	O
.	O

Results	O
of	O
the	O
SNAC	O
trial	O
will	O
provide	O
scientific	O
rationale	O
for	O
the	O
implementation	O
of	O
this	O
lifestyle	O
intervention	O
in	O
primary	O
care	O
.	O

TRIAL	O
REGISTRATION	O
ISRCTN	O
:	O
ISRCTN:42921300	O
.	O

Perioperative	O
myocardial	O
infarctions	O
are	O
common	O
and	O
often	O
unrecognized	O
in	O
patients	O
undergoing	O
hip	O
fracture	O
surgery	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
prospective	O
cohort	O
study	O
was	O
to	O
assess	O
the	O
incidence	O
and	O
characteristics	O
of	O
acute	O
myocardial	O
infarction	O
in	O
patients	O
undergoing	O
surgery	O
for	O
acute	O
hip	O
fracture	O
.	O

METHODS	O
A	O
consecutive	O
cohort	O
of	O
patients	O
(	O
n	O
=	O
200	O
,	O
68	O
men	O
)	O
referred	O
to	O
acute	O
surgical	O
correction	O
of	O
hip	O
fracture	O
was	O
studied	O
.	O

Troponin	O
T	O
(	O
TnT	O
)	O
measurements	O
and	O
electrocardiographic	O
(	O
ECG	O
)	O
recordings	O
were	O
performed	O
at	O
admission	O
,	O
before	O
operation	O
,	O
and	O
on	O
the	O
first	O
and	O
2nd	O
postoperative	O
days	O
,	O
which	O
were	O
used	O
for	O
diagnosis	O
.	O

RESULTS	O
The	O
age	O
of	O
the	O
patients	O
ranged	O
from	O
32	O
to	O
98	O
years	O
(	O
mean	O
,	O
80.8	O
years	O
)	O
,	O
and	O
65	O
patients	O
had	O
a	O
history	O
of	O
coronary	O
artery	O
disease	O
.	O

A	O
significant	O
rise	Physical
in	Physical
TnT	Physical
as	O
a	O
sign	O
of	O
myocardial	O
infarction	O
was	O
observed	O
in	O
71	O
patients	O
(	O
35.5	O
%	O
)	O
,	O
and	O
25	O
of	O
them	O
had	O
a	O
TnT	Physical
elevation	Physical
exceeding	O
five	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

TnT	Physical
elevation	Physical
was	O
observed	O
in	O
36	O
patients	O
(	O
51	O
%	O
)	O
already	O
before	O
surgery	O
.	O

Seven	O
patients	O
(	O
10	O
%	O
)	O
had	O
ST	O
elevation	O
myocardial	O
infarction	O
,	O
23	O
patients	O
(	O
32	O
%	O
)	O
had	O
new	Physical
ST	Physical
depressions	Physical
,	O
and	O
21	O
patients	O
(	O
30	O
%	O
)	O
had	O
no	O
new	O
ST	O
segment	O
changes	O
in	O
the	O
serial	O
electrocardiographic	O
recordings	O
.	O

In	O
40	O
patients	O
(	O
56	O
%	O
)	O
,	O
the	O
perioperative	O
myocardial	O
infarction	O
was	O
the	O
first	O
manifestation	O
of	O
coronary	O
artery	O
disease	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
that	O
old	O
age	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.06	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.02-1.10	O
;	O
p	O
=	O
0.002	O
)	O
,	O
earlier	O
revascularization	O
(	O
OR	O
,	O
3.29	O
;	O
95	O
%	O
CI	O
1.12-9.73	O
;	O
p	O
=	O
0.03	O
)	O
,	O
and	O
heart	O
failure	O
(	O
OR	O
,	O
2.42	O
;	O
95	O
%	O
CI	O
1.04-5.61	O
;	O
p	O
=	O
0.04	O
)	O
were	O
independent	O
predictors	O
of	O
TnT	O
elevation	O
.	O

Majority	O
of	O
myocardial	Physical
infarctions	Physical
were	O
asymptomatic	O
or	O
unrecognized	O
.	O

Evidence-based	O
medications	O
of	O
myocardial	O
infarction	O
were	O
seldom	O
started	O
and	O
cardiologist	O
was	O
consulted	O
in	O
12	O
patients	O
(	O
16.9	O
%	O
)	O
.	O

CONCLUSION	O
Patients	O
with	O
hip	O
fracture	O
often	O
develop	O
asymptomatic	O
and	O
clinically	O
unrecognized	O
perioperative	O
myocardial	O
infarctions	O
.	O

Earlier	O
diagnosis	O
and	O
appropriate	O
treatment	O
of	O
cardiac	O
infarction	O
may	O
improve	O
survival	O
of	O
hip	O
fracture	O
patients	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
Epidemiologic	O
study	O
,	O
level	O
III	O
.	O

Dose	O
response	O
effect	O
of	O
cyclical	O
medroxyprogesterone	O
on	O
blood	Physical
pressure	Physical
in	O
postmenopausal	O
women	O
.	O

OBJECTIVE	O
This	O
study	O
was	O
designed	O
to	O
compare	O
with	O
placebo	O
the	O
dose-response	O
effect	O
of	O
cyclical	O
doses	O
of	O
the	O
C21	O
progestogen	O
,	O
medroxyprogesterone	O
acetate	O
(	O
MPA	O
)	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
when	O
administered	O
to	O
normotensive	O
postmenopausal	O
women	O
receiving	O
a	O
fixed	O
mid-range	O
daily	O
dose	O
of	O
conjugated	O
equine	O
oestrogen	O
(	O
CEE	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
Twenty	O
normotensive	O
postmenopausal	O
women	O
(	O
median	O
age	O
53	O
years	O
)	O
participated	O
in	O
the	O
study	O
which	O
used	O
a	O
double-blind	O
crossover	O
design	O
.	O

There	O
were	O
four	O
randomised	O
treatment	O
phases	O
,	O
each	O
of	O
4	O
weeks	O
duration	O
.	O

The	O
four	O
blinded	O
treatments	O
were	O
MPA	O
2.5	O
mg	O
,	O
MPA	O
5	O
mg	O
,	O
MPA	O
10	O
mg	O
and	O
matching	O
placebo	O
,	O
taken	O
for	O
the	O
last	O
14	O
days	O
of	O
each	O
28	O
day	O
treatment	O
cycle	O
.	O

CEE	O
0.625	O
mg	O
was	O
also	O
administered	O
once	O
daily	O
as	O
open	O
labelled	O
tablets	O
to	O
all	O
subjects	O
throughout	O
the	O
study	O
.	O

Clinic	Physical
BP	Physical
was	O
measured	O
weekly	O
with	O
the	O
mean	O
values	O
of	O
weeks	O
3	O
and	O
4	O
of	O
each	O
phase	O
used	O
for	O
analysis	O
.	O

Ambulatory	Physical
BP	Physical
was	O
performed	O
in	O
the	O
final	O
week	O
of	O
each	O
phase	O
.	O

RESULTS	O
Compared	O
with	O
the	O
placebo	O
phase	O
,	O
end	O
of	O
phase	O
clinic	Physical
BP	Physical
was	O
unchanged	O
by	O
any	O
of	O
the	O
progestogen	O
treatments	O
.	O

There	O
was	O
a	O
dose-dependent	O
decrease	Physical
in	Physical
ambulatory	Physical
daytime	Physical
diastolic	Physical
and	Physical
mean	Physical
arterial	Physical
BP	Physical
with	O
the	O
progestogen	O
treatments	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
In	O
a	O
regimen	O
of	O
postmenopausal	O
hormone	O
replacement	O
therapy	O
with	O
a	O
fixed	O
mid-range	O
daily	O
dose	O
of	O
CEE	O
combined	O
with	O
a	O
cyclical	O
regimen	O
of	O
a	O
C21	O
progestogen	O
spanning	O
the	O
current	O
clinical	O
dose	O
range	O
,	O
the	O
progestogen	O
has	O
either	O
no	O
effect	O
or	O
a	O
small	O
dose-dependent	O
reduction	O
in	O
clinic	Physical
and	Physical
ambulatory	Physical
BPs	Physical
over	O
one	O
treatment	O
cycle	O
.	O

Moderate	O
sodium	O
restriction	O
,	O
angiotensin	O
converting	O
enzyme	O
inhibition	O
,	O
and	O
thiazide	O
diuretic	O
in	O
the	O
management	O
of	O
essential	O
hypertension	O
.	O

Dietary	O
sodium	O
restriction	O
alone	O
is	O
effective	O
in	O
lowering	O
blood	Physical
pressure	Physical
in	O
some	O
,	O
but	O
not	O
all	O
,	O
patients	O
with	O
essential	O
hypertension	O
.	O

Homeostatic	O
mechanisms	O
,	O
including	O
activation	O
of	O
the	O
renin-aldosterone	O
system	O
,	O
may	O
counteract	O
the	O
effects	O
of	O
sodium	O
restriction	O
.	O

Angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
are	O
also	O
effective	Others
as	O
sole	O
therapy	O
in	O
many	O
patients	O
with	O
essential	O
hypertension	O
,	O
but	O
may	O
be	O
less	O
effective	O
in	O
those	O
with	O
low-renin	O
hypertension	O
.	O

The	O
combination	O
of	O
dietary	O
sodium	O
restriction	O
with	O
blockade	O
of	O
the	O
renin	O
system	O
by	O
an	O
ACE	O
inhibitor	O
is	O
a	O
particularly	O
effective	O
way	O
to	O
improve	O
blood	Physical
pressure	Physical
control	Physical
.	Physical

Addition	O
of	O
a	O
thiazide	O
diuretic	O
will	O
reduce	O
pressure	O
further	O
.	O

Long-term	O
evaluation	O
of	O
tamsulosin	O
in	O
benign	O
prostatic	O
hyperplasia	O
:	O
placebo-controlled	O
,	O
double-blind	O
extension	O
of	O
phase	O
III	O
trial	O
.	O

Tamsulosin	O
Investigator	O
Group	O
.	O

OBJECTIVES	O
To	O
evaluate	O
the	O
long-term	O
efficacy	O
and	O
safety	O
of	O
once-daily	O
tamsulosin	O
(	O
0.4	O
and	O
0.8	O
mg	O
)	O
,	O
a	O
unique	O
selective	O
alpha1A-adrenoceptor	O
antagonist	O
in	O
patients	O
with	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

METHODS	O
This	O
trial	O
extended	O
a	O
13-week	O
,	O
Phase	O
III	O
multicenter	O
placebo-controlled	O
,	O
double-blind	O
outpatient	O
trial	O
for	O
an	O
additional	O
40	O
weeks	O
.	O

Of	O
618	O
patients	O
,	O
418	O
(	O
68	O
%	O
)	O
continued	O
into	O
the	O
extension	O
phase	O
on	O
the	O
same	O
double-blind	O
medication	O
and	O
dose	O
.	O

The	O
primary	O
efficacy	O
parameters	O
were	O
total	Physical
American	Physical
Urological	Physical
Association	Physical
(	Physical
AUA	Physical
)	Physical
symptom	Physical
score	Physical
and	O
maximum	Physical
urinary	Physical
flow	Physical
(	Physical
Qmax	Physical
)	Physical
.	O

RESULTS	O
The	O
mean	O
changes	O
in	O
AUA	Physical
symptom	Physical
score	Physical
from	O
baseline	O
to	O
end	O
point	O
were	O
statistically	O
significant	O
in	O
all	O
groups	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Significant	O
improvements	O
were	O
observed	O
in	O
Qmax	Physical
for	O
both	O
tamsulosin	O
groups	O
but	O
not	O
for	O
the	O
placebo	O
group	O
.	O

The	O
statistically	O
significant	Physical
improvements	Others
from	O
baseline	O
in	O
efficacy	O
parameters	O
observed	O
for	O
each	O
tamsulosin	O
group	O
at	O
the	O
end	O
of	O
the	O
13-week	O
Phase	O
III	O
trial	O
were	O
maintained	O
during	O
the	O
long-term	O
extension	O
phase	O
.	O

Tamsulosin	O
at	O
both	O
dosages	O
was	O
well	O
tolerated	Others
as	O
maintenance	O
therapy	O
.	O

Clinically	O
significant	O
orthostatic	Physical
hypotension	Physical
was	O
not	O
observed	O
.	O

Vital	Physical
sign	Physical
changes	Physical
in	O
either	O
hypertensive	O
or	O
normotensive	O
patients	O
were	O
not	O
clinically	O
significantly	O
different	O
across	O
the	O
three	O
groups	O
.	O

CONCLUSIONS	O
Tamsulosin	O
once-daily	O
at	O
0.4	O
or	O
0.8	O
mg	O
was	O
shown	O
to	O
be	O
effective	O
,	O
safe	O
,	O
and	O
well	O
tolerated	O
in	O
the	O
target	O
BPH	O
population	O
during	O
long-term	O
use	O
.	O

Effect	O
of	O
upper	O
arm	O
brachial	O
basilic	O
and	O
prosthetic	O
forearm	O
arteriovenous	O
fistula	O
on	O
left	Physical
ventricular	Physical
hypertrophy	Physical
.	O

BACKGROUND	O
Creation	O
of	O
an	O
arteriovenous	O
fistula	O
(	O
AVF	O
)	O
may	O
increase	O
left	Physical
ventricular	Physical
hypertrophy	Physical
in	O
the	O
hemodialysis	O
population	O
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
a	O
brachial-basilic	O
(	O
BB	O
)	O
AVF	O
and	O
the	O
prosthetic	O
brachial-antecubital	O
forearm	O
loop	O
access	O
(	O
PTFE	O
)	O
on	O
cardiac	Physical
performance	Physical
.	Physical

METHODS	O
Patients	O
were	O
randomized	O
to	O
receive	O
BB-AVF	O
or	O
prosthetic	O
brachial-antecubital	O
forearm	O
loop	O
access	O
.	O

Before	O
and	O
three	O
months	O
after	O
AVF	O
creation	O
patients	O
underwent	O
an	O
echocardiographic	O
examination	O
.	O

Mann-Whitney	Physical
U-test	Physical
was	O
used	O
to	O
compare	O
relative	O
increase	O
between	O
the	O
measured	Physical
cardiac	Physical
parameters	Physical
for	O
the	O
two	O
groups	O
.	O

RESULTS	O
Twenty-seven	O
patients	O
participated	O
in	O
the	O
study	O
.	O

The	O
relative	O
increase	O
in	O
left	Physical
ventricular	Physical
parameters	Physical
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Only	O
left	Physical
ventricular	Physical
end-diastolic	Physical
diameter	Physical
tended	O
to	O
be	O
of	O
significance	O
.	O

Mean	Physical
blood	Physical
flow	Physical
through	O
the	O
brachial	O
artery	O
was	O
1680+/-156	O
and	O
1450+/-221	O
mL/min	O
three	O
months	O
after	O
surgery	O
for	O
the	O
PTFE	O
and	O
the	O
BB-AVF	O
group	O
,	O
respectively	O
.	O

CONCLUSION	O
After	O
three	O
months	O
of	O
follow-up	O
,	O
changes	Physical
in	Physical
cardiac	Physical
structure	Physical
were	O
comparable	O
between	O
patients	O
with	O
BB	O
and	O
PTFE	O
AVFs	O
.	O

Also	O
access	Physical
flow	Physical
was	O
comparable	O
at	O
this	O
time	O
.	O

In	O
general	O
,	O
the	O
effects	O
of	O
creation	O
of	O
a	O
fistula	O
on	O
LV	O
structure	O
were	O
limited	O
.	O

Longer	O
follow	O
up	O
time	O
may	O
be	O
needed	O
to	O
explore	O
the	O
long	O
term	O
effects	O
of	O
different	O
vascular	O
accesses	O
on	O
cardiac	Physical
function	Physical
.	Physical

Low-dose	O
aspirin	O
and	O
incidence	O
of	O
colorectal	O
tumors	O
in	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
Laboratory	O
,	O
clinical	O
,	O
and	O
epidemiologic	O
studies	O
have	O
recently	O
suggested	O
that	O
regular	O
use	O
of	O
aspirin	O
can	O
reduce	O
colorectal	O
cancer	O
incidence	O
or	O
mortality	O
.	O

However	O
,	O
observational	O
epidemiologic	O
analyses	O
have	O
had	O
limited	O
opportunity	O
to	O
control	O
for	O
confounding	O
bias	O
or	O
to	O
specify	O
aspirin	O
doses	O
used	O
.	O

PURPOSE	O
Our	O
purpose	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
regular	O
use	O
of	O
low-dose	O
aspirin	O
and	O
incidence	O
of	O
invasive	O
and	O
noninvasive	O
colorectal	O
tumors	O
by	O
utilizing	O
data	O
from	O
the	O
Physicians	O
'	O
Health	O
Study	O
,	O
a	O
randomized	O
,	O
double-blinded	O
,	O
placebo-controlled	O
trial	O
of	O
aspirin	O
and	O
beta	O
carotene	O
.	O

We	O
also	O
attempted	O
to	O
determine	O
whether	O
invasive	O
cancers	O
among	O
aspirin	O
users	O
were	O
associated	O
with	O
rectal	O
bleeding	O
and	O
early	O
stage	O
at	O
diagnosis	O
.	O

METHODS	O
The	O
Physicians	O
'	O
Health	O
Study	O
includes	O
22071	O
U.S.	O
male	O
physicians	O
.	O

The	O
aspirin	O
arm	O
was	O
terminated	O
in	O
1988	O
after	O
a	O
mean	O
follow-up	O
of	O
5	O
years	O
.	O

Stage	O
at	O
diagnosis	O
and	O
signs	O
and/or	O
symptoms	O
during	O
presentation	O
were	O
abstracted	O
from	O
medical	O
records	O
.	O

Cox	O
proportional	O
hazards	O
models	O
were	O
used	O
to	O
estimate	O
relative	Physical
risk	Physical
(	O
RR	O
)	O
,	O
95	O
%	O
confidence	Physical
intervals	Physical
(	O
CIs	O
)	O
,	O
and	O
the	O
association	O
between	O
aspirin	O
and	O
bleeding	O
.	O

Differences	O
between	O
aspirin	O
and	O
placebo	O
groups	O
in	O
tumor	O
risk	O
over	O
time	O
were	O
visualized	O
with	O
Kaplan-Meier	O
curves	O
.	O

We	O
assessed	O
the	O
association	O
between	O
aspirin	O
and	O
stage	O
at	O
diagnosis	O
with	O
a	O
Mann-Whitney	O
rank	O
sum	O
statistic	O
for	O
non-parametric	O
comparison	O
of	O
two	O
ordinal	O
distributions	O
.	O

RESULTS	O
The	O
RR	O
of	O
developing	O
colorectal	O
cancer	O
for	O
aspirin	O
compared	O
with	O
placebo	O
was	O
1.15	O
(	O
95	O
%	O
CI	O
=	O
0.80-1.65	O
)	O
.	O

For	O
in	O
situ	O
cancers	O
and	O
polyps	O
,	O
the	O
RR	O
was	O
0.86	O
(	O
95	O
%	O
CI	O
=	O
0.68-1.10	O
)	O
.	O

There	O
was	O
no	O
significant	O
trend	O
for	O
decreasing	O
RR	Physical
by	O
year	O
of	O
follow-up	O
for	O
invasive	O
cancers	O
(	O
P	O
=	O
.09	O
)	O
or	O
noninvasive	O
tumors	O
(	O
P	O
=	O
.96	O
)	O
.	O

Aspirin	O
and	O
placebo	O
groups	O
did	O
not	O
differ	O
in	O
stage	O
or	O
prevalence	O
of	O
rectal	Physical
bleeding	Physical
at	O
diagnosis	O
.	O

CONCLUSIONS	O
Regular	O
aspirin	O
use	O
,	O
at	O
a	O
dose	O
adequate	O
for	O
preventing	O
myocardial	O
infarction	O
,	O
was	O
not	O
associated	O
with	O
a	O
substantial	O
reduction	O
in	O
the	O
incidence	O
of	O
colorectal	Physical
cancer	Physical
during	O
5	O
years	O
of	O
randomized	O
treatment	O
and	O
follow-up	O
.	O

A	O
small	O
decrease	O
in	O
polyps	O
in	O
the	O
aspirin	O
group	O
could	O
not	O
be	O
reliably	O
distinguished	O
from	O
a	O
chance	O
association	O
.	O

Our	O
results	O
suggest	O
that	O
among	O
low-dose	O
aspirin	O
users	O
,	O
(	O
a	O
)	O
colorectal	O
cancer	O
mortality	O
is	O
not	O
likely	O
to	O
be	O
reduced	O
by	O
earlier	O
detection	O
and	O
(	O
b	O
)	O
incidence	O
is	O
not	O
likely	O
to	O
be	O
increased	O
due	O
to	O
aspirin-induced	O
gastrointestinal	O
bleeding	O
.	O

IMPLICATIONS	O
The	O
potential	O
for	O
a	O
benefit	O
from	O
higher	O
doses	O
of	O
aspirin	O
or	O
longer	O
duration	O
of	O
use	O
should	O
be	O
addressed	O
by	O
more	O
detailed	O
observational	O
epidemiologic	O
studies	O
and	O
prevention	O
trials	O
with	O
longer	O
follow-up	O
of	O
randomized	O
participants	O
.	O

Effects	O
of	O
interaction	O
of	O
RRR-alpha-tocopheryl	O
acetate	O
and	O
fish	O
oil	O
on	O
low-density-lipoprotein	O
oxidation	O
in	O
postmenopausal	O
women	O
with	O
and	O
without	O
hormone-replacement	O
therapy	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
RRR-alpha-tocpheryl	O
acetate	O
(	O
alpha-tocopheryl	O
acetate	O
)	O
and	O
hormone-replacement	O
therapy	O
(	O
HRT	O
)	O
on	O
the	O
oxidative	O
susceptibility	O
of	O
low-density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
postmenopausal	O
women	O
consuming	O
a	O
fish	O
oil	O
supplement	O
.	O

The	O
independent	O
effect	Physical
of	O
fish	O
oil	O
was	O
also	O
assessed	O
.	O

Forty-eight	O
women	O
,	O
equally	O
divided	O
between	O
women	O
using	O
and	O
not	O
using	O
HRT	O
,	O
participated	O
in	O
a	O
double-blind	O
crossover	O
trial	O
.	O

Each	O
of	O
the	O
four	O
periods	O
lasted	O
5	O
wk	O
and	O
was	O
followed	O
by	O
a	O
4-wk	O
washout	O
interval	O
.	O

During	O
each	O
period	O
all	O
subjects	O
were	O
given	O
a	O
15-g	O
supplement	O
of	O
fish	O
oil	O
and	O
either	O
0	O
(	O
placebo	O
)	O
,	O
100	O
,	O
200	O
,	O
or	O
400	O
mg	O
alpha-tocopheryl	O
acetate	O
daily	O
.	O

LDL	Physical
resistance	Physical
to	Physical
oxidative	Physical
modification	Physical
was	O
assessed	O
by	O
calculating	Physical
lag	Physical
time	Physical
,	O
propagation	Physical
rate	Physical
,	O
and	O
maximum	Physical
production	Physical
of	Physical
conjugated	Physical
dienes	Physical
.	O

Supplementation	O
with	O
fish	O
oil	O
and	O
placebo	O
shortened	O
lag	Physical
time	Physical
and	O
slowed	Physical
propagation	Physical
rate	Physical
in	O
women	O
both	O
using	O
and	O
not	O
using	O
HRT	O
.	O

After	O
subjects	O
consumed	O
fish	O
oil	O
,	O
supplementation	O
with	O
alpha-tocopheryl	O
acetate	O
increased	O
plasma	Physical
and	Physical
LDL	Physical
alpha-tocopherol	Physical
contents	Physical
significantly	O
and	O
lengthened	Physical
lag	Physical
time	Physical
(	O
at	O
even	O
the	O
lowest	O
concentration	O
)	O
but	O
had	O
no	O
significant	O
effect	O
on	O
propagation	Physical
rate	Physical
or	O
maximum	Physical
production	Physical
compared	O
with	O
values	O
measured	O
after	O
consumption	O
of	O
fish	O
oil	O
alone	O
.	O

Women	O
not	O
using	O
HRT	O
had	O
faster	O
propagation	Physical
rates	Physical
and	O
higher	O
maximum	Physical
production	Physical
than	O
women	O
using	O
HRT	O
;	O
after	O
supplementation	O
with	O
fish	O
oil	O
and	O
alpha-tocopheryl	O
acetate	O
these	O
differences	O
prevailed	O
.	O

Supplements	O
as	O
low	O
as	O
100	O
mg	O
alpha-tocopheryl	O
acetate/d	O
increase	O
the	O
resistance	Physical
of	Physical
LDL	Physical
to	Physical
oxidation	Physical
when	O
fish	O
oil	O
supplements	O
are	O
used	O
.	O

HRT	O
and	O
fish	O
oil	O
supplements	O
may	O
independently	O
affect	O
LDL	Physical
oxidative	Physical
susceptibility	Physical
.	O

Nutritional	O
orientation	O
,	O
knowledge	O
and	O
quality	O
of	O
diet	O
in	O
heart	O
failure	O
:	O
randomized	O
clinical	O
trial	O
.	O

BACKGROUND	O
Non-pharmacological	O
measures	O
are	O
recommended	O
for	O
heart	O
failure	O
patients	O
.	O

However	O
,	O
most	O
studies	O
evaluate	O
low	O
sodium	O
diet	O
,	O
while	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
interventions	O
to	O
improve	O
adherence	O
and	O
knowledge	O
of	O
patients	O
about	O
diet	O
content	O
.	O

OBJECTIVE	O
To	O
evaluate	O
if	O
a	O
global	O
nutritional	O
orientation	O
could	O
affect	O
nutritional	Others
knowledge	Others
,	O
adherence	Others
to	Others
food	Others
guidelines	Others
,	O
anthropometrics	Physical
and	O
quality	Others
of	Others
life	Others
in	O
heart	O
failure	O
patients	O
.	O

METHODS	O
Forty	O
six	O
patients	O
were	O
randomized	O
to	O
intervention	O
or	O
control	O
group	O
.	O

Both	O
groups	O
received	O
usual	O
care	O
with	O
medical	O
and	O
nursing	O
staff	O
;	O
the	O
intervention	O
group	O
received	O
additional	O
nutritional	O
guidance	O
about	O
diet	O
and	O
its	O
relationship	O
with	O
disease	O
,	O
sources	O
of	O
nutrients	O
,	O
and	O
reduction	O
of	O
dietary	O
sodium	O
and	O
fats	O
.	O

Enforcement	O
of	O
the	O
nutritional	O
guidance	O
was	O
performed	O
after	O
4	O
weeks	O
.	O

Both	O
groups	O
were	O
evaluated	O
at	O
baseline	O
,	O
and	O
after	O
6	O
weeks	O
and	O
6	O
months	O
.	O

Evaluations	O
included	O
anthropometric	Physical
parameters	Physical
,	O
sodium	Physical
excretion	Physical
in	Physical
24-hour	Physical
urine	Physical
,	O
dietary	Mental
recall	Mental
,	O
nutrition	Mental
knowledge	Mental
and	O
quality	Others
of	Others
life	Others
questionnaires	Physical
.	O

RESULTS	O
Mean	O
age	O
of	O
included	O
patients	O
was	O
58	O
?	O
10	O
years	O
and	O
70	O
%	O
were	O
male	O
.	O

After	O
6	O
months	O
of	O
follow-up	O
,	O
the	O
nutritional	Others
knowledge	Others
of	O
intervention	O
group	O
increased	O
compared	O
to	O
control	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Caloric	O
,	O
fat	O
and	O
sodium	O
intake	O
decreased	O
in	O
the	O
intervention	O
group	O
compared	O
to	O
control	O
(	O
p	O
<	O
0.05	O
)	O
.	O

No	O
significant	O
differences	O
were	O
seen	O
in	O
quality	Others
of	Others
life	Others
or	O
anthropometric	Physical
parameters	Physical
.	O

CONCLUSIONS	O
Nutritional	O
orientation	O
was	O
effective	O
to	O
modify	O
1	O
)	O
knowledge	Others
about	O
food	O
and	O
nutrition	O
,	O
and	O
2	O
)	O
quality	Others
of	Others
diet	Others
in	O
outpatients	O
with	O
heart	O
failure	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
evaluate	O
the	O
benefits	O
on	O
quality	O
of	O
life	O
and	O
prognosis	O
.	O

Effects	O
of	O
long-term	O
vitamin	O
E	O
supplementation	O
on	O
cardiovascular	Physical
events	Physical
and	O
cancer	Physical
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

CONTEXT	O
Experimental	O
and	O
epidemiological	O
data	O
suggest	O
that	O
vitamin	O
E	O
supplementation	O
may	O
prevent	O
cancer	O
and	O
cardiovascular	O
events	O
.	O

Clinical	O
trials	O
have	O
generally	O
failed	O
to	O
confirm	O
benefits	O
,	O
possibly	O
due	O
to	O
their	O
relatively	O
short	O
duration	O
.	O

OBJECTIVE	O
To	O
evaluate	O
whether	O
long-term	O
supplementation	O
with	O
vitamin	O
E	O
decreases	O
the	O
risk	Physical
of	Physical
cancer	Physical
,	O
cancer	Adverseeffect
death	Adverseeffect
,	O
and	O
major	Physical
cardiovascular	Physical
events	Physical
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
international	O
trial	O
(	O
the	O
initial	O
Heart	O
Outcomes	O
Prevention	O
Evaluation	O
[	O
HOPE	O
]	O
trial	O
conducted	O
between	O
December	O
21	O
,	O
1993	O
,	O
and	O
April	O
15	O
,	O
1999	O
)	O
of	O
patients	O
at	O
least	O
55	O
years	O
old	O
with	O
vascular	O
disease	O
or	O
diabetes	O
mellitus	O
was	O
extended	O
(	O
HOPE-The	O
Ongoing	O
Outcomes	O
[	O
HOPE-TOO	O
]	O
)	O
between	O
April	O
16	O
,	O
1999	O
,	O
and	O
May	O
26	O
,	O
2003	O
.	O

Of	O
the	O
initial	O
267	O
HOPE	O
centers	O
that	O
had	O
enrolled	O
9541	O
patients	O
,	O
174	O
centers	O
participated	O
in	O
the	O
HOPE-TOO	O
trial	O
.	O

Of	O
7030	O
patients	O
enrolled	O
at	O
these	O
centers	O
,	O
916	O
were	O
deceased	O
at	O
the	O
beginning	O
of	O
the	O
extension	O
,	O
1382	O
refused	O
participation	O
,	O
3994	O
continued	O
to	O
take	O
the	O
study	O
intervention	O
,	O
and	O
738	O
agreed	O
to	O
passive	O
follow-up	O
.	O

Median	O
duration	O
of	O
follow-up	O
was	O
7.0	O
years	O
.	O

INTERVENTION	O
Daily	O
dose	O
of	O
natural	O
source	O
vitamin	O
E	O
(	O
400	O
IU	O
)	O
or	O
matching	O
placebo	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
outcomes	O
included	O
cancer	Physical
incidence	Physical
,	O
cancer	Adverseeffect
deaths	Adverseeffect
,	O
and	O
major	Physical
cardiovascular	Physical
events	Physical
(	Physical
myocardial	Physical
infarction	Physical
,	Physical
stroke	Physical
,	Physical
and	Physical
cardiovascular	Adverseeffect
death	Adverseeffect
)	Physical
.	O

Secondary	O
outcomes	O
included	O
heart	Physical
failure	Physical
,	O
unstable	Physical
angina	Physical
,	O
and	O
revascularizations	Physical
.	O

RESULTS	O
Among	O
all	O
HOPE	O
patients	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
primary	O
analysis	O
:	O
for	O
cancer	Physical
incidence	Physical
,	O
there	O
were	O
552	O
patients	O
(	O
11.6	O
%	O
)	O
in	O
the	O
vitamin	O
E	O
group	O
vs	O
586	O
(	O
12.3	O
%	O
)	O
in	O
the	O
placebo	O
group	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
,	O
0.94	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.84-1.06	O
;	O
P	O
=	O
.30	O
)	O
;	O
for	O
cancer	Adverseeffect
deaths	Adverseeffect
,	O
156	O
(	O
3.3	O
%	O
)	O
vs	O
178	O
(	O
3.7	O
%	O
)	O
,	O
respectively	O
(	O
RR	O
,	O
0.88	O
;	O
95	O
%	O
CI	O
,	O
0.71-1.09	O
;	O
P	O
=	O
.24	O
)	O
;	O
and	O
for	O
major	Physical
cardiovascular	Physical
events	Physical
,	O
1022	O
(	O
21.5	O
%	O
)	O
vs	O
985	O
(	O
20.6	O
%	O
)	O
,	O
respectively	O
(	O
RR	O
,	O
1.04	O
;	O
95	O
%	O
CI	O
,	O
0.96-1.14	O
;	O
P	O
=	O
.34	O
)	O
.	O

Patients	O
in	O
the	O
vitamin	O
E	O
group	O
had	O
a	O
higher	O
risk	Physical
of	Physical
heart	Physical
failure	Physical
(	O
RR	O
,	O
1.13	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.26	O
;	O
P	O
=	O
.03	O
)	O
and	O
hospitalization	Adverseeffect
for	Adverseeffect
heart	Adverseeffect
failure	Adverseeffect
(	O
RR	O
,	O
1.21	O
;	O
95	O
%	O
CI	O
,	O
1.00-1.47	O
;	O
P	O
=	O
.045	O
)	O
.	O

Similarly	O
,	O
among	O
patients	O
enrolled	O
at	O
the	O
centers	O
participating	O
in	O
the	O
HOPE-TOO	O
trial	O
,	O
there	O
were	O
no	O
differences	O
in	O
cancer	Physical
incidence	Physical
,	O
cancer	Adverseeffect
deaths	Adverseeffect
,	O
and	O
major	Physical
cardiovascular	Physical
events	Physical
,	O
but	O
higher	O
rates	Physical
of	Physical
heart	Physical
failure	Physical
and	O
hospitalizations	Adverseeffect
for	Adverseeffect
heart	Adverseeffect
failure	Adverseeffect
.	O

CONCLUSION	O
In	O
patients	O
with	O
vascular	O
disease	O
or	O
diabetes	O
mellitus	O
,	O
long-term	O
vitamin	O
E	O
supplementation	O
does	O
not	O
prevent	O
cancer	Physical
or	O
major	Physical
cardiovascular	Physical
events	Physical
and	O
may	O
increase	O
the	O
risk	Physical
for	Physical
heart	Physical
failure	Physical
.	O

Intravenous	O
or	O
intramuscular	O
teicoplanin	O
once	O
daily	O
for	O
skin	O
and	O
soft-tissue	O
infections	O
.	O

Teicoplanin	O
is	O
a	O
new	O
glycopeptide	O
antibiotic	O
with	O
potent	O
activity	O
against	O
gram-positive	O
bacteria	O
and	O
pharmacokinetics	O
that	O
allow	O
once	O
daily	O
administration	O
.	O

To	O
study	O
the	O
efficacy	Others
and	O
safety	Others
of	O
teicoplanin	O
for	O
skin	O
and	O
soft-tissue	O
infections	O
,	O
75	O
patients	O
received	O
teicoplanin	O
intravenously	O
(	O
38	O
)	O
or	O
intramuscularly	O
(	O
37	O
,	O
of	O
which	O
16	O
were	O
outpatients	O
)	O
.	O

Of	O
62	O
clinically	O
evaluable	O
patients	O
,	O
97	O
percent	O
of	O
teicoplanin	O
iv	O
and	O
93	O
percent	O
of	O
teicoplanin	O
im	O
patients	O
were	O
cured	O
or	O
improved	O
.	O

All	O
teicoplanin	O
iv	O
patients	O
and	O
64	O
percent	O
of	O
teicoplanin	O
im	O
patients	O
were	O
cured	O
microbiologically	O
at	O
24-48	O
hours	O
posttherapy	O
.	O

Persistence	O
of	O
organisms	O
frequently	O
was	O
associated	O
with	O
skin	Physical
ulcers	Physical
or	Physical
abscess	Physical
cavities	Physical
and	O
usually	O
had	O
no	O
bearing	O
on	O
clinical	O
outcome	O
.	O

Possible	O
adverse	Adverseeffect
clinical	Adverseeffect
and	Adverseeffect
laboratory	Adverseeffect
reactions	Adverseeffect
caused	O
by	O
teicoplanin	O
occurred	O
in	O
4	O
of	O
38	O
teicoplanin	O
iv	O
patients	O
(	O
11	O
percent	O
)	O
and	O
in	O
8	O
of	O
37	O
teicoplanin	O
im	O
patients	O
(	O
22	O
percent	O
)	O
.	O

Reactions	O
were	O
mild	Physical
and	O
resolved	O
with	O
discontinuation	O
of	O
teicoplanin	O
in	O
most	O
cases	O
.	O

In	O
this	O
study	O
,	O
teicoplanin	O
appeared	O
to	O
be	O
safe	Others
,	O
efficacious	Others
,	O
and	O
convenient	Others
for	O
both	O
hospital	O
staff	O
and	O
patients	O
,	O
and	O
potentially	O
cost-effective	Others
for	O
the	O
treatment	O
of	O
skin	O
and	O
soft-tissue	O
infections	O
.	O

In	O
particular	O
,	O
teicoplanin	O
appears	O
to	O
be	O
appropriate	O
for	O
outpatient	O
parenteral	O
therapy	O
.	O

Comparison	O
of	O
neodymium-doped	O
yttrium	O
aluminum	O
garnet	O
laser	O
treatment	O
with	O
cold	O
knife	O
endoscopic	O
incision	O
of	O
urethral	O
strictures	O
in	O
male	O
patients	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	Others
of	O
visual	O
laser	O
ablation	O
treatment	O
with	O
neodymium-doped	O
yttrium	O
aluminum	O
garnet	O
(	O
Nd	O
:	O
YAG	O
)	O
laser	O
in	O
male	O
patients	O
with	O
urethral	O
strictures	O
and	O
to	O
compare	O
the	O
effects	O
with	O
those	O
obtained	O
in	O
patients	O
treated	O
with	O
Sachse	O
's	O
optical	O
urethrotomy	O
.	O

MATERIALS	O
AND	O
METHODS	O
Fifty	O
patients	O
aged	O
22	O
to	O
83	O
(	O
mean	O
age	O
61.8	O
)	O
with	O
primary	O
(	O
n	O
=	O
26	O
,	O
52	O
%	O
)	O
and	O
recurrent	O
(	O
n	O
=	O
24	O
,	O
48	O
%	O
)	O
urethral	O
strictures	O
0.3	O
to	O
2.4	O
cm	O
long	O
qualified	O
for	O
the	O
study	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
30	O
men	O
treated	O
using	O
visual	O
laser	O
ablation	O
of	O
urethral	O
strictures	O
(	O
VLASU	O
)	O
with	O
Nd	O
:	O
YAGlaser	O
and	O
20	O
men	O
treated	O
by	O
correction	O
of	O
urethral	O
strictures	O
using	O
Sachse	O
's	O
optical	O
urethrotomy	O
.	O

RESULTS	O
At	O
12-month	O
follow-up	O
,	O
seven	O
(	O
35	O
%	O
)	O
patients	O
who	O
underwent	O
optical	O
urethrotomy	O
and	O
21	O
(	O
70	O
%	O
)	O
in	O
the	O
VLASU	O
group	O
did	O
not	O
require	O
repetition	Others
of	Others
the	Others
procedure	Others
.	Others

The	O
choice	O
of	O
VLASU	O
as	O
a	O
method	O
of	O
treatment	O
significantly	O
decreased	O
the	O
probability	Others
of	Others
therapeutic	Others
failure	Others
and	O
recurrence	Physical
of	Physical
urethral	Physical
strictures	Physical
(	O
p	O
=	O
0.02	O
)	O
.	O

CONCLUSION	O
VLASU	O
can	O
be	O
used	O
as	O
a	O
method	O
of	O
treatment	O
of	O
this	O
disorder	O
.	O

It	O
is	O
an	O
effective	O
,	O
modern	O
,	O
low-invasive	O
,	O
and	O
repeatable	O
technique	O
and	O
is	O
technically	O
simple	O
and	O
easy	O
to	O
master	O
.	O

It	O
can	O
be	O
used	O
in	O
cases	O
in	O
which	O
introduction	O
of	O
a	O
22	O
Char	O
optical	O
urethrotome	O
into	O
the	O
stricture	O
site	O
is	O
impossible	O
,	O
as	O
well	O
as	O
for	O
treatment	O
of	O
multiple	O
strictures	O
during	O
one	O
procedure	O
.	O

Transdermal	O
scopolamine	O
patch	O
in	O
addition	O
to	O
ondansetron	O
for	O
postoperative	O
nausea	O
and	O
vomiting	O
prophylaxis	O
in	O
patients	O
undergoing	O
ambulatory	O
cosmetic	O
surgery	O
.	O

STUDY	O
OBJECTIVE	O
To	O
determine	O
the	O
efficacy	O
of	O
transdermal	O
scopolamine	O
in	O
addition	O
to	O
ondansetron	O
in	O
decreasing	O
the	O
incidence	O
of	O
postoperative	Physical
nausea	Physical
and	Physical
vomiting	Physical
(	O
PONV	O
)	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Academic	O
hospital	O
.	O

PATIENTS	O
126	O
ASA	O
physical	O
status	O
I	O
and	O
II	O
patients	O
undergoing	O
outpatient	O
plastic	O
surgery	O
with	O
three	O
or	O
more	O
risk	O
factors	O
for	O
PONV	O
.	O

INTERVENTIONS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
to	O
receive	O
(	O
Group	O
1	O
)	O
a	O
transdermal	O
scopolamine	O
(	O
TDS	O
)	O
patch	O
or	O
(	O
Group	O
2	O
)	O
,	O
a	O
placebo	O
patch	O
two	O
hours	O
before	O
surgery	O
.	O

MEASUREMENTS	O
Occurrence	Physical
of	Physical
vomiting	Physical
,	O
severity	Physical
of	Physical
nausea	Physical
using	Physical
a	Physical
visual	Physical
analog	Physical
scale	Physical
(	Physical
VAS	Physical
)	Physical
,	O
rescue	Others
medication	Others
,	O
pain	Pain
intensity	Pain
and	Physical
pain	Others
medications	Others
,	O
and	O
side	Adverseeffect
effects	Adverseeffect
were	O
recorded	O
every	O
hour	O
until	O
discharge	O
from	O
hospital	O
,	O
then	O
every	O
4	O
hours	O
thereafter	O
for	O
a	O
total	O
of	O
24	O
hours	O
.	O

MAIN	O
RESULTS	O
A	O
statistically	O
significant	O
reduction	O
in	O
postoperative	Physical
nausea	Physical
between	O
8	O
and	O
24	O
hours	O
in	O
patients	O
receiving	O
TDS	O
was	O
noted	O
.	O

CONCLUSIONS	O
Transdermal	O
scopolamine	O
in	O
addition	O
to	O
ondansetron	O
benefits	O
patients	O
at	O
high	O
risk	O
for	O
PONV	O
undergoing	O
outpatient	O
plastic	O
surgery	O
for	O
up	O
to	O
20	O
hours	O
after	O
surgery	O
.	O

The	O
costs	Others
and	O
effects	Others
of	O
a	O
nutritional	O
education	O
program	O
following	O
work-site	O
cholesterol	O
screening	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
costs	Others
and	O
impact	Others
of	O
a	O
nutrition	O
education	O
program	O
following	O
a	O
cholesterol	O
screening	O
.	O

METHODS	O
Forty	O
work-sites	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
educational	O
interventions	O
:	O
a	O
usual	O
intervention	O
of	O
5	O
minutes	O
of	O
counseling	O
,	O
or	O
a	O
special	O
intervention	O
of	O
2	O
hours	O
of	O
behaviorally	O
based	O
education	O
on	O
dietary	O
changes	O
to	O
lower	O
serum	O
cholesterol	O
.	O

Costs	Others
were	O
monitored	O
,	O
and	O
cholesterol	Physical
levels	Physical
were	O
retested	O
6	O
and	O
12	O
months	O
later	O
.	O

RESULTS	O
The	O
total	Others
per-person	Others
cost	Others
for	O
screening	O
and	O
the	O
educational	O
intervention	O
was	O
about	O
$	O
50	O
.	O

Cholesterol	Physical
levels	Physical
differed	O
little	O
between	O
the	O
two	O
intervention	O
groups	O
6	O
months	O
after	O
screening	O
,	O
but	O
after	O
12	O
months	O
those	O
in	O
the	O
special	O
intervention	O
worksites	O
showed	O
a	O
6.5	O
%	O
drop	O
in	O
cholesterol	Physical
,	O
whereas	O
those	O
at	O
the	O
usual	O
intervention	O
worksites	O
showed	O
a	O
drop	O
of	O
only	O
3.0	O
%	O
.	O

Hence	O
a	O
3.5	O
%	O
cholesterol	Physical
reduction	Physical
was	O
attributable	O
to	O
the	O
special	O
intervention	O
.	O

CONCLUSIONS	O
A	O
behaviorally	O
based	O
nutrition	O
education	O
program	O
following	O
cholesterol	O
screening	O
can	O
have	O
a	O
meaningful	O
impact	O
on	O
long-term	O
cholesterol	O
levels	O
at	O
a	O
low	O
cost	O
.	O

Nutrition	O
education	O
in	O
work-sites	O
may	O
therefore	O
be	O
a	O
useful	O
way	O
to	O
lower	O
the	O
risk	O
of	O
heart	O
disease	O
in	O
communities	O
.	O

Echocardiographic	O
evaluation	O
of	O
children	O
with	O
systemic	O
ventricular	O
dysfunction	O
treated	O
with	O
carvedilol	O
.	O

Echocardiography	O
is	O
used	O
to	O
measure	O
the	O
therapeutic	O
effectiveness	O
of	O
heart	O
failure	O
therapy	O
in	O
adults	O
and	O
children	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
(	O
1	O
)	O
to	O
assess	O
baseline	O
echocardiographic	O
predictors	O
of	O
clinical	O
outcome	O
,	O
(	O
2	O
)	O
to	O
investigate	O
changes	O
in	O
echocardiographic	O
parameters	O
,	O
and	O
(	O
3	O
)	O
to	O
compare	O
these	O
echocardiographic	O
changes	O
with	O
changes	O
in	O
plasma	O
levels	O
of	O
b-type	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
in	O
a	O
population	O
of	O
children	O
with	O
systemic	O
ventricular	O
dysfunction	O
and	O
symptomatic	O
heart	O
failure	O
treated	O
with	O
carvedilol	O
or	O
placebo	O
.	O

All	O
available	O
baseline	O
and	O
6-month	O
echocardiograms	O
from	O
Pediatric	O
Carvedilol	O
Trial	O
(	O
PCT	O
)	O
participants	O
(	O
carvedilol	O
n	O
=	O
161	O
;	O
placebo	O
n	O
=	O
55	O
)	O
were	O
reviewed	O
.	O

Systolic	Physical
and	O
diastolic	Physical
sphericity	Physical
index	Physical
(	O
SI	O
;	O
n	O
=	O
110	O
)	O
,	O
TEI	O
index	O
(	O
n	O
=	O
145	O
)	O
,	O
and	O
systemic	O
ventricular	O
dP/dt	O
(	O
n	O
=	O
70	O
)	O
were	O
measured	O
.	O

The	O
PCT	O
composite	O
definition	O
of	O
clinical	O
outcome	O
(	O
i.e.	O
,	O
worsened	O
,	O
improved	O
,	O
or	O
unchanged	O
)	O
was	O
used	O
.	O

For	O
all	O
patients	O
,	O
baseline	O
TEI	O
index	O
was	O
a	O
predictor	O
of	O
worsened	Physical
outcome	Physical
.	O

Only	O
children	O
treated	O
with	O
carvedilol	O
showed	O
a	O
significant	O
decrease	O
in	O
systolic	Physical
SI	Physical
(	O
P	O
B	O
0.0001	O
)	O
,	O
diastolic	Physical
SI	Physical
(	O
P	O
B	O
0.0001	O
)	O
,	O
and	O
TEI	Physical
index	Physical
(	O
P	O
=	O
0.02	O
)	O
.	O

An	O
inverse	O
correlation	O
between	O
changes	Physical
in	Physical
BNP	Physical
and	O
changes	Physical
in	Physical
dP/dt	Physical
(	O
r	O
=	O
-0.45	O
,	O
P	O
=	O
0.04	O
)	O
was	O
found	O
only	O
in	O
the	O
carvedilol	O
group	O
.	O

In	O
conclusion	O
,	O
TEI	O
index	O
predicted	O
outcome	O
in	O
children	O
with	O
systemic	O
ventricular	O
dysfunction	O
and	O
heart	O
failure	O
.	O

Carvedilol	O
may	O
have	O
a	O
beneficial	O
effect	O
on	O
reversal	O
of	O
left	O
ventricular	O
remodeling	O
and	O
global	O
ventricular	O
function	O
in	O
pediatric	O
heart	O
failure	O
.	O

[	O
Dose-reduced	O
antihypertensive	O
agents	O
--	O
use	O
in	O
complex	O
nonmedicamentous	O
therapy	O
of	O
hypertension	O
]	O
.	O

In	O
order	O
to	O
estimate	O
the	O
influence	O
of	O
a	O
non-medicamentous	O
therapy	O
(	O
CNT	O
)	O
on	O
the	O
consumption	O
of	O
medicaments	O
and	O
coronary	O
risk	O
in	O
high	O
blood	O
pressure	O
73	O
hypertensives	O
of	O
a	O
medicamentously	O
stabilized	O
CNT-group	O
were	O
examined	O
in	O
comparison	O
to	O
a	O
group	O
of	O
the	O
same	O
size	O
of	O
patients	O
with	O
hypertension	O
who	O
were	O
managed	O
exclusively	O
medicamentously	O
for	O
behaviour	O
of	O
blood	O
pressure	O
,	O
need	O
of	O
antihypertensive	O
drugs	O
and	O
changes	O
of	O
hypertension-associated	O
risk	O
factors	O
.	O

After	O
an	O
exactly	O
controlled	O
6-month	O
treatment	O
hypertensives	O
with	O
additionally	O
recommended	O
far-reaching	O
CNT	O
showed	O
an	O
economization	O
of	O
medicaments	O
by	O
scarcely	O
the	O
half	O
in	O
comparison	O
to	O
the	O
reference	O
group	O
.	O

By	O
means	O
of	O
suitable	O
control	O
methods	O
a	O
causal	O
non-medicamentously	O
conditioned	O
decrease	O
of	O
blood	Physical
pressure	Physical
could	O
be	O
excluded	O
.	O

A	O
different	O
need	O
of	O
antihypertensive	O
drugs	O
was	O
simulated	O
by	O
the	O
exacter	O
intake	O
of	O
medicaments	O
in	O
the	O
index-patients	O
.	O

Notwithstanding	O
the	O
metabolic	O
effects	O
of	O
the	O
additional	O
therapy	O
have	O
induced	O
a	O
positive	O
change	O
of	O
atherogenic	Physical
lipids	Physical
.	Physical

The	O
examinations	O
indicate	O
in	O
general	O
the	O
difficulty	O
of	O
the	O
judgement	O
of	O
efficacy	O
of	O
non-medicamentous	O
therapeutic	O
measures	O
in	O
connection	O
with	O
a	O
rational	O
dose-reduced	O
long-term	O
therapy	O
with	O
antihypertensive	O
drugs	O
.	O

Bitewing	O
film	O
quality	O
:	O
a	O
clinical	O
comparison	O
of	O
the	O
loop	O
vs.	O
holder	O
techniques	O
.	O

OBJECTIVE	O
To	O
compare	O
in	O
vivo	O
bitewing	O
film	O
quality	O
using	O
the	O
holder	O
versus	O
the	O
paper	O
loop	O
technique	O
.	O

METHOD	O
AND	O
MATERIALS	O
Four	O
bitewing	O
films	O
were	O
taken	O
from	O
the	O
right	O
and	O
left	O
premolar	O
and	O
molar	O
regions	O
of	O
45	O
dental	O
students	O
using	O
both	O
the	O
bitewing	O
holder	O
and	O
paper	O
loop	O
techniques	O
.	O

A	O
total	O
of	O
360	O
films	O
were	O
taken	O
and	O
assessed	O
by	O
an	O
experienced	O
practitioner	O
not	O
apprised	O
of	O
the	O
bitewing	O
technique	O
used	O
.	O

Of	O
interest	O
were	O
:	O
(	O
1	O
)	O
the	O
number	O
of	O
overlaps	O
and	O
the	O
percentage	O
of	O
teeth	O
showing	O
the	O
alveolar	O
crest	O
;	O
(	O
2	O
)	O
proper	O
film	O
positioning	O
;	O
and	O
(	O
3	O
)	O
the	O
percentage	O
of	O
cone	O
cutting	O
.	O

A	O
Poisson	O
regression	O
using	O
generalized	O
estimating	O
equations	O
(	O
GEEs	O
)	O
was	O
used	O
to	O
estimate	O
the	O
difference	O
in	O
overlap	O
between	O
the	O
two	O
techniques	O
.	O

For	O
proper	O
positioning	O
and	O
cone	O
cutting	O
,	O
logistic	O
regressions	O
using	O
GEEs	O
were	O
used	O
.	O

RESULTS	O
The	O
average	Others
number	Others
of	Others
horizontal	Others
overlaps	Others
for	Others
the	Others
loop	Others
and	Others
holder	Others
techniques	Others
at	O
the	O
right	O
premolar	O
,	O
right	O
molar	O
,	O
left	O
premolar	O
,	O
and	O
left	O
molar	O
were	O
1.64	O
,	O
2.11	O
,	O
2.16	O
,	O
2.78	O
,	O
and	O
1.64	O
,	O
2.00	O
,	O
2.00	O
,	O
2.18	O
,	O
respectively	O
.	O

The	O
loop	O
technique	O
was	O
1.11	O
times	O
more	O
likely	O
to	O
cause	O
overlapping	Others
than	O
the	O
holder	O
technique	O
.	O

The	O
highest	Others
percentage	Others
of	Others
teeth	Others
showing	Others
the	Others
alveolar	Others
crest	Others
by	Others
the	Others
loop	Others
technique	Others
was	O
97.8	O
%	O
in	O
the	O
mandibular	O
second	O
premolar	O
and	O
first	O
molar	O
.	O

With	O
respect	O
to	O
film	O
positioning	O
,	O
the	O
loop	O
technique	O
was	O
1.12	O
times	O
more	O
likely	O
to	O
cause	O
improper	Others
positioning	Others
than	O
the	O
holder	O
technique	O
.	O

Both	O
techniques	O
demonstrated	O
minimal	Others
cone	Others
cutting	Others
(	O
1	O
in	O
the	O
loop	O
versus	O
0	O
in	O
the	O
holder	O
)	O
.	O

CONCLUSION	O
The	O
quality	O
of	O
bitewing	O
films	O
taken	O
by	O
the	O
loop	O
and	O
holder	O
techniques	O
was	O
not	O
significantly	O
different	O
.	O

A	O
comparative	O
study	O
of	O
methyldopa	O
and	O
labetalol	O
in	O
the	O
treatment	O
of	O
hypertension	O
.	O

1	O
Twenty	O
patients	O
with	O
essential	O
hypertension	O
completed	O
a	O
double-blind	O
,	O
dose-tritrated	O
,	O
cross-over	O
comparison	O
of	O
methyldopa	O
and	O
labetalol	O
.	O

2	O
Average	Physical
lying	Physical
BPs	Physical
(	Physical
systolic/diastolic	Physical
)	Physical
were	O
reduced	O
by	O
28/15	O
mmHg	O
with	O
methyldopa	O
and	O
by	O
23/15	O
mmHg	O
with	O
labetalol	O
.	O

3	O
Average	Physical
standing	Physical
BPs	Physical
(	Physical
systolic/diastolic	Physical
)	Physical
were	O
reduced	O
by	O
29/14	O
mmHg	O
with	O
methyldopa	O
and	O
by	O
29/15	O
mmHg	O
with	O
labetalol	O
.	O

4	O
Both	O
lying	Physical
and	Physical
standing	Physical
heart	Physical
rates	Physical
were	O
reduced	O
with	O
labetalol	O
.	O

5	O
It	O
is	O
concluded	O
that	O
the	O
antihypertensive	Others
properties	Others
of	O
labetalol	O
and	O
methyldopa	O
are	O
similar	O
but	O
that	O
larger	O
patient	O
populations	O
are	O
needed	O
to	O
study	O
the	O
relative	O
incidence	O
of	O
subjective	O
adverse	O
effects	O
.	O

Clonidine	O
increases	O
the	O
sweating	Physical
threshold	Physical
,	O
but	O
does	O
not	O
reduce	O
the	O
gain	Physical
of	Physical
sweating	Physical
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
clonidine	O
produces	O
a	O
dose-dependent	O
increase	Physical
in	Physical
the	Physical
sweating	Physical
threshold	Physical
but	O
does	O
not	O
reduce	Physical
the	Physical
gain	Physical
of	Physical
sweating	Physical
.	O

Six	O
healthy	O
male	O
volunteers	O
were	O
evaluated	O
,	O
each	O
on	O
three	O
separate	O
days	O
in	O
random	O
order	O
.	O

In	O
one	O
,	O
saline	O
was	O
administered	O
;	O
in	O
another	O
,	O
a	O
2-micrograms/kg	O
bolus	O
of	O
clonidine	O
was	O
followed	O
by	O
an	O
infusion	O
at	O
2	O
micrograms.kg-1.h-1	O
,	O
and	O
on	O
a	O
third	O
day	O
,	O
a	O
4-micrograms/kg	O
bolus	O
was	O
followed	O
by	O
an	O
infusion	O
at	O
4	O
micrograms.kg-1.h-1	O
.	O

Core	Physical
temperature	Physical
was	O
measured	O
at	O
the	O
tympanic	O
membrane	O
and	O
mean	Physical
skin	Physical
temperature	Physical
was	O
determined	O
from	O
four	O
sites	O
.	O

A	O
chest	Physical
sweating	Physical
rate	Physical
of	O
40	O
g.m-2.h-1	O
was	O
considered	O
significant	O
.	O

The	O
core	O
temperature	O
triggering	O
sweating	Physical
,	O
adjusted	O
to	O
a	O
designated	O
mean	O
skin	O
temperature	O
of	O
34	O
degrees	O
C	O
,	O
identified	O
the	O
threshold	O
for	O
this	O
response	O
.	O

Gain	O
was	O
defined	O
by	O
the	O
adjusted	O
core	Physical
temperature	Physical
increase	O
required	O
to	O
augment	O
sweating	O
from	O
100	O
to	O
300	O
g.m-2.h-1	O
.	O

degree	O
C-1	O
.	O

Plasma	Physical
clonidine	Physical
concentrations	Physical
were	O
0.8	O
+/-	O
0.1	O
and	O
1.6	O
+/-	O
0.2	O
ng/mL	O
on	O
the	O
small-	O
and	O
large-dose	O
days	O
,	O
respectively	O
.	O

Clonidine	O
administration	O
increased	O
the	O
sweating	O
threshold	O
approximately	O
0.4	O
degree	O
C	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
the	O
increase	O
was	O
comparable	O
at	O
each	O
dose	O
.	O

The	O
gain	Physical
of	Physical
sweating	Physical
was	O
approximately	O
0.2	O
degree	O
C	O
and	O
was	O
not	O
influenced	O
by	O
clonidine	O
administration	O
.	O

The	O
thermoregulatory	Physical
effects	Physical
of	O
clonidine	O
thus	O
resemble	O
those	O
of	O
volatile	O
anesthetics	O
,	O
opioids	O
,	O
and	O
propofol	O
.	O

These	O
data	O
suggest	O
that	O
the	O
antishivering	O
effect	O
of	O
clonidine	O
results	O
from	O
central	O
thermoregulatory	O
inhibition	O
rather	O
than	O
a	O
specific	O
peripheral	O
action	O
on	O
thermogenic	O
muscular	O
activity	O
.	O

Unlike	O
other	O
sedatives	O
and	O
anesthetics	O
,	O
the	O
concentration-dependence	O
of	O
clonidine	O
demonstrates	O
a	O
ceiling	O
beyond	O
which	O
the	O
administration	O
of	O
an	O
additional	O
drug	O
fails	O
to	O
enhance	O
the	O
effect	O
,	O
suggesting	O
that	O
the	O
thermoregulatory	O
effect	O
of	O
clonidine	O
may	O
be	O
limited	O
,	O
even	O
at	O
high	O
plasma	O
concentrations	O
.	O

The	O
gain	O
of	O
sweating	O
was	O
well	O
preserved	O
indicating	O
that	O
this	O
response	O
remains	O
effective	O
in	O
the	O
presence	O
of	O
sedatives	O
and	O
anesthetics	O
.	O

Combined	O
typhoid	O
fever	O
and	O
hepatitis	O
A	O
vaccine	O
:	O
comparison	O
of	O
immunogenicity	Others
and	O
safety	Others
to	O
concomitant	O
monovalent	O
vaccine	O
over	O
3	O
years	O
.	O

BACKGROUND	O
The	O
safety	Others
and	O
immunogenicity	Others
of	O
Viatim	O
,	O
a	O
combined	O
hepatitis	O
A	O
(	O
HA	O
)	O
and	O
typhoid	O
fever	O
(	O
Vi	O
)	O
vaccine	O
,	O
were	O
compared	O
with	O
the	O
monovalent	O
component	O
vaccines	O
up	O
to	O
and	O
1	O
month	O
after	O
a	O
booster	O
dose	O
at	O
3	O
years	O
.	O

METHODS	O
Healthy	O
,	O
adult	O
volunteers	O
were	O
randomized	O
to	O
receive	O
Viatim	O
(	O
group	O
A	O
,	O
n	O
=	O
179	O
)	O
or	O
separate	O
HA	O
and	O
Vi	O
vaccines	O
(	O
group	O
B	O
,	O
n	O
=	O
181	O
)	O
;	O
subgroups	O
were	O
boosted	O
after	O
3	O
years	O
with	O
Viatim	O
(	O
groups	O
C	O
and	O
D	O
,	O
n	O
=	O
56	O
and	O
46	O
,	O
respectively	O
)	O
.	O

Local	O
and	O
systemic	O
reactions	O
were	O
recorded	O
for	O
28	O
days	O
postvaccination	O
.	O

Seroconversion	Physical
and	O
seroprotection	Physical
rates	Physical
and	O
geometric	Physical
mean	Physical
antibody	Physical
concentrations	Physical
were	O
measured	O
at	O
14	O
and	O
28	O
days	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
years	O
postvaccination	O
,	O
and	O
28	O
days	O
after	O
the	O
booster	O
dose	O
.	O

RESULTS	O
Local	Others
and	Others
systemic	Others
safety	Others
profiles	Others
were	O
equivalent	O
between	O
the	O
two	O
groups	O
.	O

Immediate	Physical
local	Physical
reactions	Physical
were	O
infrequent	O
(	O
1	O
in	O
group	O
A	O
and	O
2	O
in	O
group	O
B	O
)	O
.	O

Local	Physical
reactions	Physical
,	O
consisting	Pain
mostly	Pain
of	Pain
mild	Pain
or	Pain
moderate	Pain
pain	Pain
,	O
were	O
least	O
frequent	O
with	O
monovalent	O
HA	O
.	O

Antibody	Physical
concentrations	Physical
to	O
both	O
antigens	O
were	O
similar	O
in	O
groups	O
A	O
and	O
B	O
,	O
in	O
which	O
HA	Physical
seroprotection	Physical
rates	Physical
(	O
>	O
or	O
=	O
20	O
mIU/mL	O
)	O
were	O
respectively	O
,	O
98.7	O
%	O
and	O
100	O
%	O
at	O
day	O
28	O
,	O
and	O
99.1	O
%	O
and	O
99.0	O
%	O
after	O
3	O
years	O
,	O
achieving	O
100	O
%	O
after	O
the	O
booster	O
.	O

Vi	Physical
seroprotection	Physical
rates	Physical
(	O
>	O
or	O
=	O
1	O
microg/mL	O
)	O
of	O
85.2	O
%	O
and	O
84.9	O
%	O
after	O
28	O
days	O
fell	O
to	O
32.1	O
%	O
and	O
35.6	O
%	O
after	O
3	O
years	O
,	O
increasing	O
to	O
67.3	O
%	O
and	O
69.8	O
%	O
after	O
the	O
booster	O
dose	O
.	O

CONCLUSIONS	O
The	O
combined	O
HA/Vi	O
vaccine	O
,	O
Viatim	O
,	O
had	O
equivalent	O
tolerability	Others
and	O
safety	Others
and	O
was	O
as	O
rapidly	Physical
immunogenic	Others
as	O
its	O
component	O
monovalent	O
vaccines	O
when	O
given	O
concurrently	O
.	O

A	O
booster	O
dose	O
after	O
3	O
years	O
significantly	O
increased	O
antibody	Physical
levels	Physical
with	O
some	O
evidence	O
of	O
relative	O
hyporesponsiveness	Physical
of	Physical
the	Physical
typhoid	Physical
response	Physical
.	O

Acute	O
exposure	O
to	O
acid	O
fog	O
:	O
influence	O
of	O
breathing	O
pattern	O
on	O
effective	Physical
dose	Physical
.	O

Concern	O
about	O
the	O
possible	O
adverse	Adverseeffect
health	Adverseeffect
effects	Adverseeffect
of	O
acid	O
fog	O
has	O
been	O
fed	O
by	O
two	O
observations	O
:	O
air	O
pollution	O
disasters	O
earlier	O
in	O
this	O
century	O
were	O
typically	O
associated	O
with	O
fog	O
,	O
and	O
current	O
samples	O
of	O
fog	O
water	O
can	O
be	O
strongly	O
acid	O
.	O

To	O
study	O
the	O
acute	O
effects	O
of	O
acid	O
fog	O
on	O
the	O
lung	O
,	O
the	O
authors	O
generated	O
a	O
monodisperse	O
10	O
microM	O
MMAD	O
aerosol	O
of	O
H2SO4	O
with	O
a	O
pH	O
of	O
2.0	O
and	O
a	O
nominal	O
concentration	O
of	O
500	O
micrograms/m3	O
.	O

They	O
exposed	O
seven	O
healthy	O
young	O
men	O
on	O
alternate	O
days	O
to	O
acid	O
or	O
control	O
equiosmolar	O
NaCl	O
aerosol	O
during	O
40	O
min	O
of	O
resting	O
ventilation	O
and	O
20	O
min	O
of	O
exercise	O
;	O
the	O
latter	O
was	O
sufficiently	O
intense	O
to	O
induce	O
oronasal	Physical
breathing	Physical
.	O

Exposure	O
was	O
by	O
means	O
of	O
a	O
head	O
dome	O
,	O
a	O
head-only	O
exposure	O
device	O
that	O
permitted	O
continuous	O
measurement	O
(	O
unfettered	O
breathing	O
)	O
of	O
Vr	O
,	O
f	O
,	O
VE	O
,	O
and	O
the	O
onset	O
and	O
persistence	O
of	O
oronasal	Physical
breathing	Physical
.	O

In	O
this	O
article	O
the	O
authors	O
compare	O
the	O
relative	O
importance	O
of	O
parameters	O
contributing	O
to	O
the	O
between-subject	O
variability	O
in	O
estimated	O
hydrogen	O
ion	O
dose	O
to	O
the	O
lower	O
airways	O
(	O
H+LAW	O
)	O
,	O
based	O
on	O
analysis	O
of	O
variance	O
.	O

Physiologic	O
parameters	O
accounted	O
for	O
70	O
%	O
of	O
the	O
variability	O
,	O
of	O
which	O
34	O
%	O
was	O
due	O
to	O
differences	O
in	O
duration	Physical
of	Physical
oronasal	Physical
breathing	Physical
(	Physical
tON	Physical
)	Physical
and	O
36	O
%	O
to	O
differences	O
in	O
ventilation	Physical
rate	Physical
during	Physical
oronasal	Physical
breathing	Physical
(	Physical
VE	Physical
(	Physical
ON	Physical
)	Physical
)	Physical
;	O
inhaled	Physical
hydrogen	Physical
ion	Physical
concentration	Physical
[	Physical
H+	Physical
]	Physical
,	O
the	O
environmental	O
parameter	O
,	O
contributed	O
only	O
30	O
%	O
.	O

Minute	O
ventilation	O
at	O
the	O
time	O
of	O
transition	O
from	O
nasal	O
to	O
oronasal	O
breathing	O
varied	O
significantly	O
among	O
subjects	O
even	O
if	O
normalized	O
to	O
FVC	O
,	O
an	O
index	O
of	O
lung	O
size	O
.	O

B-type	O
natriuretic	O
peptide	O
in	O
the	O
evaluation	O
and	O
management	O
of	O
dyspnoea	O
in	O
primary	O
care	O
.	O

OBJECTIVES	O
The	O
rapid	O
and	O
accurate	O
diagnosis	O
of	O
heart	O
failure	O
in	O
primary	O
care	O
is	O
a	O
major	O
unmet	O
clinical	O
need	O
.	O

We	O
evaluated	O
the	O
additional	O
use	O
of	O
B-type	Physical
natriuretic	Physical
peptide	Physical
(	Physical
BNP	Physical
)	Physical
levels	Physical
.	O

DESIGN	O
A	O
randomized	O
controlled	O
trial	O
.	O

SETTING	O
Twenty-nine	O
primary	O
care	O
physicians	O
in	O
Switzerland	O
and	O
Germany	O
coordinated	O
by	O
the	O
University	O
Hospital	O
Basel	O
,	O
Switzerland	O
.	O

SUBJECTS	O
A	O
total	O
of	O
323	O
consecutive	O
patients	O
presenting	O
with	O
dyspnoea	O
.	O

INTERVENTIONS	O
Assignment	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
a	O
diagnostic	O
strategy	O
including	O
point-of-care	O
measurement	O
of	O
BNP	O
(	O
n	O
=	O
163	O
)	O
or	O
standard	O
assessment	O
without	O
BNP	O
(	O
n	O
=	O
160	O
)	O
.	O

The	O
total	Others
medical	Others
cost	Others
at	Others
3	Others
months	Others
was	O
the	O
primary	O
end-point	O
.	O

Secondary	O
end-points	O
were	O
diagnostic	Others
certainty	Others
,	O
time	Others
to	Others
appropriate	Others
therapy	Others
,	O
functional	Others
capacity	Others
,	O
hospitalization	Adverseeffect
and	O
mortality	Mortality
.	O

The	O
final	O
diagnosis	O
was	O
adjudicated	O
by	O
a	O
physician	O
blinded	O
to	O
the	O
BNP	O
levels	O
.	O

RESULTS	O
Heart	Physical
failure	Physical
was	O
the	O
final	O
diagnosis	O
in	O
34	O
%	O
of	O
patients	O
.	O

The	O
number	Others
of	Others
hospitalizations	Others
,	O
functional	Others
status	Others
and	O
total	Others
medical	Others
cost	Others
at	Others
3	Others
months	Others
[	O
median	O
$	O
1655	O
,	O
interquartile	O
range	O
(	O
IQR	O
)	O
,	O
850-3331	O
vs.	O
$	O
1541	O
,	O
IQR	O
859-2827	O
;	O
P	O
=	O
0.68	O
]	O
were	O
similar	O
in	O
both	O
groups	O
.	O

BNP	Physical
increased	O
diagnostic	Others
certainty	Others
as	O
defined	O
by	O
the	O
need	O
for	O
further	O
diagnostic	O
work-up	O
(	O
33	O
%	O
vs.	O
45	O
%	O
;	O
P	O
=	O
0.02	O
)	O
and	O
accelerated	O
the	O
initiation	O
of	O
the	O
appropriate	O
treatment	O
(	O
13	O
days	O
vs.	O
25	O
days	O
;	O
P	O
=	O
0.01	O
)	O
.	O

The	O
area	O
under	O
the	O
receiver-operating	O
characteristics	O
curve	O
for	O
BNP	O
to	O
identify	O
heart	O
failure	O
was	O
0.87	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0.81-0.93	O
)	O
.	O

CONCLUSIONS	O
The	O
use	O
of	O
BNP	O
levels	O
in	O
primary	O
care	O
did	O
not	O
reduce	O
total	O
medical	O
cost	O
,	O
but	O
improved	O
some	O
of	O
the	O
secondary	O
end-points	O
including	O
diagnostic	O
certainty	O
and	O
time	O
to	O
initiation	O
of	O
appropriate	O
treatment	O
.	O

Anxiety	O
sensitivity	O
as	O
an	O
incremental	O
predictor	O
of	O
later	O
anxiety	O
symptoms	O
and	O
syndromes	O
.	O

Although	O
anxiety	O
sensitivity	O
(	O
AS	O
)	O
has	O
been	O
shown	O
to	O
predict	O
anxiety	O
symptoms	O
and	O
panic	O
,	O
this	O
literature	O
is	O
limited	O
in	O
regard	O
to	O
evaluating	O
AS	O
as	O
an	O
incremental	O
predictor	O
of	O
anxiety	O
psychopathology	O
relative	O
to	O
other	O
established	O
risk	O
factors	O
including	O
sex	O
and	O
negative	O
affect	O
.	O

The	O
present	O
report	O
prospectively	O
evaluated	O
whether	O
AS	O
was	O
predictive	O
of	O
later	O
changes	O
in	O
anxiety	Mental
symptoms	Mental
after	O
controlling	O
for	O
potential	O
confounding	O
factors	O
.	O

Consistent	O
with	O
hypothesis	O
,	O
AS	O
was	O
found	O
to	O
be	O
a	O
significant	O
,	O
incremental	O
predictor	O
of	O
anxiety	Mental
symptoms	Mental
over	O
time	O
,	O
even	O
after	O
controlling	O
for	O
sex	O
and	O
negative	O
affectivity	O
.	O

These	O
data	O
provide	O
novel	O
evidence	O
for	O
the	O
unique	O
association	O
between	O
AS	O
of	O
the	O
development	O
of	O
anxiety	O
symptoms	O
.	O

Behavioral	Mental
effects	Mental
of	O
Org	O
2766	O
,	O
a	O
synthetic	O
analog	O
of	O
the	O
adrenocorticotrophic	O
hormone	O
(	O
4-9	O
)	O
,	O
in	O
14	O
outpatient	O
autistic	O
children	O
.	O

Fourteen	O
children	O
(	O
12	O
infantile	O
autism	O
full	O
syndrome	O
present	O
,	O
2	O
atypical	O
pervasive	O
developmental	O
disorder	O
)	O
between	O
5	O
and	O
13	O
years	O
of	O
age	O
participated	O
in	O
a	O
double-blind	O
placebo-controlled	O
cross-over	O
trial	O
.	O

Each	O
child	O
received	O
20	O
mg	O
Org	O
2766	O
(	O
synthetic	O
analog	O
of	O
ACTH	O
4-9	O
)	O
/day	O
during	O
4	O
weeks	O
,	O
or	O
placebo	O
in	O
a	O
randomly	O
assigned	O
sequence	O
.	O

Drug	Mental
effects	Mental
were	O
monitored	O
by	O
ethological	Mental
playroom	Mental
observation	Mental
and	O
by	O
Aberrant	Mental
Behavior	Mental
Checklist	Mental
ratings	Mental
by	O
parents	O
and	O
teachers	O
.	O

Data	O
of	O
the	O
playroom	O
observation	O
pointed	O
to	O
an	O
activating	Mental
influence	Mental
of	O
Org	O
2766	O
,	O
as	O
revealed	O
by	O
a	O
significant	O
decrease	O
of	O
stereotypic	Mental
behavior	Mental
and	O
significant	O
increases	O
in	O
change	Mental
toys	Mental
,	Mental
locomote	Mental
,	Mental
and	Mental
talk	Mental
.	Mental

Checklist	O
ratings	O
did	O
not	O
show	O
significant	O
changes	O
.	O

The	O
clinical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Social	O
support	O
and	O
abstinence	Mental
from	O
opiates	O
and	O
cocaine	O
during	O
opioid	O
maintenance	O
treatment	O
.	O

Social	O
support	O
may	O
play	O
an	O
important	O
role	O
in	O
helping	O
drug	O
users	O
achieve	O
abstinence	Mental
;	Mental
however	O
these	O
benefits	O
may	O
depend	O
on	O
the	O
type	O
of	O
support	O
experienced	O
.	O

In	O
this	O
prospective	O
observational	O
study	O
,	O
we	O
examined	O
the	O
extent	O
to	O
which	O
general	O
and	O
abstinence-specific	O
support	O
,	O
both	O
structural	O
and	O
functional	O
,	O
predicted	O
opiate	O
and	O
cocaine	O
abstinence	O
in	O
128	O
opioid	O
maintenance	O
patients	O
receiving	O
either	O
methadone	O
or	O
LAAM	O
.	O

A	O
new	O
multidimensional	O
self-report	O
instrument	O
assessing	O
abstinence-specific	O
functional	O
support	O
was	O
developed	O
for	O
the	O
study	O
.	O

Previously	O
validated	O
measures	O
were	O
used	O
to	O
assess	O
the	O
remaining	O
types	O
of	O
support	O
.	O

With	O
baseline	O
abstinence	O
and	O
other	O
statistically	O
important	O
covariates	O
adjusted	O
,	O
hierarchical	O
logistic	O
regression	O
analyses	O
demonstrated	O
that	O
the	O
associations	O
between	O
social	O
support	O
at	O
study	O
baseline	O
and	O
biochemically	O
confirmed	O
abstinence	O
3	O
months	O
later	O
varied	O
by	O
type	O
of	O
support	O
and	O
by	O
drug	O
.	O

Greater	O
abstinence-specific	Mental
structural	Mental
support	Mental
(	O
operationalized	O
as	O
fewer	O
drug	O
users	O
in	O
the	O
social	O
network	O
)	O
and	O
decreases	O
in	O
three	O
types	O
of	O
negative	Mental
abstinence-specific	Mental
functional	Mental
support	Mental
(	Mental
Complaints	Mental
about	Mental
Drug	Mental
Use	Mental
,	Mental
Drug	Mental
Exposure	Mental
,	Mental
and	Mental
Demoralization	Mental
)	Mental
predicted	Mental
cocaine	Mental
,	O
but	O
not	O
opiate	Mental
abstinence	Mental
.	Mental

There	O
were	O
no	O
effects	O
for	O
general	O
support	O
,	O
whether	O
structural	O
or	O
functional	O
,	O
on	O
abstinence	Mental
from	O
either	O
drug	O
.	O

Interventions	O
that	O
focus	O
on	O
modifying	O
patients	O
'	O
abstinence-specific	O
support	O
may	O
be	O
helpful	O
in	O
reducing	O
the	O
high	O
rates	Mental
of	Mental
cocaine	Mental
use	Mental
disorders	Mental
in	O
this	O
population	O
.	O

Creon	O
10,000	O
Minimicrospheres	O
vs.	O
Creon	O
8,000	O
microspheres	O
--	O
an	O
open	O
randomised	O
crossover	O
preference	O
study	O
.	O

Creon	O
10,000	O
Minimicrospherestrade	O
mark	O
(	O
Creon	O
)	O
10,000	O
MMS	O
)	O
is	O
a	O
pancreatic	O
enzyme	O
formulation	O
that	O
contains	O
smaller	O
spheres	O
of	O
pancreatin	O
in	O
a	O
50	O
%	O
smaller	O
capsule	O
than	O
conventional	O
microspheres	O
(	O
Creon	O
)	O
8,000	O
)	O
.	O

This	O
three-centre	O
study	O
investigated	O
the	O
preference	O
of	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
for	O
these	O
products	O
.	O

In	O
one	O
centre	O
,	O
72	O
h	O
stool	Physical
fat	Physical
excretion	Physical
and	O
coefficient	Physical
of	Physical
fat	Physical
absorption	Physical
(	Physical
CFA	Physical
)	Physical
were	O
also	O
compared	O
.	O

Fifty-nine	O
patients	O
with	O
a	O
mean	O
age	O
10	O
years	O
(	O
range	O
3-17	O
)	O
took	O
Creon	O
8,000	O
ms	O
for	O
14	O
days	O
and	O
were	O
then	O
randomised	O
to	O
28	O
days	O
of	O
Creon	O
8,000	O
ms	O
followed	O
by	O
28	O
days	O
of	O
Creon	O
10,000	O
MMS	O
,	O
or	O
vice	O
versa	O
.	O

Dosing	O
was	O
lipase	O
for	O
lipase	O
according	O
to	O
the	O
labelled	O
declaration	O
.	O

At	O
the	O
end	O
of	O
the	O
second	O
treatment	O
period	O
,	O
51	O
of	O
54	O
patients	O
who	O
completed	O
the	O
study	O
expressed	O
a	O
preference	O
,	O
with	O
a	O
statistically	O
significant	O
preference	O
in	O
favour	O
of	O
Creon	O
10,000	O
MMS	O
(	O
47/51	O
;	O
87	O
%	O
)	O
vs.	O
Creon	O
8,000	O
ms	O
(	O
4/51	O
;	O
7.4	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Stool	Physical
fat	Physical
(	Physical
g/day	Physical
)	Physical
and	O
CFA	Physical
(	O
%	O
)	O
were	O
measured	O
in	O
24	O
patients	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
:	O
the	O
products	O
were	O
therapeutically	O
equivalent	O
(	O
Creon	O
10,000	O
:	O
8.4	O
g/day	O
,	O
91.3	O
%	O
CFA	O
;	O
Creon	O
8,000	O
:	O
6.7	O
g/day	O
,	O
93.5	O
%	O
CFA	O
)	O
.	O

Both	O
products	O
were	O
well	O
tolerated	O
.	O

In	O
conclusion	O
,	O
in	O
CF	O
children	O
we	O
found	O
a	O
clear	O
preference	O
for	O
Creon	O
10,000	O
MMS	O
compared	O
with	O
Creon	O
8,000	O
ms	O
with	O
no	O
difference	O
in	O
fat	Physical
absorption	Physical
between	O
the	O
two	O
products	O
.	O

Creon	O
10,000s	O
smaller	O
capsules	O
are	O
easier	O
to	O
take	O
and	O
should	O
aid	O
patient	O
compliance	O
.	O

Whole-body	O
CT	O
screening	O
:	O
scan	O
delay	O
and	O
contrast	O
injection	O
duration	O
for	O
optimal	Others
enhancement	Others
of	Others
abdominal	Others
organs	Others
and	O
deep	Others
vessels	Others
.	O

PURPOSE	O
To	O
assess	O
the	O
optimal	O
scan	O
delays	O
and	O
contrast	O
injection	O
durations	O
for	O
contrast-enhanced	O
whole-body	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
One	O
hundred	O
forty-two	O
patients	O
were	O
randomized	O
into	O
three	O
groups	O
:	O
protocol	O
A-scan	O
delay	O
of	O
65	O
s	O
after	O
starting	O
contrast	O
injection	O
over	O
30	O
s	O
;	O
protocol	O
B-105	O
and	O
70	O
s	O
;	O
and	O
protocol	O
C-145	O
and	O
110	O
s	O
,	O
respectively	O
.	O

Contrast	Others
enhancement	Others
and	O
diagnostic	Others
acceptability	Others
were	O
assessed	O
.	O

RESULTS	O
Qualitative	Others
assessment	Others
was	O
subtle	O
among	O
the	O
three	O
protocols	O
.	O

Homogenous	Others
enhancement	Others
of	Others
deep	Others
veins	Others
was	O
more	O
assuredly	O
achieved	O
with	O
protocol	O
C.	O
CONCLUSION	O
With	O
protocol	O
C	O
,	O
qualitatively	O
acceptable	O
enhancement	O
can	O
be	O
obtained	O
in	O
whole-body	O
CT	O
.	O

[	O
Effects	O
of	O
small	O
needle-knife	O
comprehensive	O
therapy	O
on	O
pain	O
and	O
lumbar	O
flexion	O
range	O
in	O
the	O
chronic	O
nonspecific	O
low	O
back	O
pain	O
patient	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
therapeutic	O
effect	O
of	O
small	O
needle-knife	O
comprehensive	O
therapy	O
on	O
pain	Pain
and	O
lumbar	Physical
flexion	Physical
range	Physical
in	O
the	O
chronic	O
nonspecific	O
low	O
back	O
pain	O
patient	O
.	O

METHODS	O
Three	O
hundred	O
and	O
five	O
cases	O
were	O
randomly	O
divided	O
into	O
a	O
needle-knife	O
group	O
of	O
153	O
cases	O
and	O
a	O
physiotherapy	O
group	O
of	O
152	O
cases	O
.	O

The	O
needle-knife	O
group	O
were	O
treated	O
with	O
small	O
needle-knife	O
releasing	O
therapy	O
,	O
blocking	O
and	O
functional	O
training	O
.	O

The	O
physiotherapy	O
group	O
were	O
treated	O
with	O
ultra-short	O
wave	O
,	O
modulated	O
medium	O
frequency	O
current	O
,	O
massage	O
and	O
functional	O
training	O
.	O

Pain	Pain
was	O
assessed	O
by	O
visual	Pain
analogue	Pain
scale	Pain
(	Pain
VAS	Pain
)	Pain
and	O
the	O
lumbar	Physical
flexion	Physical
range	Physical
was	O
determined	O
before	O
and	O
after	O
treatment	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
pain	Pain
and	O
the	O
lumbar	Physical
flexion	Physical
range	Physical
were	O
significantly	O
improved	O
in	O
the	O
two	O
groups	O
;	O
and	O
after	O
treatment	O
,	O
the	O
VAS	Pain
score	Pain
and	O
the	O
lumbar	Physical
flexion	Physical
range	Physical
were	O
(	O
1.60	O
+/-	O
0.38	O
)	O
points	O
and	O
(	O
65.76	O
+/-	O
15.11	O
)	O
cm	O
in	O
the	O
needle-knife	O
group	O
and	O
(	O
4.59	O
+/-	O
1.09	O
)	O
points	O
and	O
(	O
53.74	O
+/-	O
15.13	O
)	O
cm	O
in	O
the	O
physiotherapy	O
group	O
,	O
respectively	O
,	O
the	O
needle-knife	O
group	O
being	O
significantly	O
better	O
than	O
the	O
physiotherapy	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Follow-up	O
survey	O
of	O
6-36	O
months	O
showed	O
that	O
the	O
VAS	Pain
score	Pain
and	O
the	O
lumbar	Physical
flexion	Physical
range	Physical
in	O
the	O
needle-knife	O
group	O
were	O
superior	O
to	O
those	O
in	O
the	O
physiotherapy	O
group	O
.	O

CONCLUSION	O
Small	O
needle-knife	O
comprehensive	O
therapy	O
can	O
significantly	O
improve	O
pain	Pain
and	O
lumbar	Physical
flexion	Physical
range	Physical
in	O
the	O
chronic	O
nonspecific	O
low	O
back	O
pain	O
patient	O
,	O
with	O
a	O
stable	O
long-term	O
therapeutic	O
effect	O
.	O

Salbutamol	O
or	O
mist	O
in	O
acute	O
bronchiolitis	O
.	O

BACKGROUND	O
The	O
role	O
of	O
bronchodilators	O
in	O
the	O
treatment	O
of	O
bronchiolitis	O
remains	O
controversial	O
.	O

METHODS	O
A	O
double-blind	O
,	O
placebo	O
controlled	O
trial	O
was	O
performed	O
to	O
evaluate	O
the	O
clinical	O
response	O
to	O
nebulized	O
salbutamol	O
.	O

One	O
hundred	O
and	O
fifty-six	O
infants	O
aged	O
between	O
7	O
weeks	O
and	O
24	O
months	O
who	O
had	O
had	O
an	O
episode	O
of	O
wheezing	O
and	O
other	O
signs	O
and	O
symptoms	O
of	O
bronchiolitis	O
were	O
randomized	O
to	O
three	O
groups	O
as	O
follows	O
:	O
(	O
i	O
)	O
nebulized	O
salbutamol	O
was	O
administered	O
to	O
52	O
patients	O
in	O
group	O
I	O
at	O
a	O
dose	O
of	O
0.15	O
mg/kg	O
in	O
2	O
mL	O
saline	O
;	O
(	O
ii	O
)	O
saline	O
was	O
nebulized	O
to	O
52	O
patients	O
in	O
group	O
II	O
and	O
(	O
iii	O
)	O
in	O
group	O
III	O
52	O
patients	O
received	O
mist	O
in	O
a	O
tent	O
.	O

All	O
three	O
groups	O
were	O
administered	O
oxygen	O
during	O
the	O
procedures	O
.	O

Treatment	O
was	O
repeated	O
with	O
the	O
same	O
agent	O
after	O
30	O
min	O
if	O
the	O
respiratory	O
score	O
was	O
5	O
or	O
more	O
.	O

Respiratory	Physical
rate	Physical
,	O
heart	Physical
rate	Physical
,	O
oxygen	Physical
saturation	Physical
and	O
presence	Physical
of	Physical
cyanosis	Physical
,	Physical
wheezing	Physical
,	Physical
retractions	Physical
were	O
recorded	O
before	O
and	O
after	O
each	O
treatment	O
.	O

RESULTS	O
The	O
decrease	O
in	O
the	O
respiratory	Physical
score	Physical
was	O
5.2	O
+/-	O
1.8	O
,	O
0.82	O
+/-	O
2.4	O
and	O
1.7	O
+/-	O
1.3	O
in	O
group	O
I	O
,	O
II	O
and	O
III	O
,	O
respectively	O
.	O

The	O
decrease	O
in	O
group	O
I	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
other	O
groups	O
.	O

Heart	Physical
rate	Physical
was	O
similar	O
between	O
groups	O
.	O

Oxygen	Physical
saturation	Physical
decreased	O
in	O
group	O
I	O
without	O
reaching	O
statistical	O
significance	O
.	O

CONCLUSIONS	O
Salbutamol	O
was	O
shown	O
to	O
be	O
effective	Others
and	O
safe	Others
in	O
the	O
treatment	O
of	O
acute	O
bronchiolitis	O
.	O

Computer-navigated	O
versus	O
conventional	O
total	O
knee	O
arthroplasty	O
a	O
prospective	O
randomized	O
trial	O
.	O

BACKGROUND	O
The	O
literature	O
lacks	O
studies	O
that	O
confirm	O
whether	O
the	O
improved	O
radiographic	O
alignment	O
that	O
can	O
be	O
achieved	O
with	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
improves	O
patients?	O
activities	O
of	O
daily	O
living	O
or	O
the	O
durability	O
of	O
total	O
knee	O
prostheses	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
improves	O
the	O
clinical	O
function	O
,	O
alignment	O
,	O
and	O
survivorship	O
of	O
the	O
components	O
.	O

METHODS	O
We	O
prospectively	O
compared	O
the	O
results	O
of	O
520	O
patients	O
with	O
osteoarthritis	O
who	O
underwent	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
for	O
one	O
knee	O
and	O
conventional	O
total	O
knee	O
arthroplasty	O
for	O
the	O
other	O
.	O

The	O
assignment	O
of	O
the	O
knee	O
to	O
navigation	O
or	O
not	O
was	O
done	O
randomly	O
.	O

There	O
were	O
452	O
women	O
(	O
904	O
knees	O
)	O
and	O
sixty-eight	O
men	O
(	O
136	O
knees	O
)	O
with	O
a	O
mean	O
age	O
of	O
sixty-eight	O
years	O
(	O
range	O
,	O
forty-nine	O
to	O
eighty-eight	O
years	O
)	O
at	O
the	O
time	O
of	O
the	O
index	O
arthroplasty	O
.	O

The	O
mean	O
follow-up	O
period	O
was	O
10.8	O
years	O
(	O
range	O
,	O
ten	O
to	O
twelve	O
years	O
)	O
.	O

The	O
patients	O
were	O
assessed	O
clinically	O
and	O
radiographically	O
with	O
the	O
rating	O
system	O
of	O
the	O
Knee	Physical
Society	Physical
and	O
with	O
the	O
Western	Physical
Ontario	Physical
and	Physical
McMaster	Physical
Universities	Physical
Osteoarthritis	Physical
Index	Physical
(	Physical
WOMAC	Physical
)	Physical
score	Physical
at	O
three	O
months	O
,	O
one	O
year	O
,	O
and	O
annually	O
thereafter	O
.	O

RESULTS	O
Total	Physical
knee	Physical
scores	Physical
,	O
knee	Physical
function	Physical
scores	Physical
,	O
pain	Pain
scores	Pain
,	O
WOMAC	Physical
scores	Physical
,	O
knee	Physical
motion	Physical
,	O
and	O
activity	Physical
scores	Physical
did	O
not	O
show	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
preoperatively	O
or	O
at	O
the	O
time	O
of	O
the	O
final	O
follow-up	O
.	O

Alignment	O
and	O
the	O
survivorship	O
of	O
the	O
components	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
Kaplan-Meier	O
survivorship	O
with	O
revision	O
as	O
the	O
end	O
point	O
at	O
10.8	O
years	O
was	O
98.8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	O
computernavigated	O
total	O
knee	O
arthroplasty	O
group	O
and	O
99.2	O
%	O
(	O
95	O
%	O
CI	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	O
conventional	O
total	O
knee	O
arthroplasty	O
group	O
.	O

CONCLUSIONS	O
Our	O
data	O
demonstrated	O
no	O
difference	O
in	O
clinical	O
function	O
or	O
alignment	O
and	O
survivorship	O
of	O
the	O
components	O
between	O
the	O
knees	O
that	O
underwent	O
computer-navigated	O
total	O
knee	O
arthroplasty	O
and	O
those	O
that	O
underwent	O
conventional	O
total	O
knee	O
arthroplasty	O
.	O

Autism-Spectrum	O
Quotient-Japanese	O
version	O
and	O
its	O
short	O
forms	O
for	O
screening	O
normally	O
intelligent	O
persons	O
with	O
pervasive	O
developmental	O
disorders	O
.	O

A	O
Japanese	O
version	O
of	O
the	O
Autism	O
Spectrum	O
Quotient	O
(	O
AQ	O
)	O
,	O
AQ-J	O
was	O
administered	O
to	O
25	O
normally	O
intelligent	O
high-functioning	O
pervasive	O
developmental	O
disorder	O
(	O
HPDD	O
)	O
patients	O
(	O
mean	O
age	O
,	O
24.2	O
years	O
;	O
24	O
male	O
,	O
one	O
female	O
)	O
and	O
215	O
controls	O
(	O
mean	O
age	O
,	O
30.4	O
years	O
;	O
86	O
male	O
,	O
129	O
female	O
)	O
randomly	O
selected	O
from	O
the	O
general	O
population	O
.	O

The	O
AQ-J	O
had	O
satisfactory	Others
internal	Others
consistency	Others
reliability	Others
(	O
Cronbach	O
's	O
alpha	O
>	O
0.70	O
in	O
the	O
two	O
groups	O
)	O
,	O
test-retest	Others
reliability	Others
,	O
and	O
discriminant	Others
validity	Others
[	O
i.e	O
.	O

the	O
AQ-J	O
score	O
was	O
significantly	O
higher	O
in	O
the	O
HPDD	O
(	O
mean	O
,	O
29.6	O
)	O
than	O
controls	O
(	O
mean	O
,	O
22.2	O
)	O
]	O
.	O

At	O
a	O
cut-off	O
of	O
26	O
,	O
the	O
AQ-J	Physical
had	O
satisfactory	Others
sensitivity	Others
,	O
specificity	Others
,	O
and	O
negative	Others
predictive	Others
value	Others
,	O
but	O
it	O
had	O
low	Others
positive	Others
predictive	Others
value	Others
(	O
0.24	O
)	O
possibly	O
due	O
to	O
the	O
facts	O
that	O
the	O
25	O
mild	O
HPDD	O
patients	O
scored	O
lower	O
and	O
the	O
controls	O
scored	O
higher	O
on	O
the	O
AQ-J	O
than	O
British	O
counterparts	O
on	O
the	O
AQ	O
.	O

The	O
AQ-J-21	Physical
(	Physical
consisting	Physical
of	Physical
21	Physical
items	Physical
significantly	Physical
associated	Physical
with	Physical
HPDD	Physical
diagnosis	Physical
)	Physical
and	O
the	O
AQ-J-10	Physical
(	Physical
consisting	Physical
of	Physical
10	Physical
of	Physical
the	Physical
21	Physical
items	Physical
with	Physical
an	Physical
effect	Physical
size	Physical
>	Physical
0.17	Physical
)	Physical
had	O
higher	O
,	O
although	O
not	Physical
satisfactory	Physical
,	O
positive	Others
predictive	Others
values	Others
of	O
0.35	O
and	O
0.46	O
at	O
cut-offs	O
of	O
12	O
and	O
7	O
,	O
respectively	O
,	O
than	O
the	O
AQ-J	O
.	O

The	O
AQ-J	O
and	O
two	O
short	O
forms	O
are	O
useful	O
not	O
to	O
predict	O
but	O
to	O
rule	O
out	O
mild	Physical
HPDD	Physical
,	O
the	O
most	O
difficult	O
part	O
of	O
HPDD	O
to	O
be	O
distinguished	O
from	O
non-PDD	O
conditions	O
,	O
in	O
persons	O
scoring	O
under	O
the	O
cut-offs	O
and	O
to	O
consider	O
professionals	O
'	O
examination	O
of	O
HPDD	O
in	O
persons	O
scoring	O
over	O
them	O
,	O
because	O
their	O
negative	O
predictive	O
values	O
were	O
satisfactory	O
.	O

The	O
aging	O
motor	O
system	O
as	O
a	O
model	O
for	O
plastic	O
changes	O
of	O
GABA-mediated	O
intracortical	O
inhibition	O
and	O
their	O
behavioral	O
relevance	O
.	O

Since	O
GABAA-mediated	O
intracortical	O
inhibition	O
has	O
been	O
shown	O
to	O
underlie	O
plastic	O
changes	O
throughout	O
the	O
lifespan	O
from	O
development	O
to	O
aging	O
,	O
here	O
,	O
the	O
aging	O
motor	O
system	O
was	O
used	O
as	O
a	O
model	O
to	O
analyze	O
the	O
interdependence	O
of	O
plastic	O
alterations	O
within	O
the	O
inhibitory	O
motorcortical	O
network	O
and	O
level	O
of	O
behavioral	O
performance	O
.	O

Double-pulse	O
transcranial	O
magnetic	O
stimulation	O
(	O
dpTMS	O
)	O
was	O
used	O
to	O
examine	O
inhibition	O
by	O
means	O
of	O
short-interval	O
intracortical	O
inhibition	O
(	O
SICI	O
)	O
of	O
the	O
contralateral	O
primary	O
motor	O
cortex	O
in	O
a	O
sample	O
of	O
64	O
healthy	O
right-handed	O
human	O
subjects	O
covering	O
a	O
wide	O
range	O
of	O
the	O
adult	O
lifespan	O
(	O
age	O
range	O
20-88	O
years	O
,	O
mean	O
47.6	O
?	O
20.7	O
,	O
34	O
female	O
)	O
.	O

SICI	O
was	O
evaluated	O
during	O
resting	O
state	O
and	O
in	O
an	O
event-related	O
condition	O
during	O
movement	O
preparation	O
in	O
a	O
visually	O
triggered	O
simple	O
reaction	O
time	O
task	O
.	O

In	O
a	O
subgroup	O
(	O
N	O
=	O
23	O
)	O
,	O
manual	O
motor	Physical
performance	Physical
was	O
tested	O
with	O
tasks	O
of	O
graded	O
dexterous	O
demand	O
.	O

Weak	O
resting-state	O
inhibition	O
was	O
associated	O
with	O
an	O
overall	O
lower	O
manual	O
motor	O
performance	O
.	O

Better	O
event-related	O
modulation	O
of	O
inhibition	O
correlated	O
with	O
better	O
performance	O
in	O
more	O
demanding	O
tasks	O
,	O
in	O
which	O
fast	O
alternating	O
activation	O
of	O
cortical	O
representations	O
are	O
necessary	O
.	O

Declining	O
resting-state	O
inhibition	O
was	O
associated	O
with	O
weakened	O
event-related	O
modulation	O
of	O
inhibition	O
.	O

Therefore	O
,	O
reduced	O
resting-state	O
inhibition	O
might	O
lead	O
to	O
a	O
subsequent	O
loss	O
of	O
modulatory	O
capacity	O
,	O
possibly	O
reflecting	O
malfunctioning	O
precision	O
in	O
GABAAergic	O
neurotransmission	O
;	O
the	O
consequence	O
is	O
an	O
inevitable	O
decline	O
in	O
motor	O
function	O
.	O

Transurethral	O
prostate	O
resection	O
and	O
bleeding	O
:	O
a	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
of	O
role	O
of	O
finasteride	O
for	O
decreasing	O
operative	O
blood	O
loss	O
.	O

PURPOSE	O
Bleeding	O
associated	O
with	O
transurethral	O
prostate	O
resection	O
can	O
often	O
be	O
significant	O
and	O
lead	O
to	O
increased	O
morbidity	O
and	O
occasionally	O
mortality	O
.	O

It	O
has	O
been	O
shown	O
that	O
finasteride	O
decreases	O
bleeding	O
in	O
patients	O
with	O
hematuria	O
of	O
prostatic	O
origin	O
.	O

We	O
hypothesized	O
that	O
bleeding	O
in	O
patients	O
undergoing	O
transurethral	O
prostate	O
resection	O
could	O
be	O
decreased	O
by	O
giving	O
finasteride	O
for	O
2	O
weeks	O
before	O
surgery	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
70	O
patients	O
scheduled	O
to	O
undergo	O
elective	O
transurethral	O
prostate	O
resection	O
were	O
randomized	O
to	O
receive	O
5	O
mg.	O
finasteride	O
daily	O
or	O
placebo	O
for	O
2	O
weeks	O
before	O
surgery	O
.	O

Serum	Physical
hemoglobin	Physical
was	O
measured	O
before	O
and	O
after	O
surgery	O
,	O
and	O
the	O
following	O
day	O
.	O

The	O
volume	Others
of	Others
irrigation	Others
fluid	Others
used	O
and	O
its	O
hemoglobin	O
concentration	O
as	O
well	O
as	O
resected	O
prostate	O
weight	O
were	O
recorded	O
.	O

RESULTS	O
Of	O
the	O
68	O
patients	O
who	O
underwent	O
transurethral	O
prostate	O
resection	O
2	O
were	O
withdrawn	O
before	O
surgery	O
,	O
and	O
so	O
32	O
received	O
finasteride	O
and	O
36	O
received	O
placebo	O
.	O

There	O
was	O
significantly	O
less	O
mean	Physical
blood	Physical
loss	Physical
in	Physical
irrigation	Physical
fluid	Physical
in	O
the	O
finasteride	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
43.6	O
versus	O
69.3	O
gm	O
.	O

hemoglobin	O
,	O
p	O
=	O
0.011	O
)	O
.	O

The	O
mean	O
difference	O
was	O
more	O
significant	O
when	O
blood	Physical
loss	Physical
per	O
gm	O
.	O

resected	O
prostate	O
was	O
calculated	O
(	O
2.65	O
versus	O
4.65	O
gm	O
.	O

hemoglobin	O
per	O
gm	O
.	O

prostate	O
,	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
This	O
study	O
shows	O
that	O
finasteride	O
given	O
for	O
2	O
weeks	O
preoperatively	O
decreases	O
bleeding	Physical
in	O
patients	O
undergoing	O
transurethral	O
prostate	O
resection	O
.	O

Further	O
study	O
is	O
required	O
to	O
determine	O
the	O
optimal	O
timing	O
and	O
dose	O
duration	O
to	O
minimize	O
blood	Physical
loss	Physical
and	O
identify	O
how	O
relevant	O
such	O
a	O
decrease	O
in	O
bleeding	O
is	O
in	O
clinical	O
practice	O
.	O

Effect	O
of	O
acute	O
exercise	O
on	O
executive	Mental
function	Mental
in	O
children	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
effect	O
of	O
acute	O
aerobic	O
exercise	O
on	O
executive	Mental
function	Mental
in	O
children	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O

Forty	O
children	O
with	O
ADHD	O
were	O
randomly	O
assigned	O
into	O
exercise	O
or	O
control	O
groups	O
.	O

Participants	O
in	O
the	O
exercise	O
group	O
performed	O
a	O
moderate	O
intensity	O
aerobic	O
exercise	O
for	O
30	O
min	O
,	O
whereas	O
the	O
control	O
group	O
watched	O
a	O
running/exercise-related	O
video	O
.	O

Neuropsychological	Others
tasks	Others
,	Others
the	Others
Stroop	Others
Test	Others
and	Others
the	Others
Wisconsin	Others
Card	Others
Sorting	Others
Test	Others
(	Others
WCST	Others
)	Others
,	O
were	O
assessed	O
before	O
and	O
after	O
each	O
treatment	O
.	O

The	O
results	O
indicated	O
that	O
acute	O
exercise	O
facilitated	O
performance	O
in	O
the	O
Stroop	O
Test	O
,	O
particularly	O
in	O
the	O
Stroop	Others
Color-Word	Others
condition	Others
.	Others

Additionally	O
,	O
children	O
in	O
the	O
exercise	O
group	O
demonstrated	O
improvement	O
in	O
specific	O
WCST	Mental
performances	Mental
in	O
Non-perseverative	Mental
Errors	Mental
and	Mental
Categories	Mental
Completed	Mental
,	O
whereas	O
no	O
influences	O
were	O
found	O
in	O
those	O
performances	O
in	O
the	O
control	O
group	O
.	O

Tentative	O
explanations	O
for	O
the	O
exercise	O
effect	O
postulate	O
that	O
exercise	O
allocates	O
attention	O
resources	O
,	O
influences	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
,	O
and	O
is	O
implicated	O
in	O
exercise-induced	O
dopamine	O
release	O
.	O

These	O
findings	O
are	O
promising	O
and	O
additional	O
investigations	O
to	O
explore	O
the	O
efficacy	Others
of	O
exercise	O
on	O
executive	O
function	O
in	O
children	O
with	O
ADHD	O
are	O
encouraged	O
.	O

Mechanisms	O
underlying	O
the	O
lack	O
of	O
effect	O
of	O
implantable	O
cardioverter-defibrillator	O
therapy	O
on	O
mortality	Mortality
in	O
high-risk	O
patients	O
with	O
recent	O
myocardial	O
infarction	O
:	O
insights	O
from	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O

BACKGROUND	O
although	O
implantable	O
cardioverter-defibrillators	O
(	O
ICDs	O
)	O
lower	O
mortality	O
in	O
stable	O
patients	O
with	O
low	O
ejection	O
fraction	O
late	O
after	O
myocardial	O
infarction	O
,	O
randomized	O
trials	O
of	O
ICD	O
versus	O
control	O
subjects	O
implanted	O
early	O
after	O
myocardial	O
infarction	O
do	O
not	O
show	O
mortality	O
benefit	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
possible	O
mechanisms	O
underlying	O
the	O
lack	O
of	O
mortality	Mortality
benefit	O
in	O
the	O
Defibrillation	O
in	O
Acute	O
Myocardial	O
Infarction	O
Trial	O
(	O
DINAMIT	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
this	O
is	O
a	O
secondary	O
analysis	O
of	O
the	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

Outpatients	O
with	O
recent	O
(	O
6	O
to	O
40	O
days	O
)	O
acute	O
myocardial	O
infarction	O
,	O
left	O
ventricular	O
dysfunction	O
(	O
ejection	O
fraction	O
<	O
35	O
%	O
)	O
,	O
and	O
low	O
heart	O
rate	O
variability	O
were	O
randomized	O
to	O
ICD	O
(	O
n=311	O
)	O
or	O
to	O
standard	O
medical	O
therapy	O
(	O
n=342	O
)	O
.	O

In	O
a	O
competing-risks	O
analysis	O
,	O
those	O
factors	O
that	O
increased	O
the	O
risk	Mortality
of	Mortality
arrhythmic	Mortality
death	Mortality
also	O
increased	O
the	O
risk	Mortality
of	Mortality
nonarrhythmic	Mortality
deaths	Mortality
.	O

After	O
adjustment	O
for	O
these	O
factors	O
,	O
receiving	O
an	O
ICD	O
was	O
associated	O
with	O
a	O
decreased	O
risk	Mortality
of	Mortality
arrhythmic	Mortality
death	Mortality
(	O
hazard	O
ratio	O
,	O
0.33	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.15	O
to	O
0.71	O
)	O
but	O
an	O
increase	O
in	O
nonarrhythmic	Mortality
death	Mortality
(	O
hazard	O
ratio	O
,	O
1.70	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.00	O
to	O
2.80	O
)	O
.	O

In	O
an	O
adjusted	O
time-dependent	O
analysis	O
,	O
patients	O
receiving	O
an	O
ICD	O
and	O
having	O
appropriate	O
ICD	O
therapy	O
had	O
a	O
15.1	O
%	O
yearly	Mortality
hazard	Mortality
of	Mortality
mortality	Mortality
compared	O
with	O
5.2	O
%	O
in	O
ICD	O
patients	O
with	O
no	O
appropriate	O
therapy	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
reduction	O
in	O
sudden	Mortality
death	Mortality
in	O
ICD	O
patients	O
was	O
completely	O
offset	O
by	O
increased	O
nonarrhythmic	Mortality
deaths	Mortality
,	O
which	O
were	O
greatest	O
in	O
patients	O
receiving	O
ICD	O
shock	O
therapy	O
(	O
hazard	O
ratio	O
,	O
6.0	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
2.8	O
to	O
12.7	O
)	O
.	O

CONCLUSIONS	O
in	O
patients	O
receiving	O
ICDs	O
early	O
after	O
myocardial	O
infarction	O
,	O
those	O
factors	O
that	O
are	O
associated	O
with	O
arrhythmia	O
requiring	O
ICD	O
therapy	O
are	O
also	O
associated	O
with	O
a	O
high	O
risk	O
of	O
nonsudden	Mortality
death	Mortality
,	O
negating	O
the	O
benefit	O
of	O
ICDs	O
in	O
this	O
setting	O
.	O

Double-blind	O
randomized	O
evaluation	O
of	O
intercostal	O
nerve	O
blocks	O
as	O
an	O
adjuvant	O
to	O
subarachnoid	O
administered	O
morphine	O
for	O
post-thoracotomy	O
analgesia	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Thoracotomy	O
is	O
associated	O
with	O
pain	O
and	O
compromised	O
pulmonary	O
function	O
.	O

Intercostal	O
nerve	O
blocks	O
(	O
INB	O
)	O
and	O
subarachnoid	O
morphine	O
(	O
SM	O
)	O
act	O
on	O
different	O
portions	O
of	O
the	O
pain	O
pathway	O
.	O

Each	O
is	O
effective	O
for	O
post-thoracotomy	O
pain	Pain
relief	O
.	O

The	O
combination	O
of	O
these	O
two	O
modalities	O
in	O
relieving	O
post-thoracotomy	Pain
pain	Pain
and	O
improving	O
postoperative	Physical
pulmonary	Physical
function	Physical
has	O
not	O
been	O
investigated	O
.	O

METHODS	O
In	O
a	O
double-blind	O
study	O
,	O
20	O
patients	O
undergoing	O
lateral	O
thoracotomy	O
for	O
lung	O
resection	O
were	O
randomized	O
to	O
receive	O
0.5	O
mg	O
SM	O
preoperatively	O
and	O
INB	O
with	O
bupivacaine	O
(	O
INB+	O
)	O
prior	O
to	O
wound	O
closure	O
or	O
0.5	O
mg	O
SM	O
with	O
INB	O
using	O
saline	O
(	O
INB-	O
)	O
.	O

Visual	Pain
analog	Pain
scale	Pain
pain	Pain
scores	Pain
at	O
rest	O
,	O
with	Physical
cough	Physical
,	Physical
and	Physical
with	Physical
movement	Physical
of	Physical
the	Physical
ipsilateral	Physical
arm	Physical
,	Physical
forced	Physical
expiratory	Physical
volume	Physical
in	Physical
1	Physical
second	Physical
(	Physical
FEV1	Physical
)	Physical
,	O
and	O
forced	Physical
vital	Physical
capacity	Physical
(	Physical
FVC	Physical
)	Physical
were	O
measured	O
at	O
4	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
after	O
the	O
operation	O
.	O

Opioid	Others
use	Others
was	O
measured	O
during	O
the	O
initial	O
24	O
hours	O
after	O
the	O
operation	O
.	O

RESULTS	O
At	O
4	O
hours	O
,	O
the	O
INB+	O
group	O
demonstrated	O
better	O
FEV1	Physical
(	O
56.6	O
%	O
vs.	O
40.4	O
%	O
of	O
baseline	O
,	O
P	O
<	O
.05	O
)	O
and	O
FVC	Physical
values	O
(	O
54.6	O
%	O
vs.	O
39.6	O
%	O
of	O
baseline	O
,	O
P	O
<	O
.05	O
)	O
and	O
less	O
resting	O
and	O
cough	O
pain	O
(	O
P	O
<	O
.05	O
)	O
.	O

However	O
,	O
FEV1	Physical
continued	O
to	O
decline	O
in	O
the	O
INB+	O
group	O
at	O
24	O
hours	O
to	O
lower	O
than	O
the	O
INB-	O
group	O
although	O
pain	Pain
scores	Pain
were	O
similar	O
beyond	O
4	O
hours	O
.	O

Opioid	Others
usage	Others
during	O
the	O
first	O
24	O
hours	O
was	O
similar	O
(	O
INB-	O
,	O
16.7	O
mg	O
vs.	O
INB+	O
,	O
13.2	O
mg	O
,	O
P	O
=	O
.7	O
)	O
.	O

CONCLUSIONS	O
Although	O
postoperative	O
INB	O
provided	O
modest	O
improvements	O
in	O
pain	O
and	O
pulmonary	O
function	O
when	O
used	O
as	O
an	O
adjuvant	O
to	O
0.5	O
mg	O
SM	O
for	O
post-thoracotomy	O
analgesia	O
,	O
the	O
benefits	O
were	O
transient	O
.	O

The	O
authors	O
do	O
not	O
recommend	O
adding	O
INB	O
for	O
patients	O
undergoing	O
lateral	O
thoracotomy	O
who	O
receive	O
0.5	O
mg	O
SM	O
.	O

Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
oral	O
sirolimus	O
for	O
restenosis	Physical
prevention	O
in	O
patients	O
with	O
in-stent	O
restenosis	O
:	O
the	O
Oral	O
Sirolimus	O
to	O
Inhibit	O
Recurrent	O
In-stent	O
Stenosis	O
(	O
OSIRIS	O
)	O
trial	O
.	O

BACKGROUND	O
Despite	O
recent	O
advances	O
in	O
interventional	O
cardiology	O
,	O
including	O
the	O
introduction	O
of	O
drug-eluting	O
stents	O
for	O
de	O
novo	O
coronary	O
lesions	O
,	O
the	O
treatment	O
of	O
in-stent	O
restenosis	O
(	O
ISR	O
)	O
remains	O
a	O
challenging	O
clinical	O
issue	O
.	O

Given	O
the	O
efficacy	O
of	O
systemic	O
sirolimus	O
administration	O
to	O
prevent	O
neointimal	Physical
hyperplasia	Physical
in	O
animal	O
models	O
and	O
to	O
halt	O
and	O
even	O
reverse	O
the	O
progression	O
of	O
allograft	O
vasculopathy	O
,	O
the	O
aim	O
of	O
the	O
present	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
10-day	O
oral	O
sirolimus	O
treatment	O
with	O
2	O
different	O
loading	O
regimens	O
for	O
the	O
prevention	O
of	O
recurrent	O
restenosis	O
in	O
patients	O
with	O
ISR	O
.	O

METHODS	O
AND	O
RESULTS	O
Three	O
hundred	O
symptomatic	O
patients	O
with	O
ISR	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
treatment	O
arms	O
:	O
placebo	O
or	O
usual-dose	O
or	O
high-dose	O
sirolimus	O
.	O

Patients	O
received	O
a	O
cumulative	O
loading	O
dose	O
of	O
0	O
,	O
8	O
,	O
or	O
24	O
mg	O
of	O
sirolimus	O
2	O
days	O
before	O
and	O
the	O
day	O
of	O
repeat	O
intervention	O
followed	O
by	O
maintenance	O
therapy	O
of	O
2	O
mg/d	O
for	O
7	O
days	O
.	O

Angiographic	Physical
restenosis	Physical
at	Physical
6-month	Physical
angiography	Physical
was	O
the	O
primary	O
end	O
point	O
of	O
the	O
study	O
.	O

Restenosis	Physical
was	O
significantly	O
reduced	O
from	O
42.2	O
%	O
to	O
38.6	O
%	O
and	O
to	O
22.1	O
%	O
in	O
the	O
placebo	O
,	O
usual-dose	O
,	O
and	O
high-dose	O
sirolimus	O
groups	O
,	O
respectively	O
(	O
P=0.005	O
)	O
.	O

Similarly	O
,	O
the	O
need	Others
for	Others
target	Others
vessel	Others
revascularization	Others
was	O
reduced	O
from	O
25.5	O
%	O
to	O
24.2	O
%	O
and	O
to	O
15.2	O
%	O
in	O
the	O
placebo	O
,	O
usual-dose	O
,	O
and	O
high-dose	O
groups	O
,	O
respectively	O
(	O
P=0.08	O
)	O
.	O

The	Physical
sirolimus	Physical
blood	Physical
concentration	Physical
on	O
the	O
day	O
of	O
the	O
procedure	O
correlated	O
significantly	O
with	O
the	O
late	O
lumen	O
loss	O
at	O
follow-up	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
ISR	O
,	O
an	O
oral	O
adjunctive	O
sirolimus	O
treatment	O
with	O
an	O
intensified	O
loading	O
regimen	O
before	O
coronary	O
intervention	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
the	O
angiographic	Physical
parameters	Physical
of	Physical
restenosis	Physical
.	Physical

Step-down	O
approach	O
using	O
either	O
cyclosporin	O
A	O
or	O
methotrexate	O
as	O
maintenance	O
therapy	O
in	O
early	O
rheumatoid	O
arthritis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
feasibility	Others
and	O
outcome	Others
of	O
the	O
step-down	O
approach	O
using	O
either	O
cyclosporin	O
A	O
(	O
CSA	O
)	O
or	O
methotrexate	O
(	O
MTX	O
)	O
as	O
maintenance	O
therapy	O
following	O
6	O
months	O
treatment	O
with	O
these	O
2	O
agents	O
in	O
combination	O
in	O
early	O
,	O
nonerosive	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
Fifty-seven	O
patients	O
younger	O
than	O
65	O
years	O
with	O
early	O
,	O
nonerosive	O
RA	O
were	O
first	O
treated	O
with	O
CSA	O
and	O
MTX	O
in	O
combination	O
for	O
6	O
months	O
.	O

They	O
were	O
then	O
randomly	O
stepped	O
down	O
to	O
single-agent	O
maintenance	O
treatment	O
for	O
another	O
18	O
months	O
.	O

Safety	Others
,	O
clinical	Others
efficacy	Others
,	O
survival	Others
on	Others
treatment	Others
,	O
and	O
radiographic	Physical
progression	Physical
were	O
evaluated	O
.	O

RESULTS	O
When	O
being	O
treated	O
with	O
combination	O
therapy	O
,	O
7	O
of	O
the	O
57	O
patients	O
(	O
12.3	O
%	O
)	O
withdrew	O
because	O
of	O
adverse	Adverseeffect
events	Adverseeffect
.	O

Of	O
the	O
remaining	O
50	O
patients	O
,	O
42	O
(	O
84.0	O
%	O
)	O
were	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
20	O
%	O
responders	O
,	O
30	O
(	O
60.0	O
%	O
)	O
were	O
ACR	O
50	O
%	O
responders	O
,	O
and	O
23	O
(	O
46.0	O
%	O
)	O
were	O
ACR	O
70	O
%	O
responders	O
.	O

At	O
month	O
6	O
,	O
22	O
patients	O
were	O
randomized	O
to	O
CSA	O
and	O
27	O
to	O
MTX	O
.	O

During	O
this	O
trial	O
period	O
,	O
the	O
treatment	O
was	O
discontinued	O
by	O
16	O
patients	O
taking	O
CSA	O
(	O
mainly	O
because	O
of	O
loss	O
of	O
efficacy	Others
)	O
and	O
by	O
4	O
taking	O
MTX	O
.	O

At	O
month	O
24	O
,	O
the	O
probability	O
(	O
+/-	O
SEM	O
)	O
of	O
survival	Mortality
on	O
treatment	O
was	O
0.273	O
+/-	O
0.09	O
for	O
CSA	O
and	O
0.852	O
+/-	O
0.07	O
for	O
MTX	O
.	O

Of	O
the	O
6	O
CSA	O
patients	O
who	O
completed	O
the	O
trial	O
,	O
4	O
(	O
66.7	O
%	O
)	O
were	O
ACR	O
20	O
%	O
responders	O
,	O
and	O
3	O
(	O
50	O
%	O
)	O
were	O
both	O
ACR	O
50	O
%	O
and	O
ACR	O
70	O
%	O
responders	O
.	O

Of	O
the	O
23	O
completers	O
in	O
the	O
MTX	O
arm	O
,	O
21	O
(	O
91.3	O
%	O
)	O
were	O
ACR	O
20	O
%	O
responders	O
,	O
18	O
(	O
78.3	O
%	O
)	O
were	O
ACR	O
50	O
%	O
,	O
and	O
10	O
(	O
43.5	O
%	O
)	O
were	O
ACR	O
70	O
%	O
responders	O
.	O

The	O
treatment	O
was	O
not	O
responsible	O
for	O
severe	O
adverse	Adverseeffect
events	Adverseeffect
.	O

Radiography	O
showed	O
a	O
slow	O
progression	O
in	O
the	O
damage	Physical
score	Physical
and	O
number	Physical
of	Physical
eroded	Physical
joints	Physical
in	O
both	O
treatment	O
groups	O
.	O

CONCLUSION	O
Stepping	O
down	O
to	O
single	O
agent	O
maintenance	O
therapy	O
following	O
6	O
months	O
of	O
combination	O
treatment	O
with	O
CSA	O
and	O
MTX	O
in	O
early	O
RA	O
was	O
only	O
successful	O
with	O
MTX	O
.	O

Because	O
this	O
treatment	O
did	O
not	O
prevent	O
some	O
radiographic	Physical
progression	Physical
,	O
other	O
approaches	O
(	O
e.g.	O
,	O
step-up	O
approach	O
)	O
may	O
be	O
more	O
appropriate	O
in	O
early	O
RA	O
.	O

Acute	O
effects	O
of	O
decaffeinated	O
coffee	O
and	O
the	O
major	O
coffee	O
components	O
chlorogenic	O
acid	O
and	O
trigonelline	O
on	O
glucose	Physical
tolerance	Physical
.	Physical

OBJECTIVE	O
Coffee	O
consumption	O
has	O
been	O
associated	O
with	O
lower	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

We	O
evaluated	O
the	O
acute	O
effects	O
of	O
decaffeinated	O
coffee	O
and	O
the	O
major	O
coffee	O
components	O
chlorogenic	O
acid	O
and	O
trigonelline	O
on	O
glucose	O
tolerance	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
We	O
conducted	O
a	O
randomized	O
crossover	O
trial	O
of	O
the	O
effects	O
of	O
12	O
g	O
decaffeinated	O
coffee	O
,	O
1	O
g	O
chlorogenic	O
acid	O
,	O
500	O
mg	O
trigonelline	O
,	O
and	O
placebo	O
(	O
1	O
g	O
mannitol	O
)	O
on	O
glucose	O
and	O
insulin	O
concentrations	O
during	O
a	O
2-h	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
in	O
15	O
overweight	O
men	O
.	O

RESULTS	O
Chlorogenic	O
acid	O
and	O
trigonelline	O
ingestion	O
significantly	O
reduced	O
glucose	Physical
(	O
-0.7	O
mmol/l	O
,	O
P	O
=	O
0.007	O
,	O
and	O
-0.5	O
mmol/l	O
,	O
P	O
=	O
0.024	O
,	O
respectively	O
)	O
and	O
insulin	Physical
(	O
-73	O
pmol/l	O
,	O
P	O
=	O
0.038	O
,	O
and	O
-117	O
pmol/l	O
,	O
P	O
=	O
0.007	O
)	O
concentrations	O
15	O
min	O
following	O
an	O
OGTT	O
compared	O
with	O
placebo	O
.	O

None	O
of	O
the	O
treatments	O
affected	O
insulin	Physical
or	Physical
glucose	Physical
area	Physical
under	Physical
the	Physical
curve	Physical
values	Physical
during	O
the	O
OGTT	O
compared	O
with	O
placebo	O
.	O

CONCLUSIONS	O
Chlorogenic	O
acid	O
and	O
trigonelline	O
reduced	O
early	O
glucose	Physical
and	Physical
insulin	Physical
responses	Physical
during	O
an	O
OGTT	O
.	O

Smoking	Mental
cessation	Mental
with	O
smokeless	O
tobacco	O
and	O
group	O
therapy	O
:	O
an	O
open	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

Smokeless	O
tobacco	O
might	O
be	O
effective	O
as	O
an	O
adjunct	O
for	O
smoking	Mental
cessation	Mental
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
smokeless	O
tobacco	O
and	O
group	O
support	O
for	O
smoking	Mental
cessation	Mental
in	O
an	O
open	O
,	O
randomized	O
study	O
that	O
compared	O
smokeless	O
tobacco	O
plus	O
group	O
support	O
versus	O
group	O
support	O
only	O
.	O

The	O
study	O
enrolled	O
263	O
healthy	O
smokers	O
(	O
M	O
(	O
age	O
)	O
=	O
49	O
years	O
)	O
who	O
smoked	O
a	O
mean	O
of	O
24	O
cigarettes/day	O
,	O
with	O
a	O
mean	O
of	O
31	O
pack-years	O
.	O

Smokeless	O
tobacco	O
was	O
provided	O
for	O
7	O
weeks	O
(	O
or	O
up	O
to	O
12	O
)	O
,	O
combined	O
with	O
eight	O
group	O
support	O
visits	O
provided	O
by	O
nurses	O
.	O

The	O
control	O
group	O
received	O
group	O
support	O
only	O
.	O

Smoking	Others
cessation	Others
rates	Others
were	O
statistically	O
significantly	O
better	O
in	O
the	O
smokeless	O
tobacco	O
group	O
than	O
in	O
the	O
control	O
group	O
during	O
the	O
first	O
7	O
weeks	O
.	O

Point-prevalence	Others
abstinence	Others
rates	Others
at	O
7	O
weeks	O
were	O
36.4	O
%	O
versus	O
20.8	O
%	O
(	O
OR	O
=	O
2.52	O
,	O
p	O
=	O
.001	O
)	O
,	O
respectively	O
;	O
and	O
continuous	Others
abstinence	Others
rates	Others
from	O
weeks	O
4	O
to	O
7	O
were	O
31.5	O
%	O
versus	O
19.2	O
%	O
(	O
OR	O
=	O
1.94	O
,	O
p	O
=	O
.023	O
)	O
,	O
respectively	O
.	O

The	O
primary	O
outcomes	O
(	O
i.e.	O
,	O
6-month	Others
point	Others
prevalence	Others
)	O
were	O
23.1	O
%	O
versus	O
20.8	O
%	O
,	O
respectively	O
(	O
OR	O
=	O
1.31	O
,	O
ns	O
)	O
.	O

Smokeless	O
tobacco	O
was	O
relatively	O
well	O
tolerated	Others
,	O
although	O
15	O
subjects	O
(	O
11.2	O
%	O
)	O
stopped	O
use	O
due	O
to	O
adverse	Adverseeffect
events	Adverseeffect
.	O

A	O
total	O
of	O
25	O
subjects	O
(	O
17.5	O
%	O
)	O
were	O
still	O
using	O
smokeless	O
tobacco	O
after	O
6	O
months	O
.	O

This	O
trial	O
demonstrated	O
short-term	Others
efficacy	Others
of	Others
smokeless	Others
tobacco	Others
in	O
combination	O
with	O
group	O
support	O
for	O
smoking	O
cessation	O
but	O
no	O
long-term	Others
efficacy	Others
.	O

Comparison	O
of	O
patient-controlled	O
and	O
nurse-administered	O
analgesia	O
using	O
intravenous	O
fentanyl	O
during	O
labor	O
.	O

Preliminary	O
observations	O
have	O
shown	O
that	O
fentanyl	O
citrate	O
,	O
a	O
potent	O
narcotic	O
,	O
is	O
helpful	O
during	O
labor	O
without	O
undue	O
side	O
effects	O
.	O

This	O
randomized	O
prospective	O
investigation	O
compared	O
the	O
patient-controlled	O
administration	O
of	O
fentanyl	O
with	O
that	O
of	O
administration	O
by	O
nurses	O
on	O
request	O
.	O

Eighty	O
healthy	O
women	O
beginning	O
active	O
labor	O
(	O
cervical	O
dilation	O
4	O
cm	O
)	O
at	O
term	O
were	O
assigned	O
to	O
receive	O
fentanyl	O
intravenously	O
by	O
either	O
patient-controlled	O
administration	O
(	O
n=37	O
)	O
or	O
nurse	O
administration	O
on	O
demand	O
(	O
n=43	O
)	O
.	O

Pain	Pain
intensity	Pain
measurements	Pain
during	O
early	O
and	O
late	O
labor	O
revealed	O
the	O
degree	Pain
of	Pain
analgesia	Pain
to	O
be	O
the	O
same	O
in	O
both	O
groups	O
.	O

The	O
delay	O
in	O
setting	Others
up	Others
the	Others
infusion	Others
system	Others
and	O
the	O
short	O
time	Others
between	Others
requesting	Others
analgesia	Others
and	Others
vaginal	Others
delivery	Others
were	O
limitations	O
with	O
self-administration	O
.	O

Maternal	Adverseeffect
oversedation	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
did	O
not	O
occur	O
.	O

Neonatal	Others
naloxone	Others
therapy	Others
was	O
used	O
infrequently	O
,	O
umbilical	Others
serum	Others
levels	Others
of	Others
fentanyl	Others
were	O
the	O
same	O
in	O
both	O
groups	O
,	O
and	O
postnatal	Physical
neuroadaptive	Physical
testing	Physical
revealed	O
comparable	O
results	O
in	O
both	O
groups	O
.	O

Despite	O
the	O
usefulness	O
of	O
fentanyl	O
during	O
labor	O
,	O
administration	O
by	O
the	O
patient	O
had	O
no	O
advantages	O
over	O
administration	O
by	O
the	O
nurses	O
in	O
significantly	O
reducing	O
drug	Others
use	Others
,	O
improving	Pain
pain	Pain
relief	Pain
,	O
or	O
avoiding	Physical
drowsiness	Adverseeffect
.	O

Immunological	Physical
changes	Physical
after	O
minimally	O
invasive	O
or	O
conventional	O
esophageal	O
resection	O
for	O
cancer	O
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
This	O
study	O
was	O
performed	O
as	O
a	O
substudy	O
analysis	O
of	O
a	O
randomized	O
trial	O
comparing	O
conventional	O
open	O
esophagectomy	O
[	O
open	O
surgical	O
technique	O
(	O
OE	O
)	O
]	O
by	O
thoracotomy	O
and	O
laparotomy	O
with	O
minimally	O
invasive	O
esophagectomy	O
[	O
minimally	O
invasive	O
procedure	O
(	O
MIE	O
)	O
]	O
by	O
thoracoscopy	O
and	O
laparoscopy	O
.	O

This	O
additional	O
analysis	O
focuses	O
on	O
the	O
immunological	Physical
changes	Physical
and	O
surgical	Physical
stress	Physical
response	Physical
in	O
these	O
two	O
randomized	O
groups	O
of	O
a	O
single	O
center	O
.	O

METHODS	O
Patients	O
with	O
a	O
resectable	O
esophageal	O
cancer	O
were	O
randomized	O
to	O
OE	O
(	O
n	O
=	O
13	O
)	O
or	O
MIE	O
(	O
n	O
=	O
14	O
)	O
.	O

All	O
patients	O
received	O
neoadjuvant	O
chemoradiotherapy	O
.	O

The	O
immunological	Physical
response	Physical
was	O
measured	O
by	O
means	O
of	O
leukocyte	Physical
counts	Physical
,	Physical
HLA-DR	Physical
expression	Physical
on	Physical
monocytes	Physical
,	O
the	Physical
acute-phase	Physical
response	Physical
by	Physical
means	Physical
of	Physical
C-reactive	Physical
protein	Physical
(	Physical
CRP	Physical
)	Physical
,	O
interleukin-6	Physical
(	Physical
IL-6	Physical
)	Physical
,	O
and	O
interleukin-8	Physical
(	Physical
IL-8	Physical
)	Physical
,	O
and	O
the	O
stress	Physical
response	Physical
was	Physical
measured	Physical
by	Physical
cortisol	Physical
,	Physical
growth	Physical
hormone	Physical
,	Physical
and	Physical
prolactin	Physical
.	O

All	O
parameters	O
were	O
determined	O
at	O
baseline	O
(	O
preoperatively	O
)	O
and	O
24	O
,	O
72	O
,	O
96	O
,	O
and	O
168	O
h	O
postoperatively	O
.	O

RESULTS	O
Significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
seen	O
in	O
favor	O
of	O
the	O
MIE	O
group	O
with	O
regard	O
to	O
leukocyte	Physical
counts	Physical
,	Physical
IL-8	Physical
,	Physical
and	Physical
prolactin	Physical
at	O
168	O
h	O
(	O
1	O
week	O
)	O
postoperatively	O
.	O

For	O
HLA-DR	Physical
expression	Physical
,	Physical
IL-6	Physical
,	Physical
and	Physical
CRP	Physical
levels	Physical
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
although	O
there	O
was	O
a	O
clear	O
rise	O
in	O
levels	O
upon	O
operation	O
in	O
both	O
groups	O
.	O

CONCLUSION	O
In	O
this	O
substudy	O
of	O
a	O
randomized	O
trial	O
comparing	O
minimally	O
invasive	O
and	O
conventional	O
open	O
esophagectomies	O
for	O
cancer	O
,	O
significantly	O
better	O
preserved	O
leukocyte	Physical
counts	Physical
and	Physical
IL-8	Physical
levels	Physical
were	O
observed	O
in	O
the	O
MIE	O
group	O
compared	O
to	O
the	O
open	O
group	O
.	O

Both	O
findings	O
can	O
be	O
related	O
to	O
fewer	Adverseeffect
respiratory	Adverseeffect
infections	Adverseeffect
found	O
postoperatively	O
in	O
the	O
MIE	O
group	O
.	O

Moreover	O
,	O
significant	O
differences	O
in	O
the	O
prolactin	Physical
levels	Physical
at	O
168	O
h	O
after	O
surgery	O
imply	O
that	O
the	O
stress	Physical
response	Physical
is	O
better	O
preserved	O
in	O
the	O
MIE	O
group	O
.	O

These	O
findings	O
indicate	O
that	O
less	O
surgical	O
trauma	O
could	O
lead	O
to	O
better	O
preserved	O
acute-phase	O
and	O
stress	O
responses	O
and	O
fewer	O
clinical	O
manifestations	O
of	O
respiratory	O
infections	O
.	O

Treatment	O
of	O
stable	O
angina	O
of	O
effort	O
with	O
verapamil	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
randomized	O
crossover	O
study	O
.	O

The	O
effects	O
of	O
verapamil	O
were	O
assessed	O
in	O
26	O
patients	O
with	O
stable	O
exertional	O
angina	O
pectoris	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
randomized	O
crossover	O
protocol	O
using	O
serial	O
treadmill	O
tests	O
.	O

Verapamil	O
,	O
480	O
mg/day	O
,	O
reduced	O
anginal	Physical
frequency	Physical
from	O
5.6	O
+/-	O
7.3	O
to	O
2.2	O
+/-	O
3.9	O
attacks	O
per	O
week	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
nitroglycerin	Others
consumption	Others
from	O
3.4	O
+/-	O
4.9	O
to	O
1.2	O
+/-	O
2.5	O
tablets	O
per	O
week	O
(	O
p	O
less	O
than	O
0.05	O
)	O
compared	O
with	O
placebo	O
.	O

Treadmill	Physical
time	Physical
increased	O
from	O
6.4	O
+/-	O
2.1	O
minutes	O
during	O
the	O
placebo	O
phase	O
to	O
7.5	O
+/-	O
1.8	O
minutes	O
during	O
the	O
verapamil	O
phase	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Verapamil	O
's	O
beneficial	O
effect	O
appeared	O
to	O
be	O
related	O
,	O
in	O
part	O
,	O
to	O
a	O
10	O
%	O
reduction	O
of	O
the	O
rate-pressure	Physical
product	Physical
at	O
rest	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
a	O
12	O
%	O
reduction	O
during	O
submaximal	O
exercise	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Verapamil	O
also	O
caused	O
less	O
marked	O
ST-segment	Physical
depressions	Physical
at	Physical
peak	Physical
exercise	Physical
(	O
p	O
less	O
than	O
0.05	O
)	O
at	O
a	O
similar	O
rate-pressure	O
product	O
,	O
suggesting	O
a	O
favorable	O
redistribution	O
of	O
coronary	Physical
blood	Physical
flow	Physical
to	O
the	O
ischemic	O
zone	O
.	O

Side	O
effects	O
from	O
verapamil	O
were	O
minimal	O
,	O
consisting	O
mainly	O
of	O
constipation	Adverseeffect
(	O
six	O
patients	O
)	O
.	O

Verapamil	O
appears	O
to	O
be	O
a	O
safe	Others
and	Others
effective	Others
drug	O
for	O
treating	O
angina	O
of	O
effort	O
.	O

The	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
adherence	O
to	O
a	O
low-fat	O
dietary	O
pattern	O
in	O
the	O
Women	O
's	O
Health	O
Initiative	O
.	O

OBJECTIVE	O
To	O
examine	O
whether	O
the	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
adherance	O
to	O
a	O
low-fat	O
(	O
20	O
%	O
energy	O
)	O
dietary	O
pattern	O
are	O
mediated	O
by	O
participation	O
in	O
an	O
intervention	O
program	O
(	O
attending	O
sessions	O
and	O
self-monitoring	O
)	O
.	O

DESIGN	O
The	O
Baron	O
and	O
Kenny	O
mediator	O
model	O
,	O
a	O
series	O
of	O
4	O
regression	O
analyses	O
,	O
was	O
used	O
to	O
evaluate	O
whether	O
:	O
a	O
)	O
physical	O
and	O
emotional	O
status	O
predicted	O
program	O
participation	O
,	O
b	O
)	O
program	O
participation	O
predicted	O
dietary	O
adherence	O
,	O
c	O
)	O
physical	O
and	O
emotional	O
status	O
factors	O
predicted	O
dietary	O
adherence	O
,	O
and	O
,	O
ultimately	O
d	O
)	O
the	O
effects	O
of	O
physical	O
and	O
emotional	O
status	O
on	O
dietary	O
adherence	O
were	O
mediated	O
by	O
program	O
participation	O
.	O

SUBJECTS/SETTING	O
Data	O
from	O
13,277	O
postmenopausal	O
women	O
randomly	O
assigned	O
to	O
the	O
low-fat	O
intervention	O
arm	O
of	O
the	O
Women	O
's	O
Health	O
Initiative	O
Dietary	O
Modification	O
Trial	O
.	O

INTERVENTION	O
The	O
nutrition	O
goals	O
for	O
women	O
randomly	O
assigned	O
to	O
the	O
low-fat	O
intervention	O
were	O
to	O
reduce	O
total	O
fat	O
intake	O
to	O
20	O
%	O
or	O
less	O
of	O
energy	O
from	O
fat	O
and	O
to	O
consume	O
5	O
or	O
more	O
fruit/vegetable	O
servings	O
daily	O
and	O
6	O
or	O
more	O
grain	O
servings	O
daily	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Year	Mental
1	Mental
program	Mental
participation	Mental
(	Mental
degree	Mental
of	Mental
attending	Mental
group	Mental
sessions	Mental
and	Mental
submitting	Mental
fat	Mental
scores	Mental
)	Mental
and	O
adherence	Mental
to	Mental
the	Mental
low-fat	Mental
dietary	Mental
pattern	Mental
(	Mental
percent	Mental
energy	Mental
from	Mental
fat	Mental
)	Mental
as	O
predicted	O
by	O
baseline	O
physical	O
and	O
emotional	O
status	O
(	O
eight	O
SF-36	O
Health	O
Survey	O
subscales	O
)	O
.	O

RESULTS	O
Participating	O
in	O
the	O
dietary	O
intervention	O
program	O
reduced	O
(	O
mediated	O
)	O
the	O
negative	O
effect	Mental
of	Mental
poorer	Mental
mental	Mental
health	Mental
on	O
dietary	Mental
adherence	Mental
by	O
15	O
%	O
.	O

Additional	O
findings	O
included	O
that	O
a	O
10	O
%	O
increase	O
in	O
physical	Physical
functioning	Physical
increased	O
session	Mental
attendance	Mental
by	O
0.4	O
%	O
(	O
P	O
<	O
.001	O
)	O
and	O
a	O
10	O
%	O
increase	O
in	O
mental	Mental
health	Mental
predicted	O
a	O
decrease	O
in	O
percent	O
energy	O
from	O
fat	O
of	O
0.3	O
%	O
(	O
P	O
<	O
.001	O
)	O
.	O

Program	O
participation	O
had	O
a	O
marked	O
effect	O
on	O
dietary	Mental
adherence	Mental
:	O
a	O
10	O
%	O
increase	O
in	O
session	Mental
attendance	Mental
predicted	O
a	O
1.2	O
%	O
decrease	O
in	O
percent	O
energy	O
from	O
fat	O
(	O
P	O
<	O
.001	O
)	O
.	O

APPLICATIONS/CONCLUSIONS	O
Understanding	O
and	O
using	O
instruments	O
to	O
assess	O
the	O
physical	O
and	O
emotional	O
status	O
of	O
a	O
target	O
population	O
will	O
help	O
dietetic	O
professionals	O
promote	O
healthful	O
dietary	O
change	O
and	O
maintenance	O
.	O

Menopausal	Others
quality	Others
of	Others
life	Others
:	O
RCT	O
of	O
yoga	O
,	O
exercise	O
,	O
and	O
omega-3	O
supplements	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
3	O
nonhormonal	O
therapies	O
for	O
the	O
improvement	O
of	O
menopause-related	Others
quality	Others
of	Others
life	Others
in	O
women	O
with	O
vasomotor	O
symptoms	O
.	O

STUDY	O
DESIGN	O
We	O
conducted	O
a	O
12-week	O
3	O
?	O
2	O
randomized	O
,	O
controlled	O
,	O
factorial	O
design	O
trial	O
.	O

Peri-	O
and	O
postmenopausal	O
women	O
,	O
40-62	O
years	O
old	O
,	O
were	O
assigned	O
randomly	O
to	O
yoga	O
(	O
n	O
=	O
107	O
)	O
,	O
exercise	O
(	O
n	O
=	O
106	O
)	O
,	O
or	O
usual	O
activity	O
(	O
n	O
=	O
142	O
)	O
and	O
also	O
assigned	O
randomly	O
to	O
a	O
double-blind	O
comparison	O
of	O
omega-3	O
(	O
n	O
=	O
177	O
)	O
or	O
placebo	O
(	O
n	O
=	O
178	O
)	O
capsules	O
.	O

We	O
performed	O
the	O
following	O
interventions	O
:	O
(	O
1	O
)	O
weekly	O
90-minute	O
yoga	O
classes	O
with	O
daily	O
at-home	O
practice	O
,	O
(	O
2	O
)	O
individualized	O
facility-based	O
aerobic	O
exercise	O
training	O
3	O
times/week	O
,	O
and	O
(	O
3	O
)	O
0.615	O
g	O
omega-3	O
supplement	O
,	O
3	O
times/day	O
.	O

The	O
outcomes	O
were	O
assessed	O
with	O
the	O
following	O
scores	O
:	O
Menopausal	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
MENQOL	O
)	O
total	O
and	O
domain	O
(	O
vasomotor	O
symptoms	O
,	O
psychosocial	O
,	O
physical	O
and	O
sexual	O
)	O
.	O

RESULTS	O
Among	O
355	O
randomly	O
assigned	O
women	O
who	O
average	O
age	O
was	O
54.7	O
years	O
,	O
338	O
women	O
(	O
95	O
%	O
)	O
completed	O
12-week	O
assessments	O
.	O

Mean	O
baseline	O
vasomotor	O
symptoms	O
frequency	O
was	O
7.6/day	O
,	O
and	O
the	O
mean	O
baseline	O
total	O
MENQOL	O
score	O
was	O
3.8	O
(	O
range	O
,	O
1-8	O
from	O
better	O
to	O
worse	O
)	O
with	O
no	O
between-group	O
differences	O
.	O

For	O
yoga	O
compared	O
to	O
usual	O
activity	O
,	O
baseline	O
to	O
12-week	O
improvements	O
were	O
seen	O
for	O
MENQOL	O
total	O
-0.3	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-0.6	O
to	O
0	O
;	O
P	O
=	O
.02	O
)	O
,	O
vasomotor	O
symptom	O
domain	O
(	O
P	O
=	O
.02	O
)	O
,	O
and	O
sexuality	O
domain	O
(	O
P	O
=	O
.03	O
)	O
scores	O
.	O

For	O
women	O
who	O
underwent	O
exercise	O
and	O
omega-3	O
therapy	O
compared	O
with	O
control	O
subjects	O
,	O
improvements	O
in	O
baseline	O
to	O
12-week	O
total	O
MENQOL	O
scores	O
were	O
not	O
observed	O
.	O

Exercise	O
showed	O
benefit	O
in	O
the	O
MENQOL	O
physical	O
domain	O
score	O
at	O
12	O
weeks	O
(	O
P	O
=	O
.02	O
)	O
.	O

CONCLUSION	O
All	O
women	O
become	O
menopausal	O
,	O
and	O
many	O
of	O
them	O
seek	O
medical	O
advice	O
on	O
ways	O
to	O
improve	O
quality	O
of	O
life	O
;	O
little	O
evidence-based	O
information	O
exists	O
.	O

We	O
found	O
that	O
,	O
among	O
healthy	O
sedentary	O
menopausal	O
women	O
,	O
yoga	O
appears	O
to	O
improve	O
menopausal	O
quality	O
of	O
life	O
;	O
the	O
clinical	O
significance	O
of	O
our	O
finding	O
is	O
uncertain	O
because	O
of	O
the	O
modest	O
effect	O
.	O

Short-	Physical
and	Physical
long-term	Physical
effects	Physical
of	O
tactile	O
massage	O
on	O
salivary	Physical
cortisol	Physical
concentrations	Physical
in	O
Parkinson	O
's	O
disease	O
:	O
a	O
randomised	O
controlled	O
pilot	O
study	O
.	O

BACKGROUND	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
chronic	O
neurodegenerative	O
disorder	O
with	O
limited	O
knowledge	O
about	O
the	O
normal	O
function	O
and	O
effects	O
of	O
non-pharmacological	O
therapies	O
on	O
the	O
hypothalamic-pituitary-adrenal	Physical
(	Physical
HPA	Physical
)	Physical
axis	Physical
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyse	O
the	O
basal	Physical
diurnal	Physical
and	Physical
total	Physical
secretion	Physical
of	Physical
salivary	Physical
cortisol	Physical
in	O
short-	O
and	O
long-term	O
aspects	O
of	O
tactile	O
massage	O
(	O
TM	O
)	O
.	O

METHODS	O
DESIGN	O
Prospective	O
,	O
Controlled	O
and	O
Randomised	O
Multicentre	O
Trial	O
.	O

SETTING	O
AND	O
INTERVENTIONS	O
Forty-five	O
women	O
and	O
men	O
,	O
aged	O
50-79	O
years	O
,	O
were	O
recruited	O
.	O

Twenty-nine	O
of	O
them	O
were	O
blindly	O
randomised	O
to	O
tactile	O
massage	O
(	O
TM	O
)	O
and	O
16	O
of	O
them	O
to	O
the	O
control	O
group	O
,	O
rest	O
to	O
music	O
(	O
RTM	O
)	O
.	O

Ten	O
interventions	O
were	O
given	O
during	O
8	O
weeks	O
followed	O
by	O
a	O
26	O
weeks	O
of	O
follow	O
up	O
.	O

Salivary	Physical
cortisol	Physical
was	O
collected	O
at	O
8	O
am	O
,	O
1	O
pm	O
,	O
8	O
pm	O
,	O
and	O
8	O
am	O
the	O
next	O
day	O
,	O
on	O
five	O
occasions	O
.	O

With	O
the	O
first	O
and	O
eighth	O
interventions	O
,	O
it	O
was	O
collected	O
immediately	O
before	O
and	O
after	O
intervention	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
aim	O
was	O
to	O
assess	Physical
and	Physical
compare	Physical
cortisol	Physical
concentrations	Physical
before	O
and	O
immediately	O
after	O
intervention	O
and	O
also	O
during	O
the	O
follow-up	O
period	O
.	O

The	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
impact	Physical
of	Physical
age	Physical
,	Physical
gender	Physical
,	Physical
body	Physical
mass	Physical
index	Physical
(	Physical
BMI	Physical
)	Physical
,	O
duration	Physical
and	Physical
severity	Physical
of	Physical
PD	Physical
,	O
effects	Physical
of	Physical
interventional	Physical
time-point	Physical
of	Physical
the	Physical
day	Physical
,	O
and	O
levodopa	Physical
doses	Physical
on	Physical
cortisol	Physical
concentration	Physical
.	O

RESULTS	O
The	O
median	Physical
cortisol	Physical
concentrations	Physical
for	O
all	O
participants	O
were	O
16.0	O
,	O
5.8	O
,	O
2.8	O
,	O
and	O
14.0	O
nmol/L	O
at	O
baseline	O
,	O
later	O
reproduced	O
four	O
times	O
without	O
significant	O
differences	O
.	O

Cortisol	Physical
concentrations	Physical
decreased	O
significantly	O
after	O
TM	O
intervention	O
but	O
no	O
change	O
in	O
diurnal	O
salivary	O
cortisol	O
pattern	O
was	O
found	O
.	O

The	O
findings	O
of	O
reduced	O
salivary	Physical
cortisol	Physical
concentrations	Physical
immediately	O
after	O
the	O
interventions	O
are	O
in	O
agreement	O
with	O
previous	O
studies	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
TM	O
and	O
control	O
groups	O
.	O

There	O
were	O
no	O
significant	O
correlations	O
between	O
cortisol	Physical
concentrations	Physical
and	O
age	Physical
,	Physical
gender	Physical
,	Physical
BMI	Physical
,	O
time-point	Physical
for	Physical
intervention	Physical
,	O
time	Physical
interval	Physical
between	Physical
anti-parkinson	Physical
pharmacy	Physical
intake	Physical
and	Physical
sampling	Physical
,	O
levodopa	Physical
doses	Physical
,	Physical
duration	Physical
,	Physical
or	Physical
severity	Physical
of	Physical
PD	Physical
.	O

CONCLUSIONS	O
Diurnal	Physical
salivary	Physical
cortisol	Physical
rhythm	Physical
was	O
normal	O
.	O

Salivary	Physical
cortisol	Physical
concentrations	Physical
were	O
significantly	O
reduced	O
after	O
the	O
TM	O
intervention	O
and	O
after	O
RTM	O
,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
and	O
no	O
sustained	O
long-term	O
effect	O
.	O

No	O
associations	O
were	O
seen	O
between	O
salivary	Physical
cortisol	Physical
concentration	Physical
and	O
clinical	O
and/or	O
pharmacological	O
characteristics	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrial.gov	O
,	O
NCT01734876	O
and	O
FoU	O
Sweden	O
108881	O
.	O

Relation	O
of	O
total	O
homocysteine	O
and	O
lipid	O
levels	O
in	O
children	O
to	O
premature	O
cardiovascular	O
death	O
in	O
male	O
relatives	O
.	O

We	O
assessed	O
the	O
relative	Others
importance	Others
of	O
lipid	Physical
,	Physical
apo	Physical
B	Physical
,	Physical
lipoprotein	Physical
(	Physical
a	Physical
)	Physical
[	Physical
Lp	Physical
(	Physical
a	Physical
)	Physical
]	Physical
,	Physical
and	Physical
total	Physical
homocysteine	Physical
(	Physical
tHcy	Physical
)	Physical
levels	Physical
in	O
children	O
in	O
relation	O
to	O
premature	O
cardiovascular	O
disease	O
in	O
family	O
members	O
.	O

Parents	O
of	O
381	O
girls	O
and	O
375	O
boys	O
age	O
8-12	O
y	O
completed	O
family	O
history	O
questionnaires	O
.	O

Nonfasting	Physical
serum	Physical
lipid	Physical
and	Physical
lipoproteins	Physical
and	Physical
plasma	Physical
tHcy	Physical
and	Physical
cysteine	Physical
levels	Physical
were	O
measured	O
in	O
the	O
children	O
.	O

Serum	Physical
folate	Physical
and	Physical
vitamin	Physical
B12	Physical
levels	Physical
were	O
determined	O
in	O
a	O
random	O
subsample	O
of	O
23	O
%	O
of	O
the	O
children	O
,	O
who	O
participated	O
in	O
a	O
food	O
frequency	O
interview	O
.	O

Children	O
whose	O
parents	O
reported	O
hypercholesterolemia	O
had	O
higher	O
total	Physical
and	Physical
non-HDL	Physical
cholesterol	Physical
and	Physical
apo	Physical
B	Physical
levels	Physical
than	O
the	O
rest	O
,	O
but	O
these	O
levels	O
were	O
not	O
associated	O
with	O
cardiovascular	O
disease	O
.	O

tHcy	Physical
levels	Physical
were	O
similar	O
in	O
girls	O
and	O
boys	O
.	O

tHcy	Physical
was	O
higher	O
in	O
children	O
whose	O
father	O
,	O
grandfather	O
,	O
or	O
uncle	O
died	O
at	O
age	O
<	O
or	O
=	O
55	O
y	O
of	O
myocardial	O
infarction	O
or	O
sudden	O
cardiac	O
arrest	O
(	O
n	O
=	O
42	O
)	O
than	O
in	O
control	O
children	O
[	O
5.92	O
mumol/L	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
of	O
5.47-6.36	O
)	O
versus	O
5.25	O
mumol/L	O
(	O
95	O
%	O
CI	O
,	O
5.16-5.34	O
)	O
]	O
,	O
also	O
after	O
adjustment	O
for	O
socioeconomic	O
group	O
.	O

Intake	Physical
and	Physical
serum	Physical
levels	Physical
of	Physical
vitamin	Physical
B12	Physical
and	Physical
folate	Physical
were	O
within	O
recommended	O
or	O
reference	O
ranges	O
.	O

In	O
a	O
stepwise	O
multiple	O
regression	O
analysis	O
,	O
serum	Physical
folate	Physical
(	Physical
negative	Physical
correlation	Physical
)	Physical
,	Physical
plasma	Physical
creatinine	Physical
,	Physical
and	Physical
sugar	Physical
intake	Physical
as	O
percent	O
of	O
dietary	O
energy	O
(	O
positive	O
correlations	O
)	O
were	O
significantly	O
associated	O
with	O
tHcy	Physical
(	O
multiple	O
r	O
=	O
0.44	O
,	O
adjusted	O
r2	O
=	O
18	O
%	O
;	O
95	O
%	O
CI	O
,	O
5-30	O
%	O
)	O
.	O

Our	O
data	O
show	O
that	O
a	O
modest	O
elevation	O
in	O
tHcy	Physical
in	O
children	O
was	O
related	O
to	O
premature	Mortality
cardiovascular	Mortality
death	Mortality
in	O
their	O
male	O
relatives	O
and	O
may	O
partly	O
account	O
for	O
the	O
contribution	O
of	O
family	O
history	O
to	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

tHcy	Physical
may	O
be	O
modifiable	O
through	O
the	O
diet	O
,	O
even	O
in	O
children	O
with	O
apparently	O
adequate	O
vitamin	O
nutriture	O
.	O

Mechanical	Physical
efficiency	Physical
and	O
propulsion	Physical
technique	Physical
after	O
7	O
weeks	O
of	O
low-intensity	O
wheelchair	O
training	O
.	O

BACKGROUND	O
To	O
evaluate	O
the	O
effect	O
of	O
a	O
7-week	O
low-intensity	O
hand	O
rim	O
wheelchair	O
training	O
on	O
the	O
submaximal	O
metabolic	O
cost	O
,	O
mechanical	Physical
efficiency	Physical
and	O
propulsion	O
technique	O
in	O
able-bodied	O
participants	O
.	O

METHODS	O
Participants	O
were	O
randomly	O
divided	O
over	O
an	O
experimental	O
group	O
(	O
n=14	O
)	O
and	O
a	O
control	O
group	O
(	O
n=7	O
)	O
.	O

The	O
experimental	O
group	O
received	O
7	O
weeks	O
wheelchair	O
training	O
(	O
3	O
week	O
(	O
-1	O
)	O
,	O
70	O
min	O
)	O
at	O
a	O
low	O
intensity	O
(	O
30	O
%	O
of	O
the	O
heart	O
rate	O
reserve	O
)	O
,	O
whereas	O
the	O
control	O
group	O
did	O
not	O
receive	O
training	O
.	O

During	O
pre-	O
and	O
post-tests	O
,	O
submaximal	O
exercise	O
was	O
performed	O
on	O
a	O
stationary	O
wheelchair	O
ergometer	O
at	O
fixed	O
levels	O
of	O
power	O
output	O
.	O

Mechanical	Physical
efficiency	Physical
,	O
oxygen	Physical
uptake	Physical
,	O
heart	Physical
rate	Physical
,	O
timing	Others
parameters	Others
and	O
stroke	Physical
angles	Physical
were	O
measured	O
.	O

Video	O
recordings	O
were	O
made	O
to	O
determine	O
the	O
stroke	Physical
pattern	Physical
.	O

FINDINGS	O
Mechanical	Physical
efficiency	Physical
increased	O
and	O
metabolic	Physical
cost	Physical
decreased	O
significantly	O
in	O
the	O
experimental	O
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

Push	Others
time	Others
increased	O
and	O
cycle	Others
frequency	Others
decreased	O
as	O
a	O
result	O
of	O
training	O
.	O

The	O
stroke	Physical
angle	Physical
increased	O
in	O
the	O
experimental	O
group	O
during	O
the	O
training	O
period	O
.	O

The	O
experimental	O
group	O
preferred	O
double-looping	O
over	O
propulsion	O
,	O
while	O
the	O
control	O
group	O
mainly	O
used	O
single-looping	Others
over	Others
propulsion	Others
patterns	O
during	O
the	O
post-test	O
.	O

INTERPRETATION	O
A	O
low-intensity	O
,	O
7-week	O
training	O
protocol	O
has	O
a	O
beneficial	O
effect	O
on	O
the	O
mechanical	Physical
efficiency	Physical
and	O
metabolic	Physical
cost	Physical
of	O
wheelchair	O
propulsion	O
in	O
able-bodied	O
participants	O
.	O

The	O
improved	O
mechanical	O
efficiency	O
seems	O
to	O
be	O
the	O
result	O
of	O
changes	O
in	O
propulsion	O
technique	O
that	O
were	O
found	O
.	O

Comparing	O
the	O
effectiveness	Others
of	O
peer	O
mentoring	O
and	O
student	O
mentoring	O
in	O
a	O
35-week	O
fitness	O
program	O
for	O
older	O
adults	O
.	O

To	O
investigate	O
the	O
applicability	Others
and	O
effectiveness	Others
of	O
a	O
peer-mentored	O
exercise	O
program	O
,	O
this	O
study	O
compared	O
the	O
retention	Others
and	Others
participation	Others
rates	Others
,	O
and	O
physical	Physical
improvements	Physical
of	O
older	O
adults	O
trained	O
by	O
peer	O
mentors	O
(	O
PM	O
)	O
to	O
a	O
group	O
trained	O
by	O
young	O
qualified	O
student	O
mentors	O
(	O
SM	O
)	O
.	O

A	O
group	O
of	O
older	O
adults	O
were	O
prepared	O
as	O
peer	O
mentors	O
through	O
a	O
30-week	O
preparation	O
program	O
.	O

Later	O
,	O
60	O
older	O
adults	O
(	O
mean	O
?	O
SD	O
age	O
:	O
68.7	O
?	O
6.1	O
years	O
)	O
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
either	O
the	O
PM	O
or	O
SM	O
group	O
.	O

Both	O
groups	O
completed	O
an	O
identical	O
35-week	O
fitness	O
program	O
.	O

Pre-	O
,	O
midterm-	O
and	O
post-training	O
assessments	O
of	O
fitness	O
were	O
completed	O
and	O
rates	O
of	O
participation	O
and	O
retention	O
were	O
documented	O
.	O

The	O
same	O
retention	O
rates	O
were	O
observed	O
in	O
the	O
two	O
groups	O
,	O
but	O
SM	O
group	O
had	O
higher	O
participation	O
.	O

Both	O
groups	O
improved	O
significantly	O
in	O
all	O
measures	O
of	O
fitness	O
and	O
there	O
were	O
no	O
significant	O
post-test	O
differences	O
between	O
the	O
groups	O
in	O
the	O
fitness	O
measures	O
.	O

Findings	O
suggest	O
that	O
the	O
peer	O
mentor	O
model	O
is	O
applicable	O
in	O
an	O
older	O
adult	O
exercise	O
program	O
and	O
may	O
be	O
as	O
effective	O
as	O
a	O
program	O
mentored	O
by	O
young	O
professionals	O
.	O

Comparison	O
of	O
thiopentone/guaifenesin	O
,	O
ketamine/guaifenesin	O
and	O
ketamine/midazolam	O
for	O
the	O
induction	O
of	O
horses	O
to	O
be	O
anaesthetised	O
with	O
isoflurane	O
.	O

Forty-eight	O
horses	O
subjected	O
to	O
elective	O
surgery	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
of	O
16	O
horses	O
.	O

After	O
premedication	O
with	O
0.1	O
mg/kg	O
acepromazine	O
intramuscularly	O
and	O
0.6	O
mg/kg	O
xylazine	O
intravenously	O
,	O
anaesthesia	O
was	O
induced	O
either	O
with	O
2	O
g	O
thiopentone	O
in	O
500	O
ml	O
of	O
a	O
10	O
per	O
cent	O
guaifenesin	O
solution	O
,	O
given	O
intravenously	O
at	O
a	O
dose	O
of	O
1	O
ml/kg	O
(	O
group	O
TG	O
)	O
,	O
or	O
with	O
100	O
mg/kg	O
guaifenesin	O
and	O
2.2	O
mg/kg	O
ketamine	O
given	O
intravenously	O
(	O
group	O
KG	O
)	O
,	O
or	O
with	O
0.06	O
mg/kg	O
midazolam	O
,	O
and	O
2.2	O
mg/kg	O
ketamine	O
given	O
intravenously	O
(	O
group	O
KM	O
)	O
.	O

Anaesthesia	Others
was	O
maintained	O
with	O
isoflurane	O
.	O

The	O
mean	Others
(	Others
sd	Others
)	Others
end	Others
tidal	Others
isoflurane	Others
concentration	Others
(	Others
per	Others
cent	Others
)	Others
needed	O
to	O
maintain	O
a	O
light	Others
surgical	Others
anaesthesia	Others
(	O
stage	O
III	O
,	O
plane	O
2	O
)	O
was	O
significantly	O
lower	O
in	O
group	O
KM	O
(	O
0.91	O
[	O
0.03	O
]	O
)	O
than	O
in	O
groups	O
TG	O
(	O
1.11	O
[	O
0.03	O
]	O
)	O
and	O
KG	O
(	O
1.14	O
[	O
0.03	O
]	O
)	O
.	O

The	O
mean	Physical
(	Physical
sd	Physical
)	Physical
arterial	Physical
pressure	Physical
(	Physical
mmHg	Physical
)	Physical
was	O
significantly	O
lower	O
in	O
group	O
KG	O
(	O
67.4	O
[	O
2.07	O
]	O
)	O
than	O
in	O
groups	O
TC	O
(	O
75.6	O
[	O
2.23	O
]	O
)	O
and	O
KM	O
(	O
81.0	O
[	O
2.16	O
]	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
logarithm	O
of	O
the	O
heart	Physical
rate	Physical
,	Others
recovery	Physical
time	Physical
or	Others
quality	Physical
of	Physical
recovery	Physical
between	O
the	O
three	O
induction	O
groups	O
.	O

However	O
,	O
pronounced	O
ataxia	O
was	O
observed	O
in	O
the	O
horses	O
of	O
group	O
KM	O
,	O
especially	O
after	O
periods	O
of	O
anaesthesia	Others
lasting	O
less	O
than	O
75	O
minutes	O
.	O

Extracorporeal	O
shock	O
wave	O
therapy	O
(	O
ESWT	O
)	O
in	O
patients	O
with	O
chronic	O
proximal	O
plantar	O
fasciitis	O
:	O
a	O
2-year	O
follow-up	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
extracorporeal	O
shock	O
wave	O
therapy	O
(	O
ESWT	O
)	O
in	O
patients	O
with	O
chronically	O
painful	O
proximal	O
plantar	O
fasciitis	O
with	O
a	O
further	O
conventional	O
conservative	O
treatment	O
.	O

Forty-seven	O
patients	O
(	O
49	O
feet	O
)	O
with	O
a	O
previously	O
unsuccessful	O
nonsurgical	O
treatment	O
of	O
at	O
least	O
6	O
months	O
were	O
randomized	O
to	O
two	O
groups	O
.	O

Heel	O
cups	O
had	O
to	O
be	O
worn	O
throughout	O
the	O
study	O
.	O

Group	O
1	O
(	O
25	O
heels	O
)	O
was	O
treated	O
immediately	O
with	O
three	O
sessions	O
of	O
ESWT	O
(	O
3000	O
shock	O
waves/session	O
of	O
0.2	O
mJ/mm2	O
)	O
at	O
weekly	O
intervals	O
.	O

The	O
patients	O
of	O
group	O
2	O
(	O
24	O
heels	O
)	O
continued	O
nonsurgical	O
treatment	O
(	O
iontophoresis	O
with	O
diclofenac	O
and	O
an	O
oral	O
nonsteroidal	O
anti-inflammatory	O
drug	O
)	O
for	O
12	O
weeks	O
.	O

After	O
this	O
period	O
they	O
were	O
treated	O
using	O
the	O
protocol	O
of	O
group	O
1	O
.	O

No	O
significant	O
difference	O
of	O
pain	Pain
and	O
walking	Physical
time	Physical
after	O
further	O
nonsurgical	O
treatment	O
(	O
3	O
months	O
)	O
was	O
seen	O
in	O
group	O
2	O
.	O

At	O
12	O
weeks	O
after	O
ESWT	O
,	O
the	O
pain	Pain
estimation	Pain
on	Pain
the	Pain
visual	Pain
analogue	Pain
scale	Pain
(	Pain
VAS	Pain
)	Pain
for	Pain
activities	Pain
of	Pain
daily	Pain
living	Pain
diminished	O
significantly	O
by	O
62.9	O
%	O
in	O
group	O
1	O
and	O
by	O
63.0	O
%	O
in	O
group	O
2	O
.	O

The	O
comfortable	Physical
walking	Physical
time	Physical
had	O
increased	O
significantly	O
in	O
both	O
groups	O
.	O

Two	O
years	O
after	O
ESWT	O
,	O
pain	Pain
during	Pain
activities	Pain
of	Pain
daily	Pain
living	Pain
decreased	O
by	O
94	O
%	O
in	O
group	O
1	O
and	O
by	O
90	O
%	O
in	O
group	O
2	O
on	O
the	O
VAS	O
and	O
the	O
comfortable	Physical
walking	Physical
time	Physical
had	O
increased	O
significantly	O
in	O
both	O
groups	O
.	O

Lactobacillus	O
plantarum	O
CECT7315	O
and	O
CECT7316	O
stimulate	O
immunoglobulin	Physical
production	Physical
after	O
influenza	O
vaccination	O
in	O
elderly	O
.	O

OBJECTIVE	O
The	O
effectiveness	O
of	O
influenza	O
vaccination	O
in	O
preventing	O
illness	O
is	O
lower	O
in	O
the	O
elderly	O
;	O
this	O
is	O
why	O
the	O
ability	O
of	O
Lactobacillus	O
plantarum	O
CECT	O
7315/7316	O
to	O
stimulate	Physical
the	Physical
response	Physical
to	Physical
influenza	Physical
vaccination	Physical
in	O
elderly	O
was	O
evaluated	O
.	O

RESEARCH	O
METHODS	O
AND	O
PROCEDURES	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
human	O
trial	O
including	O
60	O
institutionalized	O
volunteers	O
aged	O
65-85	O
years	O
was	O
performed	O
.	O

All	O
the	O
volunteers	O
were	O
vaccinated	O
with	O
a	O
trivalent	O
influenza	O
vaccine	O
(	O
A/Wisconsin/67/2005	O
NYMC	O
X-161B	O
(	O
H3N2	O
)	O
,	O
A/Solomon	O
Islands/3/2006	O
(	O
H1N1	O
)	O
and	O
B/Malaysia/2506/2004	O
)	O
for	O
the	O
Spanish	O
vaccine	O
campaign	O
2006/2007	O
.	O

The	O
consumption	O
of	O
the	O
probiotic	O
began	O
between	O
three	O
and	O
four	O
months	O
after	O
the	O
vaccination	O
.	O

Volunteers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
following	O
groups	O
:	O
group	O
A	O
(	O
receiving	O
5*10	O
(	O
9	O
)	O
cfu/day	O
of	O
L.	O
plantarum	O
CECT	O
7315/7316	O
in	O
20	O
g	O
powdered	O
skim	O
milk	O
)	O
,	O
group	O
B	O
(	O
receiving	O
5*10	O
(	O
8	O
)	O
cfu/day	O
of	O
L.	O
plantarum	O
CECT	O
7315/7316	O
in	O
20	O
g	O
powdered	O
skim	O
milk	O
)	O
and	O
group	O
C	O
or	O
placebo	O
(	O
20	O
g	O
powered	O
skim	O
milk	O
)	O
.	O

The	O
participants	O
consumed	O
the	O
probiotic	O
during	O
3	O
months	O
.	O

RESULTS	O
The	O
consumption	O
of	O
L.	O
plantarum	O
CECT	O
7315/7316	O
during	O
3	O
months	O
after	O
influenza	O
vaccination	O
increased	O
the	O
levels	Physical
of	Physical
influenza-specific	Physical
IgA	Physical
and	Physical
IgG	Physical
antibodies	Physical
.	Physical

Moreover	O
,	O
a	O
trend	O
towards	O
an	O
increase	O
in	O
influenza-specific	Physical
IgM	Physical
antibodies	Physical
was	O
also	O
observed	O
.	O

CONCLUSION	O
L.	O
plantarum	O
CECT7315/7316	O
has	O
an	O
immunostimulating	O
effect	O
and	O
could	O
be	O
used	O
to	O
improve	O
the	O
response	O
to	O
influenza	O
vaccination	O
in	O
elderly	O
.	O

The	O
prophylactic	Others
effect	Others
of	O
valproate	O
on	O
glyceryltrinitrate	Physical
induced	Physical
migraine	Physical
.	Physical

In	O
this	O
study	O
the	O
human	O
glyceryltrinitrate	O
(	O
GTN	O
)	O
model	O
of	O
migraine	O
was	O
for	O
the	O
first	O
time	O
used	O
to	O
test	O
the	O
effect	O
of	O
a	O
prophylactic	O
drug	O
.	O

We	O
chose	O
to	O
test	O
valproate	O
due	O
to	O
its	O
well	O
documented	O
effect	O
as	O
a	O
migraine	O
prophylactic	O
drug	O
.	O

Efficacy	Others
of	O
this	O
compound	O
would	O
support	O
the	O
usefulness	O
of	O
the	O
model	O
in	O
prophylactic	O
antimigraine	O
drug	O
development	O
.	O

Twelve	O
patients	O
with	O
migraine	O
without	O
aura	O
were	O
included	O
in	O
a	O
randomized	O
double	O
blind	O
crossover	O
study	O
.	O

Valproate	O
1000	O
mg	O
or	O
placebo	O
was	O
given	O
daily	O
,	O
each	O
for	O
a	O
minimum	O
of	O
13	O
days	O
.	O

On	O
the	O
last	O
treatment	O
day	O
of	O
each	O
arm	O
a	O
20	O
min	O
intravenous	O
infusion	O
of	O
GTN	O
(	O
0.25	O
microg/kg/min	O
)	O
was	O
given	O
.	O

Headache	Adverseeffect
was	O
registered	O
for	O
12	O
h	O
after	O
the	O
infusion	O
and	O
headache	Adverseeffect
intensity	Adverseeffect
was	O
scored	O
on	O
a	O
scale	O
from	O
0	O
to	O
10	O
.	O

Fulfillment	O
of	O
IHS	O
criteria	O
was	O
recorded	O
for	O
24	O
h.	O
The	O
middle	Physical
cerebral	Physical
arteries	Physical
were	O
evaluated	O
by	O
transcranial	Physical
Doppler	Physical
and	O
the	O
diameter	Physical
of	Physical
the	Physical
superficial	Physical
temporal	Physical
and	Physical
radial	Physical
arteries	Physical
were	O
measured	O
with	O
high	Physical
frequency	Physical
ultrasound	Physical
.	Others

GTN	Physical
evoked	Physical
migraine	Pain
fulfilling	Pain
IHS	Pain
criteria	Pain
1.1	O
in	O
6	O
patients	O
after	O
placebo	O
and	O
in	O
2	O
patients	O
after	O
valproate	O
(	O
P	O
=	O
0.125	O
)	O
.	O

Including	O
additionally	O
3	O
patients	O
on	O
placebo	O
and	O
1	O
patient	O
on	O
valproate	O
who	O
felt	O
they	O
had	O
suffered	O
a	O
migraine	Adverseeffect
attack	Adverseeffect
,	O
but	O
who	O
had	O
as	O
associated	O
symptoms	O
only	O
photophobia	Physical
or	O
phonophobia	Physical
,	O
a	O
significant	O
reduction	O
in	O
the	O
number	Others
of	Others
patients	Others
with	Others
induced	Others
migraine	Others
after	O
valproate	O
was	O
seen	O
(	O
P	O
=	O
0.031	O
)	O
.	O

Median	Physical
peak	Physical
headache	Physical
intensity	Physical
was	O
1	O
(	O
range	O
0-9	O
)	O
after	O
valproate	O
compared	O
to	O
4.5	O
(	O
range	O
0-8	O
)	O
after	O
placebo	O
(	O
P	O
=	O
0.120	O
)	O
.	O

Pretreatment	O
with	O
valproate	O
as	O
compared	O
to	O
placebo	O
reduced	O
the	O
velocity	Physical
in	O
both	O
middle	Others
cerebral	Others
arteries	Others
after	O
GTN	O
(	O
left	O
P	O
=	O
0.021	O
,	O
right	O
P	O
=	O
0.031	O
)	O
.	O

No	O
effect	O
of	O
valproate	O
was	O
seen	O
in	O
the	O
diameter	Physical
of	Physical
the	Physical
superficial	Physical
temporal	Physical
artery	Physical
(	O
P	O
=	O
0.781	O
)	O
or	O
the	O
radial	O
artery	O
(	O
P	O
=	O
0.367	O
)	O
before	O
or	O
after	O
GTN	O
.	O

The	O
study	O
indicates	O
that	O
a	O
prophylactic	O
effect	O
of	O
valproate	O
may	O
be	O
demonstrated	O
using	O
the	O
GTN	Physical
human	Physical
migraine	Physical
model	O
.	O

Although	O
,	O
all	O
headache	Adverseeffect
parameters	Adverseeffect
were	O
reduced	O
after	O
valproate	O
compared	O
to	O
placebo	O
,	O
only	O
one	O
parameter	O
was	O
statistically	O
significantly	O
reduced	O
probably	O
because	O
of	O
the	O
small	O
number	O
of	O
patients	O
.	O

The	O
size	O
of	O
the	O
effect	O
was	O
similar	O
to	O
that	O
of	O
valproate	O
in	O
clinical	O
trials	O
.	O

The	O
GTN	O
model	O
may	O
therefore	O
be	O
a	O
valid	O
tool	O
for	O
testing	O
new	O
prophylactic	O
antimigraine	O
drugs	O
.	O

Effect	Others
of	O
a	O
multi-faceted	O
intervention	O
on	O
gingival	Physical
health	Physical
among	O
adults	O
with	O
systemic	O
sclerosis	O
.	O

OBJECTIVES	O
To	O
evaluate	Others
the	Others
effect	Others
of	O
adaptive	O
oral	O
hygiene	O
devices	O
and	O
orofacial	O
exercise	O
to	O
improve	O
gingival	Physical
health	Physical
among	O
adults	O
with	O
systemic	O
sclerosis	O
(	O
SSc	O
)	O
.	O

METHODS	O
Forty-eight	O
patients	O
with	O
SSc	O
were	O
assigned	O
randomly	O
to	O
the	O
multifaceted	O
oral	O
health	O
intervention	O
or	O
usual	O
dental	O
care	O
control	O
group	O
.	O

Participants	O
in	O
the	O
intervention	O
group	O
received	O
a	O
rechargeable	O
,	O
powered	O
Oral-B?	O
oscillating-rotating-pulsating	O
toothbrush	O
and	O
a	O
Reach?	O
Access?	O
Flosser	O
that	O
has	O
a	O
toothbrush-like	O
handle	O
.	O

For	O
those	O
with	O
an	O
oral	O
aperture	O
of	O
less	O
than	O
40	O
mm	O
,	O
orofacial	O
exercises	O
were	O
taught	O
.	O

Participants	O
in	O
the	O
control	O
group	O
were	O
each	O
given	O
a	O
manual	O
toothbrush	O
and	O
dental	O
floss	O
.	O

Participants	O
in	O
both	O
groups	O
received	O
instructions	O
and	O
demonstration	O
on	O
the	O
use	O
of	O
the	O
devices	O
,	O
and	O
were	O
requested	O
to	O
perform	O
the	O
respective	O
intervention	O
twice	O
a	O
day	O
for	O
6	O
months	O
.	O

Evaluations	O
were	O
at	O
baseline	O
,	O
3-	O
,	O
and	O
6-months	O
.	O

The	O
main	O
outcome	O
was	O
gingival	Physical
index	Physical
(	Physical
GI	Physical
)	Physical
,	O
an	O
indicator	O
of	O
gingival	O
inflammation	O
.	O

RESULTS	O
Both	O
groups	O
showed	O
significant	O
reduction	O
in	O
GI	O
scores	O
at	O
6	O
months	O
(	O
ps	O
<	O
0.005	O
)	O
.	O

Reduction	O
in	O
GI	O
scores	O
of	O
the	O
intervention	O
group	O
at	O
6	O
months	O
was	O
20.8	O
%	O
which	O
is	O
considered	O
to	O
be	O
clinically	O
significant	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
the	O
intervention	O
group	O
showed	O
a	O
significant	O
and	O
larger	O
reduction	O
in	O
GI	O
score	O
by	O
8	O
%	O
at	O
6	O
months	O
(	O
p=0.0007	O
)	O
.	O

CONCLUSIONS	O
Results	O
support	O
the	O
use	O
of	O
adaptive	O
devices	O
and	O
orofacial	O
exercise	O
to	O
improve	O
gingival	Physical
health	Physical
in	O
adults	O
with	O
SSc	O
when	O
compared	O
to	O
use	O
of	O
manual	O
toothbrushing	O
and	O
finger-held	O
flossing	O
.	O

Recommending	O
and	O
educating	O
patients	O
with	O
SSc	O
to	O
use	O
adaptive	O
devices	O
to	O
clean	O
the	O
tooth	O
surfaces	O
looks	O
promising	O
for	O
long-term	O
oral	O
health	O
improvement	O
.	O

Prophylactic	O
vs	O
therapeutic	O
blood	O
patch	O
for	O
obstetric	O
patients	O
with	O
accidental	O
dural	O
puncture	O
--	O
a	O
randomised	O
controlled	O
trial	O
.	O

Epidural	O
blood	O
patch	O
is	O
a	O
standard	O
treatment	O
for	O
obstetric	O
patients	O
experiencing	O
a	O
severe	O
post-dural	O
puncture	O
headache	O
.	O

Patients	O
who	O
sustained	O
an	O
accidental	O
dural	O
puncture	O
during	O
establishment	O
of	O
epidural	O
analgesia	O
during	O
labour	O
or	O
at	O
caesarean	O
delivery	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
prophylactic	O
epidural	O
blood	O
patch	O
or	O
conservative	O
treatment	O
with	O
a	O
therapeutic	O
epidural	O
blood	O
patch	O
if	O
required	O
.	O

Eleven	O
of	O
60	O
(	O
18.3	O
%	O
)	O
patients	O
in	O
the	O
prophylactic	O
epidural	O
blood	O
patch	O
group	O
developed	O
a	O
post-dural	Adverseeffect
puncture	Adverseeffect
headache	Adverseeffect
compared	O
with	O
39	O
of	O
49	O
(	O
79.6	O
%	O
)	O
in	O
the	O
therapeutic	O
epidural	O
blood	O
patch	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

A	O
blood	O
patch	O
was	O
performed	O
in	O
36	O
(	O
73.4	O
%	O
)	O
of	O
patients	O
in	O
the	O
therapeutic	O
group	O
.	O

The	O
number	Others
of	Others
patients	Others
who	Others
needed	Others
a	Others
second	Others
blood	Others
patch	Others
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
6	O
(	O
10.0	O
%	O
)	O
for	O
prophylactic	O
epidural	O
blood	O
patch	O
and	O
4	O
(	O
11.1	O
%	O
)	O
for	O
therapeutic	O
epidural	O
blood	O
patch	O
.	O

We	O
conclude	O
that	O
prophylactic	O
epidural	O
blood	O
patch	O
is	O
an	O
effective	Others
method	O
to	O
reduce	O
the	O
development	O
of	O
post-dural	O
puncture	O
headache	O
in	O
obstetric	O
patients	O
.	O

A	O
randomized	O
,	O
evaluator-blind	O
,	O
multicenter	O
comparison	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
Perlane	O
versus	O
Zyplast	O
in	O
the	O
correction	O
of	O
nasolabial	O
folds	O
.	O

Bovine	O
collagen	O
is	O
widely	O
used	O
as	O
a	O
dermal	O
filler	O
for	O
facial	O
soft-tissue	O
augmentation	O
,	O
but	O
it	O
provides	O
only	O
temporary	O
cosmetic	O
improvement	O
.	O

Nonanimal	O
stabilized	O
hyaluronic	O
acid	O
has	O
reduced	O
potential	O
for	O
immunogenicity	O
and	O
hypersensitivity	O
and	O
may	O
provide	O
a	O
more	O
durable	O
aesthetic	O
result	O
.	O

Sixty-eight	O
patients	O
with	O
prominent	O
nasolabial	O
folds	O
were	O
randomized	O
to	O
intradermal	O
treatment	O
with	O
nonanimal	O
stabilized	O
hyaluronic	O
acid	O
gel	O
(	O
Perlane	O
)	O
and	O
bovine	O
collagen	O
(	O
Zyplast	O
)	O
on	O
contralateral	O
sides	O
of	O
the	O
face	O
.	O

On	O
achievement	O
of	O
optimal	Physical
cosmetic	Physical
result	Physical
(	O
baseline	O
)	O
,	O
patients	O
were	O
followed	O
up	O
for	O
6	O
months	O
;	O
bilateral	O
retreatment	O
with	O
Perlane	O
was	O
offered	O
at	O
6	O
or	O
9	O
months	O
after	O
baseline	O
.	O

Responses	O
were	O
evaluated	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
after	O
baseline	O
.	O

Investigator-based	Others
and	Others
patient-based	Others
ratings	Others
indicated	O
that	O
Perlane	O
was	O
more	O
effective	O
than	O
Zyplast	O
in	O
maintaining	O
cosmetic	O
correction	O
.	O

According	O
to	O
investigator-based	Physical
Wrinkle	Physical
Severity	Physical
Rating	Physical
Scale	Physical
assessments	Physical
at	O
6	O
and	O
9	O
months	O
after	O
baseline	O
,	O
Perlane	O
was	O
superior	Others
in	O
50.0	O
percent	O
and	O
48.8	O
percent	O
of	O
patients	O
,	O
respectively	O
,	O
whereas	O
Zyplast	O
was	O
superior	Others
in	O
10.3	O
percent	O
and	O
14.0	O
percent	O
of	O
patients	O
,	O
respectively	O
(	O
p	O
<	O
0.0004	O
)	O
.	O

Investigator-based	O
Global	Physical
Aesthetic	Physical
Improvement	Physical
Scale	Physical
assessment	Physical
at	O
9	O
months	O
after	O
baseline	O
indicated	O
that	O
Perlane	O
was	O
superior	Others
in	O
48.8	O
percent	O
of	O
patients	O
,	O
whereas	O
Zyplast	O
was	O
superior	Others
in	O
14.0	O
percent	O
of	O
patients	O
(	O
p	O
=	O
0.0025	O
)	O
.	O

Optimal	Physical
cosmetic	Physical
result	Physical
was	O
achieved	O
with	O
a	O
smaller	O
volume	O
of	O
Perlane	O
than	O
Zyplast	O
(	O
mean	O
,	O
1.2	O
ml	O
versus	O
2.1	O
ml	O
)	O
.	O

Local	O
injection-site	O
reactions	Adverseeffect
(	Adverseeffect
redness	Adverseeffect
,	Adverseeffect
swelling	Adverseeffect
,	Adverseeffect
pruritus	Adverseeffect
,	Adverseeffect
and	Adverseeffect
induration	Adverseeffect
)	Adverseeffect
were	O
less	O
frequent	O
with	O
Perlane	O
than	O
with	O
Zyplast	O
.	O

Delayed-onset	O
reactions	O
were	O
rare	O
and	O
did	O
not	O
reoccur	O
after	O
Perlane	O
retreatment	O
.	O

Perlane	O
has	O
acceptable	O
long-term	Others
safety	Others
and	O
offers	O
a	O
longer-lasting	O
aesthetic	O
improvement	O
than	O
Zyplast	O
.	O

Motion	O
style	O
acupuncture	O
treatment	O
(	O
MSAT	O
)	O
for	O
acute	O
low	O
back	O
pain	O
with	O
severe	O
disability	O
:	O
a	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
protocol	O
.	O

BACKGROUND	O
Acupuncture	O
is	O
widely-used	O
to	O
treat	O
patients	O
with	O
low	O
back	O
pain	O
,	O
despite	O
insufficient	O
evidence	O
of	O
the	O
technique	O
's	O
efficacy	O
for	O
acute	O
back	O
pain	O
.	O

Motion	O
style	O
acupuncture	O
treatment	O
(	O
MSAT	O
)	O
is	O
a	O
non-traditional	O
acupuncture	O
treatment	O
requiring	O
a	O
patient	O
to	O
exercise	O
while	O
receiving	O
acupuncture	O
.	O

In	O
Korea	O
,	O
MSAT	O
is	O
used	O
to	O
reduce	O
musculoskeletal	O
pain	O
and	O
improve	O
functional	O
status	O
.	O

The	O
study	O
aims	O
to	O
evaluate	O
the	O
effect	O
of	O
MSAT	O
on	O
acute	O
low	O
back	O
pain	O
with	O
severe	O
disability	O
.	O

METHODS/DESIGN	O
This	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
active-controlled	O
trial	O
with	O
two	O
parallel	O
arms	O
.	O

Participants	O
with	O
acute	O
low	O
back	O
pain	O
and	O
severe	O
functional	O
disability	O
,	O
defined	O
as	O
an	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
value	O
>	O
60	O
%	O
,	O
will	O
be	O
randomly	O
allocated	O
to	O
the	O
acupuncture	O
group	O
and	O
the	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(	O
NSAID	O
)	O
injection	O
group	O
.	O

The	O
acupuncture	O
group	O
will	O
receive	O
MSAT	O
and	O
the	O
NSAID	O
injection	O
group	O
will	O
receive	O
an	O
intramuscular	O
injection	O
of	O
diclofenac	O
.	O

All	O
procedures	O
will	O
be	O
limited	O
to	O
one	O
session	O
and	O
the	O
symptoms	O
before	O
and	O
after	O
treatment	O
will	O
be	O
measured	O
by	O
assessors	O
blinded	O
to	O
treatment	O
allocation	O
.	O

The	O
primary	O
outcome	O
will	O
be	O
measured	O
at	O
30	O
minutes	O
after	O
treatment	O
using	O
the	O
numerical	Pain
rating	Pain
scale	Pain
(	Pain
NRS	Pain
)	Pain
of	Pain
low	Pain
back	Pain
pain	Pain
while	O
the	O
patient	O
is	O
moving	O
.	O

Secondary	O
outcomes	O
will	O
be	O
measured	O
at	O
30	O
minutes	O
after	O
treatment	O
using	O
the	O
NRS	Pain
of	Pain
leg	Pain
pain	Pain
,	O
ODI	Physical
,	O
patient	Others
global	Others
impression	Others
of	Others
change	Others
,	O
range	Physical
of	Physical
motion	Physical
(	Physical
ROM	Physical
)	Physical
of	Physical
the	Physical
lumbar	Physical
spine	Physical
,	O
and	O
degrees	Physical
of	Physical
straight	Physical
leg	Physical
raising	Physical
(	Physical
SLR	Physical
)	Physical
.	O

Post-treatment	O
follow-up	O
will	O
be	O
performed	O
to	O
measure	O
primary	O
and	O
secondary	O
outcomes	O
with	O
the	O
exception	O
of	O
ROM	Physical
and	O
SLR	Physical
at	O
2	O
,	O
4	O
,	O
and	O
24	O
weeks	O
after	O
treatment	O
.	O

DISCUSSION	O
The	O
results	O
of	O
this	O
trial	O
will	O
be	O
discussed	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrial.gov	O
NCT01315561	O
.	O

Brief	O
report	O
:	O
imitation	O
effects	O
on	O
children	O
with	O
autism	O
.	O

Twenty	O
children	O
with	O
autism	O
(	O
mean	O
age	O
,	O
5	O
years	O
)	O
were	O
recruited	O
for	O
the	O
study	O
from	O
a	O
school	O
for	O
children	O
with	O
autism	O
.	O

The	O
children	O
were	O
randomly	O
assigned	O
to	O
an	O
imitation	O
(	O
n	O
=	O
10	O
)	O
or	O
contingently	O
responsive	O
(	O
n	O
=	O
10	O
)	O
interaction	O
group	O
based	O
on	O
a	O
stratification	O
table	O
for	O
gender	O
and	O
developmental	O
and	O
chronological	O
age	O
.	O

The	O
sessions	O
consisted	O
of	O
four	O
phases	O
,	O
with	O
each	O
phase	O
lasting	O
3	O
minutes	O
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
child	O
walked	O
into	O
a	O
room	O
that	O
was	O
furnished	O
with	O
a	O
sofa	O
,	O
a	O
table	O
,	O
chairs	O
,	O
and	O
two	O
sets	O
of	O
identical	O
toys	O
.	O

An	O
adult	O
was	O
in	O
the	O
room	O
sitting	O
very	O
still	O
like	O
a	O
statue	O
(	O
first	O
still-face	O
condition	O
)	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
adult	O
either	O
imitated	O
the	O
child	O
or	O
was	O
contingently	O
responsive	O
to	O
the	O
child	O
.	O

In	O
the	O
third	O
phase	O
,	O
the	O
adult	O
sat	O
still	O
again	O
(	O
second	O
still-face	O
condition	O
)	O
,	O
and	O
in	O
the	O
fourth	O
phase	O
,	O
the	O
adult	O
engaged	O
in	O
a	O
spontaneous	O
interaction	O
.	O

During	O
the	O
third	O
phase	O
(	O
the	O
second	O
still-face	O
condition	O
)	O
,	O
the	O
children	O
in	O
the	O
imitation	O
group	O
spent	O
less	O
time	O
in	O
gross	O
motor	O
activity	O
and	O
more	Others
time	Others
touching	Others
the	Others
adult	Others
,	O
as	O
if	O
attempting	O
to	O
initiate	O
an	O
interaction	O
.	O

The	O
contingency	O
condition	O
appeared	O
to	O
be	O
a	O
more	Others
effective	Others
way	O
to	O
facilitate	O
a	O
distal	Mental
social	Mental
behavior	Mental
(	Mental
attention	Mental
)	Mental
,	O
whereas	O
the	O
imitative	O
condition	O
was	O
a	O
more	Others
effective	Others
way	O
to	O
facilitate	O
a	O
proximal	Mental
social	Mental
behavior	Mental
(	Mental
touching	Mental
)	Mental
.	O

Effects	O
of	O
sibutramine	O
on	O
thermogenesis	O
in	O
obese	O
patients	O
assessed	O
via	O
immersion	O
calorimetry	O
.	O

Glucose	O
utilization	O
studies	O
show	O
that	O
sibutramine-induced	O
thermogenesis	O
is	O
mediated	O
via	O
selective	O
sympathetic	O
activation	O
of	O
brown	O
adipose	O
tissue	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
use	O
a	O
new	O
calorimetry	O
method	O
in	O
which	O
resting	O
metabolic	O
rate	O
is	O
enhanced	O
to	O
evaluate	O
the	O
effects	O
of	O
sibutramine	O
treatment	O
on	O
thermogenesis	O
.	O

Sixty	O
obese	O
women	O
were	O
included	O
in	O
the	O
study	O
.	O

Subjects	O
were	O
divided	O
into	O
2	O
equal	O
groups-the	O
placebo	O
and	O
sibutramine	O
treatment	O
groups	O
.	O

The	O
sibutramine	O
group	O
was	O
given	O
sibutramine	O
10	O
mg	O
daily	O
for	O
12	O
wk	O
.	O

At	O
baseline	O
and	O
at	O
the	O
end	O
of	O
the	O
12-wk	O
treatment	O
period	O
,	O
thermogenic	O
measurements	O
were	O
taken	O
with	O
the	O
use	O
of	O
water	Physical
immersion	Physical
calorimetry	Physical
.	O

Subjects	O
were	O
examined	O
at	O
weeks	O
4	O
,	O
8	O
,	O
and	O
12	O
of	O
treatment	O
to	O
identify	O
adverse	O
effects	O
.	O

Body	Physical
mass	Physical
index	Physical
,	O
measured	O
at	O
31.5+/-2.05	O
kg/m2	O
in	O
the	O
placebo	O
group	O
,	O
decreased	O
to	O
30.4+/-2.94	O
kg/m	O
(	O
2	O
)	O
after	O
12	O
wk	O
(	O
P=.07	O
)	O
.	O

In	O
the	O
sibutramine	O
group	O
,	O
it	O
decreased	O
from	O
33.5+/-4.1	O
kg/m	O
(	O
2	O
)	O
to	O
30.9+/-4.8	O
kg/m	O
(	O
2	O
)	O
(	O
P	O
<	O
.05	O
)	O
.	O

In	O
the	O
sibutramine	O
group	O
,	O
mean	Physical
thermogenic	Physical
response	Physical
changed	O
from	O
a	O
baseline	O
value	O
of	O
1.27+/-0.29	O
kcal/kg/h	O
to	O
1.44+/-0.13	O
kcal/kg/h	O
after	O
12	O
wk	O
of	O
treatment	O
.	O

In	O
the	O
placebo	O
group	O
,	O
the	O
baseline	O
value	O
was	O
1.56+/-0.27	O
kcal/kg/h	O
;	O
it	O
changed	O
to	O
1.33+/-0.36	O
kcal/kg/h	O
at	O
the	O
end	O
of	O
12	O
wk	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
sibutramine	O
treatment	O
promotes	O
thermogenesis	Physical
,	O
thus	O
facilitating	O
weight	Physical
loss	Physical
.	O

Calorimetry	O
enhances	O
resting	Physical
metabolism	Physical
through	O
more	O
efficient	O
heat	O
transfer	O
from	O
the	O
body	O
.	O

[	O
Effects	O
of	O
transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
on	O
postoperative	O
nausea	O
and	O
vomiting	O
and	O
patient-controlled	O
epidural	O
analgesia	O
in	O
cesarean	O
section	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
effects	O
of	O
transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
on	O
postoperative	O
nausea	O
and	O
vomiting	O
and	O
patient-controlled	O
epidural	O
analgesia	O
in	O
cesarean	O
section	O
.	O

METHODS	O
After	O
IRB	O
approval	O
and	O
informed	O
consent	O
,	O
one	O
hundred	O
and	O
eighty	O
singleton	O
primiparas	O
undergoing	O
elective	O
cesarean	O
section	O
,	O
in	O
Qingdao	O
Municipal	O
Hospital	O
,	O
and	O
Qingdao	O
Hiser	O
Medical	O
Center	O
,	O
from	O
November	O
2011	O
to	O
March	O
2012	O
,	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
group	O
(	O
group	O
A	O
,	O
n	O
=	O
60	O
)	O
,	O
transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Eye	O
point	O
group	O
(	O
group	O
B	O
,	O
n	O
=	O
60	O
)	O
and	O
control	O
group	O
(	O
group	O
C	O
,	O
n	O
=	O
60	O
)	O
.	O

Women	O
of	O
group	O
A	O
received	O
transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
(	O
frequency	O
1.5	O
HZ	O
)	O
at	O
the	O
time	O
of	O
preoperation	O
,	O
4	O
,	O
10	O
and	O
22	O
hours	O
of	O
postoperation	O
for	O
30	O
minutes	O
.	O

The	O
strength	O
was	O
controlled	O
by	O
themselves	O
.	O

Women	O
of	O
group	O
B	O
received	O
stimulation	O
of	O
auricular	O
Eye	O
point	O
as	O
group	O
A	O
.	O

Women	O
of	O
group	O
C	O
received	O
pressurization	O
and	O
connected	O
line	O
were	O
the	O
same	O
with	O
group	O
A	O
,	O
but	O
without	O
electrical	O
stimulation	O
.	O

The	O
following	O
indexes	O
was	O
observed	O
:	O
the	O
incidence	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
for	O
48	O
hours	O
;	O
the	O
rate	O
of	O
metoclopramide	O
;	O
the	O
visual	Pain
analogue	Pain
scale	Pain
(	Pain
VAS	Pain
)	Pain
score	Pain
of	Pain
rest	Pain
pain	Pain
,	Pain
uterine	Pain
contration	Pain
pain	Pain
and	Pain
dynamic	Pain
pain	Pain
at	O
the	O
time	O
of	O
postoperation	O
for	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
hours	O
(	O
T	O
(	O
1	O
)	O
-T	O
(	O
4	O
)	O
)	O
;	O
the	O
total	O
number	O
and	O
effective	O
compressions	O
number	O
of	O
patient-controlled	Physical
epidural	Physical
analgesia	Physical
(	Physical
PCEA	Physical
)	Physical
;	O
the	O
dose	Others
of	Others
analgesia	Others
mixture	Others
;	O
the	O
anal	Physical
exhaust	Physical
time	Physical
;	O
the	O
volume	Physical
of	Physical
postoperative	Physical
bleeding	Physical
for	Physical
6	Physical
hours	Physical
of	Physical
postoperation	Physical
and	O
the	O
other	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
.	O

RESULTS	O
Compared	O
with	O
group	O
B	O
and	O
group	O
C	O
,	O
the	O
incidence	Physical
of	Physical
PONV	Physical
,	O
the	O
rate	Others
of	Others
metoclopramide	Others
,	O
the	O
VAS	Physical
score	Physical
at	O
the	O
time	O
T	O
(	O
1	O
)	O
-T	O
(	O
4	O
)	O
,	O
the	O
total	Physical
number	Physical
and	Physical
effective	Physical
compressions	Physical
number	Physical
of	Physical
PCEA	Physical
,	O
the	O
ratio	Physical
of	Physical
the	Physical
total	Physical
number	Physical
with	Physical
effective	Physical
compressions	Physical
number	Physical
and	O
the	O
dose	Physical
of	Physical
analgesia	Physical
mixture	Physical
were	O
decreased	O
in	O
group	O
A	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
no	O
difference	O
compared	O
group	O
B	O
with	O
group	O
C	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
anal	Physical
exhaust	Physical
time	Physical
and	O
the	Adverseeffect
volume	Physical
of	Physical
postoperative	Physical
bleeding	Physical
for	O
6	O
hours	O
of	O
postoperation	O
were	O
no	O
difference	O
in	O
the	O
three	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

No	O
other	O
side	Adverseeffect
effects	Adverseeffect
were	O
observed	O
.	O

CONCLUSION	O
Transcutaneous	O
electrical	O
stimulation	O
of	O
auricular	O
Shenmen	O
point	O
can	O
reduce	O
the	O
incidence	Physical
of	Physical
PONV	Physical
and	O
improves	O
analgesia	Pain
effect	Pain
of	Pain
PCEA	Pain
in	O
postoperation	O
of	O
cesarean	O
section	O
.	O

Use	Others
and	Others
limitations	Others
of	O
Holter	O
electrocardiography	O
in	O
assessing	O
drug	O
therapy	O
of	O
myocardial	O
ischemia	O
during	O
the	O
peri-PTCA	O
period	O
.	O

Incidence	O
and	O
pattern	O
of	O
myocardial	O
ischemia	O
during	O
the	O
peri-PTCA	O
(	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
)	O
period	O
and	O
the	O
possible	O
role	O
of	O
continuous	O
intravenous	O
isosorbide	O
dinitrate	O
in	O
its	O
prevention	O
were	O
examined	O
prospectively	O
in	O
30	O
patients	O
.	O

Holter	O
electrocardiographic	O
monitoring	O
was	O
performed	O
for	O
21	O
+/-	O
3	O
h	O
before	O
PTCA	O
and	O
continued	O
during	O
and	O
for	O
41	O
+/-	O
8	O
h	O
after	O
the	O
procedure	O
.	O

Before	O
PTCA	O
,	O
19	O
ischemic	O
episodes	O
were	O
present	O
in	O
10	O
(	O
33	O
%	O
)	O
of	O
30	O
patients	O
.	O

PTCA	O
produced	O
an	O
abrupt	O
decrease	O
in	O
number	O
(	O
p	O
=	O
0.015	O
)	O
and	O
duration	O
(	O
p	O
=	O
0.03	O
)	O
of	O
spontaneous	Physical
ischemic	Physical
episodes	Physical
.	Physical

The	O
rarity	O
of	O
recurrent	Physical
myocardial	Physical
ischemic	Physical
events	Physical
by	O
Holter	O
monitoring	O
after	O
PTCA	O
negated	O
any	O
attempt	O
at	O
assessing	O
the	O
efficacy	O
of	O
intravenous	O
isosorbide	O
dinitrate	O
in	O
their	O
prevention	O
.	O

Holter	O
monitoring	O
could	O
not	O
be	O
used	O
as	O
an	O
early	O
predictor	O
of	O
late	O
coronary	O
restenosis	O
.	O

Effects	O
of	O
tonabersat	O
on	O
migraine	O
with	O
aura	O
:	O
a	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
.	O

BACKGROUND	O
Migraine	O
with	O
aura	O
is	O
thought	O
likely	O
to	O
be	O
caused	O
by	O
cortical	O
spreading	O
depression	O
(	O
CSD	O
)	O
.	O

Tonabersat	O
inhibits	O
CSD	O
,	O
and	O
we	O
therefore	O
investigated	O
whether	O
tonabersat	O
has	O
a	O
preventive	O
effect	O
in	O
migraine	O
with	O
aura	O
.	O

METHODS	O
In	O
this	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
trial	O
,	O
40	O
mg	O
tonabersat	O
once	O
daily	O
was	O
compared	O
with	O
matched	O
placebo	O
in	O
patients	O
who	O
had	O
at	O
least	O
one	O
aura	O
attack	O
per	O
month	O
during	O
the	O
past	O
3	O
months	O
.	O

Randomisation	O
was	O
by	O
computer-generated	O
list	O
.	O

Patients	O
kept	O
a	O
detailed	O
diary	O
to	O
enable	O
objective	O
diagnosis	O
of	O
each	O
attack	O
as	O
migraine	O
with	O
aura	O
,	O
migraine	O
without	O
aura	O
,	O
or	O
other	O
type	O
of	O
headache	O
.	O

Primary	O
endpoints	O
were	O
a	O
reduction	Physical
in	Physical
aura	Physical
attacks	Physical
with	Physical
or	Physical
without	Physical
headache	Physical
and	O
a	O
reduction	Physical
in	Physical
migraine	Physical
headache	Physical
days	Physical
with	Physical
or	Physical
without	Physical
an	Physical
aura	Physical
.	O

Analysis	O
was	O
per	O
protocol	O
.	O

This	O
trial	O
is	O
registered	O
,	O
number	O
NCT00332007	O
.	O

FINDINGS	O
39	O
patients	O
were	O
included	O
in	O
the	O
study	O
,	O
of	O
whom	O
31	O
were	O
included	O
in	O
the	O
statistical	O
analysis	O
of	O
efficacy	O
.	O

Median	Physical
(	Physical
IQR	Physical
)	Physical
attacks	Physical
of	Physical
aura	Physical
were	O
reduced	O
from	O
3.2	O
(	O
1.0-5.0	O
)	O
per	O
12	O
weeks	O
on	O
placebo	O
to	O
1.0	O
(	O
0-3.0	O
)	O
on	O
tonabersat	O
(	O
p=0.01	O
)	O
,	O
whereas	O
the	O
other	O
primary	O
outcome	O
measure	O
,	O
median	Physical
migraine	Physical
headache	Physical
days	Physical
with	Physical
or	Physical
without	Physical
aura	Physical
,	O
was	O
not	O
significantly	O
different	O
between	O
placebo	O
and	O
tonabersat	O
groups	O
(	O
3.0	O
days	O
in	O
each	O
group	O
;	O
p=0.09	O
)	O
.	O

Tonabersat	O
was	O
well	O
tolerated	Others
but	O
overall	O
had	O
more	O
side-effects	O
than	O
placebo	O
.	O

INTERPRETATION	O
Tonabersat	O
showed	O
a	O
preventive	O
effect	O
on	O
attacks	O
of	O
migraine	O
aura	O
but	O
no	O
efficacy	O
on	O
non-aura	O
attacks	O
,	O
in	O
keeping	O
with	O
its	O
known	O
inhibitory	O
effect	O
on	O
CSD	O
.	O

The	O
results	O
support	O
the	O
theory	O
that	O
auras	O
are	O
caused	O
by	O
CSD	O
and	O
that	O
this	O
phenomenon	O
is	O
not	O
involved	O
in	O
attacks	O
without	O
aura	O
.	O

FUNDING	O
Minster	O
Pharmaceuticals	O
;	O
Lundbeck	O
Foundation	O
.	O

Hyperbaric	O
oxygen	O
attenuation	O
of	O
lipopolysaccharide-induced	O
acute	O
lung	O
injury	O
involves	O
heme	O
oxygenase-1	O
.	O

BACKGROUND	O
Hyperbaric	O
oxygen	O
(	O
HBO	O
)	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
acute	O
lung	O
injury	O
.	O

This	O
beneficial	O
effect	O
of	O
HBO	O
involves	O
inhibition	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
expression	O
and	O
subsequent	O
nitric	O
oxide	O
(	O
NO	O
)	O
biosynthesis	O
.	O

We	O
sought	O
to	O
investigate	O
the	O
role	O
of	O
heme	O
oxygenase-1	O
(	O
HO-1	O
)	O
on	O
this	O
HBO	O
inhibition	O
of	O
iNOS	O
induction	O
and	O
acute	O
lung	O
injury	O
in	O
septic	O
rat	O
lungs	O
.	O

METHODS	O
Before	O
the	O
experiment	O
,	O
72	O
rats	O
were	O
randomly	O
allocated	O
to	O
receive	O
HBO	O
or	O
air	O
treatment	O
.	O

With	O
or	O
without	O
HBO	O
pre-treatment	O
,	O
the	O
rats	O
were	O
further	O
divided	O
into	O
the	O
following	O
subgroups	O
(	O
n	O
=	O
6	O
)	O
:	O
(	O
i	O
)	O
LPS	O
injection	O
,	O
(	O
ii	O
)	O
normal	O
saline	O
(	O
N/S	O
)	O
injection	O
,	O
(	O
iii	O
)	O
hemin	O
(	O
a	O
HO-1	O
inducer	O
)	O
plus	O
LPS	O
,	O
(	O
iv	O
)	O
hemin	O
alone	O
,	O
(	O
v	O
)	O
tin	O
protoporphyrin	O
(	O
SnPP	O
;	O
a	O
HO-1	O
inhibitor	O
)	O
plus	O
LPS	O
,	O
and	O
(	O
vi	O
)	O
SnPP	O
alone	O
.	O

All	O
rats	O
were	O
maintained	O
for	O
6	O
h	O
and	O
then	O
sacrificed	O
with	O
a	O
high-dose	O
pentobarbital	O
injection	O
.	O

Lung	O
injuries	O
and	O
relevant	O
enzymes	O
expression	O
were	O
thus	O
assayed	O
.	O

RESULTS	O
Histological	Physical
analysis	Physical
,	Others
PMNs/alveoli	Physical
ratio	Physical
,	Others
and	Others
wet/dry	Physical
weight	Physical
ratio	Physical
measurements	Others
demonstrated	O
that	O
LPS	O
caused	O
significant	O
lung	O
injury	O
and	O
HBO	O
and/or	O
hemin	O
significantly	O
attenuated	O
this	O
LPS-induced	O
lung	O
injury	O
.	O

Increased	O
pulmonary	O
iNOS	Physical
expression	Physical
and	Physical
NO	Physical
production	Physical
were	O
associated	O
with	O
lung	O
injury	O
.	O

Induction	O
of	O
HO-1	O
,	O
by	O
HBO	O
and/or	O
hemin	O
,	O
significantly	O
attenuated	O
this	O
LPS-induced	O
iNOS	O
expression	O
and	O
acute	O
lung	O
injury	O
.	O

SnPP	O
,	O
on	O
the	O
contrary	O
,	O
offset	O
the	O
effects	O
of	O
HBO	O
and	O
worsened	O
the	O
LPS-induced	O
lung	O
injury	O
.	O

CONCLUSIONS	O
HBO	O
may	O
act	O
through	O
inhibiting	O
pulmonary	O
iNOS	O
expression	O
to	O
attenuate	O
LPS-induced	O
acute	O
lung	O
injury	O
in	O
septic	O
rats	O
.	O

Furthermore	O
,	O
this	O
HBO	O
attenuation	O
of	O
iNOS	O
expression	O
involves	O
HO-1	O
induction	O
.	O

Long-term	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
using	O
repetitive	O
education	O
at	O
six-month	O
intervals	O
and	O
monitoring	O
for	O
adherence	O
in	O
heart	O
failure	O
outpatients	O
:	O
the	O
REMADHE	O
trial	O
.	O

BACKGROUND	O
The	O
effectiveness	O
of	O
heart	O
failure	O
disease	O
management	O
programs	O
in	O
patients	O
under	O
cardiologists	O
'	O
care	O
over	O
long-term	O
follow-up	O
is	O
not	O
established	O
.	O

METHODS	O
AND	O
RESULTS	O
We	O
investigated	O
the	O
effects	O
of	O
a	O
disease	O
management	O
program	O
with	O
repetitive	O
education	O
and	O
telephone	O
monitoring	O
on	O
primary	O
(	O
combined	Physical
death	Others
or	Physical
unplanned	Others
first	Others
hospitalization	Others
and	Physical
quality-of-life	Others
changes	Others
)	O
and	O
secondary	O
end	O
points	O
(	O
hospitalization	Others
,	Physical
death	Others
,	Physical
and	Physical
adherence	Mental
)	O
.	O

The	O
REMADHE	O
[	O
Repetitive	O
Education	O
and	O
Monitoring	O
for	O
ADherence	O
for	O
Heart	O
Failure	O
]	O
trial	O
is	O
a	O
long-term	O
randomized	O
,	O
prospective	O
,	O
parallel	O
trial	O
designed	O
to	O
compare	O
intervention	O
with	O
control	O
.	O

One	O
hundred	O
seventeen	O
patients	O
were	O
randomized	O
to	O
usual	O
care	O
,	O
and	O
233	O
to	O
additional	O
intervention	O
.	O

The	O
mean	O
follow-up	O
was	O
2.47+/-1.75	O
years	O
,	O
with	O
54	O
%	O
adherence	O
to	O
the	O
program	O
.	O

In	O
the	O
intervention	O
group	O
,	O
the	O
primary	O
end	O
point	O
composite	Mortality
of	Mortality
death	Mortality
or	Physical
unplanned	Mortality
hospitalization	Mortality
was	O
reduced	O
(	O
hazard	O
ratio	O
,	O
0.64	O
;	O
confidence	O
interval	O
,	O
0.43	O
to	O
0.88	O
;	O
P=0.008	O
)	O
,	O
driven	O
by	O
reduction	O
in	O
hospitalization	Others
.	Physical

The	O
quality-of-life	Others
questionnaire	Others
score	Others
improved	O
only	O
in	O
the	O
intervention	O
group	O
(	O
P	O
<	O
0.003	O
)	O
.	O

Mortality	Mortality
was	O
similar	O
in	O
both	O
groups	O
.	O

Number	Adverseeffect
of	Adverseeffect
hospitalizations	Adverseeffect
(	O
1.3+/-1.7	O
versus	O
0.8+/-1.3	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
total	Others
hospital	Others
days	Others
during	Others
the	Others
follow-up	Others
(	O
19.9+/-51	O
versus	O
11.1+/-24	O
days	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
the	O
need	Others
for	Others
emergency	Others
visits	Others
(	O
4.5+/-10.6	O
versus	O
1.6+/-2.4	O
,	O
P	O
<	O
0.0001	O
)	O
were	O
lower	O
in	O
the	O
intervention	O
group	O
.	O

Beneficial	Others
effects	Others
were	O
homogeneous	O
for	O
sex	O
,	O
race	O
,	O
diabetes	O
and	O
no	O
diabetes	O
,	O
age	O
,	O
functional	O
class	O
,	O
and	O
etiology	O
.	O

CONCLUSIONS	O
For	O
a	O
longer	O
follow-up	O
period	O
than	O
in	O
previous	O
studies	O
,	O
this	O
heart	O
failure	O
disease	O
management	O
program	O
model	O
of	O
patients	O
under	O
the	O
supervision	O
of	O
a	O
cardiologist	O
is	O
associated	O
with	O
a	O
reduction	O
in	O
unplanned	Others
hospitalization	Others
,	O
a	O
reduction	O
of	O
total	Others
hospital	Others
days	Others
,	O
and	O
a	O
reduced	O
need	Others
for	Others
emergency	Others
care	Others
,	O
as	O
well	O
as	O
improved	Physical
quality	Others
of	Others
life	Others
,	O
despite	O
modest	O
program	Mental
adherence	Mental
over	O
time	O
.	O

Induction	O
chemotherapy	O
in	O
head	O
and	O
neck	O
cancer	O
:	O
results	O
of	O
a	O
phase	O
III	O
trial	O
.	O

Between	O
December	O
1982	O
and	O
October	O
1986	O
,	O
131	O
patients	O
with	O
stage	O
II-III-IV	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oropharynx	O
or	O
oral	O
cavity	O
were	O
randomized	O
to	O
induction	O
chemotherapy	O
,	O
consisting	O
of	O
bleomycin	O
(	O
10	O
mg/m2/day	O
in	O
continuous	O
infusion	O
from	O
day	O
1	O
to	O
day	O
5	O
)	O
,	O
methotrexate	O
(	O
120	O
mg/m2	O
on	O
day	O
2	O
)	O
followed	O
by	O
folinic	O
acid	O
,	O
5-fluorouracil	O
(	O
5	O
FU	O
)	O
(	O
600	O
mg/m2	O
on	O
day	O
2	O
)	O
,	O
and	O
cisplatin	O
(	O
120	O
mg/m2	O
on	O
day	O
4	O
)	O
every	O
4	O
weeks	O
for	O
a	O
total	O
of	O
three	O
cycles	O
followed	O
by	O
definitive	O
locoregional	O
treatment	O
versus	O
locoregional	O
treatment	O
alone	O
.	O

The	O
modalities	O
of	O
definitive	O
treatment	O
(	O
radiotherapy	O
+/-	O
surgery	O
)	O
were	O
chosen	O
prior	O
to	O
randomization	O
.	O

A	O
total	O
of	O
116	O
patients	O
were	O
evaluable	O
.	O

Of	O
55	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
,	O
four	O
(	O
7	O
%	O
)	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
and	O
23	O
(	O
42	O
%	O
)	O
a	O
partial	O
response	O
(	O
PR	O
)	O
following	O
the	O
induction	O
regimen	O
.	O

At	O
the	O
completion	O
of	O
locoregional	O
treatment	O
,	O
76	O
%	O
(	O
42	O
of	O
55	O
)	O
of	O
patients	O
in	O
the	O
experimental	O
group	O
were	O
in	O
CR	O
compared	O
to	O
89	O
%	O
(	O
54	O
of	O
61	O
)	O
in	O
the	O
control	O
group	O
.	O

There	O
was	O
no	O
difference	O
in	O
survival	Others
,	O
cause-specific	Others
survival	Others
,	O
and	O
pattern	Physical
of	Physical
relapse	Physical
between	O
both	O
groups	O
.	O

The	O
median	Others
survival	Others
was	O
22	O
months	O
in	O
the	O
chemotherapy	O
group	O
and	O
29	O
months	O
in	O
the	O
control	O
group	O
.	O

Responders	O
to	O
chemotherapy	O
did	O
not	O
fare	O
better	O
than	O
nonresponders	O
.	O

Chemotherapy-related	Adverseeffect
toxicities	Adverseeffect
were	O
few	O
and	O
most	O
of	O
them	O
related	O
to	O
cisplatin	O
which	O
was	O
reduced	O
to	O
100	O
mg/m2	O
for	O
35	O
patients	O
.	O

There	O
were	O
no	O
treatment-related	O
deaths	Mortality
and	O
,	O
in	O
the	O
experimental	O
arm	O
of	O
the	O
trial	O
,	O
no	O
increased	O
morbidity	Adverseeffect
from	O
locoregional	O
treatment	O
.	O

This	O
induction	O
regimen	O
does	O
not	O
offer	O
any	O
advantages	O
over	O
standard	O
treatment	O
.	O

Learning	O
about	O
the	O
equal	O
sign	O
:	O
does	O
comparing	O
with	O
inequality	O
symbols	O
help	O
?	O
This	O
study	O
investigated	O
whether	O
instruction	O
that	O
involves	O
comparing	O
the	O
equal	O
sign	O
with	O
other	O
relational	O
symbols	O
is	O
more	O
effective	O
at	O
imparting	O
a	O
relational	Mental
interpretation	Mental
of	Mental
the	Mental
equal	Mental
sign	Mental
than	O
instruction	O
about	O
the	O
equal	O
sign	O
alone	O
.	O

Third-	O
and	O
fourth-grade	O
students	O
in	O
a	O
comparing	O
symbols	O
group	O
learned	O
about	O
the	O
greater	O
than	O
,	O
less	O
than	O
,	O
and	O
equal	O
signs	O
and	O
had	O
the	O
opportunity	O
to	O
compare	O
the	O
inequality	O
symbols	O
with	O
the	O
equal	O
sign	O
.	O

Students	O
in	O
an	O
equal	O
sign	O
group	O
learned	O
about	O
the	O
equal	O
sign	O
only	O
.	O

A	O
third	O
group	O
of	O
students	O
served	O
as	O
a	O
control	O
group	O
.	O

Three	O
aspects	O
of	O
students	O
'	O
knowledge	O
were	O
assessed	O
before	O
and	O
after	O
the	O
lesson	O
:	O
(	O
a	O
)	O
conceptual	Mental
understanding	Mental
of	Mental
the	Mental
equal	Mental
sign	Mental
,	O
(	O
b	O
)	O
equation	Mental
encoding	Mental
,	O
and	O
(	O
c	O
)	O
problem	Mental
solving	Mental
.	O

Students	O
in	O
the	O
comparing	O
symbols	O
group	O
showed	O
greater	O
gains	O
in	O
conceptual	Mental
understanding	Mental
from	O
pretest	O
to	O
posttest	O
than	O
students	O
in	O
the	O
other	O
two	O
groups	O
,	O
and	O
students	O
in	O
the	O
comparing	O
symbols	O
group	O
also	O
scored	O
higher	O
on	O
a	O
posttest	O
that	O
assessed	O
knowledge	Mental
about	Mental
inequality	Mental
symbols	Mental
and	O
inequality	Mental
problem	Mental
solving	Mental
.	O

Thus	O
,	O
they	O
learned	O
about	O
three	O
symbols	O
in	O
the	O
same	O
amount	O
of	O
time	O
as	O
other	O
students	O
learned	O
about	O
the	O
equal	O
sign	O
alone	O
or	O
not	O
at	O
all	O
.	O

Therefore	O
,	O
an	O
instructional	O
approach	O
involving	O
comparison	O
can	O
be	O
an	O
effective	O
tool	O
for	O
learning	O
about	O
concepts	O
in	O
mathematics	O
.	O

Differential	O
effects	O
of	O
amino	O
acid	O
and	O
ketoacid	O
on	O
protein	O
metabolism	O
in	O
humans	O
.	O

We	O
examined	O
the	O
effects	O
of	O
insulin	O
,	O
amino	O
acid	O
(	O
AA	O
)	O
,	O
and	O
branched-chain	O
ketoacid	O
(	O
KA	O
)	O
availability	O
on	O
leucine	O
kinetics	O
in	O
eight	O
healthy	O
volunteers	O
(	O
age	O
=	O
22	O
+/-	O
2	O
y	O
,	O
body	O
mass	O
index	O
=	O
24	O
+/-	O
1	O
kg	O
)	O
by	O
using	O
the	O
euglycemic	O
insulin	O
clamp	O
and	O
[	O
1-14C	O
]	O
leucine	O
turnover	O
techniques	O
.	O

Four	O
experimental	O
conditions	O
were	O
studied	O
:	O
study	O
I	O
,	O
hyperinsulinemia	O
;	O
study	O
II	O
,	O
hyperinsulinemia	O
with	O
maintenance	O
of	O
basal	O
plasma	O
AA	O
and	O
branched-chain	O
KA	O
concentrations	O
;	O
study	O
III	O
,	O
hyperinsulinemia	O
with	O
hyperaminoacidemia	O
and	O
basal	O
plasma	O
branched-chain	O
KA	O
concentrations	O
;	O
and	O
study	O
IV	O
,	O
hyperinsulinemia	O
plus	O
basal	O
plasma	O
AA	O
concentrations	O
and	O
elevated	O
branched-chain	O
KA	O
levels	O
.	O

Basal	O
endogenous	Physical
leucine	Physical
flux	Physical
(	Physical
ELF	Physical
)	Physical
averaged	O
1.20	O
+/-	O
0.05	O
(	O
mumol.kg-1.min-1	O
,	O
mean	O
+/-	O
SE	O
)	O
;	O
basal	O
leucine	Physical
oxidation	Physical
(	Physical
LOX	Physical
)	Physical
was	O
0.25	O
+/-	O
0.01	O
;	O
and	O
basal	O
non-oxidative	Physical
leucine	Physical
disposal	Physical
(	Physical
NOLD	Physical
)	Physical
was	O
0.95	O
+/-	O
0.04	O
.	O

ELF	Physical
significantly	O
decreased	O
in	O
study	O
I	O
(	O
0.77	O
+/-	O
0.06	O
mumol.kg-1.min-1	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
.	O

When	O
plasma	Physical
AA	Physical
and	Physical
branched-chain	Physical
KA	Physical
were	O
either	O
maintained	O
at	O
their	O
basal	O
levels	O
(	O
study	O
II	O
)	O
or	O
increased	O
above	O
baseline	O
values	O
(	O
studies	O
III	O
and	O
IV	O
)	O
,	O
ELF	O
declined	O
further	O
(	O
0.64	O
+/-	O
0.05	O
,	O
0.66	O
+/-	O
0.02	O
,	O
and	O
0.66	O
+/-	O
0.03	O
mumol.kg-1.min-1	O
,	O
respectively	O
;	O
all	O
Ps	O
<	O
0.01	O
versus	O
basal	O
and	O
P	O
<	O
0.01	O
versus	O
study	O
I	O
)	O
.	O

LOX	Physical
declined	O
in	O
study	O
I	O
(	O
0.12	O
+/-	O
0.02	O
mumol.kg-1.min-1	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
but	O
increased	O
significantly	O
in	O
studies	O
II	O
,	O
III	O
,	O
and	O
IV	O
(	O
0.31	O
+/-	O
0.04	O
,	O
0.37	O
+/-	O
0.03	O
,	O
and	O
0.40	O
+/-	O
0.03	O
mumol.kg-1.min-1	O
,	O
respectively	O
,	O
all	O
Ps	O
<	O
0.01	O
versus	O
basal	O
,	O
P	O
<	O
0.05	O
study	O
IV	O
versus	O
study	O
II	O
,	O
and	O
P	O
<	O
0.05	O
study	O
III	O
versus	O
study	O
II	O
)	O
.	O

NOLD	Physical
declined	O
in	O
study	O
I	O
(	O
0.65	O
+/-	O
0.05	O
mumol/kg.min	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
,	O
whereas	O
neither	O
the	O
maintenance	O
of	O
basal	Physical
plasma	Physical
AA/branched-chain	Physical
KA	Physical
levels	Physical
(	O
study	O
II	O
;	O
0.89	O
+/-	O
0.2	O
mumol.kg-1.min-1	O
)	O
nor	O
the	O
elevation	O
of	O
plasma	Physical
branched-chain	Physical
KA	Physical
concentration	Physical
(	O
study	O
IV	O
;	O
0.96	O
+/-	O
0.1	O
mumol.kg-1.min-1	O
)	O
increased	O
NOLD	Physical
above	O
baseline	O
level	O
.	O

A	O
stimulation	O
of	O
NOLD	Physical
was	O
observed	O
only	O
when	O
plasma	Physical
AA	Physical
levels	Physical
were	O
increased	O
(	O
study	O
III	O
;	O
1.23	O
+/-	O
0.03	O
mumol/kg.min	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
data	O
do	O
not	O
support	O
the	O
concept	O
of	O
a	O
direct	O
anabolic	O
action	O
of	O
ketoanalogs	O
but	O
do	O
provide	O
additional	O
evidence	O
for	O
the	O
pivotal	O
role	O
of	O
AA	O
availability	O
in	O
the	O
stimulation	O
of	O
whole-body	O
protein	O
synthesis	O
.	O

A	O
description	O
of	O
the	O
clinical	O
characteristics	O
at	O
baseline	O
of	O
patients	O
recruited	O
into	O
the	O
Carvedilol	O
or	O
Metoprolol	O
European	O
Trial	O
(	O
COMET	O
)	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
COMET	O
trial	O
was	O
a	O
prospective	O
,	O
double-blind	O
,	O
randomised	O
trial	O
comparing	O
carvedilol	O
,	O
a	O
comprehensive	O
adrenergic	O
receptor	O
antagonist	O
,	O
with	O
metoprolol	O
,	O
a	O
beta-1-selective	O
agent	O
in	O
patients	O
with	O
heart	O
failure	O
and	O
left	O
ventricular	O
systolic	O
dysfunction	O
.	O

The	O
trial	O
showed	O
a	O
reduction	O
in	O
mortality	Mortality
with	O
carvedilol	O
that	O
was	O
consistent	O
across	O
subgroups	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
in	O
greater	O
detail	O
the	O
heterogeneity	O
of	O
this	O
population	O
at	O
baseline	O
with	O
particular	O
reference	O
to	O
the	O
impact	O
of	O
symptomatic	O
severity	O
,	O
age	O
and	O
gender	O
on	O
patient	O
characteristics	O
.	O

METHODS	O
A	O
descriptive	O
report	O
using	O
data	O
entered	O
in	O
the	O
COMET	O
study	O
data-base	O
.	O

RESULTS	O
The	O
characteristics	O
of	O
the	O
population	O
studied	O
were	O
similar	O
to	O
those	O
reported	O
in	O
previous	O
trials	O
of	O
beta-blockers	O
.	O

Almost	O
all	O
patients	O
were	O
receiving	O
diuretics	O
and	O
ACE	O
inhibitors	O
with	O
few	O
patients	O
taking	O
angiotensin	O
receptor	O
blockers	O
.	O

As	O
expected	O
,	O
older	O
patients	O
had	O
more	O
co-morbidity	Physical
.	Physical

Older	O
patients	O
and	O
women	O
reported	O
worse	O
symptoms	Physical
and	Physical
poorer	Physical
well-being	Physical
despite	O
similar	O
ventricular	Physical
dimensions	Physical
and	Physical
systolic	Physical
dysfunction	Physical
.	Physical

NT-proBNP	Physical
was	O
higher	O
in	O
patients	O
with	O
more	O
severe	O
symptoms	O
and	O
older	O
patients	O
but	O
not	O
in	O
women	O
,	O
although	O
differences	O
in	O
NT-proBNP	O
may	O
have	O
been	O
confounded	O
by	O
differences	O
in	O
renal	Physical
function	Physical
.	Physical

CONCLUSION	O
Age	O
and	O
gender	O
,	O
as	O
well	O
as	O
the	O
severity	O
of	O
cardiac	O
dysfunction	O
,	O
appear	O
to	O
have	O
an	O
important	O
effect	O
on	O
the	O
severity	O
of	O
heart	Physical
failure	Physical
symptoms	Physical
and	O
patient	Physical
'well-being	Physical
'	Physical
.	Physical

This	O
could	O
have	O
important	O
implications	O
for	O
the	O
relationship	O
between	O
symptoms	O
and	O
prognosis	O
and	O
therefore	O
the	O
way	O
in	O
which	O
patients	O
are	O
selected	O
for	O
clinical	O
trials	O
and	O
the	O
goals	O
of	O
treatment	O
.	O

This	O
will	O
be	O
the	O
subject	O
of	O
further	O
analyses	O
.	O

Concurrent	O
alcohol	O
dependence	O
among	O
methadone-maintained	O
cocaine	O
abusers	O
is	O
associated	O
with	O
greater	O
abstinence	Mental
.	Physical

Concurrent	O
alcohol	O
dependence	O
(	O
AD	O
)	O
among	O
polysubstance	O
abusers	O
has	O
been	O
associated	O
with	O
negative	O
consequences	O
,	O
although	O
it	O
may	O
not	O
necessarily	O
lead	O
to	O
poor	O
treatment	O
outcomes	O
.	O

One	O
of	O
the	O
most	O
efficacious	O
treatments	O
for	O
cocaine	O
abuse	O
is	O
contingency	O
management	O
(	O
CM	O
)	O
,	O
but	O
little	O
research	O
has	O
explored	O
the	O
impact	O
of	O
AD	O
on	O
abstinence	Mental
outcomes	Mental
,	O
particularly	O
among	O
patients	O
in	O
methadone	O
maintenance	O
.	O

Using	O
data	O
from	O
three	O
trials	O
of	O
CM	O
for	O
cocaine	O
use	O
,	O
we	O
compared	O
baseline	Physical
characteristics	Physical
and	Physical
posttreatment	Physical
and	Physical
follow-up	Physical
cocaine	Physical
outcomes	Physical
between	O
methadone-maintained	O
,	O
cocaine-dependent	O
patients	O
(	O
N	O
=	O
193	O
)	O
with	O
and	O
without	O
concurrent	O
AD	O
,	O
randomized	O
to	O
standard	O
care	O
(	O
SC	O
)	O
with	O
or	O
without	O
CM	O
.	O

Patients	O
with	O
and	O
without	O
concurrent	O
AD	O
had	O
similar	O
baseline	O
characteristics	O
,	O
with	O
the	O
exception	O
that	O
AD	O
patients	O
reported	O
more	O
alcohol	O
use	O
.	O

AD	O
patients	O
achieved	O
longer	O
durations	Mental
of	Mental
cocaine	Mental
abstinence	Mental
and	O
were	O
more	O
likely	O
to	O
submit	O
a	O
cocaine-negative	Mental
sample	Mental
at	O
follow-up	O
than	O
non-AD	O
patients	O
.	O

Patients	O
randomized	O
to	O
CM	O
achieved	O
better	O
outcomes	O
than	O
those	O
randomized	O
to	O
SC	O
,	O
but	O
there	O
was	O
no	O
interaction	O
between	O
treatment	O
condition	O
and	O
AD	O
status	O
.	O

These	O
findings	O
suggest	O
that	O
cocaine-using	O
methadone	O
patients	O
with	O
AD	O
achieve	O
greater	O
cocaine	Mental
abstinence	Mental
than	O
their	O
non-AD	O
counterparts	O
and	O
should	O
not	O
necessarily	O
be	O
viewed	O
as	O
more	O
difficult	O
to	O
treat	O
.	O

The	O
effects	O
of	O
hypoxemia	O
on	O
cardiac	O
output	O
.	O

A	O
dose-response	O
curve	O
.	O

To	O
establish	O
a	O
dose-response	O
curve	O
for	O
the	O
effects	O
of	O
isocapnic	O
hypoxemia	O
on	O
cardiac	Physical
output	Physical
(	Physical
CO	Physical
)	Physical
,	O
we	O
studied	O
20	O
healthy	O
men	O
,	O
aged	O
20	O
to	O
34	O
years	O
,	O
using	O
a	O
tight-fitting	O
face	O
mask	O
and	O
an	O
isocapnic	O
partial	O
rebreathing	O
system	O
(	O
a	O
modified	O
anesthesia	O
machine	O
)	O
.	O

We	O
blended	O
oxygen	O
and	O
hypoxic	O
gas	O
to	O
achieve	O
arterial	O
oxygen	O
saturations	O
(	O
SaO2	O
)	O
of	O
80	O
,	O
85	O
,	O
and	O
90	O
percent	O
;	O
subjects	O
also	O
breathed	O
100	O
percent	O
oxygen	O
and	O
room	O
air	O
(	O
RA	O
)	O
.	O

Target	O
SaO2	O
and	O
end-tidal	O
carbon	O
dioxide	O
were	O
continuously	O
monitored	O
using	O
an	O
ear	O
oximeter	O
and	O
CO2	O
gas	O
analyzer	O
.	O

Subjects	O
experienced	O
the	O
five	O
SaO2	O
measurements	O
in	O
random	O
order	O
.	O

CO	Physical
was	O
measured	O
noninvasively	O
at	O
approximately	O
two-minute	O
intervals	O
,	O
using	O
continuous-wave	O
Doppler	O
echocardiography	O
.	O

Mean	Physical
cardiac	Physical
output	Physical
increased	O
with	O
increasing	O
hypoxemia	Physical
from	O
6.84	O
L/min	O
at	O
FIo2	O
1.0	O
to	O
8.44	O
L/min	O
at	O
SaO2	O
80	O
percent	O
(	O
p	O
less	O
than	O
0.0005	O
)	O
;	O
the	O
increase	O
was	O
entirely	O
due	O
to	O
increased	O
heart	Physical
rate	Physical
.	O

We	O
concluded	O
that	O
cardiac	Physical
output	Physical
increases	O
significantly	O
in	O
a	O
dose-response	O
manner	O
in	O
response	O
to	O
acute	O
isocapnic	O
hypoxemia	O
in	O
normal	O
persons	O
.	O

Transcutaneous	O
electrical	O
nerve	O
stimulation	O
following	O
appendicectomy	O
:	O
the	O
placebo	O
effect	O
.	O

A	O
controlled	O
trial	O
was	O
undertaken	O
to	O
compare	O
the	O
efficacy	O
of	O
transcutaneous	O
electrical	O
nerve	O
stimulation	O
(	O
TENS	O
)	O
with	O
standard	O
intramuscular	O
opiate	O
analgesia	O
in	O
the	O
management	O
of	O
postoperative	O
pain	O
following	O
appendicectomy	O
.	O

Consecutive	O
patients	O
undergoing	O
emergency	O
appendicectomy	O
were	O
randomised	O
into	O
control	O
,	O
sham	O
TENS	O
and	O
active	O
TENS	O
groups	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
pain	Pain
severity	Pain
and	O
analgesic	Others
intake	Others
in	O
both	O
active	O
and	O
sham	O
TENS	O
groups	O
when	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

No	O
difference	O
was	O
demonstrated	O
in	O
pain	Pain
severity	Pain
between	O
active	O
and	O
sham	O
TENS	O
groups	O
but	O
the	O
active	O
TENS	O
group	O
required	O
slightly	O
less	O
analgesia	O
.	O

These	O
results	O
suggest	O
that	O
the	O
major	O
benefit	O
of	O
TENS	O
in	O
the	O
postappendicectomy	O
patient	O
is	O
due	O
to	O
its	O
'placebo	O
effect	O
'	O
and	O
its	O
use	O
in	O
this	O
situation	O
can	O
not	O
be	O
recommended	O
.	O

[	O
Radiotherapy	O
of	O
malignant	O
brain	O
gliomas	O
using	O
teniposide	O
]	O
.	O

Efficacy	Others
of	O
radiochemotherapy	O
of	O
malignantly-converted	O
brain	O
gliomas	O
using	O
teniposide	O
was	O
evaluated	O
in	O
a	O
randomized	O
prospective	O
study	O
.	O

Combined	O
use	O
of	O
cytostatics	O
and	O
irradiation	O
appeared	O
safe	O
,	O
tolerable	O
and	O
significantly	O
more	O
effective	O
than	O
radiotherapy	O
alone	O
as	O
assessed	O
by	O
local	Physical
control	Physical
of	Physical
tumor	Physical
and	O
survival	Mortality
.	O

In-hospital	Others
costs	Others
of	O
self-expanding	O
nitinol	O
stent	O
implantation	O
versus	O
balloon	O
angioplasty	O
in	O
the	O
femoropopliteal	O
artery	O
(	O
the	O
VascuCoil	O
Trial	O
)	O
.	O

PURPOSE	O
Although	O
several	O
prospective	O
studies	O
have	O
examined	O
the	O
safety	Others
and	O
efficacy	Others
of	O
stent	O
placement	O
for	O
femoropopliteal	O
arterial	O
disease	O
,	O
the	O
current	O
cost	O
of	O
these	O
procedures	O
is	O
unknown	O
.	O

To	O
estimate	O
and	O
compare	O
hospital	Others
costs	Others
associated	O
with	O
conventional	O
balloon	O
angioplasty	O
(	O
percutaneous	O
transluminal	O
angioplasty	O
[	O
PTA	O
]	O
)	O
and	O
stent	O
placement	O
for	O
patients	O
with	O
symptomatic	O
peripheral	O
arterial	O
disease	O
,	O
the	O
authors	O
performed	O
a	O
prospective	O
economic	O
evaluation	O
in	O
conjunction	O
with	O
the	O
Intracoil	O
Femoropopliteal	O
Stent	O
Trial	O
(	O
VascuCoil	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
Between	O
May	O
1997	O
and	O
December	O
1999	O
,	O
266	O
patients	O
with	O
stenotic	O
or	O
occluded	O
superficial	O
femoral	O
or	O
popliteal	O
arteries	O
were	O
prospectively	O
randomized	O
to	O
treatment	O
with	O
the	O
IntraCoil	O
stent	O
or	O
PTA	O
.	O

Detailed	O
resource	Others
use	Others
and	O
cost	Others
data	Others
for	O
each	O
patient	O
's	O
initial	O
revascularization	O
procedure	O
and	O
ensuing	O
hospitalization	O
were	O
collected	O
and	O
analyzed	O
on	O
an	O
intention-to-treat	O
basis	O
.	O

RESULTS	O
Compared	O
with	O
conventional	O
balloon	O
angioplasty	O
,	O
stent	O
placement	O
did	O
not	O
improve	O
clinical	Physical
outcomes	Physical
but	O
increased	O
procedure	Others
duration	Others
,	O
equipment	Others
costs	Others
,	O
and	O
physician	Others
services	Others
.	O

As	O
a	O
result	O
,	O
initial	Others
hospital	Others
costs	Others
were	O
approximately	O
3,500	O
dollars	O
higher	O
for	O
patients	O
randomized	O
to	O
the	O
IntraCoil	O
stent	O
,	O
compared	O
with	O
PTA	O
(	O
8,435	O
dollars	O
vs	O
4,980	O
dollars	O
;	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSIONS	O
As	O
performed	O
in	O
the	O
VascuCoil	O
trial	O
,	O
primary	O
stent	O
placement	O
for	O
femoropopliteal	O
disease	O
did	O
not	O
improve	O
clinical	Physical
outcomes	Physical
but	O
increased	O
initial	Others
treatment	Others
costs	Others
by	O
more	O
than	O
3,000	O
dollars	O
.	O

Because	O
there	O
were	O
no	O
substantial	O
differences	O
in	O
subsequent	O
clinical	Physical
outcomes	Physical
between	O
the	O
two	O
treatments	O
,	O
it	O
is	O
unlikely	O
that	O
these	O
increased	O
initial	Others
costs	Others
would	O
be	O
offset	O
by	O
savings	O
in	O
follow-up	Others
costs	Others
.	O

These	O
findings	O
suggest	O
that	O
a	O
strategy	O
of	O
routine	O
stent	O
implantation	O
for	O
patients	O
undergoing	O
femoropopliteal	O
PTA	O
is	O
not	O
optimal	O
on	O
economic	O
grounds	O
and	O
that	O
PTA	O
with	O
provisional	O
stent	O
implantation	O
is	O
preferred	O
.	O

[	O
Methodologic	O
comparison	O
of	O
the	O
polyfrequency	O
oscillation	O
method	O
,	O
transcutaneous	O
oxygen	O
pressure	O
measurement	O
and	O
body	O
plethysmography	O
in	O
bronchial	O
provocation	O
with	O
methacholine	O
]	O
.	O

A	O
bronchial	O
provocation	O
challenge	O
test	O
was	O
conducted	O
with	O
30	O
subjects	O
using	O
metacholin	O
.	O

In	O
randomised	O
sequence	O
lung	O
function	O
analysis	O
tests	O
were	O
carried	O
out	O
with	O
the	O
bodyplethysmograph	O
(	O
Raw	O
,	O
FEV1	O
)	O
and	O
the	O
polyfrequent	O
oscillation	O
method	O
(	O
resistance	O
,	O
reactance	O
between	O
2	O
and	O
52	O
Hz	O
)	O
,	O
whereas	O
the	O
transcutaneous	O
oxygen	O
pressure	O
(	O
tc-PO2	O
)	O
was	O
measured	O
continuously	O
.	O

Correlations	O
between	O
the	O
various	O
parameters	O
,	O
the	O
change	O
of	O
the	O
values	O
at	O
PD60	O
sGaw	O
in	O
relation	O
to	O
the	O
initial	O
values	O
,	O
the	O
interindividual	O
variability	O
and	O
the	O
reactivity	O
were	O
determined	O
.	O

Medium	O
correlations	O
were	O
found	O
for	O
the	O
oscillatory	Physical
parameters	Physical
and	Others
Raw	Physical
,	O
whereas	O
for	O
tc-PO2	Physical
and	Others
Raw	Physical
the	O
correlation	O
was	O
markedly	O
lower	O
.	O

In	O
terms	O
of	O
percentage	O
the	O
greatest	O
change	O
was	O
found	O
in	O
reactance	O
,	O
in	O
relation	O
to	O
the	O
initial	O
value	O
,	O
followed	O
by	O
Raw	Physical
and	Others
FEV1	Physical
.	Others

The	O
interindividual	O
variability	O
resulted	O
in	O
the	O
highest	O
values	O
for	O
the	O
reactance	O
,	O
followed	O
by	O
Raw	Physical
and	O
FEV1	Physical
.	Others

Interindividual	O
variability	O
showed	O
the	O
highest	O
values	O
for	O
the	O
reactance	O
before	O
oscillatory	Physical
resistance	Physical
and	Others
Raw	Physical
.	Others

In	O
respect	O
of	O
reactivity	O
,	O
reactance	O
also	O
had	O
the	O
highest	O
values	O
.	O

Overall	O
evaluation	O
showed	O
that	O
bodyplethysmography	O
and	O
the	O
polyfrequent	O
oscillation	O
method	O
(	O
reactance	O
or	O
resonance	O
frequency	O
)	O
are	O
comparably	O
sensitive	O
.	O

The	O
relationship	O
between	O
repetitive	Mental
behaviors	Mental
and	O
growth	Physical
hormone	Physical
response	Physical
to	O
sumatriptan	O
challenge	O
in	O
adult	O
autistic	O
disorder	O
.	O

Autism	O
is	O
heterogeneous	O
with	O
respect	O
to	O
clinical	O
symptoms	O
and	O
etiology	O
.	O

To	O
sort	O
out	O
this	O
heterogeneity	O
in	O
autism	O
,	O
we	O
investigated	O
whether	O
specific	Physical
neurobiological	Physical
markers	Physical
vary	O
in	O
parallel	O
to	O
core	Physical
symptomatology	Physical
.	O

Specifically	O
,	O
we	O
assessed	O
growth	Physical
hormone	Physical
response	Physical
to	O
the	O
5-HT	O
1d	O
agonist	O
,	O
sumatriptan	O
,	O
and	O
linked	Physical
this	Physical
measure	Physical
of	Physical
serotonergic	Physical
function	Physical
to	O
the	Mental
severity	Mental
of	Mental
repetitive	Mental
behaviors	Mental
in	O
adult	O
autistic	O
patients	O
.	O

Eleven	O
adult	O
patients	O
with	O
autism	O
or	O
Asperger	O
's	O
disorder	O
were	O
randomized	O
to	O
single	O
dose	O
sumatriptan	O
(	O
6	O
mg	O
SQ	O
)	O
and	O
placebo	O
challenges	O
,	O
separated	O
by	O
a	O
one-week	O
interval	O
.	O

In	O
adult	O
autistic	O
disorders	O
,	O
severity	Mental
of	Mental
repetitive	Mental
behaviors	Mental
at	Mental
baseline	Mental
,	O
as	O
measured	O
by	O
YBOCS-compulsion	Mental
score	Mental
,	O
significantly	O
positively	O
correlated	O
with	O
both	O
peak	Physical
delta	Physical
growth	Physical
hormone	Physical
response	Physical
and	O
area	Physical
under	Physical
the	Physical
curve	Physical
growth	Physical
hormone	Physical
response	Physical
to	O
sumatriptan	O
.	O

Thus	O
,	O
the	O
severity	Mental
of	Mental
a	Mental
specific	Mental
behavioral	Mental
dimension	Mental
in	O
autism	O
(	Mental
repetitive	Mental
behaviors	Mental
)	Mental
parallels	Mental
the	Mental
sensitivity	Mental
of	O
the	O
5-HT	O
1d	O
receptor	O
,	O
as	O
manifest	O
by	O
sumatriptan	Physical
elicited	Physical
GH	Physical
response	Physical
.	O

Physostigmine	O
reverses	O
propofol-induced	O
unconsciousness	O
and	O
attenuation	O
of	O
the	O
auditory	O
steady	O
state	O
response	O
and	O
bispectral	O
index	O
in	O
human	O
volunteers	O
.	O

BACKGROUND	O
It	O
is	O
postulated	O
that	O
alteration	O
of	O
central	O
cholinergic	O
transmission	O
plays	O
an	O
important	O
role	O
in	O
the	O
mechanism	O
by	O
which	O
anesthetics	O
produce	O
unconsciousness	O
.	O

The	O
authors	O
investigated	O
the	O
effect	O
of	O
altering	O
central	O
cholinergic	O
transmission	O
,	O
by	O
physostigmine	O
and	O
scopolamine	O
,	O
on	O
unconsciousness	O
produced	O
by	O
propofol	O
.	O

METHODS	O
Propofol	O
was	O
administered	O
to	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
1	O
(	O
n	O
=	O
17	O
)	O
volunteers	O
with	O
use	O
of	O
a	O
computer-controlled	O
infusion	O
pump	O
at	O
increasing	O
concentrations	O
until	O
unconsciousness	O
resulted	O
(	O
inability	O
to	O
respond	O
to	O
verbal	O
commands	O
,	O
abolition	O
of	O
spontaneous	O
movement	O
)	O
.	O

Central	Physical
nervous	Physical
system	Physical
function	Physical
was	O
assessed	O
by	O
use	O
of	O
the	O
Auditory	Physical
Steady	Physical
State	Physical
Response	Physical
(	Physical
ASSR	Physical
)	Physical
and	O
Bispectral	Physical
Index	Physical
(	Physical
BIS	Physical
)	Physical
analysis	Physical
of	Physical
electrooculogram	Physical
.	O

During	O
continuous	O
administration	O
of	O
propofol	O
,	O
reversal	Physical
of	Physical
unconsciousness	Physical
produced	O
by	O
physostigmine	O
(	O
28	O
microgram/kg	O
)	O
and	O
block	Physical
of	Physical
this	Physical
reversal	Physical
by	O
scopolamine	O
(	O
8.6	O
microgram/kg	O
)	O
were	O
evaluated	O
.	O

RESULTS	O
Propofol	O
produced	O
unconsciousness	Physical
at	O
a	O
plasma	O
concentration	O
of	O
3.2	O
+/-	O
0.8	O
(	O
+/-	O
SD	O
)	O
microgram/ml	O
(	O
n	O
=	O
17	O
)	O
.	O

Unconsciousness	Physical
was	O
associated	O
with	O
reductions	O
in	O
ASSR	Physical
(	O
0.10	O
+/-	O
0.08	O
microV	O
[	O
awake	O
baseline	O
0.32	O
+/-	O
0.18	O
microV	O
]	O
,	O
P	O
<	O
0.001	O
)	O
and	O
BIS	Physical
(	O
55.7	O
+/-	O
8.8	O
[	O
awake	O
baseline	O
92.4	O
+/-	O
3.9	O
]	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Physostigmine	O
restored	Physical
consciousness	Physical
in	O
9	O
of	O
11	O
subjects	O
,	O
with	O
concomitant	O
increases	O
in	O
ASSR	Physical
(	O
0.38	O
+/-	O
0.17	O
microV	O
,	O
P	O
<	O
0.01	O
)	O
and	O
BIS	Physical
(	O
75.3	O
+/-	O
8.3	O
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
all	O
subjects	O
(	O
n	O
=	O
6	O
)	O
scopolamine	O
blocked	O
the	O
physostigmine-induced	Physical
reversal	Physical
of	Physical
unconsciousness	Physical
and	O
the	O
increase	O
of	O
the	O
ASSR	Physical
and	O
BIS	Physical
(	O
ASSR	Physical
and	O
BIS	Physical
during	O
propofol-induced	O
unconsciousness	O
:	O
0.09	O
+/-	O
0.09	O
microV	O
and	O
58.2	O
+/-	O
7.5	O
,	O
respectively	O
;	O
ASSR	Physical
and	O
BIS	Physical
after	O
physostigmine	O
administration	O
:	O
0.08	O
+/-	O
0.06	O
microV	O
and	O
56.8	O
+/-	O
6.7	O
,	O
respectively	O
,	O
NS	O
)	O
.	O

CONCLUSIONS	O
These	O
findings	O
suggest	O
that	O
the	O
unconsciousness	O
produced	O
by	O
propofol	O
is	O
mediated	O
at	O
least	O
in	O
part	O
via	O
interruption	O
of	O
central	O
cholinergic	O
muscarinic	O
transmission	O
.	O

A	O
prospective	O
randomised	O
comparison	O
of	O
sublingual	O
and	O
vaginal	O
misoprostol	O
in	O
second	O
trimester	O
termination	O
of	O
pregnancy	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	Others
,	O
side	Adverseeffect
effects	Adverseeffect
and	O
acceptability	Others
of	O
sublingual	O
and	O
vaginal	O
misoprostol	O
for	O
second	O
trimester	O
medical	O
abortion	O
.	O

DESIGN	O
Prospective	O
randomised	O
controlled	O
trial	O
.	O

SETTING	O
Tertiary	O
referral	O
unit	O
and	O
a	O
teaching	O
hospital	O
.	O

POPULATION	O
Two	O
hundred	O
and	O
twenty-four	O
women	O
at	O
12	O
to	O
20	O
weeks	O
of	O
gestation	O
.	O

METHODS	O
The	O
women	O
were	O
randomised	O
to	O
receive	O
either	O
sublingual	O
or	O
vaginal	O
misoprostol	O
400	O
microg	O
every	O
3	O
hours	O
for	O
a	O
maximum	O
of	O
five	O
doses	O
.	O

The	O
course	O
of	O
misoprostol	O
was	O
repeated	O
if	O
the	O
woman	O
did	O
not	O
abort	O
within	O
24	O
hours	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
success	Others
rate	Others
at	Others
48	Others
hours	Others
,	O
induction-to-abortion	Others
interval	Others
and	O
the	O
side	Physical
effects	Physical
.	Physical

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
success	Others
rate	Others
at	Others
48	Others
hours	Others
(	O
sublingual	O
:	O
91	O
%	O
;	O
vaginal	O
:	O
95	O
%	O
)	O
.	O

However	O
,	O
the	O
success	Others
rate	Others
at	Others
24	Others
hours	Others
was	O
significantly	O
higher	O
in	O
the	O
vaginal	O
group	O
(	O
85	O
%	O
)	O
compared	O
with	O
the	O
sublingual	O
group	O
(	O
64	O
%	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
median	Others
induction-to-abortion	Others
interval	Others
(	O
sublingual	O
:	O
13.8	O
hours	O
;	O
vaginal	O
:	O
12.0	O
hours	O
)	O
.	O

Significantly	O
more	O
women	O
in	O
the	O
sublingual	O
group	O
preferred	O
the	O
route	O
to	O
which	O
they	O
were	O
assigned	O
when	O
compared	O
with	O
the	O
vaginal	O
group	O
.	O

The	Adverseeffect
incidence	Adverseeffect
of	Adverseeffect
fever	Adverseeffect
was	O
also	O
less	O
in	O
the	O
sublingual	O
group	O
.	O

CONCLUSION	O
The	O
use	O
of	O
vaginal	O
misoprostol	O
for	O
second	O
trimester	O
medical	O
abortion	O
resulted	O
in	O
a	O
higher	O
success	Others
rate	Others
than	O
sublingual	O
misoprostol	O
at	O
24	O
hours	O
but	O
the	O
abortion	Others
rate	Others
was	O
similar	O
at	O
48	O
hours	O
.	O

Vaginal	O
misoprostol	O
should	O
be	O
the	O
regimen	O
of	O
choice	O
but	O
sublingual	O
misoprostol	O
is	O
also	O
an	O
effective	O
alternative	O
.	O

The	O
influence	O
of	O
dietary	O
fibre	O
source	O
and	O
gender	O
on	O
the	O
postprandial	Physical
glucose	Physical
and	O
lipid	Physical
response	Physical
in	O
healthy	O
subjects	O
.	O

BACKGROUND	O
Consumption	O
of	O
soluble	O
dietary	O
fibre	O
is	O
correlated	O
with	O
decreased	O
postprandial	Physical
glucose	Physical
and	O
insulin	Physical
responses	Physical
and	O
hence	O
has	O
beneficial	O
effects	O
on	O
the	O
metabolic	O
syndrome	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
To	O
investigate	O
the	O
effects	O
on	O
postprandial	Physical
glucose	Physical
,	O
insulin	Physical
and	O
triglyceride	Physical
concentrations	Physical
of	O
meals	O
enriched	O
with	O
soluble	O
dietary	O
fibres	O
from	O
oats	O
,	O
rye	O
bran	O
,	O
sugar	O
beet	O
fibre	O
or	O
a	O
mixture	O
of	O
these	O
three	O
fibres	O
.	O

METHODS	O
Thirteen	O
healthy	O
human	O
volunteers	O
(	O
6	O
men	O
and	O
7	O
women	O
,	O
aged	O
20-28	O
years	O
)	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
subjects	O
came	O
to	O
the	O
study	O
centre	O
once	O
a	O
week	O
after	O
an	O
overnight	O
fast	O
to	O
ingest	O
test	O
meals	O
and	O
a	O
control	O
meal	O
in	O
random	O
order	O
.	O

The	O
meals	O
contained	O
either	O
oat	O
powder	O
(	O
62	O
g	O
,	O
of	O
which	O
2.7	O
soluble	O
fibre	O
)	O
,	O
rye	O
bran	O
(	O
31	O
g	O
,	O
of	O
which	O
1.7	O
g	O
soluble	O
fibre	O
)	O
,	O
sugar	O
beet	O
fibre	O
(	O
19	O
g	O
,	O
of	O
which	O
5	O
g	O
soluble	O
fibre	O
)	O
,	O
a	O
mixture	O
of	O
these	O
three	O
fibres	O
(	O
74	O
g	O
,	O
of	O
which	O
1.7	O
g	O
soluble	O
fibre	O
from	O
each	O
source	O
,	O
giving	O
5	O
g	O
soluble	O
fibre	O
)	O
or	O
no	O
added	O
fibre	O
(	O
control	O
)	O
and	O
were	O
all	O
adjusted	O
to	O
contain	O
the	O
same	O
total	O
amount	O
of	O
available	O
carbohydrates	O
.	O

Blood	O
samples	O
were	O
drawn	O
before	O
and	O
every	O
30	O
min	O
up	O
to	O
180	O
min	O
after	O
the	O
meals	O
.	O

RESULTS	O
Meals	O
with	O
rye	O
bran	O
gave	O
a	O
lower	O
postprandial	Physical
glucose	Physical
peak	Physical
when	O
compared	O
with	O
the	O
control	O
meal	O
,	O
and	O
this	O
effect	O
was	O
more	O
pronounced	O
in	O
women	O
compared	O
to	O
men	O
.	O

Oat	O
powder	O
,	O
containing	O
a	O
low	O
amount	O
of	O
total	O
fibre	O
and	O
a	O
high	O
amount	O
of	O
carbohydrates	O
in	O
liquid	O
matrix	O
,	O
gave	O
a	O
higher	O
incremental	Physical
glucose	Physical
peak	Physical
concentration	Physical
compared	O
to	O
rye	O
bran	O
and	O
sugar	O
beet	O
fibre	O
and	O
higher	O
insulin	Physical
incremental	Physical
area	Physical
under	Physical
curve	Physical
compared	O
to	O
control	O
.	O

The	O
oat	O
powder	O
also	O
influenced	O
the	O
effects	O
of	O
the	O
mixed	O
meal	O
,	O
diminishing	O
the	O
glucose-lowering	Physical
effects	Physical
.	O

Postprandial	Physical
triglyceride	Physical
levels	Physical
tended	O
to	O
be	O
higher	O
after	O
all	O
fibre-rich	O
meals	O
,	O
but	O
only	O
significant	O
for	O
oat	O
powder	O
and	O
the	O
mixed	O
meal	O
when	O
compared	O
with	O
the	O
control	O
meal	O
.	O

CONCLUSIONS	O
Postprandial	Physical
glucose	Physical
,	O
insulin	Physical
and	O
triglyceride	Physical
concentrations	Physical
are	O
influenced	O
by	O
dietary	O
fibre-rich	O
meals	O
,	O
depending	O
on	O
fibre	O
source	O
,	O
dose	O
of	O
soluble	O
and	O
total	O
fibre	O
and	O
possibly	O
gender	O
.	O

Small	O
but	O
important	O
errors	O
in	O
cardiovascular	O
risk	O
calculation	O
by	O
practice	O
nurses	O
:	O
a	O
cross-sectional	O
study	O
in	O
randomised	O
trial	O
setting	O
.	O

BACKGROUND	O
Practice	O
nurses	O
play	O
an	O
increasingly	O
important	O
role	O
in	O
the	O
prevention	O
of	O
cardiovascular	O
diseases	O
but	O
we	O
do	O
not	O
have	O
evidence	O
about	O
the	O
accuracy	O
of	O
their	O
cardiovascular	O
risk	O
assessments	O
during	O
real	O
practice	O
consultations	O
.	O

OBJECTIVES	O
To	O
examine	O
how	O
nurses	O
perform	O
with	O
regard	O
to	O
absolute	O
10-year	O
cardiovascular	Others
risk	Others
assessment	Others
in	O
actual	O
practice	O
.	O

DESIGN	O
Cross-sectional	O
study	O
.	O

SETTING	O
This	O
study	O
was	O
nested	O
in	O
the	O
IMPALA	O
study	O
,	O
a	O
clustered	O
randomised	O
controlled	O
trial	O
involving	O
24	O
general	O
practices	O
in	O
The	O
Netherlands	O
.	O

PARTICIPANTS	O
24	O
practice	O
nurses	O
,	O
trained	O
in	O
10-year	O
cardiovascular	O
risk	O
assessment	O
,	O
calculated	O
the	O
risk	O
of	O
a	O
total	O
of	O
421	O
patients	O
without	O
established	O
cardiovascular	O
diseases	O
but	O
eligible	O
for	O
cardiovascular	Others
risk	Others
assessment	Others
.	Others

METHODS	O
The	O
main	O
outcome	O
measure	O
was	O
the	O
accuracy	Others
of	Others
risk	Others
assessments	Others
,	O
defined	O
as	O
(	O
1	O
)	O
the	O
difference	Others
between	Others
the	Others
10-year	Others
cardiovascular	Others
risk	Others
percentage	Others
calculated	Others
by	Others
nurses	Others
and	Others
an	Others
independent	Others
assessor	Others
,	O
and	O
(	O
2	O
)	O
the	O
agreement	Others
between	Others
the	Others
treatment	Others
categories	Others
assigned	Others
by	Others
the	Others
nurses	Others
(	Others
low	Others
,	Others
moderate	Others
or	Others
high	Others
risk	Others
)	Others
and	Others
those	Others
assigned	Others
by	Others
the	Others
independent	Others
assessor	Others
.	O

RESULTS	O
Thirty-one	O
(	O
7.4	O
%	O
)	O
of	O
the	O
calculated	O
risk	O
percentages	O
differed	O
by	O
more	O
than	O
our	O
preset	O
limits	O
,	O
25	O
(	O
81	O
%	O
)	O
being	O
underestimations	O
.	O

Elderly	O
patients	O
(	O
OR	O
1.1	O
,	O
95	O
%	O
CI	O
1.0-1.1	O
)	O
,	O
male	O
patients	O
(	O
vs.	O
female	O
OR	O
3.1	O
,	O
95	O
%	O
CI	O
1.2-7.3	O
)	O
,	O
and	O
smoking	O
patients	O
(	O
vs.	O
non-smoking	O
OR	O
3.8	O
,	O
95	O
%	O
CI	O
1.7-8.9	O
)	O
were	O
more	O
likely	O
to	O
have	O
their	O
cardiovascular	Others
risk	Others
miscalculated	O
.	O

Ten	O
(	O
28	O
%	O
)	O
of	O
the	O
36	O
patients	O
who	O
should	O
be	O
assigned	O
to	O
the	O
high-risk	O
treatment	O
category	O
according	O
to	O
the	O
independent	O
calculation	O
,	O
were	O
missed	O
as	O
high-risk	O
patients	O
by	O
the	O
practice	O
nurses	O
.	O

CONCLUSIONS	O
The	O
overall	O
standard	O
of	O
accuracy	O
of	O
cardiovascular	O
risk	O
assessment	O
by	O
trained	O
practice	O
nurses	O
in	O
actual	O
practice	O
is	O
high	O
.	O

However	O
,	O
a	O
significant	O
number	O
of	O
high-risk	O
patients	O
were	O
misclassified	O
,	O
with	O
the	O
probability	O
that	O
it	O
led	O
to	O
missed	O
opportunities	O
for	O
risk-reducing	O
interventions	O
.	O

As	O
cardiovascular	O
risk	O
assessments	O
are	O
frequently	O
done	O
by	O
nurses	O
in	O
general	O
practice	O
,	O
further	O
specific	O
training	O
should	O
be	O
considered	O
to	O
prevent	O
undertreatment	O
.	O

Predictors	O
of	O
postdischarge	O
outcomes	O
from	O
information	O
acquired	O
shortly	O
after	O
admission	O
for	O
acute	O
heart	O
failure	O
:	O
a	O
report	O
from	O
the	O
Placebo-Controlled	O
Randomized	O
Study	O
of	O
the	O
Selective	O
A1	O
Adenosine	O
Receptor	O
Antagonist	O
Rolofylline	O
for	O
Patients	O
Hospitalized	O
With	O
Acute	O
Decompensated	O
Heart	O
Failure	O
and	O
Volume	O
Overload	O
to	O
Assess	O
Treatment	O
Effect	O
on	O
Congestion	O
and	O
Renal	O
Function	O
(	O
PROTECT	O
)	O
Study	O
.	O

BACKGROUND	O
Acute	O
heart	O
failure	O
is	O
a	O
common	O
reason	O
for	O
admission	O
,	O
and	O
outcome	O
is	O
often	O
poor	O
.	O

Improved	O
prognostic	O
risk	O
stratification	O
may	O
assist	O
in	O
the	O
design	O
of	O
future	O
trials	O
and	O
in	O
patient	O
management	O
.	O

Using	O
data	O
from	O
a	O
large	O
randomized	O
trial	O
,	O
we	O
explored	O
the	O
prognostic	O
value	O
of	O
clinical	O
variables	O
,	O
measured	O
at	O
hospital	O
admission	O
for	O
acute	O
heart	O
failure	O
,	O
to	O
determine	O
whether	O
a	O
few	O
selected	O
variables	O
were	O
inferior	O
to	O
an	O
extended	O
data	O
set	O
.	O

METHODS	O
AND	O
RESULTS	O
The	O
prognostic	O
model	O
included	O
37	O
clinical	O
characteristics	O
collected	O
at	O
baseline	O
in	O
PROTECT	O
,	O
a	O
study	O
comparing	O
rolofylline	O
and	O
placebo	O
in	O
2033	O
patients	O
admitted	O
with	O
acute	O
heart	O
failure	O
.	O

Prespecified	O
outcomes	O
at	O
30	O
days	O
were	O
death	Mortality
or	Adverseeffect
rehospitalization	Mortality
for	Mortality
any	Mortality
reason	Mortality
;	Adverseeffect
death	Mortality
or	Adverseeffect
rehospitalization	Mortality
for	Mortality
cardiovascular	Mortality
or	Mortality
renal	Mortality
reasons	Mortality
;	Adverseeffect
and	O
,	O
at	O
both	O
30	O
and	O
180	O
days	O
,	O
all-cause	O
mortality	O
.	O

No	O
variable	O
had	O
a	O
c-index	O
>	O
0.70	O
,	O
and	O
few	O
had	O
values	O
>	O
0.60	O
;	O
c-indices	O
were	O
lower	O
for	O
composite	O
outcomes	O
than	O
for	O
mortality	O
.	O

Blood	Physical
urea	Physical
was	O
generally	O
the	O
strongest	O
single	O
predictor	O
.	O

Eighteen	O
variables	O
contributed	O
independent	O
prognostic	O
information	O
,	O
but	O
a	O
reduced	O
model	O
using	O
only	O
8	O
items	O
(	O
age	O
,	O
previous	O
heart	O
failure	O
hospitalization	O
,	O
peripheral	O
edema	O
,	O
systolic	O
blood	O
pressure	O
,	O
serum	O
sodium	O
,	O
urea	O
,	O
creatinine	O
,	O
and	O
albumin	O
)	O
performed	O
similarly	O
.	O

For	O
prediction	O
of	O
all-cause	Mortality
mortality	Mortality
at	O
180	O
days	O
,	O
the	O
model	O
c-index	O
using	O
all	O
variables	O
was	O
0.72	O
and	O
for	O
the	O
simplified	O
model	O
,	O
also	O
0.72	O
.	O

CONCLUSIONS	O
A	O
few	O
simple	O
clinical	O
variables	O
measured	O
on	O
admission	O
in	O
patients	O
with	O
acute	O
heart	O
failure	O
predict	O
a	O
variety	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
outcomes	Adverseeffect
with	O
accuracy	Others
similar	O
to	O
more	O
complex	O
models	O
.	O

However	O
,	O
predictive	O
models	O
were	O
of	O
only	O
moderate	Others
accuracy	Others
,	O
especially	O
for	O
outcomes	Adverseeffect
that	Adverseeffect
included	Adverseeffect
nonfatal	Adverseeffect
events	Adverseeffect
.	O

Better	O
methods	O
of	O
risk	O
stratification	O
are	O
required	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
URL	O
:	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Unique	O
identifiers	O
:	O
NCT00328692	O
and	O
NCT00354458	O
.	O

Laser	O
conization	O
versus	O
cold	O
knife	O
conization	O
.	O

This	O
prospective	O
,	O
randomized	O
study	O
compares	O
,	O
for	O
the	O
first	O
time	O
,	O
measured	O
blood	O
loss	O
at	O
conization	O
and	O
within	O
24	O
hours	O
after	O
using	O
either	O
the	O
cold	O
knife	O
technique	O
or	O
the	O
carbon	O
dioxide	O
laser	O
scalpel	O
.	O

One	O
hundred	O
and	O
ten	O
consecutive	O
patients	O
were	O
evaluated	O
.	O

The	O
median	Physical
blood	Physical
loss	Physical
in	O
the	O
laser	O
group	O
of	O
55	O
patients	O
was	O
4.6	O
milliliters	O
at	O
,	O
and	O
within	O
,	O
24	O
hours	O
after	O
operation	O
compared	O
with	O
30.1	O
milliliters	O
in	O
the	O
cold	O
knife	O
group	O
of	O
55	O
patients	O
.	O

More	O
important	O
,	O
however	O
,	O
is	O
that	O
the	O
corresponding	O
figures	O
for	O
the	O
range	Physical
of	Physical
bleeding	Physical
were	O
0.4	O
to	O
155.4	O
milliliters	O
and	O
5.6	O
to	O
1,570.9	O
milliliters	O
,	O
respectively	O
.	O

The	O
incidence	Physical
rate	Physical
for	Physical
bleeding	Physical
complications	Physical
requiring	Physical
surgical	Physical
intervention	Physical
was	O
1.8	O
per	O
cet	O
for	O
the	O
laser	O
group	O
and	O
14.6	O
per	O
cent	O
for	O
the	O
cold	O
knife	O
group	O
.	O

This	O
difference	O
was	O
statistically	O
significant	O
,	O
p	O
less	O
than	O
0.015	O
--	O
Fischer	O
's	O
exact	O
test	O
.	O

Conization	O
for	O
treatment	O
of	O
premalignant	O
changes	O
of	O
the	O
cervix	O
uteri	O
will	O
probably	O
remain	O
the	O
treatment	O
of	O
choice	O
for	O
some	O
time	O
to	O
come	O
.	O

It	O
is	O
our	O
opinion	O
that	O
,	O
in	O
the	O
future	O
,	O
laser	O
conization	O
will	O
replace	O
cold	O
knife	O
conization	O
.	O

A	O
double-blind	O
randomized	O
clinical	O
evaluation	O
of	O
enamel	O
matrix	O
derivative	O
proteins	O
for	O
the	O
treatment	O
of	O
proximal	O
class-II	O
furcation	O
involvements	O
.	O

OBJECTIVE	O
The	O
aim	O
of	O
the	O
present	O
randomized	O
,	O
double-blind	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	Physical
response	Physical
of	O
proximal	O
furcations	O
treated	O
with	O
enamel	O
matrix	O
derivative	O
proteins	O
(	O
EMD	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
Fifteen	O
patients	O
,	O
each	O
with	O
a	O
pair	O
of	O
contralateral	O
class-II	O
proximal	O
furcation	O
involvements	O
,	O
presenting	O
probing	O
depths	O
(	O
PDs	O
)	O
>	O
/=5	O
mm	O
and	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
were	O
selected	O
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
:	O
control	O
group	O
(	O
n=15	O
)	O
-	O
open	O
flap	O
debridement	O
(	O
OFD	O
)	O
+24	O
%	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
conditioning	O
;	O
test	O
group	O
(	O
n=15	O
)	O
-	O
OFD+24	O
%	O
EDTA	O
conditioning+EMD	O
application	O
.	O

Plaque	Physical
index	Physical
(	Physical
PI	Physical
)	Physical
,	O
BOP	Physical
,	O
PD	Physical
,	O
gingival	Physical
margin	Physical
position	Physical
(	Physical
GMP	Physical
)	Physical
,	O
relative	Physical
vertical	Physical
and	Physical
horizontal	Physical
clinical	Physical
attachment	Physical
level	Physical
(	Physical
RVCAL	Physical
and	Physical
RHCAL	Physical
)	Physical
,	O
vertical	Physical
and	Physical
horizontal	Physical
bone	Physical
level	Physical
(	Physical
VBL	Physical
and	Physical
HBL	Physical
)	Physical
and	O
furcation	O
closure	O
were	O
evaluated	O
immediately	O
before	O
and	O
2	O
,	O
4	O
and	O
6	O
months	O
after	O
the	O
surgeries	O
.	O

RESULTS	O
At	O
6	O
months	O
,	O
the	O
RVCAL	Physical
gains	Physical
of	O
the	O
control	O
and	O
test	O
group	O
were	O
0.39	O
+/-	O
1.00	O
and	O
0.54	O
+/-	O
0.95	O
mm	O
,	O
while	O
the	O
RHCAL	Physical
gains	O
were	O
1.21	O
+/-	O
2.28	O
and	O
1.36	O
+/-	O
1.26	O
mm	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
VBL	Physical
and	Physical
HBL	Physical
gains	O
of	O
the	O
control	O
group	O
were	O
1.04	O
+/-	O
1.12	O
and	O
1.00	O
+/-	O
1.79	O
mm	O
,	O
and	O
0.82	O
+/-	O
1.82	O
and	O
1.17	O
+/-	O
1.38	O
mm	O
for	O
the	O
test	O
group	O
(	O
p	O
>	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
a	O
statistical	O
difference	O
was	O
observed	O
in	O
the	O
number	Physical
of	Physical
the	Physical
remaining	Physical
class-II	Physical
furcations	Physical
between	O
the	O
test	O
and	O
control	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
in	O
this	O
period	O
.	O

CONCLUSION	O
It	O
may	O
be	O
concluded	O
that	O
the	O
use	O
of	O
EMD	O
in	O
proximal	O
furcations	O
did	O
not	O
promote	O
a	O
superior	O
reduction	O
in	O
PD	Physical
or	O
a	O
gain	O
in	O
clinical	Physical
and	Physical
osseous	Physical
attachment	Physical
levels	Physical
,	O
but	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
class-II	Physical
to	Physical
class-I	Physical
furcation	Physical
conversion	Physical
.	O

Chemotherapy	O
of	O
large	O
bowel	O
carcinoma	O
--	O
fluorouracil	O
(	O
FU	O
)	O
+	O
hydroxyurea	O
(	O
HU	O
)	O
vs.	O
methyl-CCNU	O
,	O
oncovin	O
,	O
fluorouracil	O
,	O
and	O
streptozotocin	O
(	O
MOF-Strep	O
)	O
.	O

An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
.	O

In	O
this	O
prospective	O
randomized	O
study	O
of	O
initial	O
chemotherapy	O
for	O
advanced	O
measurable	O
metastatic	O
large	O
bowel	O
carcinoma	O
,	O
the	O
response	Physical
rate	Physical
was	O
6/32	O
(	O
19	O
%	O
)	O
for	O
FU	O
+	O
HU	O
and	O
5/32	O
(	O
16	O
%	O
)	O
for	O
MOF-Strep	O
;	O
the	O
estimated	O
median	Mortality
survival	Mortality
is	O
43	O
weeks	O
for	O
both	O
treatments	O
.	O

Patients	O
who	O
received	O
MOF-Strep	O
experienced	O
substantially	O
greater	O
vomiting	Adverseeffect
and	Adverseeffect
hematologic	Adverseeffect
toxicity	Adverseeffect
than	O
patients	O
who	O
received	O
FU	O
+	O
HU	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Enhanced	O
small	O
group	O
instruction	O
using	O
choral	O
responding	O
and	O
student	O
interaction	O
for	O
children	O
with	O
autism	O
and	O
developmental	O
disabilities	O
.	O

The	O
use	O
of	O
effective	O
instructional	O
strategies	O
in	O
small	O
groups	O
was	O
investigated	O
to	O
determine	O
learning	O
effects	O
for	O
24	O
elementary	O
age	O
students	O
with	O
autism	O
and	O
developmental	O
disabilities	O
.	O

Effective	O
strategies	O
included	O
(	O
a	O
)	O
the	O
use	O
of	O
choral	O
responding	O
;	O
(	O
b	O
)	O
the	O
use	O
of	O
student-to-student	O
responding	O
;	O
(	O
c	O
)	O
the	O
rotation	O
of	O
materials	O
every	O
5	O
minutes	O
during	O
the	O
30-minute	O
group	O
while	O
teaching	O
2	O
to	O
3	O
concepts	O
;	O
and	O
(	O
d	O
)	O
the	O
use	O
of	O
random	O
,	O
unpredictable	O
trials	O
for	O
student	O
responding	O
.	O

Thirty-minute	O
language	O
groups	O
were	O
targeted	O
to	O
teach	O
receptive	O
and	O
expressive	O
skills	O
using	O
pictures	O
and	O
common	O
objects	O
across	O
five	O
categories	O
(	O
e.g.	O
,	O
household	O
items	O
,	O
foods	O
)	O
.	O

Results	O
showed	O
increased	O
opportunities	Mental
to	Mental
respond	Mental
,	O
increased	Mental
levels	Mental
of	Mental
responding	Mental
and	Mental
academic	Mental
engagement	Mental
,	O
higher	Physical
gains	Physical
on	Physical
weekly	Mental
criterion-referenced	Mental
pre-	Mental
and	Mental
posttests	Mental
,	O
and	O
decreased	Physical
passive	Mental
and	Mental
inappropriate	Mental
student	Mental
behavior	Mental
during	O
interventions	O
.	O

White	O
coat	O
effect	O
detected	O
using	O
self-monitoring	O
of	O
blood	O
pressure	O
at	O
home	O
:	O
comparison	O
with	O
ambulatory	O
blood	O
pressure	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
investigate	O
whether	O
home	Physical
blood	Physical
pressure	Physical
(	O
HBP	O
)	O
is	O
a	O
reliable	O
alternative	O
to	O
ambulatory	O
blood	Physical
pressure	Physical
(	O
ABP	O
)	O
for	O
the	O
detection	O
of	O
the	O
white	O
coat	O
effect	O
(	O
WCE	O
)	O
.	O

Hypertensive	O
patients	O
were	O
randomized	O
to	O
measure	O
HBP	O
for	O
2	O
weeks	O
or	O
ABP	O
for	O
24	O
h.	O
The	O
alternative	O
measurement	O
was	O
then	O
performed	O
.	O

Clinic	Physical
blood	Physical
pressure	Physical
(	Physical
CBP	Physical
)	Physical
was	O
measured	O
in	O
the	O
beginning	O
and	O
end	O
of	O
the	O
study	O
.	O

Subjects	O
with	O
a	O
difference	O
of	O
>	O
or	O
=	O
20	O
mm	O
Hg	O
systolic	O
or	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
diastolic	O
BP	O
between	O
CBP	O
and	O
awake	O
ABP	O
or	O
CBP	O
and	O
HBP	O
,	O
were	O
classified	O
as	O
clinic	O
reactors	O
.	O

A	O
total	O
of	O
189	O
patients	O
completed	O
the	O
study	O
(	O
79	O
on	O
stable	O
antihypertensive	O
treatment	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
magnitude	O
of	O
WCE	Physical
assessed	O
using	O
the	O
ABP	Others
or	O
the	O
HBP	Others
method	O
(	O
mean	O
discrepancy	O
,	O
systolic	Physical
BP	Physical
:	Physical
-1.5	O
+/-	O
11.7	O
mm	O
Hg	O
,	O
95	O
%	O
CI	O
-3.2	O
,	O
0.2	O
;	O
diastolic	Physical
BP	Physical
:	Physical
0.9	O
+/-	O
7.0	O
,	O
95	O
%	O
CI	O
-0.1	O
,	O
1.9	O
)	O
.	O

A	O
strong	O
association	O
existed	O
between	O
WCE	Physical
calculated	O
using	O
the	O
HBP	Others
or	O
the	O
ABP	Others
method	O
(	O
r	O
=	O
0.64/0.59	O
systolic/diastolic	O
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
classified	O
as	O
clinic	Physical
reactors	Physical
was	O
identical	O
using	O
the	O
HBP	O
or	O
the	O
ABP	O
method	O
(	O
25.9	O
%	O
)	O
.	O

Agreement	O
between	O
methods	O
in	O
the	O
classification	O
of	O
clinic	O
reactors	O
was	O
found	O
in	O
147	O
patients	O
(	O
78	O
%	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
HBP	O
method	O
to	O
classify	O
correctly	O
clinic	O
reactors	O
(	O
ABP	O
method	O
used	O
as	O
the	O
standard	O
)	O
were	O
57	O
%	O
and	O
85	O
%	O
,	O
respectively	O
,	O
whereas	O
its	O
positive	O
and	O
negative	O
predictive	O
value	O
were	O
57	O
%	O
and	O
85	O
%	O
.	O

These	O
results	O
indicate	O
that	O
HBP	Others
is	O
not	O
appropriate	O
as	O
an	O
alternative	O
to	O
ABP	O
diagnostic	O
testing	O
in	O
the	O
detection	O
of	O
WCE	O
.	O

Nevertheless	O
,	O
HBP	Others
appears	O
useful	O
as	O
a	O
screening	O
test	O
for	O
the	O
detection	O
of	O
this	O
phenomenon	O
.	O

An	O
open	O
and	O
randomized	O
study	O
comparing	O
the	O
efficacy	Others
of	O
standard	O
danazol	O
and	O
modified	O
triptorelin	O
regimens	O
for	O
postoperative	O
disease	O
management	O
of	O
moderate	O
to	O
severe	O
endometriosis	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	Others
of	O
danazol	O
and	O
triptorelin	O
(	O
Decapeptyl	O
CR	O
,	O
Ferring	O
,	O
Kiel	O
,	O
Germany	O
)	O
in	O
the	O
management	O
of	O
moderate	O
and	O
severe	O
endometriosis	O
in	O
terms	O
of	O
symptom	Physical
control	Physical
and	O
revised	O
American	Physical
Fertility	Physical
Society	Physical
(	Physical
AFS	Physical
)	Physical
score	Physical
reduction	Physical
,	O
and	O
to	O
evaluate	O
the	O
hormonal	Physical
profile	Physical
of	O
patients	O
treated	O
with	O
triptorelin	O
every	O
6	O
weeks	O
.	O

DESIGN	O
Open	O
and	O
randomized	O
trial	O
.	O

SETTING	O
Kwong	O
Wah	O
Hospital	O
,	O
a	O
large	O
public	O
hospital	O
in	O
an	O
urban	O
location	O
(	O
Hong	O
Kong	O
)	O
.	O

PATIENT	O
(	O
S	O
)	O
Forty	O
patients	O
after	O
their	O
first	O
conservative	O
operation	O
for	O
endometriosis	O
,	O
with	O
surgical	O
confirmation	O
of	O
revised	O
AFS	O
stage	O
III	O
or	O
IV	O
endometriosis	O
.	O

INTERVENTION	O
(	O
S	O
)	O
Postoperative	O
6	O
months	O
'	O
therapy	O
of	O
danazol	O
or	O
triptorelin	O
every	O
6	O
weeks	O
,	O
postmedical	O
therapy	O
second-look	O
laparoscopy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Symptom	Physical
control	Physical
and	O
patients	Physical
'	Physical
tolerance	Physical
during	O
medical	O
therapy	O
,	O
posttherapy	Physical
revised	Physical
AFS	Physical
score	Physical
,	O
hormonal	Physical
profile	Physical
during	O
triptorelin	O
therapy	O
.	O

RESULT	O
(	O
S	O
)	O
Pain	Pain
control	Pain
was	O
similar	O
between	O
danazol	O
and	O
triptorelin	O
therapy	O
.	O

There	O
was	O
less	O
breakthrough	Physical
bleeding	Physical
with	O
triptorelin	O
.	O

More	O
patients	O
failed	O
to	O
complete	O
the	O
whole	O
course	O
of	O
danazol	O
because	O
of	O
its	O
side	Adverseeffect
effects	Adverseeffect
.	Adverseeffect

The	O
revised	Physical
AFS	Physical
score	Physical
at	O
second-look	O
laparoscopy	O
did	O
not	O
show	O
a	O
significant	O
difference	O
between	O
the	O
two	O
medications	O
.	O

Adequate	Physical
pituitary	Physical
suppression	Physical
was	O
observed	O
with	O
injection	O
of	O
triptorelin	O
every	O
6	O
weeks	O
.	O

CONCLUSION	O
(	O
S	O
)	O
Lengthening	O
of	O
triptorelin	O
administration	O
intervals	O
from	O
4	O
weeks	O
to	O
6	O
weeks	O
is	O
effective	O
in	O
maintaining	O
a	O
hypoestrogenic	Physical
state	Physical
.	O

Patients	O
were	O
more	O
compliant	O
with	O
triptorelin	O
than	O
danazol	O
.	O

Thus	O
,	O
triptorelin	O
injection	O
every	O
6	O
weeks	O
is	O
more	O
cost-effective	O
than	O
conventional	O
regimens	O
.	O

Changes	O
in	O
H	O
reflex	O
and	O
V	O
wave	O
following	O
short-term	O
endurance	O
and	O
strength	O
training	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
3	O
wk	O
of	O
either	O
endurance	O
or	O
strength	O
training	O
on	O
plasticity	O
of	O
the	O
neural	O
mechanisms	O
involved	O
in	O
the	O
soleus	O
H	O
reflex	O
and	O
V	O
wave	O
.	O

Twenty-five	O
sedentary	O
healthy	O
subjects	O
were	O
randomized	O
into	O
an	O
endurance	O
group	O
(	O
n	O
=	O
13	O
)	O
or	O
strength	O
group	O
(	O
n	O
=	O
12	O
)	O
.	O

Evoked	O
V-wave	O
,	O
H-reflex	O
,	O
and	O
M-wave	O
recruitment	O
curves	O
,	O
maximal	O
voluntary	O
contraction	O
(	O
MVC	O
)	O
,	O
and	O
time-to-task-failure	O
(	O
isometric	O
contraction	O
at	O
40	O
%	O
MVC	O
)	O
of	O
the	O
plantar	O
flexors	O
were	O
recorded	O
before	O
and	O
after	O
training	O
.	O

Following	O
strength	O
training	O
,	O
MVC	Physical
of	Physical
the	Physical
plantar	Physical
flexors	Physical
increased	O
by	O
14.4	O
?	O
5.2	O
%	O
in	O
the	O
strength	O
group	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
time-to-task-failure	O
was	O
prolonged	O
in	O
the	O
endurance	O
group	O
(	O
22.7	O
?	O
17.1	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O

The	O
V	Physical
wave-to-maximal	Physical
M	Physical
wave	Physical
(	Physical
V/M	Physical
(	Physical
max	Physical
)	Physical
)	Physical
ratio	Physical
increased	O
significantly	O
(	O
55.1	O
?	O
28.3	O
%	O
;	O
P	O
<	O
0.001	O
)	O
following	O
strength	O
training	O
,	O
but	O
the	O
maximal	O
H	Physical
wave-to-maximal	Physical
M	Physical
wave	Physical
(	Physical
H	Physical
(	Physical
max	Physical
)	Physical
/M	Physical
(	Physical
max	Physical
)	Physical
)	Physical
ratio	Physical
remained	O
unchanged	O
.	O

Conversely	O
,	O
in	O
the	O
endurance	O
group	O
the	O
V/M	Physical
(	Physical
max	Physical
)	Physical
ratio	Physical
was	O
not	O
altered	O
,	O
whereas	O
the	O
H	Physical
(	Physical
max	Physical
)	Physical
/M	Physical
(	Physical
max	Physical
)	Physical
ratio	O
increased	O
by	O
30.8	O
?	O
21.7	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
endurance	O
training	O
group	O
also	O
displayed	O
a	O
reduction	O
in	O
the	O
H-reflex	O
excitability	O
threshold	O
while	O
the	O
H-reflex	O
amplitude	O
on	O
the	O
ascending	O
limb	O
of	O
the	O
recruitment	O
curve	O
increased	O
.	O

Strength	O
training	O
only	O
elicited	O
a	O
significant	O
decrease	O
in	O
H-reflex	O
excitability	O
threshold	O
,	O
while	O
H-reflex	O
amplitudes	O
over	O
the	O
ascending	O
limb	O
remained	O
unchanged	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
H-reflex	O
pathway	O
is	O
strongly	O
involved	O
in	O
the	O
enhanced	O
endurance	O
resistance	O
that	O
occurs	O
following	O
endurance	O
training	O
.	O

On	O
the	O
contrary	O
,	O
the	O
improvements	O
in	O
MVC	O
following	O
strength	O
training	O
are	O
likely	O
attributed	O
to	O
increased	O
descending	O
drive	O
and/or	O
modulation	O
in	O
afferents	O
other	O
than	O
Ia	O
afferents	O
.	O

No	O
effect	O
of	O
acetylsalicylic	O
acid	O
on	O
B-thromboglobulin	Physical
and	O
platelet	Physical
factor	Physical
4	Physical
plasma	Physical
levels	Physical
in	O
patients	O
with	O
transient	O
ischaemic	O
attacks	O
.	O

We	O
studied	O
the	O
effect	O
of	O
acetylsalicylic	O
acid	O
(	O
ASA	O
)	O
versus	O
placebo	O
on	O
B-thromboglobulin	Physical
(	Physical
B-TG	Physical
)	Physical
and	O
platelet	Physical
factor	Physical
4	Physical
(	Physical
PF4	Physical
)	Physical
plasma	Physical
levels	Physical
and	O
ADP-induced	Physical
platelet	Physical
aggregation	Physical
in	O
25	O
male	O
patients	O
with	O
transient	O
ischaemic	O
attacks	O
(	O
TIA	O
)	O
.	O

The	O
patients	O
were	O
allocated	O
randomly	O
to	O
two	O
groups	O
:	O
14	O
patients	O
received	O
oral	O
treatment	O
with	O
ASA	O
500	O
mg	O
b.i.d	O
.	O

for	O
14	O
days	O
,	O
11	O
patients	O
placebo	O
b.i.d	O
.	O

for	O
the	O
same	O
period	O
.	O

B-TG	Physical
and	O
PF4	Physical
plasma	Physical
levels	Physical
and	O
ADP-induced	Physical
platelet	Physical
aggregation	Physical
were	O
determined	O
in	O
basal	O
conditions	O
,	O
and	O
two	O
hours	O
,	O
and	O
seven	O
and	O
fourteen	O
days	O
after	O
starting	O
with	O
ASA	O
or	O
placebo	O
.	O

In	O
addition	O
,	O
the	O
same	O
parameters	O
were	O
studied	O
in	O
a	O
group	O
of	O
20	O
healthy	O
males	O
of	O
matched	O
age	O
.	O

Basal	Physical
levels	Physical
of	Physical
plasma	Physical
B-TG	Physical
and	O
PF4	Physical
and	O
the	O
maximal	O
amplitude	Physical
of	Physical
ADP-induced	Physical
platelet	Physical
aggregation	Physical
were	O
abnormally	O
high	O
in	O
TIA	O
patients	O
.	O

ASA	O
caused	O
a	O
significant	O
reduction	O
of	O
B-TG	Physical
plasma	Physical
levels	Physical
in	O
TIA	O
patients	O
2	O
hours	O
after	O
the	O
first	O
administration	O
,	O
but	O
no	O
effect	O
was	O
observed	O
at	O
the	O
7th	O
and	O
14th	O
day	O
of	O
treatment	O
.	O

PF4	Physical
plasma	Physical
levels	Physical
were	O
unaffected	O
by	O
ASA	O
treatment	O
.	O

It	O
is	O
concluded	O
that	O
ASA	O
,	O
at	O
the	O
dose	O
conventionally	O
used	O
in	O
clinical	O
trials	O
,	O
does	O
not	O
affect	O
the	O
release	O
of	O
two	O
alpha-granule	O
proteins	O
.	O

Reactive	O
balance	O
adjustments	O
to	O
unexpected	O
perturbations	O
during	O
human	O
walking	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
the	O
effect	O
of	O
unexpected	O
forward	O
perturbations	O
(	O
FP	O
)	O
during	O
gait	O
on	O
lower	Physical
extremity	Physical
joint	Physical
mechanics	Physical
and	O
muscle	Physical
Electromyographic	Physical
(	Physical
EMG	Physical
)	Physical
patterns	Physical
in	O
healthy	O
adults	O
.	O

The	O
muscles	O
surrounding	O
the	O
hip	O
were	O
found	O
to	O
be	O
most	O
important	O
in	O
maintaining	Physical
control	Physical
of	Physical
the	Physical
trunk	Physical
and	O
preventing	Physical
collapse	Physical
in	O
response	O
to	O
the	O
FP	O
.	O

Distinct	Physical
lower	Physical
extremity	Physical
joint	Physical
moment	Physical
and	O
power	Physical
patterns	Physical
were	O
observed	O
in	O
response	O
to	O
the	O
FP	O
but	O
an	O
overall	O
positive	O
moment	Physical
of	Physical
support	Physical
(	O
M	O
(	O
s	O
)	O
)	O
was	O
maintained	O
.	O

Therefore	O
,	O
reactive	Physical
balance	Physical
control	Physical
was	O
a	O
synchronized	O
effort	O
of	O
the	O
lower	O
extremity	O
joints	O
to	O
prevent	O
collapse	O
during	O
the	O
FP	O
.	O

The	O
effect	O
of	O
use	O
of	O
pyridostigmine	O
and	O
requirement	O
of	O
vecuronium	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
.	O

CONTEXT	O
Patients	O
with	O
myasthenia	O
gravis	O
receive	O
pyridostigmine	O
,	O
an	O
anticholinesterase	O
agent	O
,	O
as	O
a	O
part	O
of	O
therapy	O
.	O

These	O
patients	O
demonstrate	O
a	O
heightened	O
sensitivity	O
towards	O
non-depolarising	O
muscle	O
relaxants	O
.	O

Continuing	O
pyridostigmine	O
till	O
the	O
day	O
of	O
the	O
surgery	O
or	O
omitting	O
it	O
on	O
the	O
night	O
before	O
surgery	O
could	O
provide	O
variable	O
results	O
with	O
regards	O
to	O
the	O
effect	O
of	O
vecuronium	O
.	O

AIMS	O
Myographic	O
evaluation	O
of	O
a	O
dose	O
of	O
vecuronium	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
on	O
pyridostigmine	O
therapy	O
.	O

SETTING	O
AND	O
DESIGN	O
A	O
randomised	O
,	O
double-blind	O
,	O
clinical	O
study	O
conducted	O
in	O
a	O
teaching	O
hospital	O
.	O

SUBJECTS	O
AND	O
METHODS	O
Medically	O
(	O
oral	O
pyridostigmine	O
)	O
well-controlled	O
adult	O
patients	O
with	O
myasthenia	O
gravis	O
who	O
were	O
posted	O
for	O
thymectomy	O
,	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

Patients	O
in	O
Group	O
1	O
received	O
their	O
last	O
dose	O
of	O
pyridostigmine	O
on	O
the	O
night	O
before	O
surgery	O
while	O
those	O
in	O
Group	O
2	O
received	O
even	O
the	O
morning	O
dose	O
of	O
the	O
drug	O
on	O
the	O
day	O
of	O
surgery	O
.	O

Neostigmine	O
(	O
1-2	O
mg	O
)	O
intravenously	O
was	O
used	O
as	O
rescue	O
medication	O
.	O

Vecuronium	O
(	O
0.01	O
mg/kg	O
)	O
was	O
used	O
for	O
intubation	O
and	O
muscle	O
relaxation	O
during	O
trans-sternal	O
thymectomy	O
and	O
its	O
effect	O
was	O
reversed	O
using	O
neostigmine	O
and	O
atropine	O
.	O

RESULTS	O
Fourteen	O
patients	O
(	O
7	O
in	O
each	O
group	O
)	O
belonging	O
to	O
both	O
sexes	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

The	O
intubating	O
dose	O
of	O
vecuronium	O
showed	O
quicker	O
onset	Physical
time	Physical
(	O
155	O
sec	O
or	O
2.7	O
min	O
approx	O
.	O

)	O
and	O
peak	Physical
effect	Physical
(	O
99	O
%	O
T1	O
suppression	O
)	O
in	O
patients	O
belonging	O
to	O
Group	O
1	O
,	O
and	O
3/7	O
(	O
43	O
%	O
)	O
complained	O
of	O
respiratory	O
discomfort	O
while	O
waiting	O
for	O
surgery	O
.	O

By	O
giving	O
the	O
morning	O
dose	O
of	O
pyridostigmine	O
(	O
Group	O
2	O
)	O
,	O
an	O
identical	O
intubating	O
dose	O
of	O
vecuronium	O
showed	O
relative	Physical
resistance	Physical
(	O
peak	O
effect-97	O
%	O
T1	O
suppression	O
)	O
and	O
delayed	Physical
onset	Physical
time	Physical
(	O
198	O
sec	O
approx.	O
)	O
.	O

However	O
,	O
the	O
reversal	O
was	O
complete	O
at	O
the	O
end	O
of	O
surgery	O
in	O
both	O
the	O
regimens	O
.	O

CONCLUSIONS	O
Omission	O
of	O
the	O
pyridostigmine	O
dose	O
on	O
the	O
day	O
of	O
surgery	O
predisposed	O
patients	O
with	O
myasthenia	O
gravis	O
to	O
the	O
possibility	O
of	O
respiratory	O
discomfort	O
and	O
sensitivity	O
to	O
vecuronium	O
.	O

Continued	O
administration	O
significantly	O
prolonged	O
the	O
onset	O
time	O
of	O
vecuronium	O
and	O
the	O
patients	O
required	O
a	O
higher	O
dose	O
of	O
vecuronium	O
.	O

Clinically	O
relevant	O
improvement	O
of	O
recurrence-free	Others
survival	Others
with	O
5-aminolevulinic	O
acid	O
induced	O
fluorescence	O
diagnosis	O
in	O
patients	O
with	O
superficial	O
bladder	O
tumors	O
.	O

PURPOSES	O
Fluorescence	O
diagnosis	O
induced	O
by	O
5-aminolevulinic	O
acid	O
enables	O
more	O
thorough	O
transurethral	O
resection	O
of	O
superficial	O
bladder	O
carcinoma	O
compared	O
with	O
conventional	O
white	O
light	O
.	O

We	O
performed	O
a	O
prospective	O
,	O
single	O
institution	O
,	O
randomized	O
trial	O
to	O
investigate	O
whether	O
the	O
residual	O
tumor	O
rate	O
and	O
long-term	O
tumor	O
recurrence	O
can	O
be	O
decreased	O
by	O
fluorescence	O
diagnosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
A	O
total	O
of	O
301	O
patients	O
underwent	O
transurethral	O
resection	O
of	O
bladder	O
tumors	O
with	O
white	O
light	O
or	O
fluorescence	O
diagnosis	O
.	O

Transurethral	O
resection	O
was	O
repeated	O
5	O
to	O
6	O
weeks	O
later	O
to	O
evaluate	O
the	O
residual	O
tumor	O
rate	O
.	O

To	O
determine	O
recurrence-free	Others
survival	Others
patient	O
followup	O
was	O
performed	O
every	O
3	O
months	O
by	O
white	O
light	O
cystoscopy	O
and	O
urine	O
cytology	O
.	O

Recurrence-free	Others
survival	Others
was	O
analyzed	O
via	O
Kaplan-Meier	O
methods	O
and	O
multivariable	O
Cox	O
regression	O
analysis	O
.	O

RESULTS	O
A	O
total	O
of	O
191	O
patients	O
with	O
superficial	O
bladder	O
carcinoma	O
were	O
available	O
for	O
efficacy	O
analysis	O
.	O

The	O
residual	Physical
tumor	Physical
rate	Physical
was	O
25.2	O
%	O
in	O
the	O
white	O
light	O
arm	O
versus	O
4.5	O
%	O
in	O
the	O
fluorescence	O
diagnosis	O
arm	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Median	O
followup	O
in	O
the	O
white	O
light	O
arm	O
in	O
103	O
cases	O
was	O
21.2	O
months	O
(	O
range	O
4	O
to	O
40	O
)	O
compared	O
with	O
20.5	O
(	O
range	O
3	O
to	O
40	O
)	O
in	O
the	O
88	O
in	O
the	O
fluorescence	O
diagnosis	O
arm	O
.	O

Recurrence-free	Others
survival	Others
in	O
the	O
fluorescence	O
diagnosis	O
group	O
was	O
89.6	O
%	O
after	O
12	O
and	O
24	O
months	O
compared	O
with	O
73.8	O
%	O
and	O
65.9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
white	O
light	O
group	O
(	O
p	O
=	O
0.004	O
)	O
.	O

This	O
superiority	O
proved	O
to	O
be	O
independent	O
of	O
risk	O
group	O
.	O

The	O
adjusted	O
hazard	O
ratio	O
of	O
fluorescence	O
diagnosis	O
versus	O
white	O
light	O
transurethral	O
resection	O
was	O
0.33	O
(	O
95	O
%	O
confidence	O
interval	O
0.16	O
to	O
0.67	O
)	O
.	O

CONCLUSIONS	O
Fluorescence	O
diagnosis	O
is	O
significantly	O
superior	O
to	O
conventional	O
white	O
light	O
transurethral	O
resection	O
with	O
respect	O
to	O
the	O
residual	Physical
tumor	Physical
rate	Physical
and	O
recurrence-free	Others
survival	Others
.	O

The	O
differences	O
in	O
recurrence-free	Others
survival	Others
imply	O
that	O
fluorescence	O
diagnosis	O
is	O
a	O
clinically	O
relevant	O
procedure	O
for	O
decreasing	O
the	O
number	Physical
of	Physical
tumor	Physical
recurrences	Physical
.	Others

Shorter	O
treatment	O
for	O
vaginal	O
candidosis	O
:	O
comparison	O
between	O
single-dose	O
oral	O
fluconazole	O
and	O
three-day	O
treatment	O
with	O
local	O
miconazole	O
.	O

Fluconazole	O
is	O
an	O
effective	O
,	O
simple	O
and	O
safe	O
,	O
although	O
slightly	O
expensive	O
,	O
agent	O
for	O
the	O
treatment	O
of	O
vaginal	O
candidosis	O
.	O

Single-dose	O
fluconazole	O
(	O
150	O
mg	O
)	O
administered	O
orally	O
in	O
capsule	O
form	O
was	O
compared	O
with	O
three-day	O
local	O
treatment	O
with	O
miconazole	O
pessaries	O
in	O
the	O
treatment	O
of	O
vaginal	O
candidosis	O
in	O
a	O
randomized	O
study	O
in	O
Finland	O
.	O

Cure	Physical
rates	Physical
were	O
good	O
(	O
>	O
80	O
%	O
)	O
in	O
randomized	O
patient	O
groups	O
assessed	O
both	O
clinically	O
and	O
by	O
the	O
results	O
of	O
yeast	O
cultures	O
.	O

Oral	O
administration	O
was	O
preferred	O
to	O
local	O
therapy	O
by	O
patients	O
in	O
both	O
the	O
miconazole	O
and	O
fluconazole	O
groups	O
.	O

For	O
the	O
time	O
being	O
,	O
fluconazole	O
is	O
not	O
recommended	O
for	O
use	O
during	O
pregnancy	O
or	O
lactation	O
.	O

Long-term	O
exposure	O
to	O
belatacept	O
in	O
recipients	O
of	O
extended	O
criteria	O
donor	O
kidneys	O
.	O

Patients	O
in	O
the	O
BENEFIT-EXT	O
study	O
received	O
extended	O
criteria	O
donor	O
kidneys	O
and	O
a	O
more	O
intensive	O
(	O
MI	O
)	O
or	O
less	O
intensive	O
(	O
LI	O
)	O
belatacept	O
immunosuppression	O
regimen	O
,	O
or	O
cyclosporine	O
A	O
(	O
CsA	O
)	O
.	O

Patients	O
who	O
remained	O
on	O
assigned	O
therapy	O
through	O
year	O
3	O
were	O
eligible	O
to	O
enter	O
a	O
long-term	O
extension	O
(	O
LTE	O
)	O
study	O
.	O

Three	O
hundred	O
four	O
patients	O
entered	O
the	O
LTE	O
(	O
n	O
=	O
104	O
MI	O
;	O
n	O
=	O
113	O
LI	O
;	O
n	O
=	O
87	O
CsA	O
)	O
,	O
and	O
260	O
continued	O
treatment	O
through	O
year	O
5	O
(	O
n	O
=	O
91	O
MI	O
;	O
n	O
=	O
100	O
LI	O
;	O
n	O
=	O
69	O
CsA	O
)	O
.	O

Twenty	O
patients	O
died	Mortality
during	O
the	O
LTE	O
(	O
n	O
=	O
5	O
MI	O
;	O
n	O
=	O
9	O
LI	O
;	O
n	O
=	O
6	O
CsA	O
)	O
,	O
and	O
eight	O
experienced	O
graft	Adverseeffect
loss	Adverseeffect
(	O
n	O
=	O
2	O
MI	O
;	O
n	O
=	O
1	O
LI	O
;	O
n	O
=	O
5	O
CsA	O
)	O
.	O

Three	O
patients	O
experienced	O
an	O
acute	Adverseeffect
rejection	Adverseeffect
episode	O
(	O
n	O
=	O
2	O
MI	O
;	O
n	O
=	O
1	O
LI	O
)	O
.	O

The	O
incidence	O
rate	O
of	O
serious	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
,	O
viral	Adverseeffect
infections	O
and	O
fungal	Adverseeffect
infections	Adverseeffect
was	O
similar	O
across	O
groups	O
during	O
the	O
LTE	O
.	O

There	O
were	O
four	O
cases	O
of	O
posttransplant	Adverseeffect
lymphoproliferative	O
disorder	Adverseeffect
(	Adverseeffect
PTLD	O
)	O
from	O
the	O
beginning	O
of	O
the	O
LTE	O
to	O
year	O
5	O
(	O
n	O
=	O
3	O
LI	O
;	O
n	O
=	O
1	O
CsA	O
)	O
;	O
two	O
of	O
three	O
PTLD	O
cases	O
in	O
the	O
LI	O
group	O
were	O
in	O
patients	O
who	O
were	O
seronegative	O
for	O
Epstein-Barr	O
virus	O
(	O
EBV	O
(	O
-	O
)	O
)	O
at	O
transplantation	O
.	O

Mean	O
?	O
SD	O
calculated	O
GFR	O
at	O
year	O
5	O
was	O
55.9	O
?	O
17.5	O
(	O
MI	O
)	O
,	O
59.0	O
?	O
29.1	O
(	O
LI	O
)	O
and	O
44.6	O
?	O
16.4	O
(	O
CsA	O
)	O
mL/min/1.73	O
m	O
(	O
2	O
)	O
.	O

Continued	O
treatment	O
with	O
belatacept	O
was	O
associated	O
with	O
a	O
consistent	O
safety	O
profile	O
and	O
sustained	O
improvement	O
in	O
renal	O
function	O
versus	O
CsA	O
over	O
time	O
.	O

Comparative	O
drug	O
effects	O
and	O
abuse	O
liability	O
of	O
lorazepam	O
,	O
buspirone	O
,	O
and	O
secobarbital	O
in	O
nondependent	O
subjects	O
.	O

The	O
pharmacologic	O
effects	O
of	O
lorazepam	O
(	O
2	O
mg	O
)	O
,	O
buspirone	O
(	O
20	O
mg	O
,	O
10	O
mg	O
)	O
,	O
secobarbital	O
(	O
100	O
mg	O
)	O
,	O
and	O
placebo	O
were	O
compared	O
in	O
15	O
male	O
,	O
experienced	O
,	O
intermittent	O
nontherapeutic	O
drug	O
users	O
.	O

All	O
drugs	O
produced	O
a	O
drug	O
effect	O
,	O
however	O
,	O
buspirone	O
20	O
mg	O
was	O
significantly	O
less	O
liked	O
than	O
were	O
lorazepam	O
,	O
secobarbital	O
,	O
or	O
buspirone	O
10	O
mg	O
(	O
p	O
less	O
than	O
.05	O
)	O
but	O
not	O
placebo	O
.	O

Lorazepam	O
was	O
liked	O
better	O
than	O
were	O
other	O
drugs	O
only	O
at	O
1	O
hour	O
and	O
only	O
compared	O
with	O
buspirone	O
20	O
and	O
placebo	O
.	O

Compared	O
with	O
other	O
drugs	O
,	O
lorazepam	O
drug	Others
effects	Others
were	O
greater	O
and	O
resulted	O
in	O
more	O
prolonged	Physical
impairment	Physical
of	O
a	O
motor	Physical
tracking	Physical
task	Physical
,	Physical
standing	Physical
steadiness	Physical
,	Mental
and	Mental
memory	Mental
.	Mental

Buspirone	O
20	O
mg	O
significantly	Mental
impaired	Mental
memory	Mental
at	O
1	O
hour	O
compared	O
with	O
placebo	O
.	O

Subjects	O
were	O
more	O
likely	O
to	O
identify	O
buspirone	O
as	O
unfamiliar	O
.	O

Because	O
buspirone	O
20	O
mg	O
was	O
less	O
liked	O
than	O
were	O
other	O
drugs	O
,	O
dose	O
escalation	O
as	O
part	O
of	O
drug	Mental
abuse	Mental
is	O
not	O
likely	O
to	O
occur	O
.	O

Lorazepam	O
also	O
was	O
not	O
particularly	O
liked	O
and	O
was	O
not	O
different	O
from	O
placebo	O
on	O
most	O
subjective	Others
abuse-relevant	Others
measures	Others
.	O

Lack	O
of	O
effect	Others
of	O
food	O
on	O
the	O
steady	Others
state	Others
pharmacokinetics	Others
of	Others
BMS-181101	Others
,	O
an	O
antidepressant	O
,	O
in	O
healthy	O
subjects	O
.	O

The	O
effect	Others
of	Others
food	Others
on	Others
the	Others
pharmacokinetics	Others
of	Others
BMS-181101	Others
,	O
a	O
new	O
anti-depressant	O
under	O
development	O
,	O
was	O
investigated	O
in	O
12	O
healthy	O
male	O
volunteers	O
at	O
steady	O
state	O
.	O

Each	O
subject	O
received	O
a	O
15	O
mg	O
oral	O
dose	O
of	O
BMS-181101	O
twice	O
a	O
day	O
(	O
q	O
12	O
h	O
)	O
for	O
11	O
days	O
and	O
a	O
morning	O
dose	O
of	O
BMS-181101	O
on	O
day	O
12	O
.	O

Six	O
subjects	O
were	O
randomly	O
assigned	O
to	O
receive	O
BMS-181101	O
under	O
fasted	O
conditions	O
from	O
days	O
1	O
to	O
6	O
and	O
then	O
crossed	O
over	O
to	O
fed	O
conditions	O
from	O
days	O
7	O
to	O
12	O
.	O

The	O
other	O
six	O
subjects	O
received	O
the	O
reverse	O
conditions	O
,	O
fed	O
for	O
days	O
1-6	O
and	O
fasted	O
for	O
days	O
7-12	O
.	O

Serial	O
blood	O
samples	O
were	O
collected	O
up	O
to	O
12	O
h	O
on	O
days	O
6	O
and	O
12	O
following	O
the	O
administration	O
of	O
the	O
morning	O
dose	O
.	O

In	O
addition	O
,	O
trough	O
blood	O
samples	O
were	O
collected	O
on	O
days	O
4	O
,	O
5	O
,	O
10	O
,	O
and	O
11	O
prior	O
to	O
the	O
morning	O
dose	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
for	O
intact	Physical
BMS-181101	Physical
using	O
a	O
validated	O
high-performance	O
liquid	O
chromatography	O
method	O
with	O
an	O
electrochemical	O
detector	O
.	O

BMS-181101	O
was	O
well	O
tolerated	Others
both	O
with	O
and	O
without	O
ingestion	O
of	O
food	O
.	O

The	O
statistical	O
evaluation	O
of	O
the	O
Cmin	Others
values	Others
indicated	O
that	O
steady	Others
state	Others
of	O
BMS-181101	O
was	O
achieved	O
by	O
the	O
fourth	O
day	O
of	O
dosing	O
regardless	O
of	O
whether	O
the	O
subject	O
was	O
fasted	O
or	O
fed	O
.	O

When	O
BMS-181101	O
was	O
administered	O
with	O
food	O
,	O
Cmax	Others
was	Others
reduced	Others
by	O
about	O
25	O
%	O
and	O
tmax	Others
was	Others
prolonged	Others
by	O
1	O
h.	O
However	O
,	O
AUCtau	Others
,	Others
t1/2	Others
,	Others
and	Others
time	Others
to	Others
attain	Others
steady	Others
state	Others
of	Others
BMS-181101	Others
were	O
not	O
altered	O
by	O
ingestion	O
of	O
food	O
.	O

In	O
summary	O
,	O
BMS-181101	O
can	O
be	O
given	O
with	O
food	O
without	O
adversely	O
impacting	O
the	O
safety	Others
or	O
pharmacokinetic	Others
profiles	Others
of	O
the	O
drug	O
.	O

Warfarin	O
for	O
atrial	O
fibrillation	O
.	O

The	O
patient	O
's	O
perspective	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
minimal	Others
clinically	Others
important	Others
difference	Others
(	Others
MCID	Others
)	Others
of	O
warfarin	O
therapy	O
for	O
the	O
treatment	O
of	O
nonvalvular	O
atrial	O
fibrillation	O
from	O
the	O
perspective	O
of	O
patients	O
using	O
2	O
different	O
elicitation	O
methods	O
.	O

DESIGN	O
All	O
patients	O
completed	O
2	O
face-to-face	O
interviews	O
,	O
which	O
were	O
2	O
weeks	O
apart	O
.	O

For	O
each	O
interview	O
,	O
they	O
were	O
randomized	O
to	O
receive	O
1	O
of	O
2	O
elicitation	O
methods	O
:	O
ping-ponging	O
or	O
starting	O
at	O
the	O
known	O
efficacy	O
.	O

SETTING	O
The	O
practices	O
of	O
2	O
university-affiliated	O
family	O
medicine	O
centers	O
(	O
8	O
physicians	O
each	O
)	O
,	O
14	O
community-based	O
family	O
physicians	O
,	O
and	O
2	O
cardiologists	O
.	O

PATIENTS	O
Sixty-four	O
patients	O
with	O
nonvalvular	O
atrial	O
fibrillation	O
who	O
were	O
initiated	O
with	O
warfarin	O
therapy	O
at	O
least	O
3	O
months	O
before	O
the	O
study	O
.	O

INTERVENTION	O
During	O
each	O
interview	O
,	O
the	O
patients	O
'	O
MCIDs	O
were	O
determined	O
by	O
using	O
(	O
1	O
)	O
a	O
pictorial	Others
flip	Others
chart	Others
to	Others
describe	Others
atrial	Physical
fibrillation	Physical
;	O
the	O
consequences	Physical
of	Physical
a	Physical
minor	Physical
stroke	Physical
,	Physical
a	Physical
major	Physical
stroke	Physical
,	Physical
and	Physical
a	Physical
major	Physical
bleeding	Physical
episode	Physical
;	O
the	O
chance	Physical
of	Physical
stroke	Physical
if	Physical
not	Physical
taking	Physical
warfarin	Physical
;	O
the	O
chance	Physical
of	Physical
a	Physical
major	Physical
bleeding	Physical
episode	Physical
if	Physical
taking	Physical
warfarin	Physical
;	O
examples	O
of	O
the	O
inconvenience	Others
,	Others
minor	Physical
side	Physical
effects	Physical
,	Others
and	Others
costs	Others
of	Others
warfarin	Others
therapy	Others
;	O
and	O
then	O
(	O
2	O
)	O
1	O
of	O
the	O
2	O
elicitation	O
methods	O
to	O
determine	O
their	O
MCIDs	Others
(	Others
the	Others
smallest	Others
reduction	Others
in	Others
stroke	Others
risk	Others
at	Others
which	Others
the	Others
patients	Others
were	Others
willing	Others
to	Others
take	Others
warfarin	Others
)	Others
.	O

Patients	Mental
'	Mental
knowledge	Mental
of	Mental
their	Mental
stroke	Mental
risk	Mental
,	O
acceptability	Others
of	Others
the	Others
interview	Others
process	Others
,	O
and	O
factors	Others
determining	Others
their	Others
preferences	Others
were	O
also	O
assessed	O
.	O

MAIN	O
RESULTS	O
Given	O
a	O
baseline	O
risk	O
of	O
having	O
a	O
stroke	O
in	O
the	O
next	O
2	O
years	O
,	O
if	O
not	O
taking	O
warfarin	O
,	O
of	O
10	O
of	O
100	O
,	O
the	O
mean	O
MCID	Others
was	O
2.01	O
of	O
100	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.60-2.42	O
)	O
.	O

Fifty-two	O
percent	O
of	O
the	O
patients	O
would	O
take	O
warfarin	O
for	O
an	O
absolute	O
decrease	O
in	O
stroke	Physical
risk	Physical
of	O
1	O
%	O
over	O
2	O
years	O
.	O

Before	O
eliciting	O
their	O
MCIDs	O
,	O
patients	O
showed	O
poor	O
knowledge	Mental
of	Mental
their	Mental
stroke	Mental
risk	Mental
,	O
which	O
improved	O
afterward	O
.	O

The	O
interview	O
process	O
was	O
well	O
accepted	O
by	O
the	O
patients	O
.	O

The	O
MCID	Others
using	O
the	O
ping-ponging	O
elicitation	O
method	O
was	O
1.015	O
of	O
100	O
smaller	O
compared	O
with	O
use	O
of	O
the	O
starting	O
at	O
the	O
known	O
efficacy	O
method	O
(	O
P	O
=	O
.01	O
)	O
.	O

CONCLUSIONS	O
We	O
were	O
able	O
to	O
determine	O
the	O
MCID	Others
of	O
warfarin	O
therapy	O
for	O
the	O
prevention	O
of	O
stroke	O
from	O
the	O
perspective	O
of	O
patients	O
with	O
nonvalvular	O
atrial	O
fibrillation	O
.	O

Their	O
MCIDs	O
were	O
much	O
smaller	O
than	O
those	O
that	O
have	O
been	O
implied	O
by	O
some	O
experts	O
and	O
clinicians	O
.	O

The	O
interview	O
process	O
,	O
using	O
the	O
flip	O
chart	O
approach	O
,	O
appeared	O
to	O
improve	O
the	O
patients	Mental
'	Mental
knowledge	Mental
of	Mental
their	Mental
disease	Mental
and	Mental
its	Mental
consequences	Mental
and	Mental
treatment	Mental
.	O

The	O
method	O
used	O
to	O
elicit	O
the	O
patients	O
'	O
MCIDs	Others
can	O
have	O
a	O
clinically	O
important	O
effect	O
on	O
patient	O
responses	O
.	O

The	O
method	O
used	O
in	O
our	O
study	O
can	O
be	O
generalized	O
to	O
other	O
conditions	O
and	O
,	O
thus	O
,	O
could	O
be	O
helpful	O
in	O
3	O
ways	O
:	O
(	O
1	O
)	O
from	O
a	O
clinical	O
decision-making	O
perspective	O
,	O
it	O
could	O
facilitate	O
patient-physician	O
communication	O
;	O
(	O
2	O
)	O
it	O
could	O
clarify	O
the	O
patient	O
perspective	O
when	O
interpreting	O
the	O
results	O
of	O
previously	O
completed	O
trials	O
;	O
and	O
(	O
3	O
)	O
it	O
could	O
be	O
used	O
to	O
derive	O
more	O
clinically	O
relevant	O
sample	O
sizes	O
for	O
randomized	O
treatment	O
trials	O
.	O

Maternal	O
breast-milk	O
and	O
intestinal	O
bifidobacteria	O
guide	O
the	O
compositional	O
development	O
of	O
the	O
Bifidobacterium	O
microbiota	O
in	O
infants	O
at	O
risk	O
of	O
allergic	O
disease	O
.	O

BACKGROUND	O
The	O
sources	O
and	O
the	O
impact	O
of	O
maternal	O
bacteria	O
on	O
the	O
initial	O
inoculum	O
of	O
the	O
intestinal	O
microflora	O
of	O
newborn	O
infants	O
remain	O
elusive	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
association	O
between	O
maternal	O
breast-milk	O
and	O
fecal	O
bifidobacteria	O
and	O
infants	O
'	O
fecal	O
bifidobacteria	O
.	O

METHODS	O
Sixty-one	O
mother-infant	O
pairs	O
were	O
included	O
,	O
special	O
emphasis	O
being	O
placed	O
on	O
the	O
maternal	O
allergic	O
status	O
.	O

Bifidobacteria	Physical
were	O
analysed	O
by	O
a	O
direct	O
PCR	O
method	O
in	O
fecal	O
samples	O
from	O
mothers	O
at	O
30-35	O
weeks	O
of	O
gestation	O
and	O
from	O
infants	O
at	O
1	O
month	O
of	O
age	O
and	O
from	O
breast-milk	O
samples	O
1	O
month	O
post-partum	O
.	O

RESULTS	O
Fecal	O
Bifidobacterium	O
adolescentis	O
and	O
Bifidobacterium	O
bifidum	O
colonization	O
frequencies	O
and	O
counts	O
among	O
mother-infant	O
pairs	O
correlated	O
significantly	O
(	O
P=0.005	O
and	O
0.02	O
for	O
frequencies	O
,	O
respectively	O
,	O
and	O
P=0.002	O
and	O
0.01	O
for	O
counts	O
,	O
respectively	O
)	O
.	O

Only	O
infants	O
of	O
allergic	O
,	O
atopic	O
mothers	O
were	O
colonized	O
with	O
B.	O
adolescentis	O
.	O

Each	O
of	O
the	O
breast-milk	O
samples	O
contained	O
bifidobacteria	O
[	O
median	O
1.4	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
;	O
interquartile	O
range	O
(	O
IQR	O
)	O
48.7-3.8	O
x	O
10	O
(	O
3	O
)	O
]	O
.	O

Bifidobacterium	Physical
longum	Physical
was	O
the	O
most	O
frequently	O
detected	O
species	O
in	O
breast-milk	O
.	O

Allergic	O
mothers	O
had	O
significantly	O
lower	O
amounts	O
of	O
bifidobacteria	Physical
in	O
breast-milk	O
compared	O
with	O
non-allergic	O
mothers	O
[	O
median	O
1.3	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
(	O
IQR	O
22.4-3.0	O
x	O
10	O
(	O
3	O
)	O
)	O
vs.	O
5.6	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
(	O
1.8	O
x	O
10	O
(	O
3	O
)	O
-1.8	O
x	O
10	O
(	O
4	O
)	O
)	O
,	O
respectively	O
,	O
(	O
P=0.004	O
)	O
]	O
,	O
and	O
their	O
infants	O
had	O
concurrently	O
lower	O
counts	O
of	O
bifidobacteria	Physical
in	O
feces	O
[	O
3.9	O
x	O
10	O
(	O
8	O
)	O
bacterial	O
cells/g	O
(	O
IQR	O
6.5	O
x	O
10	O
(	O
6	O
)	O
-1.5	O
x	O
10	O
(	O
9	O
)	O
)	O
in	O
infants	O
of	O
allergic	O
mothers	O
,	O
vs.	O
2.5	O
x	O
10	O
(	O
9	O
)	O
bacterial	O
cells/g	O
(	O
6.5	O
x	O
10	O
(	O
8	O
)	O
-3.2	O
x	O
10	O
(	O
10	O
)	O
)	O
in	O
infants	O
of	O
non-allergic	O
mothers	O
,	O
P=0.013	O
]	O
.	O

CONCLUSIONS	O
Breast-milk	O
contains	O
significant	O
numbers	O
of	O
bifidobacteria	O
and	O
the	O
maternal	O
allergic	O
status	O
further	O
deranges	O
the	O
counts	O
of	O
bifidobacteria	O
in	O
breast-milk	O
.	O

Maternal	O
fecal	O
and	O
breast-milk	O
bifidobacterial	O
counts	O
impacted	O
on	O
the	O
infants	O
'	O
fecal	O
Bifidobacterium	O
levels	O
.	O

Breast-milk	O
bacteria	O
should	O
thus	O
be	O
considered	O
an	O
important	O
source	O
of	O
bacteria	O
in	O
the	O
establishment	O
of	O
infantile	O
intestinal	O
microbiota	O
.	O

Sex	Mental
risk	Mental
behavior	Mental
among	O
adolescent	O
and	O
young	O
adult	O
children	O
of	O
opiate	O
addicts	O
:	O
outcomes	O
from	O
the	O
focus	O
on	O
families	O
prevention	O
trial	O
and	O
an	O
examination	O
of	O
childhood	O
and	O
concurrent	O
predictors	O
of	O
sex	O
risk	O
behavior	O
.	O

This	O
study	O
reports	O
on	O
rates	Mental
and	Mental
predictors	Mental
of	Mental
sex	Mental
risk	Mental
behavior	Mental
among	O
a	O
sample	O
of	O
adolescent	O
and	O
young	O
adult	O
children	O
of	O
parents	O
enrolled	O
in	O
methadone	O
treatment	O
for	O
opiate	O
addiction	O
.	O

Data	O
are	O
from	O
151	O
participants	O
(	O
80	O
males	O
,	O
71	O
females	O
)	O
in	O
the	O
Focus	O
on	O
Families	O
(	O
FOF	O
)	O
project	O
,	O
a	O
randomized	O
trial	O
of	O
a	O
family	O
intervention	O
and	O
a	O
study	O
of	O
the	O
development	O
of	O
at-risk	O
children	O
.	O

The	O
study	O
participants	O
are	O
children	O
of	O
parents	O
enrolled	O
in	O
methadone	O
treatment	O
between	O
1990	O
and	O
1993	O
.	O

Participants	O
were	O
interviewed	O
in	O
2005	O
when	O
they	O
ranged	O
in	O
age	O
from	O
15	O
to	O
29	O
years	O
.	O

In	O
the	O
year	O
prior	O
to	O
the	O
follow-up	O
,	O
79	O
%	O
of	O
the	O
males	O
and	O
83	O
%	O
of	O
females	O
were	O
sexually	O
active	O
,	O
26	O
%	O
of	O
males	O
and	O
10	O
%	O
of	O
females	O
had	O
more	O
than	O
one	O
partner	O
in	O
the	O
prior	O
year	O
,	O
and	O
34	O
%	O
of	O
males	O
and	O
24	O
%	O
of	O
females	O
reported	O
having	O
sex	O
outside	O
of	O
a	O
committed	O
relationship	O
.	O

Twenty-four	O
percent	O
of	O
males	O
and	O
17	O
%	O
of	O
females	O
met	O
criteria	O
for	O
high-risk	Mental
sexual	Mental
behavior	Mental
,	O
reporting	O
casual	O
or	O
multiple	O
partners	O
in	O
the	O
prior	O
year	O
and	O
inconsistent	O
condom	O
use	O
.	O

Participants	O
in	O
the	O
intervention	O
and	O
control	O
conditions	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
any	O
measure	O
of	O
sex	Mental
risk	Mental
behavior	Mental
examined	O
.	O

None	O
of	O
the	O
measures	O
of	O
parent	O
behavior	O
and	O
family	O
processes	O
derived	O
from	O
data	O
at	O
baseline	O
of	O
the	O
FOF	O
study	O
predicted	O
whether	O
participants	O
engaged	O
in	O
high-risk	Mental
sex	Mental
.	Mental

Among	O
measures	O
derived	O
from	O
data	O
collected	O
at	O
long-term	O
follow-up	O
,	O
however	O
,	O
having	O
ever	O
met	O
criteria	O
for	O
substance	O
abuse	O
or	O
dependence	O
predicted	O
greater	O
likelihood	O
of	O
high-risk	Mental
sexual	Mental
behavior	Mental
,	O
and	O
being	O
married	O
or	O
being	O
in	O
a	O
romantic	O
relationship	O
was	O
associated	O
with	O
lower	O
likelihood	O
of	O
high-risk	Mental
sexual	Mental
behavior	Mental
.	Mental

The	O
findings	O
point	O
to	O
the	O
important	O
role	O
of	O
committed	O
relationships	O
in	O
regulating	O
sex	Mental
risk	Mental
behavior	Mental
among	O
this	O
population	O
,	O
as	O
well	O
as	O
heightened	O
levels	O
of	O
sex	Mental
risk	Mental
behavior	Mental
associated	O
with	O
substance	O
abuse	O
or	O
dependence	O
.	O

LNH-84	O
regimen	O
:	O
a	O
multicenter	O
study	O
of	O
intensive	O
chemotherapy	O
in	O
737	O
patients	O
with	O
aggressive	O
malignant	O
lymphoma	O
.	O

From	O
July	O
1984	O
to	O
September	O
1987	O
,	O
737	O
patients	O
with	O
aggressive	O
malignant	O
lymphoma	O
(	O
ML	O
)	O
were	O
treated	O
by	O
an	O
intensive	O
regimen	O
(	O
LNH-84	O
)	O
comprising	O
three	O
or	O
four	O
courses	O
of	O
doxorubicin	O
,	O
75	O
mg/m2	O
;	O
cyclophosphamide	O
,	O
1,200	O
mg/m2	O
;	O
vindesine	O
,	O
2	O
mg/m2	O
x	O
2	O
;	O
bleomycin	O
,	O
10	O
mg	O
x	O
2	O
;	O
and	O
prednisolone	O
,	O
60	O
mg/m2	O
x	O
5	O
(	O
ACVB	O
)	O
,	O
consolidation	O
with	O
high-dose	O
methotrexate	O
,	O
ifosfamide	O
,	O
etoposide	O
,	O
asparaginase	O
,	O
and	O
cytarabine	O
,	O
and	O
a	O
randomized	O
late	O
intensification	O
with	O
two	O
courses	O
of	O
cytarabine	O
,	O
cyclophosphamide	O
,	O
teniposide	O
,	O
bleomycin	O
,	O
and	O
prednisone	O
(	O
AraCVmB	O
)	O
.	O

Four	O
hundred	O
forty-two	O
patients	O
had	O
intermediate-grade	O
ML	O
,	O
221	O
highgrade	O
ML	O
,	O
and	O
74	O
unclassified	O
ML	O
.	O

Most	O
of	O
the	O
patients	O
had	O
advanced	O
disease	O
:	O
stage	O
IIE	O
(	O
23	O
%	O
)	O
,	O
III	O
(	O
13	O
%	O
)	O
,	O
or	O
IV	O
(	O
47	O
%	O
)	O
;	O
38	O
%	O
disseminated	O
nodes	O
;	O
38	O
%	O
two	O
or	O
more	O
extranodal	O
sites	O
;	O
and	O
41	O
%	O
a	O
tumoral	O
mass	O
greater	O
than	O
10	O
cm	O
.	O

Five	O
hundred	O
fifty-three	O
patients	O
(	O
75	O
%	O
)	O
went	O
into	O
complete	Physical
remission	Physical
(	Physical
CR	Physical
)	Physical
,	O
63	O
(	O
9	O
%	O
)	O
into	O
partial	Physical
remission	Physical
,	O
62	O
(	O
8	O
%	O
)	O
failed	Physical
to	Physical
respond	Physical
,	O
and	O
59	O
(	O
8	O
%	O
)	O
died	Mortality
during	O
ACVB	O
courses	O
,	O
17	O
of	O
them	O
from	O
progression	O
of	O
the	O
disease	O
.	O

With	O
a	O
median	O
follow-up	O
of	O
23	O
months	O
,	O
the	O
estimated	O
2-year	O
overall	Physical
survival	Physical
time	Physical
to	Physical
failure	Physical
(	Physical
TTF	Physical
)	Physical
,	O
and	O
time	Physical
to	Physical
relapse	Physical
(	Physical
TTR	Physical
)	Physical
survival	Physical
are	O
67	O
%	O
,	O
56	O
%	O
,	O
and	O
67	O
%	O
,	O
respectively	O
.	O

Patients	O
receiving	O
a	O
late	O
intensification	O
had	O
the	O
same	O
relapse	Physical
rate	Physical
as	O
the	O
other	O
patients	O
.	O

A	O
persistent	Physical
fibronecrotic	Physical
mass	Physical
was	O
found	O
in	O
150	O
patients	O
(	O
20	O
%	O
)	O
and	O
did	O
not	O
influence	O
the	O
relapse	Physical
rate	Physical
.	Others

Toxicity	Adverseeffect
was	O
mainly	O
neutropenia	Adverseeffect
and	O
infection	Physical
during	O
the	O
ACVB	O
courses	O
,	O
with	O
40	O
patients	O
(	O
5	O
%	O
)	O
dying	Mortality
from	Mortality
septic	Mortality
complications	Mortality
while	O
responding	O
to	O
treatment	O
.	O

Fifty-three	O
percent	O
of	O
the	O
patients	O
had	O
a	O
neutropenia	Adverseeffect
less	O
than	O
0.500	O
x	O
10	O
(	O
9	O
)	O
/L	O
,	O
58	O
%	O
fever	O
(	O
6	O
%	O
grade	O
4	O
)	O
,	O
and	O
49	O
%	O
a	O
documented	Adverseeffect
infection	Adverseeffect
(	O
8	O
%	O
grade	O
4	O
)	O
.	O

These	O
results	O
obtained	O
with	O
the	O
LNH-84	O
regimen	O
demonstrate	O
that	O
this	O
therapeutic	O
scheme	O
is	O
an	O
effective	O
treatment	O
for	O
aggressive	O
ML	O
.	O

Coagulation	O
factor	O
concentrate	O
in	O
the	O
treatment	O
of	O
the	O
haemorrhagic	Physical
diathesis	Physical
of	O
fulminant	O
hepatic	O
failure	O
.	O

To	O
assess	O
the	O
value	O
of	O
clotting	O
factor	O
concentrate	O
infusions	O
in	O
fulminant	O
hepatic	Physical
failure	Physical
,	O
a	O
controlled	O
trial	O
was	O
performed	O
in	O
which	O
nine	O
patients	O
were	O
randomly	O
allocated	O
to	O
treatment	O
with	O
either	O
concentrate	O
alone	O
or	O
concentrate	O
plus	O
heparin	O
.	O

The	O
five	O
patients	O
receiving	O
concentrate	O
alone	O
all	O
died	Mortality
,	O
with	O
major	Adverseeffect
bleeding	Adverseeffect
as	O
the	O
direct	O
cause	O
of	O
death	O
in	O
three	O
,	O
whereas	O
in	O
the	O
four	O
receiving	O
heparin	O
as	O
well	O
there	O
was	O
only	O
one	O
instance	O
of	O
bleeding	Adverseeffect
and	O
one	O
patient	O
survived	Mortality
.	Physical

Clinical	O
evidence	O
of	O
intravascular	Physical
coagulation	Physical
appeared	O
in	O
two	O
patients	O
treated	O
with	O
concentrate	O
alone	O
and	O
the	O
laboratory	O
evidence	O
of	O
this	O
progressed	O
during	O
the	O
period	O
of	O
infusions	O
in	O
all	O
patients	O
in	O
both	O
treatment	O
groups	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
in	O
those	O
receiving	O
heparin	O
.	O

Additional	O
evidence	O
for	O
intravascular	O
coagulation	O
came	O
from	O
the	O
changes	O
observed	O
in	O
factor	Physical
VIII	Physical
levels	Physical
which	O
,	O
although	O
initially	O
high	O
in	O
all	O
patients	O
,	O
fell	O
subsequently	O
,	O
particularly	O
in	O
those	O
given	O
concentrate	O
alone	O
.	O

There	O
was	O
some	O
improvement	O
in	O
the	O
prothrombin	Physical
ratio	Physical
in	O
both	O
groups	O
of	O
patients	O
but	O
not	O
complete	O
correction	O
,	O
and	O
serial	O
assays	O
of	O
clotting	O
factors	O
showed	O
that	O
although	O
factor	Physical
II	Physical
rose	O
to	O
high	O
levels	O
during	O
treatment	O
,	O
factors	Physical
IX	Physical
and	Physical
X	Physical
showed	O
little	O
response	O
.	O

Thus	O
,	O
the	O
use	O
of	O
concentrate	O
of	O
factor	Physical
IX	Physical
in	O
this	O
trial	O
,	O
as	O
well	O
as	O
potentiating	O
intravascular	Physical
coagulation	Physical
,	O
was	O
inadequate	O
as	O
replacement	O
for	O
the	O
clotting	O
factor	O
deficiencies	O
.	O

Immunologic	Physical
response	Physical
after	O
laparoscopic	O
colon	O
cancer	O
operation	O
within	O
an	O
enhanced	O
recovery	O
program	O
.	O

OBJECTIVE	O
It	O
has	O
been	O
demonstrated	O
that	O
colon	O
operation	O
combined	O
with	O
fast-track	O
(	O
FT	O
)	O
surgery	O
and	O
laparoscopic	O
technique	O
can	O
shorten	O
the	O
length	Physical
of	Physical
hospital	Physical
stay	Physical
,	Physical
accelerate	Physical
recovery	Physical
of	Physical
intestinal	Physical
function	Physical
,	O
and	O
reduce	O
the	O
occurrence	Physical
of	Physical
post-operative	Physical
complications	Physical
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
regarding	O
the	O
combined	O
effects	O
of	O
FT	O
colon	O
operation	O
and	O
laparoscopic	O
technique	O
on	O
humoral	Physical
inflammatory	Physical
cellular	Physical
immunity	Physical
.	Physical

METHODS	O
This	O
was	O
a	O
prospective	O
,	O
controlled	O
study	O
.	O

One	O
hundred	O
sixty-three	O
colon	O
cancer	O
patients	O
underwent	O
the	O
traditional	O
protocol	O
and	O
open	O
operation	O
(	O
traditional	O
open	O
group	O
,	O
n=42	O
)	O
,	O
the	O
traditional	O
protocol	O
and	O
laparoscopic	O
operation	O
(	O
traditional	O
laparoscopic	O
group	O
,	O
n=40	O
)	O
,	O
the	O
FT	O
protocol	O
and	O
open	O
operation	O
(	O
FT	O
open	O
group	O
,	O
n=41	O
)	O
,	O
or	O
the	O
FT	O
protocol	O
and	O
laparoscopic	O
operation	O
(	O
FT	O
laparoscopic	O
group	O
,	O
n=40	O
)	O
.	O

Blood	O
samples	O
were	O
taken	O
prior	O
to	O
operation	O
as	O
well	O
as	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
after	O
operation	O
.	O

The	O
number	Physical
of	Physical
lymphocyte	Physical
subpopulations	Physical
was	O
determined	O
by	O
flow	O
cytometry	O
,	O
and	O
serum	Physical
interleukin-6	Physical
and	Physical
C-reactive	Physical
protein	Physical
levels	Physical
were	O
measured	O
.	O

Post-operative	Others
hospital	Others
stay	Others
,	O
post-operative	Physical
morbidity	Physical
,	O
readmission	Others
rate	Others
,	O
and	O
in-hospital	Mortality
mortality	Mortality
were	O
recorded	O
.	O

RESULTS	O
Compared	O
with	O
open	O
operation	O
,	O
laparoscopic	O
colon	O
operation	O
effectively	O
inhibited	O
the	O
release	O
of	O
post-operative	Physical
inflammatory	Physical
factors	Physical
and	O
yielded	O
good	O
protection	O
via	O
post-operative	O
cell	O
immunity	O
.	O

FT	O
surgery	O
had	O
a	O
better	O
protective	O
role	O
with	O
respect	O
to	O
the	O
post-operative	O
immune	O
system	O
compared	O
with	O
traditional	O
peri-operative	O
care	O
.	O

Inflammatory	Physical
reactions	Physical
,	O
based	Physical
on	Physical
interleukin-6	Physical
and	Physical
C-reactive	Physical
protein	Physical
levels	Physical
,	O
were	O
less	O
intense	O
following	O
FT	O
laparoscopic	O
operation	O
compared	O
to	O
FT	O
open	O
operation	O
;	O
however	O
,	O
there	O
were	O
no	O
differences	O
in	O
specific	Physical
immunity	Physical
(	Physical
CD3+	Physical
and	Physical
CD4+	Physical
counts	Physical
,	Physical
and	Physical
the	Physical
CD4+/CD8+	Physical
ratio	Physical
)	Physical
during	O
these	O
two	O
types	O
of	O
surgical	O
procedures	O
.	O

Post-operative	Adverseeffect
hospital	Adverseeffect
stay	Adverseeffect
in	O
patients	O
randomized	O
to	O
the	O
FT	O
laparoscopic	O
group	O
was	O
significantly	O
shorter	O
than	O
in	O
the	O
other	O
three	O
treatment	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Post-operative	Adverseeffect
complications	Adverseeffect
in	O
patients	O
who	O
underwent	O
FT	O
laparoscopic	O
treatment	O
were	O
less	O
than	O
in	O
the	O
other	O
three	O
treatment	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
four	O
treatment	O
groups	O
regarding	O
readmission	Mortality
rate	Mortality
and	O
in-hospital	Mortality
mortality	Mortality
.	O

CONCLUSIONS	O
The	O
laparoscopic	O
technique	O
and	O
FT	O
surgery	O
rehabilitation	O
program	O
effectively	O
inhibited	O
release	O
of	O
post-operative	Physical
inflammatory	Physical
factors	Physical
with	Physical
a	Physical
reduction	Physical
in	Physical
peri-operative	Physical
trauma	Physical
and	Physical
stress	Physical
,	O
which	O
together	O
played	O
a	O
protective	O
role	O
on	O
the	O
post-operative	O
immune	O
system	O
.	O

Combining	O
two	O
treatment	O
measures	O
during	O
colon	O
operation	O
produced	O
better	O
protective	Others
effects	Others
via	Others
the	Others
immune	Others
system	Others
.	Physical

The	O
beneficial	O
clinical	O
effects	O
support	O
that	O
the	O
better-preserved	O
post-operative	O
immune	O
system	O
may	O
also	O
contribute	O
to	O
the	O
improvement	Physical
of	Physical
post-operative	Physical
results	Physical
in	O
FT	O
laparoscopic	O
patients	O
.	O

1999	O
WHO/ISH	O
Guidelines	O
applied	O
to	O
a	O
1999	O
MONICA	O
sample	O
from	O
northern	O
Sweden	O
.	O

BACKGROUND	O
Treating	O
hypertension	O
with	O
drugs	O
is	O
so	O
far	O
the	O
most	O
cost-effective	O
way	O
to	O
reduce	O
this	O
important	O
risk	O
factor	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

It	O
is	O
,	O
however	O
,	O
important	O
to	O
determine	O
absolute	O
risk	O
,	O
and	O
thereby	O
estimate	O
indication	O
for	O
drug	O
treatment	O
,	O
in	O
order	O
to	O
maintain	O
a	O
cost-effective	O
drug	O
treatment	O
.	O

WHO/ISH	O
Hypertension	O
Guidelines	O
from	O
1999	O
propose	O
a	O
risk	O
stratification	O
for	O
estimating	O
absolute	O
risk	O
for	O
CVD	O
based	O
on	O
blood	O
pressure	O
and	O
additional	O
risk	O
factors	O
,	O
target	O
organ	O
damage	O
(	O
TOD	O
)	O
and	O
CVD	O
.	O

OBJECTIVES	O
We	O
studied	O
the	O
consequences	O
of	O
applying	O
the	O
recent	O
WHO/ISH	O
risk	O
stratification	O
scheme	O
to	O
a	O
MONICA	O
sample	O
of	O
6000	O
subjects	O
from	O
a	O
geographically	O
defined	O
population	O
in	O
northern	O
Sweden	O
,	O
regarding	O
indications	O
for	O
treatment	O
,	O
target	O
blood	O
pressure	O
and	O
risk	O
distribution	O
.	O

METHODS	O
We	O
have	O
risk-classified	O
each	O
of	O
these	O
patients	O
using	O
a	O
computer	O
program	O
,	O
according	O
to	O
the	O
WHO/ISH	O
scheme	O
.	O

Data	O
on	O
TOD	O
were	O
not	O
available	O
.	O

RESULTS	O
In	O
all	O
,	O
917	O
(	O
15	O
%	O
)	O
had	O
drug-treated	O
hypertension	O
.	O

Three-quarters	O
(	O
n	O
=	O
737	O
)	O
were	O
inadequately	O
treated	O
,	O
with	O
blood	Physical
pressure	Physical
levels	Physical
at	O
or	O
above	O
140	O
or	O
90	O
mmHg	O
.	O

1773	O
(	O
30	O
%	O
of	O
5997	O
)	O
untreated	O
subjects	O
had	O
a	O
blood	O
pressure	O
of	O
140/90	O
or	O
above	O
;	O
16	O
%	O
in	O
the	O
low-	O
,	O
62	O
%	O
in	O
the	O
medium-	O
,	O
8	O
%	O
in	O
the	O
high-	O
,	O
and	O
14	O
%	O
in	O
the	O
very-high-risk	O
group	O
.	O

The	O
corresponding	O
risk-group	O
pattern	O
for	O
the	O
inadequately	O
treated	O
hypertensives	O
(	O
n	O
=	O
737	O
)	O
was	O
5.5	O
,	O
48.3	O
,	O
11.1	O
and	O
35.2	O
%	O
,	O
respectively	O
.	O

If	O
we	O
shifted	O
the	O
target	O
blood	O
pressure	O
from	O
below	O
140/90	O
to	O
below	O
130/85	O
for	O
drug-treated	O
subjects	O
under	O
60	O
(	O
n	O
=	O
278	O
)	O
the	O
number	Others
of	Others
inadequately	Others
treated	Others
subjects	Others
increased	O
by	O
34	O
(	O
12.2	O
%	O
of	O
278	O
)	O
;	O
14	O
in	O
the	O
low-risk	O
group	O
,	O
15	O
in	O
the	O
medium-risk	O
group	O
,	O
and	O
only	O
five	O
in	O
the	O
high-	O
or	O
very-high-risk	O
groups	O
.	O

CONCLUSIONS	O
Only	O
one-fifth	O
of	O
the	O
drug-treated	O
hypertensives	O
were	O
well	O
controlled	O
.	O

Moreover	O
,	O
the	O
incidence	O
of	O
newly	Others
detected	Others
blood	Others
pressure	Others
elevation	Others
was	O
high	O
.	O

The	O
majority	O
of	O
younger	O
subjects	O
with	O
high	O
blood	O
pressure	O
had	O
low	O
risk	O
,	O
but	O
in	O
those	O
aged	O
45-54	O
this	O
had	O
already	O
risen	O
to	O
a	O
medium	O
risk	O
.	O

Changing	O
the	O
target	O
blood	O
pressure	O
to	O
below	O
130/85	O
,	O
for	O
subjects	O
aged	O
below	O
60	O
,	O
as	O
recommended	O
by	O
WHO/ISH	O
,	O
affects	O
predominantly	O
low-	O
and	O
medium-risk	O
groups	O
.	O

Treatment	O
with	O
metformin	O
of	O
non-diabetic	O
men	O
with	O
hypertension	O
,	O
hypertriglyceridaemia	O
and	O
central	O
fat	O
distribution	O
:	O
the	O
BIGPRO	O
1.2	O
trial	O
.	O

BACKGROUND	O
In	O
the	O
BIGPRO	O
1	O
trial	O
,	O
one	O
year	O
of	O
treatment	O
with	O
metformin	O
in	O
non-diabetic	O
obese	O
subjects	O
with	O
a	O
central	O
fat	O
distribution	O
had	O
no	O
significant	O
effect	O
on	O
fasting	O
plasma	O
triglyceride	O
concentration	O
or	O
on	O
blood	O
pressure	O
despite	O
a	O
decrease	O
in	O
weight	O
,	O
fasting	O
plasma	O
insulin	O
and	O
glucose	O
concentrations	O
.	O

To	O
re-evaluate	O
the	O
effect	O
of	O
metformin	O
on	O
fasting	O
triglyceride	O
concentration	O
and	O
on	O
blood	O
pressure	O
,	O
the	O
BIGPRO	O
1.2	O
trial	O
included	O
non-diabetic	O
men	O
(	O
n=168	O
)	O
with	O
a	O
fasting	O
plasma	O
triglyceride	O
concentration	O
>	O
or	O
=1.7	O
and	O
<	O
or	O
=6.5	O
mmol/l	O
,	O
high	O
blood	O
pressure	O
(	O
systolic	O
>	O
or	O
=140	O
and	O
<	O
or	O
=180	O
and/or	O
diastolic	O
>	O
or	O
=90	O
and	O
<	O
or	O
=105	O
mmHg	O
,	O
or	O
treatment	O
for	O
hypertension	O
)	O
and	O
a	O
waist-to-hip	O
ratio	O
>	O
or	O
=0.95	O
.	O

METHODS	O
A	O
randomised	O
double-blind	O
trial	O
comparing	O
metformin	O
treatment	O
(	O
850	O
mg	O
bid	O
)	O
with	O
placebo	O
.	O

RESULTS	O
Metformin	O
had	O
no	O
significant	O
effect	O
either	O
on	O
blood	Physical
pressure	Physical
or	Physical
plasma	Physical
triglyceride	Physical
concentration	Physical
.	O

In	O
comparison	O
with	O
the	O
placebo	O
group	O
,	O
fasting	Physical
plasma	Physical
insulin	Physical
(	O
p	O
<	O
0.04	O
)	O
,	O
total	Physical
cholesterol	Physical
(	O
p	O
<	O
0.05	O
)	O
and	O
Apo	Physical
B	Physical
(	O
p	O
<	O
0.008	O
)	O
concentrations	O
decreased	O
more	O
in	O
the	O
metformin	O
group	O
in	O
the	O
BIGPRO	O
1	O
.	O

2	O
trial	O
,	O
confirming	O
most	O
of	O
the	O
previous	O
results	O
of	O
the	O
BIGPRO	O
1	O
trial	O
.	O

Tissue	Physical
plasminogen	Physical
activator	Physical
antigen	Physical
concentration	Physical
decreased	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
only	O
in	O
the	O
metformin	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
placebo	O
group	O
(	O
p	O
<	O
0.12	O
)	O
;	O
further	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
change	O
in	O
plasminogen	O
activator	O
inhibitor	O
1	O
.	O

CONCLUSIONS	O
The	O
consistency	O
of	O
the	O
two	O
BIGPRO	O
trials	O
supports	O
the	O
conclusion	O
that	O
metformin	O
affects	O
several	O
cardiovascular	O
risk	O
factors	O
favourably	O
in	O
non-diabetic	O
subjects	O
with	O
a	O
central	O
fat	O
distribution	O
.	O

Pegfilgrastim	O
for	O
peripheral	O
CD34+	O
mobilization	O
in	O
patients	O
with	O
solid	O
tumours	O
.	O

The	O
efficacy	Others
of	O
pegfilgrastim+/-chemotherapy	O
for	O
mobilizing	O
stem	O
cells	O
in	O
patients	O
with	O
solid	O
tumours	O
was	O
assessed	O
.	O

In	O
cycle	O
0	O
,	O
a	O
14-day	O
prechemotherapy	O
cycle	O
,	O
patients	O
(	O
N=61	O
)	O
were	O
randomized	O
open-label	O
to	O
single	O
doses	O
of	O
pegfilgrastim	O
(	O
6	O
,	O
12	O
or	O
18	O
mg	O
)	O
on	O
day	O
1	O
,	O
or	O
daily	O
filgrastim	O
(	O
10	O
microg/kg	O
)	O
for	O
<	O
or	O
=7	O
days	O
.	O

Mean	O
peak	O
peripheral	Physical
CD34+	Physical
cell	Physical
counts	Physical
increased	O
with	O
pegfilgrastim	O
dose	O
,	O
but	O
were	O
significantly	O
higher	O
than	O
filgrastim	O
only	O
at	O
the	O
18	O
mg	O
dose	O
(	O
10.17	O
vs	O
4.96	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.014	O
)	O
.	O

In	O
the	O
clinically	O
relevant	O
period	O
of	O
days	O
3-7	O
,	O
both	O
12	O
and	O
18	O
mg	O
pegfilgrastim	O
doses	O
produced	O
significantly	Physical
higher	Physical
peak	Physical
CD34+	Physical
counts	Physical
(	O
8.18	O
and	O
9.96	O
vs	O
4.51	O
x	O
10	O
(	O
4	O
)	O
/ml	O
for	O
filgrastim	O
;	O
P=0.034	O
and	O
0.006	O
)	O
.	O

In	O
cycle	O
1	O
,	O
patients	O
received	O
carboplatin/paclitaxel	O
on	O
day	O
1	O
,	O
followed	O
from	O
day	O
2	O
by	O
pegfilgrastim	O
6-18	O
mg	O
or	O
daily	O
filgrastim	O
(	O
5	O
microg/kg/day	O
for	O
<	O
or	O
=14	O
days	O
)	O
as	O
per	O
randomization	O
in	O
cycle	O
0	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
mean	Physical
peak	Physical
CD34+	Physical
count	Physical
between	O
pegfilgrastim	O
and	O
filgrastim	O
,	O
but	O
there	O
was	O
an	O
advantage	O
for	O
pegfilgrastim	O
18	O
mg	O
in	O
the	O
relevant	O
period	O
of	O
days	O
7-12	O
(	O
3.14	O
vs	O
1.19	O
x	O
10	O
(	O
4	O
)	O
/ml	O
;	O
P=0.043	O
)	O
.	O

A	O
single	O
pegfilgrastim	O
dose	O
(	O
>	O
or	O
=6	O
mg	O
)	O
could	O
be	O
substituted	O
for	O
daily	O
filgrastim	O
in	O
cytokine-only	Physical
peripheral	Physical
CD34+	Physical
cell	Physical
mobilization	Physical
.	Physical

Aminocaproic	O
acid	O
versus	O
prednisone	O
for	O
the	O
treatment	O
of	O
traumatic	O
hyphema	O
.	O

A	O
randomized	O
clinical	O
trial	O
.	O

One	O
hundred	O
twelve	O
patients	O
who	O
sustained	O
hyphema	O
after	O
blunt	O
trauma	O
were	O
enrolled	O
in	O
a	O
double-blind	O
randomized	O
clinical	O
trial	O
to	O
determine	O
the	O
relative	O
efficacies	O
of	O
aminocaproic	O
acid	O
(	O
Amicar	O
)	O
and	O
systemic	O
prednisone	O
for	O
reducing	O
the	O
rate	Physical
of	Physical
secondary	Physical
hemorrhage	Physical
.	O

Fifty-six	O
patients	O
received	O
an	O
oral	O
dosage	O
of	O
50	O
mg/kg	O
of	O
aminocaproic	O
acid	O
every	O
4	O
hours	O
for	O
5	O
days	O
,	O
up	O
to	O
a	O
maximum	O
of	O
30	O
g	O
daily	O
,	O
and	O
56	O
patients	O
received	O
an	O
oral	O
dosage	O
of	O
40	O
mg	O
of	O
prednisone	O
daily	O
(	O
adjusted	O
for	O
weight	O
)	O
in	O
two	O
divided	O
doses	O
.	O

Placebo	O
pills	O
and	O
liquids	O
were	O
given	O
to	O
each	O
patient	O
to	O
mask	O
the	O
treatment	O
schedules	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
patient	O
populations	O
for	O
any	O
demographic	O
or	O
clinical	O
characteristic	O
(	O
e.g.	O
,	O
visual	Physical
acuity	Physical
,	O
intraocular	Physical
pressure	Physical
[	Physical
IOP	Physical
]	Physical
,	O
initial	Physical
hyphema	Physical
size	Physical
)	O
measured	O
in	O
the	O
study	O
.	O

Blacks	O
comprised	O
53	O
%	O
of	O
the	O
study	O
population	O
,	O
and	O
the	O
mean	O
age	O
of	O
the	O
patients	O
was	O
23.5	O
years	O
.	O

Four	O
patients	O
in	O
each	O
of	O
the	O
treatment	O
groups	O
experienced	O
a	O
secondary	Physical
hemorrhage	Physical
;	O
the	O
rebleed	Physical
rate	Physical
was	O
7.1	O
%	O
in	O
each	O
group	O
.	O

Teacher	O
and	O
child	O
predictors	O
of	O
achieving	O
IEP	O
goals	O
of	O
children	O
with	O
autism	O
.	O

It	O
is	O
encouraging	O
that	O
children	O
with	O
autism	O
show	O
a	O
strong	O
response	O
to	O
early	O
intervention	O
,	O
yet	O
more	O
research	O
is	O
needed	O
for	O
understanding	O
the	O
variability	O
in	O
responsiveness	O
to	O
specialized	O
programs	O
.	O

Treatment	O
predictor	O
variables	O
from	O
47	O
teachers	O
and	O
children	O
who	O
were	O
randomized	O
to	O
receive	O
the	O
COMPASS	O
intervention	O
(	O
Ruble	O
et	O
al	O
.	O

in	O
The	O
collaborative	O
model	O
for	O
promoting	O
competence	O
and	O
success	O
for	O
students	O
with	O
ASD	O
.	O

Springer	O
,	O
New	O
York	O
,	O
2012a	O
)	O
were	O
analyzed	O
.	O

Predictors	O
evaluated	O
against	O
child	Others
IEP	Others
goal	Others
attainment	Others
included	O
child	O
,	O
teacher	O
,	O
intervention	O
practice	O
,	O
and	O
implementation	O
practice	O
variables	O
based	O
on	O
an	O
implementation	O
science	O
framework	O
(	O
Dunst	O
and	O
Trivette	O
in	O
J	O
Soc	O
Sci	O
8:143-148	O
,	O
2012	O
)	O
.	O

Findings	O
revealed	O
one	O
child	O
(	O
engagement	O
)	O
,	O
one	O
teacher	O
(	O
exhaustion	O
)	O
,	O
two	O
intervention	O
quality	O
(	O
IEP	O
quality	O
for	O
targeted	O
and	O
not	O
targeted	O
elements	O
)	O
,	O
and	O
no	O
implementation	O
quality	O
variables	O
accounted	O
for	O
variance	O
in	O
child	O
outcomes	O
when	O
analyzed	O
separately	O
.	O

When	O
the	O
four	O
significant	O
variables	O
were	O
compared	O
against	O
each	O
other	O
in	O
a	O
single	O
regression	O
analysis	O
,	O
IEP	O
quality	O
accounted	O
for	O
one	O
quarter	O
of	O
the	O
variance	O
in	O
child	O
outcomes	O
.	O

Double-blind	O
comparison	O
of	O
doxepin	O
versus	O
bupropion	O
in	O
outpatients	O
with	O
a	O
major	O
depressive	O
disorder	O
.	O

A	O
double-blind	O
controlled	O
study	O
comparing	O
the	O
effects	O
of	O
bupropion	O
to	O
doxepin	O
in	O
outpatients	O
with	O
primary	O
depression	O
was	O
conducted	O
to	O
evaluate	O
efficacy	Others
and	O
safety	Others
differences	O
between	O
the	O
two	O
drugs	O
.	O

Following	O
a	O
7-day	O
placebo	O
washout	O
period	O
,	O
patients	O
could	O
be	O
treated	O
for	O
up	O
to	O
13	O
weeks	O
on	O
either	O
treatment	O
.	O

Antidepressant	Mental
response	Mental
was	O
assessed	O
by	O
the	O
Hamilton	Mental
Depression	Mental
and	Mental
Anxiety	Mental
Scales	Mental
,	O
Clinical	Mental
Global	Mental
Severity	Mental
and	O
Improvement	Mental
Ratings	Mental
,	O
and	O
the	O
Zung	Mental
Self-Rating	Mental
Depression	Mental
Scale	Mental
.	O

Comparable	O
efficacy	Others
between	O
the	O
compounds	O
was	O
found	O
across	O
the	O
13-week	O
study	O
.	O

Doxepin	O
differed	O
from	O
bupropion	O
mainly	O
on	O
the	O
sleep	Mental
factor	Mental
of	Mental
the	Mental
Hamilton	Mental
Depression	Mental
Scale	Mental
,	O
with	O
doxepin	O
improving	O
sleep	O
to	O
a	O
greater	O
extent	O
than	O
bupropion	O
.	O

Doxepin	O
produced	O
a	O
greater	O
incidence	O
of	O
anticholinergic	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
,	O
including	O
dry	Adverseeffect
mouth	Adverseeffect
,	O
constipation	Adverseeffect
,	O
sleepiness	Adverseeffect
,	O
and	O
tiredness	Adverseeffect
,	O
in	O
comparison	O
to	O
bupropion	O
.	O

Also	O
,	O
increased	O
appetite	Adverseeffect
and	Adverseeffect
weight	Adverseeffect
gain	Adverseeffect
were	O
consistent	O
side	O
effects	O
of	O
doxepin	O
relative	O
to	O
bupropion	O
.	O

Effect	O
of	O
testosterone	O
and	O
a	O
nutritional	O
supplement	O
,	O
alone	O
and	O
in	O
combination	O
,	O
on	O
hospital	Others
admissions	Others
in	O
undernourished	O
older	O
men	O
and	O
women	O
.	O

BACKGROUND	O
In	O
older	O
people	O
,	O
undernutrition	O
is	O
associated	O
with	O
increased	O
hospitalization	Physical
rates	Physical
and	O
mortality	Adverseeffect
.	O

Because	O
weight	O
loss	O
in	O
older	O
people	O
often	O
reflects	O
a	O
disproportionate	O
reduction	O
of	O
skeletal	O
muscle	O
,	O
anabolic	O
treatments	O
may	O
be	O
beneficial	O
.	O

OBJECTIVE	O
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
hypothesis	O
that	O
testosterone	O
treatment	O
and	O
a	O
nutritional	O
supplement	O
have	O
additive	O
benefits	O
.	O

DESIGN	O
Oral	O
testosterone	O
undecanoate	O
(	O
40	O
mg	O
daily	O
for	O
women	O
,	O
80	O
mg	O
twice	O
daily	O
for	O
men	O
)	O
and	O
an	O
oral	O
nutritional	O
supplement	O
(	O
475	O
kcal/d	O
)	O
were	O
administered	O
,	O
alone	O
or	O
combined	O
,	O
for	O
1	O
y	O
to	O
49	O
community-dwelling	O
,	O
undernourished	O
people	O
[	O
Mini	O
Nutritional	O
Assessment	O
score	O
<	O
24	O
and	O
low	O
body	O
weight	O
(	O
body	O
mass	O
index	O
,	O
in	O
kg/m	O
(	O
2	O
)	O
:	O
<	O
22	O
)	O
or	O
recent	O
weight	O
loss	O
(	O
>	O
7.5	O
%	O
over	O
3	O
mo	O
)	O
]	O
aged	O
>	O
65	O
y	O
(	O
mean	O
age	O
:	O
77	O
y	O
;	O
26	O
women	O
and	O
23	O
men	O
)	O
.	O

Hospital	Others
admissions	Others
and	O
other	Others
variables	Others
were	O
assessed	O
.	O

RESULTS	O
In	O
subjects	O
receiving	O
combined	O
testosterone	O
and	O
nutritional	O
supplements	O
(	O
n	O
=	O
11	O
)	O
,	O
there	O
were	O
no	O
hospital	Others
admissions	Others
,	O
whereas	O
there	O
were	O
9	O
admissions	O
(	O
2	O
elective	O
)	O
in	O
13	O
subjects	O
in	O
the	O
no-treatment	O
group	O
,	O
4	O
in	O
the	O
testosterone-treated	O
group	O
(	O
n	O
=	O
12	O
)	O
,	O
and	O
5	O
in	O
the	O
supplement-treated	O
group	O
(	O
n	O
=	O
13	O
)	O
;	O
P	O
=	O
0.06	O
with	O
no-treatment	O
compared	O
with	O
combined	O
treatment	O
.	O

When	O
compared	O
with	O
the	O
no-treatment	O
group	O
,	O
the	O
combined-treatment	O
group	O
had	O
significantly	O
fewer	O
subjects	Others
admitted	Others
to	Others
hospital	Others
(	O
0	O
compared	O
with	O
5	O
,	O
P	O
=	O
0.03	O
)	O
,	O
fewer	O
days	Others
in	Others
hospital	Others
(	O
0	O
compared	O
with	O
74	O
,	O
P	O
=	O
0.041	O
)	O
,	O
and	O
a	O
longer	O
time	O
to	O
hospital	O
admission	O
(	O
P	O
=	O
0.017	O
)	O
.	O

CONCLUSIONS	O
In	O
undernourished	O
older	O
people	O
,	O
combined	O
treatment	O
with	O
testosterone	O
and	O
nutritional	O
supplementation	O
reduced	O
the	O
number	O
of	O
people	O
hospitalized	O
and	O
the	O
duration	O
of	O
hospital	O
admissions	O
,	O
which	O
are	O
important	O
endpoints	O
in	O
this	O
group	O
.	O

Larger	O
,	O
confirmatory	O
studies	O
are	O
now	O
needed	O
.	O

This	O
trial	O
was	O
registered	O
before	O
commencement	O
at	O
clinical	O
trials.gov	O
as	O
NCT00117000	O
.	O

Immunogenicity	Others
and	O
safety	Others
of	O
a	O
plasma-derived	O
heat-inactivated	O
hepatitis	O
B	O
vaccine	O
(	O
CLB	O
)	O
.	O

Studies	O
in	O
volunteers	O
at	O
a	O
low	O
risk	O
of	O
infection	O
with	O
hepatitis	O
B	O
virus	O
.	O

The	O
safety	Others
and	O
immunogenicity	Others
of	O
a	O
plasma-derived	O
heat-inactivated	O
hepatitis	O
B	O
vaccine	O
(	O
CLB	O
)	O
were	O
evaluated	O
in	O
471	O
healthy	O
human	O
volunteers	O
,	O
who	O
,	O
both	O
in	O
their	O
occupations	O
and	O
in	O
their	O
private	O
lives	O
,	O
had	O
been	O
at	O
minimal	O
risk	O
of	O
being	O
infected	O
with	O
hepatitis	O
B	O
virus	O
.	O

The	O
first	O
202	O
individuals	O
received	O
three	O
3-micrograms	O
doses	O
of	O
heat-inactivated	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
at	O
one-month	O
intervals	O
(	O
trial	O
A	O
)	O
.	O

A	O
total	O
of	O
42	O
%	O
one	O
month	O
after	O
the	O
first	O
injection	O
,	O
84	O
%	O
after	O
two	O
months	O
,	O
and	O
93	O
%	O
after	O
five	O
months	O
had	O
become	O
anti-HBs	O
(	O
antibody	O
to	O
hepatitis	O
B	O
surface	O
antigen	O
)	O
positive	O
.	O

In	O
a	O
second	O
randomized	O
study	O
(	O
trial	O
B	O
)	O
,	O
the	O
immunogenicity	Others
of	O
five	O
different	O
dosages	O
of	O
the	O
vaccine	O
was	O
compared	O
in	O
269	O
volunteers	O
.	O

When	O
the	O
dose	O
of	O
HBsAg	O
was	O
diminished	O
from	O
3	O
micrograms	O
to	O
1.5	O
,	O
0.6	O
,	O
and	O
0.25	O
microgram	O
,	O
no	O
decrease	O
of	O
the	O
anti-HBs	Physical
response	Physical
was	O
observed	O
.	O

However	O
,	O
when	O
the	O
dose	O
was	O
diminished	O
to	O
0.1	O
microgram	O
of	O
HBsAg	O
,	O
the	O
anti-HBs	Physical
response	Physical
dropped	O
significantly	O
to	O
63	O
%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

In	O
the	O
recipients	O
of	O
all	O
five	O
vaccine	O
dosages	O
,	O
no	O
influence	O
of	O
sex	O
and	O
age	O
was	O
found	O
on	O
the	O
anti-HBs	Physical
conversion	Physical
rates	Physical
.	Physical

During	O
the	O
eight-month	O
observation	O
period	O
,	O
none	O
of	O
the	O
vaccinees	O
became	O
HBsAg	Physical
and/or	Physical
anti-HBc	Physical
(	Physical
antibody	Physical
to	Physical
hepatitis	Physical
B	Physical
core	Physical
antigen	Physical
)	Physical
positive	Physical
,	O
and	O
none	O
developed	O
antibodies	O
associated	O
with	O
autoimmune	O
liver	O
disease	O
.	O

No	O
serious	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
were	O
observed	O
.	O

Reduced	O
platelet	Physical
thromboxane	Physical
formation	Physical
after	O
long-term	O
administration	O
of	O
a	O
dihydropyridine	O
calcium	O
channel	O
blocker	O
:	O
a	O
prospective	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
with	O
nitrendipine	O
in	O
borderline	O
hypertensive	O
patients	O
with	O
IDDM-type	O
diabetes	O
mellitus	O
.	O

Twenty-nine	O
IDDM	O
patients	O
with	O
borderline	O
hypertension	O
were	O
randomly	O
allocated	O
to	O
placebo	O
or	O
nitrendipine	O
treatment	O
.	O

Nitrendipine	O
was	O
given	O
orally	O
at	O
a	O
dosage	O
of	O
20	O
mg	O
once	O
daily	O
over	O
4	O
weeks	O
.	O

Stimulated	Physical
platelet	Physical
thromboxane	Physical
formation	Physical
at	O
rest	O
and	O
after	O
standardized	O
,	O
non	O
exhausting	O
exercise	O
was	O
measured	O
by	O
standard	O
methods	O
.	O

In	O
addition	O
,	O
plasma	Physical
levels	Physical
of	Physical
platelet	Physical
factor	Physical
4	Physical
and	Physical
aggregation	Physical
responses	Physical
to	Physical
collagen	Physical
and	Physical
ADP	Physical
were	O
determined	O
.	O

In	O
the	O
treatment	O
group	O
thromboxane	Physical
formation	Physical
after	O
stimulation	O
with	O
collagen	O
(	O
0.3	O
and	O
1.0	O
micrograms/ml	O
)	O
and	O
1	O
mM	O
arachidonic	O
acid	O
(	O
AA	O
)	O
was	O
reduced	O
in	O
the	O
resting	O
state	O
.	O

Exercise	Physical
induced	Physical
change	Physical
of	Physical
thromboxane	Physical
synthesis	Physical
in	O
response	O
to	O
1.0	O
micrograms/ml	O
collagen	O
was	O
significantly	O
lower	O
as	O
compared	O
to	O
placebo	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
parallel	O
,	O
PF4	Physical
plasma	Physical
levels	Physical
were	O
significantly	O
lowered	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Whole	Physical
blood	Physical
aggregation	Physical
after	Physical
collagen	Physical
stimulation	Physical
(	O
1.0	O
micrograms/ml	O
)	O
was	O
reduced	O
after	O
4	O
weeks	O
of	O
nitrendipine	O
treatment	O
,	O
but	O
ADP	Physical
(	Physical
5	Physical
microM	Physical
)	Physical
induced	Physical
aggregation	Physical
was	O
not	O
.	O

These	O
effects	O
of	O
nitrendipine	O
were	O
not	O
seen	O
in	O
platelet	O
rich	O
plasma	O
.	O

In	O
conclusion	O
long-term	O
nitrendipine	O
treatment	O
may	O
inhibit	O
collagen	Physical
dependent	Physical
platelet	Physical
activation	Physical
in	O
the	O
blood	O
of	O
diabetic	O
patients	O
with	O
borderline	O
hypertension	O
.	O

Pedantic	O
speaking	O
style	O
differentiates	O
Asperger	O
syndrome	O
from	O
high-functioning	O
autism	O
.	O

Asperger	O
syndrome	O
(	O
AS	O
)	O
is	O
a	O
pervasive	O
developmental	O
disorder	O
recently	O
introduced	O
as	O
a	O
new	O
diagnostic	O
category	O
in	O
the	O
ICD-10	O
and	O
the	O
DSM-IV	O
.	O

Along	O
with	O
motor	O
clumsiness	O
,	O
pedantic	O
speech	O
has	O
been	O
proposed	O
as	O
a	O
clinical	O
feature	O
of	O
AS	O
.	O

However	O
,	O
few	O
attempts	O
have	O
been	O
made	O
to	O
define	O
and	O
measure	O
this	O
symptom	O
.	O

We	O
studied	O
17	O
patients	O
with	O
AS	O
(	O
ICD-10	O
;	O
14	O
male	O
,	O
3	O
female	O
;	O
mean	O
age	O
16.4	O
years	O
,	O
mean	O
full-scale	O
IQ	O
97	O
)	O
and	O
compared	O
them	O
with	O
a	O
control	O
group	O
of	O
13	O
patients	O
with	O
normal-intelligence	O
autism	O
or	O
high-functioning	O
autism	O
(	O
HFA	O
)	O
(	O
ICD-10/DSM-III-R	O
;	O
12	O
male	O
,	O
1	O
female	O
;	O
mean	O
age	O
15.5	O
years	O
,	O
mean	O
full-scale	O
IQ	O
81.2	O
)	O
.	O

An	O
operational	O
definition	O
of	O
pedantic	O
speech	O
was	O
formulated	O
and	O
a	O
rating	O
scale	O
devised	O
.	O

13	O
(	O
76	O
%	O
)	O
of	O
the	O
AS	O
patients	O
were	O
rated	O
as	O
pedantic	Others
compared	O
to	O
4	O
(	O
31	O
%	O
)	O
of	O
the	O
HFA	O
group	O
(	O
chi	O
2	O
=	O
6.3	O
;	O
p	O
=	O
.01	O
)	O
.	O

Results	O
suggest	O
that	O
pedantic	O
speech	O
is	O
common	O
in	O
AS	O
and	O
may	O
help	O
differentiate	O
AS	O
from	O
high-functioning	O
autism	O
.	O

Effect	O
of	O
patient	O
withdrawal	O
on	O
a	O
study	O
evaluating	O
pharmacist	O
management	O
of	O
hypertension	O
.	O

STUDY	O
OBJECTIVES	O
To	O
examine	O
potential	O
threats	O
to	O
internal	O
and	O
external	O
study	O
validity	O
caused	O
by	O
differential	O
patient	O
withdrawal	O
from	O
a	O
randomized	O
controlled	O
trial	O
evaluating	O
pharmacist	O
management	O
of	O
hypertension	O
,	O
to	O
compare	O
the	O
characteristics	O
of	O
patients	O
who	O
withdrew	O
with	O
those	O
of	O
patients	O
who	O
completed	O
the	O
study	O
,	O
and	O
to	O
identify	O
characteristics	O
that	O
predispose	O
patients	O
to	O
withdraw	O
from	O
hypertension	O
management	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
comparative	O
study	O
.	O

SETTING	O
Network	O
of	O
primary	O
care	O
clinics	O
.	O

PATIENTS	O
Four	O
hundred	O
sixty-three	O
patients	O
with	O
a	O
diagnosis	O
of	O
hypertension	O
and	O
a	O
last	O
documented	O
systolic	O
blood	O
pressure	O
of	O
160	O
mm	O
Hg	O
or	O
greater	O
and/or	O
diastolic	O
blood	O
pressure	O
of	O
100	O
mm	O
Hg	O
or	O
greater	O
.	O

INTERVENTION	O
Patients	O
were	O
randomly	O
allocated	O
to	O
the	O
pharmacist	O
intervention	O
or	O
usual-care	O
(	O
control	O
)	O
group	O
.	O

Those	O
in	O
the	O
pharmacist	O
intervention	O
group	O
were	O
collaboratively	O
managed	O
by	O
a	O
primary	O
care	O
clinical	O
pharmacy	O
specialist	O
and	O
their	O
primary	O
care	O
provider	O
.	O

Patients	O
in	O
the	O
control	O
group	O
received	O
usual	O
care	O
from	O
only	O
their	O
primary	O
care	O
provider	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Of	O
the	O
463	O
patients	O
,	O
191	O
(	O
41	O
%	O
)	O
withdrew	O
from	O
the	O
study	O
after	O
randomization	O
and	O
272	O
(	O
59	O
%	O
)	O
completed	O
the	O
study	O
.	O

Patients	O
who	O
withdrew	O
from	O
the	O
pharmacist	O
intervention	O
group	O
were	O
similar	O
to	O
patients	O
who	O
withdrew	O
from	O
the	O
usual-care	O
group	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
insurance	O
status	O
,	O
and	O
chronic	O
conditions	O
.	O

Patients	O
who	O
smoked	O
or	O
had	O
commercial	O
insurance	O
were	O
more	O
likely	O
to	O
withdraw	Others
from	O
the	O
study	O
than	O
the	O
other	O
participants	O
.	O

However	O
,	O
multivariate	O
analysis	O
of	O
all	O
variables	O
,	O
when	O
adjusted	O
for	O
the	O
effect	O
of	O
the	O
intervention	O
,	O
revealed	O
that	O
insurance	Others
status	Others
was	O
the	O
only	O
variable	O
associated	O
with	O
a	O
heightened	O
probability	O
of	O
withdrawal	Others
(	O
p=0.002	O
)	O
.	O

CONCLUSION	O
Although	O
this	O
study	O
had	O
a	O
high	O
withdrawal	O
rate	O
,	O
between-group	O
patient	O
characteristics	O
remained	O
balanced	O
.	O

Therefore	O
,	O
internal	O
validity	O
was	O
preserved	O
,	O
and	O
outcomes	O
from	O
the	O
study	O
groups	O
could	O
be	O
reliably	O
compared	O
.	O

A	O
lack	O
of	O
significant	O
differences	O
between	O
patients	O
who	O
withdrew	O
versus	O
those	O
who	O
completed	O
,	O
with	O
the	O
exception	O
of	O
insurance	O
status	O
,	O
suggests	O
that	O
external	O
validity	O
was	O
not	O
jeopardized	O
.	O

Effect	O
of	O
a	O
vitamin/mineral	O
supplement	O
on	O
children	O
and	O
adults	O
with	O
autism	O
.	O

BACKGROUND	O
Vitamin/mineral	O
supplements	O
are	O
among	O
the	O
most	O
commonly	O
used	O
treatments	O
for	O
autism	O
,	O
but	O
the	O
research	O
on	O
their	O
use	O
for	O
treating	O
autism	O
has	O
been	O
limited	O
.	O

METHOD	O
This	O
study	O
is	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
three	O
month	O
vitamin/mineral	O
treatment	O
study	O
.	O

The	O
study	O
involved	O
141	O
children	O
and	O
adults	O
with	O
autism	O
,	O
and	O
pre	O
and	O
post	O
symptoms	O
of	O
autism	O
were	O
assessed	O
.	O

None	O
of	O
the	O
participants	O
had	O
taken	O
a	O
vitamin/mineral	O
supplement	O
in	O
the	O
two	O
months	O
prior	O
to	O
the	O
start	O
of	O
the	O
study	O
.	O

For	O
a	O
subset	O
of	O
the	O
participants	O
(	O
53	O
children	O
ages	O
5-16	O
)	O
pre	O
and	O
post	O
measurements	O
of	O
nutritional	O
and	O
metabolic	O
status	O
were	O
also	O
conducted	O
.	O

RESULTS	O
The	O
vitamin/mineral	O
supplement	O
was	O
generally	O
well-tolerated	Others
,	O
and	O
individually	O
titrated	O
to	O
optimum	O
benefit	O
.	O

Levels	Physical
of	Physical
many	Physical
vitamins	Physical
,	O
minerals	Physical
,	O
and	O
biomarkers	Physical
improved/increased	O
showing	O
good	O
compliance	Mental
and	Physical
absorption	Physical
.	O

Statistically	O
significant	O
improvements	O
in	O
metabolic	O
status	O
were	O
many	O
including	O
:	O
total	Physical
sulfate	Physical
(	O
+17	O
%	O
,	O
p	O
=	O
0.001	O
)	O
,	O
S-adenosylmethionine	Physical
(	O
SAM	O
;	O
+6	O
%	O
,	O
p	O
=	O
0.003	O
)	O
,	O
reduced	O
glutathione	Physical
(	O
+17	O
%	O
,	O
p	O
=	O
0.0008	O
)	O
,	O
ratio	Physical
of	Physical
oxidized	Physical
glutathione	Physical
to	Physical
reduced	Physical
glutathione	Physical
(	O
GSSG	O
:	O
GSH	O
;	O
-27	O
%	O
,	O
p	O
=	O
0.002	O
)	O
,	O
nitrotyrosine	Physical
(	O
-29	O
%	O
,	O
p	O
=	O
0.004	O
)	O
,	O
ATP	Physical
(	O
+25	O
%	O
,	O
p	O
=	O
0.000001	O
)	O
,	O
NADH	Physical
(	O
+28	O
%	O
,	O
p	O
=	O
0.0002	O
)	O
,	O
and	O
NADPH	Physical
(	O
+30	O
%	O
,	O
p	O
=	O
0.001	O
)	O
.	O

Most	O
of	O
these	O
metabolic	O
biomarkers	O
improved	O
to	O
normal	O
or	O
near-normal	O
levels.The	O
supplement	O
group	O
had	O
significantly	O
greater	O
improvements	O
than	O
the	O
placebo	O
group	O
on	O
the	O
Parental	Physical
Global	Physical
Impressions-Revised	Physical
(	O
PGI-R	O
,	O
Average	O
Change	O
,	O
p	O
=	O
0.008	O
)	O
,	O
and	O
on	O
the	O
subscores	O
for	O
Hyperactivity	Physical
(	O
p	O
=	O
0.003	O
)	O
,	O
Tantrumming	Physical
(	O
p	O
=	O
0.009	O
)	O
,	O
Overall	Physical
(	O
p	O
=	O
0.02	O
)	O
,	O
and	O
Receptive	Physical
Language	Physical
(	O
p	O
=	O
0.03	O
)	O
.	O

For	O
the	O
other	O
three	O
assessment	O
tools	O
the	O
difference	O
between	O
treatment	O
group	O
and	O
placebo	O
group	O
was	O
not	O
statistically	O
significant.Regression	O
analysis	O
revealed	O
that	O
the	O
degree	O
of	O
improvement	O
on	O
the	O
Average	Physical
Change	Physical
of	Physical
the	Physical
PGI-R	Physical
was	O
strongly	O
associated	O
with	O
several	O
biomarkers	O
(	O
adj	O
.	O

R2	O
=	O
0.61	O
,	O
p	O
<	O
0.0005	O
)	O
with	O
the	O
initial	O
levels	O
of	O
biotin	O
and	O
vitamin	O
K	O
being	O
the	O
most	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
;	O
both	O
biotin	O
and	O
vitamin	O
K	O
are	O
made	O
by	O
beneficial	O
intestinal	O
flora	O
.	O

CONCLUSIONS	O
Oral	O
vitamin/mineral	O
supplementation	O
is	O
beneficial	O
in	O
improving	O
the	O
nutritional	O
and	O
metabolic	O
status	O
of	O
children	O
with	O
autism	O
,	O
including	O
improvements	O
in	O
methylation	O
,	O
glutathione	O
,	O
oxidative	O
stress	O
,	O
sulfation	O
,	O
ATP	O
,	O
NADH	O
,	O
and	O
NADPH	O
.	O

The	O
supplement	O
group	O
had	O
significantly	O
greater	O
improvements	O
than	O
did	O
the	O
placebo	O
group	O
on	O
the	O
PGI-R	O
Average	O
Change	O
.	O

This	O
suggests	O
that	O
a	O
vitamin/mineral	O
supplement	O
is	O
a	O
reasonable	O
adjunct	O
therapy	O
to	O
consider	O
for	O
most	O
children	O
and	O
adults	O
with	O
autism	O
.	O

TRIAL	O
REGISTRATION	O
CLINICAL	O
TRIAL	O
REGISTRATION	O
NUMBER	O
NCT01225198	O
.	O

Clofarabine	O
?	O
fludarabine	O
with	O
once	O
daily	O
i.v	O
.	O

busulfan	O
as	O
pretransplant	O
conditioning	O
therapy	O
for	O
advanced	O
myeloid	O
leukemia	O
and	O
MDS	O
.	O

Although	O
a	O
combination	O
of	O
i.v	O
.	O

busulfan	O
(	O
Bu	O
)	O
and	O
fludarabine	O
(	O
Flu	O
)	O
is	O
a	O
safe	O
,	O
reduced-toxicity	O
conditioning	O
program	O
for	O
acute	O
myelogenous	O
leukemia/myelodysplastic	O
syndromes	O
(	O
AML/MDS	O
)	O
,	O
recurrent	O
leukemia	O
posttransplantation	O
remains	O
a	O
problem	O
.	O

To	O
enhance	O
the	O
conditioning	O
regimen	O
's	O
antileukemic	O
effect	O
,	O
we	O
decided	O
to	O
supplant	O
Flu	O
with	O
clofarabine	O
(	O
Clo	O
)	O
,	O
and	O
assayed	O
the	O
interactions	O
of	O
these	O
nucleoside	O
analogs	O
alone	O
and	O
in	O
combination	O
with	O
Bu	O
in	O
Bu-resistant	O
human	O
cell	O
lines	O
in	O
vitro	O
.	O

We	O
found	O
pronounced	O
synergy	O
between	O
each	O
nucleoside	O
and	O
the	O
alkylator	O
but	O
even	O
more	O
enhanced	O
cytotoxic	O
synergy	O
when	O
the	O
nucleoside	O
analogs	O
were	O
combined	O
prior	O
to	O
exposing	O
the	O
cells	O
to	O
Bu	O
.	O

We	O
then	O
designed	O
a	O
4-arm	O
clinical	O
trial	O
in	O
patients	O
with	O
myeloid	O
leukemia	O
undergoing	O
allogeneic	O
stem	O
cell	O
transplantation	O
(	O
allo-SCT	O
)	O
.	O

Patients	O
were	O
adaptively	O
randomized	O
as	O
follows	O
:	O
Arm	O
I-Clo	O
:	O
Flu	O
10:30	O
mg/m	O
(	O
2	O
)	O
,	O
Arm	O
II-20:20	O
mg/m	O
(	O
2	O
)	O
,	O
Arm	O
III-30:10	O
mg/m	O
(	O
2	O
)	O
,	O
and	O
Arm	O
IV-single-agent	O
Clo	O
at	O
40	O
mg/m	O
(	O
2	O
)	O
.	O

The	O
nucleoside	O
analog	O
(	O
s	O
)	O
were/was	O
infused	O
over	O
1	O
hour	O
once	O
daily	O
for	O
4	O
days	O
,	O
followed	O
on	O
each	O
day	O
by	O
Bu	O
,	O
infused	O
over	O
3	O
hours	O
to	O
a	O
pharmacokinetically	O
targeted	O
daily	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
6000	O
?Mol-min	O
?	O
10	O
%	O
.	O

Fifty-one	O
patients	O
have	O
been	O
enrolled	O
with	O
a	O
minimum	O
follow-up	O
exceeding	O
100	O
days	O
.	O

There	O
were	O
32	O
males	O
and	O
19	O
females	O
,	O
with	O
a	O
median	O
age	O
of	O
45	O
years	O
(	O
range	O
:	O
6-59	O
)	O
.	O

Nine	O
patients	O
had	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
(	O
BC	O
:	O
2	O
,	O
second	O
AP	O
:	O
3	O
,	O
and	O
tyrosine-kinase	O
inhibitor	O
refractory	O
first	O
chronic	O
phase	O
[	O
CP	O
]	O
:	O
4	O
)	O
.	O

Forty-two	O
patients	O
had	O
AML	O
:	O
14	O
were	O
induction	O
failures	O
,	O
8	O
in	O
first	O
chemotherapy-refractory	O
relapse	O
,	O
7	O
in	O
untreated	O
relapse	O
,	O
3	O
in	O
second	O
or	O
subsequent	O
relapse	O
,	O
4	O
were	O
in	O
second	O
complete	O
remission	O
(	O
CR	O
)	O
,	O
and	O
3	O
in	O
second	O
CR	O
without	O
platelet	O
recovery	O
(	O
CRp	O
)	O
,	O
2	O
were	O
in	O
high-risk	O
CR1	O
.	O

Finally	O
,	O
1	O
patient	O
was	O
in	O
first	O
CRp	O
.	O

Graft-versus-host	O
disease	O
(	O
GVHD	O
)	O
prophylaxis	O
was	O
tacrolimus	O
and	O
mini-methorexate	O
(	O
MTX	O
)	O
,	O
and	O
those	O
who	O
had	O
an	O
unrelated	O
or	O
1	O
antigen-mismatched	O
donor	O
received	O
low-dose	O
rabbit-ATG	O
(	O
Thymoglobulin?	O
)	O
.	O

All	O
patients	O
engrafted	O
.	O

Forty-one	O
patients	O
had	O
active	O
leukemia	O
at	O
the	O
time	O
of	O
transplant	O
,	O
and	O
35	O
achieved	O
CR	O
(	O
85	O
%	O
)	O
.	O

Twenty	O
of	O
the	O
42	O
AML	O
patients	O
and	O
5	O
of	O
9	O
CML	O
patients	O
are	O
alive	O
with	O
a	O
projected	O
median	Mortality
overall	Mortality
survival	Mortality
(	Mortality
OS	Mortality
)	Mortality
of	O
23	O
months	O
.	O

Marrow	O
and	O
blood	O
(	O
T	O
cell	O
)	O
chimerism	O
studies	O
at	O
day	O
+100	O
revealed	O
that	O
both	O
in	O
the	O
lower-dose	O
Clo	O
groups	O
(	O
groups	O
1+2	O
)	O
and	O
the	O
higher-dose	O
Clo	O
groups	O
(	O
groups	O
3+4	O
)	O
,	O
the	O
patients	O
had	O
a	O
median	O
of	O
100	O
%	O
donor	O
(	O
T	O
cell	O
)	O
-derived	O
DNA	O
.	O

There	O
has	O
been	O
no	O
secondary	Adverseeffect
graft	Adverseeffect
failure	Adverseeffect
.	O

In	O
the	O
first	O
100	O
days	O
,	O
1	O
patient	O
died	O
of	O
pneumonia	O
,	O
and	O
1	O
of	O
liver	O
GVHD	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
Clo	O
?	O
Flu	O
with	O
i.v	O
.	O

Bu	O
as	O
pretransplant	O
conditioning	O
is	O
safe	O
in	O
high-risk	O
myeloid	O
leukemia	O
patients	O
;	O
(	O
2	O
)	O
clofarabine	O
is	O
sufficiently	O
immunosuppressive	O
to	O
support	O
allo-SCT	O
in	O
myeloid	O
leukemia	O
;	O
and	O
(	O
3	O
)	O
the	O
median	O
OS	O
of	O
23	O
months	O
in	O
this	O
high-risk	O
patient	O
population	O
is	O
encouraging	O
.	O

Additional	O
studies	O
to	O
evaluate	O
the	O
antileukemic	O
efficacy	O
of	O
Clo	O
?	O
Flu	O
with	O
i.v	O
.	O

Bu	O
as	O
pretransplant	O
conditioning	O
therapy	O
are	O
warranted	O
.	O

Is	O
chronic	O
sildenafil	O
therapy	O
safe	O
and	O
clinically	O
beneficial	O
in	O
patients	O
with	O
systolic	O
heart	O
failure	O
?	O
Sildenafil	O
is	O
a	O
selective	O
phosphodiesterase-5	O
inhibitor	O
and	O
causes	O
vasodilatation	O
,	O
particularly	O
in	O
pulmonary	O
circulation	O
.	O

Since	O
left	O
heart	O
failure	O
may	O
be	O
associated	O
with	O
pulmonary	O
hypertension	O
out	O
of	O
proportion	O
to	O
left	O
heart	O
disease	O
,	O
sildenafil	O
may	O
have	O
beneficial	O
effect	O
in	O
such	O
patients	O
.	O

The	O
present	O
investigation	O
was	O
designed	O
as	O
a	O
12-week	O
,	O
single-center	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
evaluating	O
the	O
effects	O
of	O
sildenafil	O
on	O
mean	Physical
blood	Physical
pressure	Physical
(	O
primary	O
endpoint	O
)	O
in	O
patients	O
with	O
left	O
systolic	O
heart	O
failure	O
.	O

Secondary	O
endpoints	O
included	O
exercise	Physical
capacity	Physical
assessed	O
by	O
6-minute	Physical
walk	Physical
test	Physical
.	O

A	O
total	O
of	O
106	O
patients	O
were	O
randomized	O
1:1	O
to	O
sildenafil	O
(	O
n=53	O
)	O
or	O
placebo	O
(	O
n=53	O
)	O
.	O

Patients	O
received	O
sildenafil	O
25	O
mg	O
twice	O
a	O
day	O
or	O
matching	O
placebo	O
for	O
the	O
first	O
2	O
weeks	O
and	O
50	O
mg	O
3	O
times	O
a	O
week	O
for	O
the	O
remainder	O
of	O
the	O
trial	O
.	O

The	O
placebo-corrected	O
effect	O
on	O
mean	Physical
blood	Physical
pressure	Physical
was	O
1.16	O
mm	O
Hg	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-1.6	O
to	O
5.1	O
,	O
P	O
>	O
.05	O
)	O
,	O
demonstrating	O
that	O
sildenafil	O
did	O
not	O
decrease	O
mean	Physical
blood	Physical
pressure	Physical
.	O

Compared	O
with	O
placebo	O
,	O
sildenafil	O
increased	O
the	O
6-minute	Physical
walk	Physical
test	Physical
by	O
a	O
nonsignificant	O
treatment	O
effect	O
of	O
14	O
m	O
(	O
P=.67	O
)	O
.	O

Adverse	Adverseeffect
effects	Adverseeffect
occurred	O
in	O
a	O
comparable	O
proportion	O
of	O
patients	O
taking	O
sildenafil	O
and	O
placebo	O
,	O
and	O
none	O
of	O
the	O
patients	O
needed	O
to	O
discontinue	O
therapy	O
.	O

Sildenafil	O
is	O
well	O
tolerated	Others
in	O
left	O
heart	O
failure	O
patients	O
and	O
does	O
not	O
decrease	O
blood	Physical
pressure	Physical
.	O

It	O
can	O
be	O
safely	O
added	O
to	O
standard	O
heart	O
failure	O
therapy	O
.	O

Gastric	O
ulcer	O
treatment	O
with	O
intravenous	O
human	O
epidermal	O
growth	O
factor	O
:	O
a	O
double-blind	O
controlled	O
clinical	O
study	O
.	O

We	O
introduced	O
a	O
double-blind	O
controlled	O
clinical	O
study	O
to	O
compare	O
intravenous	O
human	O
epidermal	O
growth	O
factor	O
(	O
hEGF	O
)	O
to	O
cetraxate	O
hydrochloride	O
(	O
CH	O
)	O
,	O
an	O
antiulcer	O
drug	O
,	O
for	O
their	O
healing	O
effect	O
on	O
gastric	Physical
ulcers	Physical
.	O

We	O
also	O
prospected	O
an	O
oral	O
use	O
of	O
EGF	O
on	O
the	O
basis	O
of	O
our	O
experimental	O
evidence	O
.	O

In	O
the	O
clinical	O
trial	O
,	O
the	O
rate	Physical
of	Physical
ulcer	Physical
healing	Physical
within	O
8	O
weeks	O
was	O
77.9	O
%	O
(	O
67/86	O
)	O
in	O
patients	O
receiving	O
6	O
micrograms	O
EGF	O
intravenously	O
twice	O
a	O
week	O
,	O
being	O
significantly	O
greater	O
than	O
51.7	O
%	O
(	O
45/87	O
)	O
in	O
those	O
given	O
CH	O
.	O

Taking	O
together	O
all	O
aspects	O
assessed	O
including	O
the	O
healing	Physical
rate	Physical
,	O
pain	Pain
relief	Pain
,	Pain
blood	Physical
examination	Physical
and	O
adverse	Adverseeffect
reactions	Adverseeffect
,	O
we	O
judged	O
the	O
hEGF	O
to	O
be	O
a	O
useful	O
and	O
safe	O
anticuler	O
drug	O
.	O

In	O
rats	O
,	O
50	O
micrograms/kg	O
mouse	O
EGF	O
(	O
mEGF	O
)	O
and	O
2	O
%	O
hydroxypropyl	O
cellulose	O
(	O
HPC	O
)	O
or	O
1.0	O
g/kg	O
sucralfate	O
given	O
by	O
gastric	O
intubation	O
significantly	O
raised	O
the	O
residual	Physical
mEGF	Physical
levels	Physical
in	O
both	O
gastric	O
luminal	O
content	O
(	O
HPC	O
:	O
x	O
30	O
;	O
sucralfate	O
:	O
x	O
300	O
as	O
high	O
as	O
those	O
in	O
EGF	O
alone	O
)	O
and	O
tissue	O
(	O
HPC	O
:	O
x	O
60	O
;	O
sucralfate	O
:	O
x	O
100	O
)	O
.	O

In	O
addition	O
,	O
the	O
combined	O
treatments	O
significantly	O
promoted	O
healing	Physical
of	Physical
rat	Physical
gastric	Physical
ulcers	Physical
whereas	O
each	O
agent	O
alone	O
had	O
no	O
significant	O
effect	O
as	O
compared	O
with	O
control	O
(	O
saline	O
)	O
.	O

This	O
indicated	O
the	O
beneficial	O
effect	O
on	O
ulcers	O
of	O
oral	O
administration	O
of	O
EGF	O
with	O
agents	O
allowing	O
it	O
to	O
remain	O
at	O
high	O
levels	O
in	O
the	O
stomach	O
,	O
whereas	O
most	O
reports	O
suggested	O
less	O
effect	O
of	O
oral	O
EGF	O
on	O
healing	O
of	O
gastroduodenal	O
ulcers	O
.	O

Subsequent	O
to	O
the	O
clinical	O
study	O
,	O
evaluation	O
of	O
oral	O
use	O
of	O
EGF	O
may	O
be	O
expected	O
as	O
the	O
next	O
step	O
in	O
the	O
treatment	O
of	O
ulcers	O
.	O

The	O
experimental	O
evidence	O
above	O
would	O
possibly	O
be	O
a	O
guide	O
for	O
such	O
trial	O
.	O

Psychosocial	O
nursing	O
therapy	O
following	O
sudden	O
cardiac	O
arrest	O
:	O
impact	O
on	O
two-year	Mortality
survival	Mortality
.	O

BACKGROUND	O
Although	O
psychosocial	O
therapy	O
has	O
been	O
shown	O
to	O
reduce	O
mortality	Mortality
after	O
myocardial	O
infarction	O
,	O
it	O
is	O
unknown	O
whether	O
the	O
benefits	O
of	O
psychosocial	O
therapy	O
on	O
mortality	O
reduction	O
extend	O
to	O
out-of-hospital	O
sudden	O
cardiac	O
arrest	O
,	O
a	O
main	O
cause	O
of	O
cardiovascular	Mortality
mortality	Mortality
.	O

OBJECTIVE	O
Describe	O
efficacy	O
of	O
psychosocial	O
therapy	O
on	O
two-year	O
cardiovascular	Mortality
mortality	Mortality
in	O
sudden	O
cardiac	O
arrest	O
survivors	O
.	O

METHOD	O
Survivors	O
of	O
out-of-hospital	O
ventricular	O
fibrillation	O
or	O
asystole	O
(	O
N	O
=	O
129	O
)	O
,	O
documented	O
by	O
electrocardiograms	O
from	O
registries	O
of	O
a	O
citywide	O
Medic	O
One	O
unit	O
and	O
two	O
countywide	O
emergency	O
units	O
,	O
were	O
randomized	O
into	O
a	O
two	O
group	O
,	O
experimental	O
,	O
longitudinal	O
design	O
.	O

The	O
intervention	O
consisted	O
of	O
11	O
individual	O
sessions	O
,	O
implementing	O
three	O
components	O
:	O
physiologic	O
relaxation	O
with	O
biofeedback	O
training	O
focused	O
on	O
altering	O
autonomic	O
tone	O
;	O
cognitive	O
behavioral	O
therapy	O
aimed	O
at	O
self-management	O
and	O
coping	O
strategies	O
for	O
depression	O
,	O
anxiety	O
,	O
and	O
anger	O
;	O
and	O
cardiovascular	O
health	O
education	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
cardiovascular	Mortality
mortality	Mortality
.	O

RESULTS	O
Risk	Mortality
of	Mortality
cardiovascular	Mortality
death	Mortality
was	O
significantly	O
reduced	O
86	O
%	O
by	O
psychosocial	O
therapy	O
,	O
p	O
=	O
.03	O
.	O

Six	O
of	O
the	O
seven	O
cardiovascular	Mortality
deaths	Mortality
in	O
the	O
control	O
group	O
were	O
caused	O
by	O
ventricular	O
arrhythmias	O
.	O

The	Mortality
cardiovascular	Mortality
death	Mortality
in	O
the	O
therapy	O
group	O
was	O
due	O
to	O
stroke	O
.	O

Controlling	O
for	O
depression	Physical
,	O
previous	Physical
myocardial	Physical
infarction	Physical
,	O
low	Physical
ejection	Physical
fraction	Physical
,	O
decreased	Physical
heart	Physical
rate	Physical
variability	Physical
,	O
and	O
ventricular	Physical
ectopic	Physical
beats	Physical
had	O
little	O
impact	O
on	O
estimated	O
treatment	O
effect	O
.	O

The	O
risk	Mortality
of	Mortality
all-cause	Mortality
mortality	Mortality
was	O
reduced	O
by	O
62	O
%	O
in	O
the	O
therapy	O
group	O
,	O
p	O
=	O
.13	O
.	O

There	O
were	O
a	O
total	O
of	O
three	O
deaths	Mortality
in	O
the	O
therapy	O
group	O
and	O
eight	O
deaths	Mortality
in	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
Psychosocial	O
therapy	O
significantly	O
reduced	O
the	O
risk	O
of	O
cardiovascular	Mortality
death	Mortality
in	O
sudden	O
cardiac	O
arrest	O
survivors	O
.	O

Pilot	O
study	O
of	O
Panax	O
quinquefolius	O
(	O
American	O
ginseng	O
)	O
to	O
improve	O
cancer-related	O
fatigue	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
dose-finding	O
evaluation	O
:	O
NCCTG	O
trial	O
N03CA	O
.	O

PURPOSE	O
This	O
pilot	O
trial	O
sought	O
to	O
investigate	O
whether	O
any	O
of	O
three	O
doses	O
of	O
American	O
ginseng	O
(	O
Panax	O
quinquefolius	O
)	O
might	O
help	O
cancer-related	O
fatigue	O
.	O

A	O
secondary	O
aim	O
was	O
to	O
evaluate	O
toxicity	O
.	O

METHODS	O
Eligible	O
adults	O
with	O
cancer	O
were	O
randomized	O
in	O
a	O
double-blind	O
manner	O
,	O
to	O
receive	O
American	O
ginseng	O
in	O
doses	O
of	O
750	O
,	O
1,000	O
,	O
or	O
2,000	O
mg/day	O
or	O
placebo	O
given	O
in	O
twice	O
daily	O
dosing	O
over	O
8	O
weeks	O
.	O

Outcome	O
measures	O
included	O
the	O
Brief	Physical
Fatigue	Physical
Inventory	Physical
,	O
vitality	Physical
subscale	Physical
of	Physical
the	Physical
Medical	Physical
Outcome	Physical
Scale	Physical
Short	Physical
Form-36	Physical
(	Physical
SF-36	Physical
)	Physical
,	O
and	O
the	O
Global	Physical
Impression	Physical
of	Physical
Benefit	Physical
Scale	Physical
at	O
4	O
and	O
8	O
weeks	O
.	O

RESULTS	O
Two	O
hundred	O
ninety	O
patients	O
were	O
accrued	O
to	O
this	O
trial	O
.	O

Nonsignificant	O
trends	O
for	O
all	O
outcomes	O
were	O
seen	O
in	O
favor	O
of	O
the	O
1,000-	O
and	O
2,000-mg/day	O
doses	O
of	O
American	O
ginseng	O
.	O

Area	O
under	O
the	O
curve	O
analysis	O
of	O
activity	O
interference	O
from	O
the	O
Brief	Physical
Fatigue	Physical
Inventory	Physical
was	O
460-467	O
in	O
the	O
placebo	O
group	O
and	O
750	O
mg/day	O
group	O
versus	O
480-551	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
,	O
respectively	O
.	O

Change	O
from	O
baseline	O
in	O
the	O
vitality	Physical
subscale	Physical
of	O
the	O
SF-36	O
was	O
7.3-7.8	O
in	O
the	O
placebo	O
and	O
the	O
750-mg/day	O
arm	O
,	O
versus	O
10.5-14.6	O
in	O
the	O
1,000-	O
and	O
2,000-mg/day	O
arms	O
.	O

Over	O
twice	O
as	O
many	O
patients	O
on	O
ginseng	O
perceived	O
a	O
benefit	O
and	O
were	O
satisfied	Others
with	O
treatment	O
over	O
those	O
on	O
placebo	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
any	O
measured	O
toxicities	Adverseeffect
between	O
any	O
of	O
the	O
arms	O
.	O

CONCLUSION	O
There	O
appears	O
to	O
be	O
some	O
activity	O
and	O
tolerable	O
toxicity	O
at	O
1,000-2,000	O
mg/day	O
doses	O
of	O
American	O
ginseng	O
with	O
regard	O
to	O
cancer-related	O
fatigue	O
.	O

Thus	O
,	O
further	O
study	O
of	O
American	O
ginseng	O
is	O
warranted	O
.	O

Dissociation	O
between	O
cortical	O
activation	O
and	O
cognitive	O
performance	O
under	O
pharmacological	O
blood	O
pressure	O
elevation	O
in	O
chronic	O
hypotension	O
.	O

The	O
present	O
study	O
explored	O
the	O
impact	O
of	O
pharmacological	O
blood	O
pressure	O
elevation	O
on	O
cortical	O
activation	O
and	O
reaction	O
time	O
in	O
chronic	O
hypotension	O
.	O

Effects	O
of	O
the	O
sympathomimetic	O
etilefrine	O
were	O
investigated	O
in	O
50	O
hypotensive	O
persons	O
based	O
on	O
a	O
randomized	O
,	O
placebo-controlled	O
double	O
blind	O
design	O
.	O

As	O
an	O
indicator	O
of	O
cortical	O
excitability	O
,	O
the	O
contingent	O
negative	O
variation	O
(	O
CNV	O
)	O
,	O
induced	O
by	O
a	O
constant	O
foreperiod	O
reaction	O
time	O
task	O
,	O
was	O
assessed	O
at	O
frontal	O
(	O
F3	O
,	O
Fz	O
,	O
F4	O
)	O
and	O
central	O
(	O
C3	O
,	O
Cz	O
,	O
C4	O
)	O
scalp	O
sites	O
.	O

Etilefrine	O
provoked	O
a	O
decrease	O
in	O
the	O
frontal	Physical
and	Physical
central	Physical
CNV	Physical
.	O

In	O
contrast	O
,	O
shorter	O
reaction	Physical
times	Physical
were	O
observed	O
following	O
drug	O
administration	O
.	O

The	O
degree	O
of	O
pharmacologically	O
induced	Physical
blood	Physical
pressure	Physical
elevation	Physical
was	O
correlated	O
to	O
CNV	O
attrition	O
as	O
well	O
as	O
to	O
performance	O
enhancement	O
.	O

Inhibitory	O
effects	O
of	O
baroreceptor	O
activation	O
on	O
cortical	O
excitability	O
and	O
enhanced	O
cerebral	O
blood	O
flow	O
are	O
considered	O
to	O
be	O
involved	O
in	O
mediating	O
the	O
effects	O
of	O
blood	Physical
pressure	Physical
elevation	Physical
on	O
cerebral	O
functioning	O
.	O

Implications	O
for	O
the	O
treatment	O
of	O
chronic	O
hypotension	O
are	O
discussed	O
.	O

The	O
ScanBrit	O
randomised	O
,	O
controlled	O
,	O
single-blind	O
study	O
of	O
a	O
gluten-	O
and	O
casein-free	O
dietary	O
intervention	O
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

There	O
is	O
increasing	O
interest	O
in	O
the	O
use	O
of	O
gluten-	O
and	O
casein-free	O
diets	O
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
.	O

We	O
report	O
results	O
from	O
a	O
two-stage	O
,	O
24-month	O
,	O
randomised	O
,	O
controlled	O
trial	O
incorporating	O
an	O
adaptive	O
'catch-up	O
'	O
design	O
and	O
interim	O
analysis	O
.	O

Stage	O
1	O
of	O
the	O
trial	O
saw	O
72	O
Danish	O
children	O
(	O
aged	O
4	O
years	O
to	O
10	O
years	O
11	O
months	O
)	O
assigned	O
to	O
diet	O
(	O
A	O
)	O
or	O
non-diet	O
(	O
B	O
)	O
groups	O
by	O
stratified	O
randomisation	O
.	O

Autism	Mental
Diagnostic	Mental
Observation	Mental
Schedule	Mental
(	Mental
ADOS	Mental
)	Mental
and	O
the	O
Gilliam	Mental
Autism	Mental
Rating	Mental
Scale	Mental
(	Mental
GARS	Mental
)	Mental
were	O
used	O
to	O
assess	O
core	Mental
autism	Mental
behaviours	Mental
,	O
Vineland	Mental
Adaptive	Mental
Behaviour	Mental
Scales	Mental
(	Mental
VABS	Mental
)	Mental
to	O
ascertain	O
developmental	O
level	O
,	O
and	O
Attention-Deficit	Mental
Hyperactivity	Mental
Disorder	Mental
-	Mental
IV	Mental
scale	Mental
(	Mental
ADHD-IV	Mental
)	Mental
to	O
determine	O
inattention	O
and	O
hyperactivity	O
.	O

Participants	O
were	O
tested	O
at	O
baseline	O
,	O
8	O
,	O
and	O
12	O
months	O
.	O

Based	O
on	O
per	O
protocol	O
repeated	O
measures	O
analysis	O
,	O
data	O
for	O
26	O
diet	O
children	O
and	O
29	O
controls	O
were	O
available	O
at	O
12	O
months	O
.	O

At	O
this	O
point	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
to	O
mean	O
diet	O
group	O
scores	O
(	O
time*treatment	O
interaction	O
)	O
on	O
sub-domains	O
of	O
ADOS	Mental
,	O
GARS	Mental
and	O
ADHD-IV	Mental
measures	O
.	O

Surpassing	O
of	O
predefined	O
statistical	O
thresholds	O
as	O
evidence	O
of	O
improvement	O
in	O
group	O
A	O
at	O
12	O
months	O
sanctioned	O
the	O
re-assignment	O
of	O
group	O
B	O
participants	O
to	O
active	O
dietary	O
treatment	O
.	O

Stage	O
2	O
data	O
for	O
18	O
group	O
A	O
and	O
17	O
group	O
B	O
participants	O
were	O
available	O
at	O
24	O
months	O
.	O

Multiple	O
scenario	O
analysis	O
based	O
on	O
inter-	O
and	O
intra-group	O
comparisons	O
showed	O
some	O
evidence	O
of	O
sustained	O
clinical	O
group	O
improvements	O
although	O
possibly	O
indicative	O
of	O
a	O
plateau	O
effect	O
for	O
intervention	O
.	O

Our	O
results	O
suggest	O
that	O
dietary	O
intervention	O
may	O
positively	O
affect	O
developmental	O
outcome	O
for	O
some	O
children	O
diagnosed	O
with	O
ASD	O
.	O

In	O
the	O
absence	O
of	O
a	O
placebo	O
condition	O
to	O
the	O
current	O
investigation	O
,	O
we	O
are	O
,	O
however	O
,	O
unable	O
to	O
disqualify	O
potential	O
effects	O
derived	O
from	O
intervention	O
outside	O
of	O
dietary	O
changes	O
.	O

Further	O
studies	O
are	O
required	O
to	O
ascertain	O
potential	O
best-	O
and	O
non-responders	O
to	O
intervention	O
.	O

The	O
study	O
was	O
registered	O
with	O
ClincialTrials.gov	O
,	O
number	O
NCT00614198	O
.	O

Study	O
of	O
the	O
therapeutic	O
effects	O
of	O
a	O
hippotherapy	O
simulator	O
in	O
children	O
with	O
cerebral	O
palsy	O
:	O
a	O
stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
hippotherapy	O
(	O
when	O
applied	O
by	O
a	O
simulator	O
)	O
improves	O
postural	O
control	O
and	O
balance	O
in	O
children	O
with	O
cerebral	O
palsy	O
.	O

DESIGN	O
Stratified	O
single-blind	O
randomized	O
controlled	O
trial	O
with	O
an	O
independent	O
assessor	O
.	O

Stratification	O
was	O
made	O
by	O
gross	O
motor	O
function	O
classification	O
system	O
levels	O
,	O
and	O
allocation	O
was	O
concealed	O
.	O

SUBJECTS	O
Children	O
between	O
4	O
and	O
18	O
years	O
old	O
with	O
cerebral	O
palsy	O
.	O

INTERVENTIONS	O
Participants	O
were	O
randomized	O
to	O
an	O
intervention	O
(	O
simulator	O
ON	O
)	O
or	O
control	O
(	O
simulator	O
OFF	O
)	O
group	O
after	O
getting	O
informed	O
consent	O
.	O

Treatment	O
was	O
provided	O
once	O
a	O
week	O
(	O
15	O
minutes	O
)	O
for	O
10	O
weeks	O
.	O

MAIN	O
MEASURES	O
Gross	Physical
Motor	Physical
Function	Physical
Measure	Physical
(	Physical
dimension	Physical
B	Physical
for	Physical
balance	Physical
and	Physical
the	Physical
Total	Physical
Score	Physical
)	Physical
and	O
Sitting	Physical
Assessment	Physical
Scale	Physical
were	O
carried	O
out	O
at	O
baseline	O
(	O
prior	O
to	O
randomization	O
)	O
,	O
end	O
of	O
intervention	O
and	O
12	O
weeks	O
after	O
completing	O
the	O
intervention	O
.	O

RESULTS	O
Thirty-eight	O
children	O
participated	O
.	O

The	O
groups	O
were	O
balanced	O
at	O
baseline	O
.	O

Sitting	Physical
balance	Physical
(	O
measured	O
by	O
dimension	O
B	O
of	O
the	O
Gross	O
Motor	O
Function	O
Measure	O
)	O
improved	O
significantly	O
in	O
the	O
treatment	O
group	O
(	O
effect	O
size	O
=	O
0.36	O
;	O
95	O
%	O
CI	O
0.01-0.71	O
)	O
and	O
the	O
effect	Physical
size	Physical
was	O
greater	O
in	O
the	O
severely	O
disabled	O
group	O
(	O
effect	O
size	O
=	O
0.80	O
;	O
95	O
%	O
CI	O
0.13-1.47	O
)	O
.	O

The	O
improvements	Physical
in	Physical
sitting	Physical
balance	Physical
were	O
not	O
maintained	O
over	O
the	O
follow-up	O
period	O
.	O

Changes	O
in	O
the	O
total	Physical
score	Physical
of	Physical
the	Physical
Gross	Physical
Motor	Physical
Function	Physical
Measure	Physical
and	O
the	O
Sitting	Physical
Assessment	Physical
Scale	Physical
were	O
not	O
significant	O
.	O

CONCLUSION	O
Hippotherapy	O
with	O
a	O
simulator	O
can	O
improve	O
sitting	Physical
balance	Physical
in	O
cerebral	O
palsy	O
children	O
who	O
have	O
higher	O
levels	O
of	O
disability	O
.	O

However	O
,	O
this	O
did	O
not	O
lead	O
to	O
a	O
change	O
in	O
the	O
overall	O
function	O
of	O
these	O
children	O
(	O
Gross	O
Motor	O
Function	O
Classification	O
System	O
level	O
V	O
)	O
.	O

Short-term	O
studies	O
on	O
the	O
use	O
of	O
glycerol	O
as	O
an	O
osmotic	O
agent	O
in	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

The	O
use	O
of	O
glycerol	O
as	O
an	O
osmotic	O
agent	O
in	O
two	O
different	O
concentrations	O
(	O
92	O
mmol/l	O
and	O
272	O
mmol/l	O
)	O
in	O
peritoneal	O
dialysis	O
fluid	O
was	O
investigated	O
over	O
3	O
days	O
in	O
six	O
patients	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
and	O
compared	O
with	O
two	O
concentrations	O
of	O
glucose	O
(	O
76	O
mmol/l	O
and	O
215	O
mmol/l	O
)	O
in	O
the	O
same	O
patients	O
.	O

The	O
calorific	Physical
value	Physical
of	O
the	O
absorbed	O
osmotic	O
agent	O
was	O
lower	O
,	O
by	O
19	O
%	O
with	O
isotonic	O
and	O
22	O
%	O
with	O
hypertonic	O
solutions	O
,	O
when	O
glycerol	O
was	O
used	O
in	O
place	O
of	O
glucose	O
.	O

However	O
,	O
glycerol	O
provided	O
significantly	O
lower	O
total	Physical
ultrafiltration	Physical
than	O
glucose	O
at	O
each	O
concentration	O
,	O
despite	O
a	O
higher	O
initial	O
osmotic	O
pressure	O
of	O
the	O
glycerol-based	O
solutions	O
.	O

Thus	O
,	O
the	O
higher	O
concentration	O
of	O
glycerol	O
required	O
to	O
provide	O
equal	Physical
ultrafiltration	Physical
may	O
offset	O
any	O
calorific	O
advantage	O
.	O

Equilibration	Physical
of	Physical
creatinine	Physical
and	Physical
urea	Physical
was	O
slower	O
and	O
creatinine	Physical
clearance	Physical
lower	O
with	O
glycerol	O
.	O

Solutions	O
containing	O
glycerol	O
were	O
initially	O
less	O
acid	O
(	O
pH	O
6.5	O
)	O
than	O
those	O
containing	O
glucose	O
(	O
pH	O
5.1	O
)	O
.	O

Blood	Physical
glycerol	Physical
levels	Physical
,	O
which	O
were	O
in	O
the	O
physiological	O
range	O
with	O
glucose	O
as	O
the	O
osmotic	O
agent	O
,	O
reached	O
a	O
peak	O
80-fold	O
greater	O
at	O
4.3	O
+/-	O
0.8	O
mmol/l	O
during	O
dialysis	O
with	O
fluid	O
containing	O
glycerol	O
at	O
272	O
mmol/l	O
and	O
eightfold	O
higher	O
at	O
0.42	O
+/-	O
0.09	O
mmol/l	O
with	O
glycerol	O
at	O
92	O
mmol/l	O
.	O

There	O
was	O
no	O
evidence	O
of	O
haemolysis	Adverseeffect
or	O
other	O
toxic	Adverseeffect
effect	Adverseeffect
despite	O
these	O
levels	O
.	O

The	O
rise	O
in	O
blood	O
glucose	O
and	O
insulin	O
noted	O
during	O
the	O
use	O
of	O
glucose-based	O
solutions	O
was	O
not	O
found	O
with	O
glycerol	O
.	O

Circulating	Physical
levels	Physical
of	Physical
lactate	Physical
,	O
pyruvate	Physical
,	O
alanine	Physical
,	O
non-esterified	Physical
fatty	Physical
acids	Physical
and	O
the	O
ketone	O
bodies	O
were	O
similar	O
with	O
the	O
two	O
agents	O
.	O

Although	O
these	O
short-term	O
studies	O
have	O
shown	O
no	O
conclusive	O
advantage	O
of	O
glycerol	O
over	O
glucose	O
,	O
long-term	O
effects	O
of	O
glycerol	O
,	O
particularly	O
on	O
circulating	Physical
lipid	Physical
levels	Physical
,	O
will	O
determine	O
its	O
future	O
role	O
as	O
an	O
osmotic	O
agent	O
in	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
.	O

Tetracaine	O
(	O
ametop	O
)	O
compared	O
to	O
placebo	O
for	O
reducing	O
pain	O
associated	O
with	O
intramuscular	O
injection	O
of	O
palivizumab	O
(	O
synagis	O
)	O
.	O

Infants	O
receive	O
many	O
painful	O
immunizations	O
before	O
they	O
are	O
2	O
years	O
old	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
if	O
topical	O
tetracaine	O
reduces	O
the	O
pain	O
of	O
intramuscular	O
palivizumab	O
compared	O
to	O
placebo	O
.	O

There	O
were	O
two	O
study	O
injections	O
,	O
one	O
with	O
tetracaine	O
and	O
one	O
with	O
placebo	O
.	O

Pain	Pain
was	O
scored	O
by	O
their	O
parents	O
and	O
a	O
pediatric	O
nurse	O
.	O

Topical	O
tetracaine	O
was	O
not	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
pain	Pain
score	Pain
,	O
although	O
it	O
did	O
lead	O
to	O
faster	O
recovery	Others
times	O
.	O

Additional	O
pain-reduction	O
strategies	O
are	O
required	O
.	O

Hip	O
protectors	O
improve	O
falls	O
self-efficacy	O
.	O

OBJECTIVES	O
To	O
investigate	O
the	O
effect	O
of	O
use	O
of	O
external	O
hip	O
protectors	O
on	O
subjects	O
'	O
fear	O
of	O
falling	O
and	O
falls	O
self-efficacy	O
(	O
belief	O
in	O
their	O
own	O
ability	O
to	O
avoid	O
falling	O
)	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Aged-care	O
health	O
services	O
in	O
Sydney	O
,	O
Australia	O
.	O

PARTICIPANTS	O
131	O
women	O
aged	O
75	O
years	O
or	O
older	O
,	O
who	O
had	O
two	O
or	O
more	O
falls	O
or	O
one	O
fall	O
requiring	O
hospital	O
admission	O
in	O
the	O
previous	O
year	O
and	O
who	O
live	O
at	O
home	O
.	O

Sixty-one	O
subjects	O
were	O
in	O
the	O
intervention	O
group	O
and	O
70	O
in	O
the	O
control	O
group	O
.	O

INTERVENTION	O
Use	O
of	O
external	O
hip	O
protectors	O
and	O
encouragement	O
to	O
use	O
the	O
protectors	O
by	O
an	O
adherence	O
nurse	O
.	O

MEASUREMENTS	O
At	O
the	O
time	O
of	O
enrolment	O
into	O
a	O
wider	O
study	O
examining	O
the	O
effect	O
of	O
hip	O
protectors	O
on	O
hip	O
fractures	O
,	O
participants	O
recruited	O
at	O
home	O
completed	O
an	O
assessment	O
of	O
fear	Others
of	Others
falling	Others
and	Others
falls	Others
efficacy	Others
as	O
measured	O
by	O
the	O
Falls	Others
Efficacy	Others
Scale	Others
and	Others
the	Others
Modified	Others
Falls	Others
Efficacy	Others
Scale	Others
.	Others

At	O
4-month	O
follow-up	O
,	O
these	O
scales	O
were	O
readministered	O
by	O
an	O
observer	O
who	O
was	O
not	O
aware	O
of	O
the	O
allocation	O
of	O
the	O
participant	O
to	O
intervention	O
or	O
control	O
groups	O
.	O

RESULTS	O
Fear	Others
of	Others
falling	Others
and	Others
falls	Others
self-efficacy	Others
,	O
as	O
measured	O
by	O
the	O
Falls	Others
Efficacy	Others
and	Others
Modified	Others
Falls	Others
Efficacy	Others
Scales	Others
,	O
were	O
similar	O
at	O
baseline	O
in	O
both	O
groups	O
.	O

Fear	Mental
of	Mental
falling	Mental
was	O
present	O
at	O
follow-up	O
in	O
43	O
%	O
of	O
subjects	O
using	O
hip	O
protectors	O
and	O
57	O
%	O
of	O
the	O
control	O
group	O
(	O
chi2	O
=	O
2.58	O
,	O
P	O
=	O
0.11	O
)	O
.	O

Hip	O
protector	O
users	O
had	O
greater	O
improvement	O
in	O
falls	O
self-efficacy	Others
at	O
follow-up	O
as	O
measured	O
by	O
the	O
Falls	Others
Efficacy	Others
Scale	Others
(	O
t	O
=	O
2.44	O
,	O
P	O
=	O
0.016	O
)	O
and	O
the	O
Modified	Others
Falls	Others
Efficacy	Others
Scale	Others
(	O
t	O
=	O
2.08	O
,	O
P	O
=	O
0.039	O
)	O
.	O

CONCLUSION	O
Hip	O
protectors	O
improve	O
falls	O
self-efficacy	O
.	O

As	O
users	O
of	O
hip	O
protectors	O
feel	O
more	O
confident	O
that	O
they	O
can	O
complete	O
tasks	O
safely	O
,	O
they	O
may	O
become	O
more	O
physically	O
active	O
and	O
require	O
less	O
assistance	O
with	O
activities	O
of	O
daily	O
living	O
.	O

Phytase	O
and	O
1alpha-hydroxycholecalciferol	O
supplementation	O
of	O
broiler	O
chickens	O
during	O
the	O
starting	O
and	O
growing/finishing	O
phases	O
.	O

Supplemental	O
1alpha-hydroxycholecalciferol	O
(	O
1alpha-OHD3	O
)	O
has	O
been	O
shown	O
to	O
have	O
qualitatively	O
similar	O
and	O
quantitatively	O
additive	O
effects	O
to	O
exogenous	O
phytase	O
.	O

Two	O
experiments	O
were	O
conducted	O
from	O
0	O
to	O
35	O
d	O
in	O
floor	O
pens	O
to	O
determine	O
the	O
additive	O
effect	O
of	O
phytase	O
and	O
1alpha-OHD3	O
when	O
supplemented	O
to	O
Ca-	O
and	O
P-deficient	O
diets	O
.	O

In	O
both	O
experiments	O
,	O
at	O
least	O
4	O
replicates	O
per	O
treatment	O
(	O
50	O
chicks	O
per	O
replicate	O
)	O
were	O
used	O
.	O

Corn-soybean-meal-and	O
soybean-oil-based	O
diets	O
were	O
fed	O
and	O
birds	O
were	O
raised	O
in	O
a	O
house	O
impervious	O
to	O
ultraviolet	O
light	O
.	O

During	O
the	O
starter	O
phase	O
(	O
ST	O
)	O
,	O
from	O
0	O
to	O
18	O
d	O
,	O
chicks	O
were	O
fed	O
a	O
23	O
%	O
CP	O
diet	O
containing	O
0.60	O
%	O
Ca	O
and	O
0.47	O
%	O
total	O
P	O
(	O
tP	O
)	O
.	O

During	O
the	O
grower/finisher	O
phase	O
(	O
GF	O
)	O
,	O
from	O
19	O
to	O
35	O
d	O
,	O
birds	O
were	O
fed	O
a	O
19	O
%	O
CP	O
diet	O
containing	O
0.30	O
%	O
Ca	O
and	O
0.37	O
%	O
tP	O
.	O

A	O
combination	O
of	O
1,000	O
phytase	O
units/kg	O
of	O
Natuphos	O
phytase	O
and	O
5	O
microg/kg	O
of	O
1alpha-OHD3	O
(	O
P+1A	O
)	O
was	O
supplemented	O
to	O
some	O
of	O
the	O
feed	O
during	O
the	O
ST	O
and	O
GF	O
.	O

Diets	O
containing	O
adequate	O
Ca	O
and	O
P	O
were	O
also	O
fed	O
during	O
the	O
ST	O
(	O
0.90	O
%	O
Ca	O
,	O
0.68	O
%	O
tP	O
)	O
and	O
GF	O
(	O
0.80	O
%	O
Ca	O
,	O
0.67	O
%	O
tP	O
)	O
.	O

Performance	Physical
characteristics	Physical
and	O
the	O
incidence	Physical
of	Physical
rickets	Physical
and	Physical
tibial	Physical
dyschondroplasia	Physical
were	O
measured	O
at	O
18	O
and	O
35	O
d.	O
In	O
experiment	O
1	O
,	O
unsupplemented	O
chicks	O
performed	O
well	O
but	O
had	O
considerable	O
leg	Physical
problems	Physical
.	O

Chicks	O
fed	O
P+1A	O
during	O
the	O
ST	O
or	O
GF	O
did	O
not	O
perform	O
as	O
well	O
as	O
birds	O
fed	O
P+1A	O
throughout	O
.	O

Birds	O
fed	O
P+1A	O
throughout	O
performed	O
as	O
well	O
birds	O
fed	O
the	O
adequate	O
diets	O
without	O
any	O
indication	O
of	O
leg	O
problems	O
.	O

In	O
experiment	O
2	O
,	O
unsupplemented	O
birds	O
performed	O
similarly	O
to	O
unsupplemented	O
birds	O
in	O
experiment	O
1	O
.	O

However	O
,	O
chicks	O
fed	O
the	O
supplements	O
or	O
the	O
control	O
diets	O
did	O
not	O
perform	O
as	O
well	O
or	O
accumulate	Physical
as	Physical
much	Physical
bone	Physical
ash	Physical
as	O
birds	O
in	O
experiment	O
1	O
,	O
although	O
the	O
diets	O
were	O
formulated	O
identically	O
in	O
both	O
experiments	O
.	O

Diets	O
with	O
as	O
little	O
as	O
0.30	O
%	O
Ca	O
and	O
0.37	O
%	O
tP	O
appear	O
to	O
be	O
adequate	O
for	O
broilers	O
older	O
than	O
18	O
d	O
if	O
supplemented	O
with	O
the	O
correct	O
amounts	O
of	O
phytase	O
and	O
1alpha-OHD3	O
.	O

However	O
,	O
there	O
are	O
unknown	O
variables	O
that	O
may	O
limit	O
the	O
potential	O
of	O
broilers	O
in	O
terms	O
of	O
bone	Physical
mineralization	Physical
and	Physical
bone	Physical
pathology	Physical
,	O
even	O
when	O
adequate	O
diets	O
are	O
fed	O
.	O

Sodium	O
bicarbonate	O
,	O
N-acetylcysteine	O
,	O
and	O
saline	O
for	O
prevention	O
of	O
radiocontrast-induced	Adverseeffect
nephropathy	Adverseeffect
.	O

A	O
comparison	O
of	O
3	O
regimens	O
for	O
protecting	O
contrast-induced	O
nephropathy	O
in	O
patients	O
undergoing	O
coronary	O
procedures	O
.	O

A	O
single-center	O
prospective	O
controlled	O
trial	O
.	O

BACKGROUND	O
Several	O
protective	O
therapies	O
have	O
been	O
developed	O
to	O
prevent	O
contrast-induced	Adverseeffect
nephropathy	Adverseeffect
(	Adverseeffect
CIN	Adverseeffect
)	Adverseeffect
.	Adverseeffect

We	O
aimed	O
to	O
investigate	O
the	O
efficacy	O
of	O
sodium	O
bicarbonate	O
by	O
comparing	O
2	O
other	O
regimens	O
,	O
including	O
combination	O
of	O
N-acetylcysteine	O
(	O
NAC	O
)	O
plus	O
sodium	O
chloride	O
and	O
sodium	O
chloride	O
alone	O
,	O
to	O
prevent	O
CIN	O
in	O
patients	O
undergoing	O
cardiovascular	O
procedures	O
.	O

METHODS	O
We	O
prospectively	O
enrolled	O
264	O
patients	O
who	O
were	O
scheduled	O
for	O
cardiovascular	O
procedures	O
and	O
had	O
a	O
baseline	O
creatinine	O
level	O
>	O
1.2	O
mg/dL	O
.	O

The	O
patients	O
were	O
assigned	O
1	O
of	O
3	O
prophylactic	O
regimens	O
:	O
infusion	O
of	O
sodium	O
bicarbonate	O
,	O
sodium	O
chloride	O
,	O
sodium	O
chloride	O
plus	O
oral	O
NAC	O
(	O
600	O
mg	O
bid	O
)	O
.	O

Contrast-induced	Adverseeffect
nephropathy	Adverseeffect
was	O
defined	O
as	O
an	O
increase	Adverseeffect
in	Adverseeffect
serum	Adverseeffect
creatinine	Adverseeffect
level	Adverseeffect
>	Adverseeffect
25	Adverseeffect
%	Adverseeffect
or	O
0.5	O
mg/dL	O
after	O
48	O
hours	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
among	O
groups	O
regarding	O
baseline	O
demographic	O
properties	O
and	O
nephropathy	O
risk	O
factors	O
.	O

The	O
change	Adverseeffect
in	Adverseeffect
creatinine	Adverseeffect
clearance	Adverseeffect
was	O
significantly	O
better	O
in	O
the	O
sodium	O
bicarbonate	O
group	O
than	O
other	O
2	O
groups	O
(	O
P	O
=	O
.007	O
)	O
.	O

The	O
incidence	Adverseeffect
of	Adverseeffect
CIN	Adverseeffect
was	O
significantly	O
lower	O
in	O
the	O
sodium	O
bicarbonate	O
group	O
(	O
4.5	O
%	O
)	O
compared	O
with	O
sodium	O
chloride	O
alone	O
(	O
13.6	O
%	O
,	O
P	O
=	O
.036	O
)	O
and	O
tended	O
to	O
be	O
lower	O
than	O
in	O
the	O
combination	O
group	O
(	O
12.5	O
%	O
,	O
P	O
=	O
.059	O
)	O
.	O

After	O
adjusting	O
the	O
Mehran	Adverseeffect
nephropathy	Adverseeffect
risk	Adverseeffect
score	Adverseeffect
,	O
the	O
risk	Adverseeffect
of	Adverseeffect
CIN	Adverseeffect
significantly	O
reduced	O
with	O
sodium	O
bicarbonate	O
compared	O
with	O
sodium	O
chloride	O
alone	O
(	O
adjusted	O
risk	O
ratio	O
0.29	O
,	O
P	O
=	O
.043	O
)	O
.	O

CONCLUSIONS	O
Hydration	O
with	O
sodium	O
bicarbonate	O
provides	O
better	O
protection	O
against	O
CIN	Adverseeffect
than	O
the	O
sodium	O
chloride	O
infusion	O
does	O
alone	O
.	O

Combination	O
therapy	O
of	O
NAC	O
plus	O
sodium	O
chloride	O
did	O
not	O
offer	O
additional	O
benefit	O
over	O
hydration	O
with	O
sodium	O
chloride	O
alone	O
.	O

A	O
randomized	O
trial	O
of	O
radiation	O
therapy	O
compared	O
to	O
split	O
course	O
radiation	O
therapy	O
combined	O
with	O
mitomycin	O
C	O
and	O
5	O
fluorouracil	O
as	O
initial	O
treatment	O
for	O
advanced	O
laryngeal	O
and	O
hypopharyngeal	O
squamous	O
carcinoma	O
.	O

Two	O
hundred	O
and	O
twelve	O
patients	O
with	O
previously	O
untreated	O
advanced	O
squamous	O
carcinoma	O
of	O
the	O
larynx	O
or	O
hypopharynx	O
were	O
randomized	O
to	O
receive	O
initial	O
treatment	O
with	O
radiotherapy	O
,	O
50	O
Gy	O
in	O
20	O
fractions	O
in	O
28	O
days	O
or	O
split	O
course	O
radiotherapy	O
and	O
concurrent	O
chemotherapy	O
,	O
25	O
Gy	O
in	O
10	O
fractions	O
in	O
14	O
days	O
followed	O
by	O
a	O
4	O
week	O
rest	O
and	O
a	O
further	O
25	O
Gy	O
in	O
10	O
fractions	O
in	O
14	O
days	O
starting	O
on	O
day	O
43	O
;	O
Mitomycin	O
C	O
was	O
given	O
on	O
day	O
1	O
and	O
day	O
43	O
and	O
5FU	O
continuous	O
infusions	O
on	O
days	O
1	O
--	O
4	O
and	O
days	O
43	O
--	O
46	O
.	O

Surgery	O
was	O
reserved	O
for	O
persistent	O
or	O
recurrent	O
disease	O
.	O

Two	O
hundred	O
and	O
nine	O
of	O
the	O
212	O
patients	O
randomized	O
were	O
included	O
in	O
the	O
analyses	O
.	O

Outcome	O
analyses	O
were	O
performed	O
at	O
a	O
median	O
follow-up	O
interval	O
of	O
4.4	O
years	O
.	O

No	O
patients	O
were	O
lost	O
to	O
follow-up	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
arms	O
for	O
the	O
end	O
points	O
of	O
local	Physical
relapse-free	Physical
rate	Physical
(	O
p	O
=	O
0.91	O
)	O
,	O
regional	Physical
relapse-free	Physical
rate	Physical
(	O
p	O
=	O
0.17	O
,	O
adjusted	O
)	O
or	O
overall	Mortality
survival	Mortality
(	O
p	O
=	O
0.86	O
)	O
.	O

Eight-eight	O
patients	O
had	O
attempted	O
surgical	O
resection	O
following	O
radiotherapy	O
failure	O
.	O

The	O
contribution	O
of	O
salvage	O
surgery	O
to	O
overall	Mortality
survival	Mortality
was	O
similar	O
for	O
both	O
arms	O
of	O
the	O
study	O
as	O
was	O
the	O
surgical	Adverseeffect
complication	Adverseeffect
rate	Adverseeffect
.	O

Serious	Adverseeffect
late	Adverseeffect
radiation	Adverseeffect
toxicity	Adverseeffect
was	O
minimal	O
(	O
3	O
%	O
in	O
the	O
RT	O
group	O
,	O
0	O
%	O
in	O
the	O
radiation	O
therapy	O
plus	O
chemotherapy	O
group	O
)	O
.	O

The	O
result	O
of	O
the	O
trial	O
shows	O
no	O
advantage	O
in	O
terms	O
of	O
local	O
control	O
or	O
survival	O
for	O
the	O
experimental	O
treatment	O
arm	O
of	O
split	O
course	O
radiotherapy	O
and	O
concurrent	O
chemotherapy	O
with	O
Mitomycin	O
C	O
and	O
5	O
Fluorouracil	O
compared	O
to	O
radiotherapy	O
alone	O
.	O

Study	O
of	O
the	O
vaginal	O
tolerance	O
to	O
Acidform	O
,	O
an	O
acid-buffering	O
,	O
bioadhesive	O
gel	O
.	O

Vaginal	O
tolerance	O
tests	O
were	O
performed	O
with	O
a	O
new	O
potential	O
microbicidal	O
and	O
spermicidal	O
product	O
,	O
an	O
acid-buffering	O
vaginal	O
gel	O
(	O
Acidform	O
)	O
without	O
or	O
with	O
nonoxynol-9	O
(	O
N-9	O
)	O
.	O

The	O
potential	O
advantages	O
over	O
other	O
vaginal	O
products	O
include	O
keeping	O
a	O
low	O
pH	O
,	O
decrease	O
of	O
the	O
irritating	O
effect	O
of	O
N-9	O
on	O
the	O
cervix	O
or	O
vaginal	O
mucosa	O
associated	O
with	O
greater	O
retention	O
of	O
the	O
product	O
after	O
application	O
,	O
and	O
decreasing	O
messiness	O
as	O
compared	O
to	O
other	O
vaginal	O
products	O
.	O

Three	O
groups	O
of	O
six	O
women	O
were	O
admitted	O
and	O
randomly	O
assigned	O
to	O
use	O
Acidform	O
with	O
0	O
%	O
,	O
2.5	O
%	O
,	O
and	O
5	O
%	O
N-9	O
.	O

Colposcopic	O
evaluation	O
for	O
vulvar	O
,	O
vaginal	O
,	O
and	O
cervical	O
signs	O
of	O
irritation	O
was	O
performed	O
and	O
photographs	O
were	O
taken	O
,	O
following	O
a	O
specific	O
World	O
Health	O
Organization	O
protocol	O
,	O
at	O
time	O
0	O
,	O
and	O
after	O
24	O
h	O
and	O
6	O
days	O
of	O
application	O
of	O
the	O
gel	O
.	O

No	Physical
irritation	Adverseeffect
or	Adverseeffect
symptom	Adverseeffect
was	O
reported	O
by	O
users	O
of	O
Acidform	O
without	O
N-9	O
.	O

A	Physical
generalized	Adverseeffect
and	Adverseeffect
intense	Adverseeffect
erythema	Adverseeffect
in	Adverseeffect
cervix	Adverseeffect
was	O
observed	O
in	O
10	O
of	O
12	O
Acidform/N-9	O
users	O
and	O
abrasion	O
occurred	O
in	O
nine	O
of	O
them	O
.	O

Vulvar	Adverseeffect
irritation	Adverseeffect
was	O
seen	O
in	O
seven	O
of	O
these	O
10	O
volunteers	O
.	O

N-9	O
concentration	O
in	O
the	O
gel	O
(	O
2.5	O
%	O
or	O
5.0	O
%	O
)	O
was	O
not	O
related	O
to	O
the	O
findings	O
.	O

No	Physical
ulcer	Adverseeffect
,	Adverseeffect
exulceration	Adverseeffect
,	Adverseeffect
or	Adverseeffect
de-epithelialization	Adverseeffect
was	O
observed	O
.	O

Acidform	O
without	O
N-9	O
was	O
well	O
tolerated	O
by	O
volunteers	O
,	O
but	O
it	O
was	O
unable	O
to	O
protect	O
the	O
cervix	O
,	O
vagina	O
,	O
and	O
vulva	O
from	O
the	O
N-9	O
effects	O
.	O

A	O
randomized	O
comparison	O
of	O
the	O
Endeavor	O
zotarolimus-eluting	O
stent	O
versus	O
the	O
TAXUS	O
paclitaxel-eluting	O
stent	O
in	O
de	O
novo	O
native	O
coronary	O
lesions	O
12-month	O
outcomes	O
from	O
the	O
ENDEAVOR	O
IV	O
trial	O
.	O

OBJECTIVES	O
The	O
ENDEAVOR	O
IV	O
(	O
Randomized	O
Comparison	O
of	O
Zotarolimus-Eluting	O
and	O
Paclitaxel-Eluting	O
Stents	O
in	O
Patients	O
with	O
Coronary	O
Artery	O
Disease	O
)	O
trial	O
evaluated	O
the	O
safety	Others
and	O
efficacy	Others
of	O
the	O
zotarolimus-eluting	O
stent	O
(	O
ZES	O
)	O
compared	O
with	O
the	O
paclitaxel-eluting	O
stent	O
(	O
PES	O
)	O
.	O

BACKGROUND	O
First-generation	O
drug-eluting	O
stents	O
have	O
reduced	O
angiographic	O
and	O
clinical	O
restenosis	O
,	O
but	O
long-term	O
safety	O
remains	O
controversial	O
.	O

A	O
second-generation	O
drug-eluting	O
stent	O
,	O
which	O
delivers	O
zotarolimus	O
,	O
a	O
potent	O
antiproliferative	O
agent	O
,	O
via	O
a	O
biocompatible	O
phosphorylcholine	O
polymer	O
on	O
a	O
cobalt	O
alloy	O
thin-strut	O
stent	O
has	O
shown	O
promising	O
experimental	O
and	O
early	O
clinical	O
results	O
.	O

METHODS	O
This	O
is	O
a	O
prospective	O
,	O
randomized	O
(	O
1:1	O
)	O
,	O
single-blind	O
,	O
controlled	O
trial	O
comparing	O
outcomes	O
of	O
patients	O
with	O
single	O
de	O
novo	O
coronary	O
lesions	O
treated	O
with	O
ZES	O
or	O
PES	O
.	O

The	O
primary	O
end	O
point	O
was	O
noninferiority	Physical
of	Physical
9-month	Physical
target	Physical
vessel	Physical
failure	Physical
defined	Physical
as	Physical
cardiac	Adverseeffect
death	Adverseeffect
,	Physical
myocardial	Physical
infarction	Physical
,	Physical
or	Physical
target	Physical
vessel	Physical
revascularization	Physical
.	O

RESULTS	O
Among	O
a	O
total	O
of	O
1,548	O
patients	O
assigned	O
to	O
ZES	O
(	O
n	O
=	O
773	O
)	O
or	O
PES	O
(	O
n	O
=	O
775	O
)	O
,	O
at	O
9	O
months	O
,	O
ZES	O
was	O
noninferior	O
to	O
PES	O
with	O
rates	O
of	O
target	Physical
vessel	Physical
failure	Physical
6.6	O
%	O
versus	O
7.1	O
%	O
,	O
respectively	O
(	O
p	O
(	O
noninferiority	O
)	O
<	O
or	O
=	O
0.001	O
)	O
.	O

There	O
were	O
fewer	O
periprocedural	Physical
myocardial	Physical
infarctions	Physical
with	O
ZES	O
(	O
0.5	O
%	O
vs.	O
2.2	O
%	O
;	O
p	O
=	O
0.007	O
)	O
,	O
whereas	O
at	O
12	O
months	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
rates	O
of	O
cardiac	Adverseeffect
death	Adverseeffect
,	Physical
myocardial	Physical
infarction	Physical
,	Physical
target	Physical
vessel	Physical
revascularization	Physical
,	Physical
or	Physical
stent	Physical
thrombosis	Physical
.	O

Although	O
incidence	O
of	O
8-month	O
binary	Physical
angiographic	Physical
in-segment	Physical
restenosis	Physical
was	O
higher	O
in	O
patients	O
treated	O
with	O
ZES	O
versus	O
PES	O
(	O
15.3	O
%	O
vs.	O
10.4	O
%	O
;	O
p	O
=	O
0.284	O
)	O
,	O
rates	O
of	O
12-month	O
target	Physical
lesion	Physical
revascularization	Physical
were	O
similar	O
(	O
4.5	O
%	O
vs.	O
3.2	O
%	O
;	O
p	O
=	O
0.228	O
)	O
,	O
especially	O
in	O
patients	O
without	O
planned	O
angiographic	O
follow-up	O
(	O
3.6	O
%	O
vs.	O
3.2	O
%	O
;	O
p	O
=	O
0.756	O
)	O
.	O

CONCLUSIONS	O
These	O
findings	O
demonstrate	O
that	O
ZES	O
has	O
similar	O
clinical	O
safety	O
and	O
efficacy	O
compared	O
with	O
PES	O
in	O
simple	O
and	O
medium	O
complexity	O
single	O
de	O
novo	O
coronary	O
lesions	O
.	O

(	O
ENDEAVOR	O
IV	O
Clinical	O
Trial	O
;	O
NCT00217269	O
)	O
.	O

Sunbathing	O
and	O
sunbed	O
use	O
related	O
to	O
self-image	O
in	O
a	O
randomized	O
sample	O
of	O
Swedish	O
adolescents	O
.	O

In	O
1996	O
a	O
randomized	O
sample	O
of	O
4,020	O
Swedish	O
adolescents	O
from	O
three	O
birth	O
cohorts	O
were	O
sent	O
a	O
questionnaire	O
consisting	O
of	O
50	O
items	O
concerning	O
habitual	O
sun-related	O
behaviours	O
and	O
attitudes	O
,	O
knowledge	O
about	O
melanoma	O
,	O
risk	O
perception	O
and	O
self-image	O
.	O

A	O
total	O
of	O
2,615	O
questionnaires	O
were	O
returned	O
.	O

Girls	O
sunbathed	O
and	O
used	O
sunbeds	O
more	O
than	O
boys	O
at	O
all	O
ages	O
.	O

Sunbathing	Mental
and	O
sunbed	Mental
use	Mental
increased	O
with	O
age	O
.	O

Boys	O
who	O
were	O
most	O
satisfied	O
and	O
girls	O
least	O
satisfied	O
with	O
themselves	O
sunbathed	Mental
most	O
.	O

Those	O
who	O
were	O
least	O
satisfied	O
with	O
themselves	O
used	Mental
sunbeds	Mental
most	O
frequently	O
.	O

Girls	O
reported	O
a	O
higher	Mental
perceived	Mental
susceptibility	Mental
to	Mental
melanoma	Mental
than	O
did	O
boys	O
.	O

The	O
perception	Mental
of	Mental
susceptibility	Mental
increased	O
with	O
age	O
.	O

Those	O
who	O
were	O
least	O
satisfied	O
with	O
themselves	O
reported	O
feeling	O
most	Mental
susceptible	Mental
.	O

The	O
overall	O
main	O
reason	Mental
for	Mental
sunbathing	Mental
was	O
appearance	O
,	O
both	O
for	O
own	O
sunbathing	O
,	O
and	O
to	O
an	O
even	O
higher	O
degree	O
,	O
as	O
a	O
supposed	O
reason	O
for	O
other	O
adolescents	O
'	O
behaviour	O
,	O
and	O
was	O
reported	O
most	O
frequently	O
by	O
girls	O
and	O
the	O
older	O
age	O
groups	O
.	O

The	O
second	O
most	O
'important	O
'	O
reason	O
for	O
sunbathing	O
was	O
'feeling	O
warm	O
and	O
comfortable	O
'	O
.	O

Preventive	O
programmes	O
aimed	O
at	O
a	O
change	O
of	O
sun	O
related	O
behaviours	O
among	O
Swedish	O
adolescents	O
have	O
to	O
be	O
tailored	O
to	O
the	O
climate	O
and	O
cultural	O
conditions	O
and	O
must	O
take	O
into	O
account	O
that	O
having	O
a	O
tan	O
,	O
and	O
the	O
warmth	O
of	O
the	O
sun	O
,	O
are	O
highly	O
valued	O
by	O
most	O
adolescents	O
.	O

Factors	O
predictive	O
of	O
severe	Physical
hypoglycemia	Physical
in	O
type	O
1	O
diabetes	O
:	O
analysis	O
from	O
the	O
Juvenile	O
Diabetes	O
Research	O
Foundation	O
continuous	O
glucose	O
monitoring	O
randomized	O
control	O
trial	O
dataset	O
.	O

OBJECTIVE	O
Identify	O
factors	O
predictive	O
of	O
severe	Physical
hypoglycemia	Physical
(	Physical
SH	Physical
)	Physical
and	O
assess	O
the	O
clinical	Others
utility	Others
of	O
continuous	Others
glucose	Others
monitoring	Others
(	Others
CGM	Others
)	Others
to	O
warn	O
of	O
impending	O
SH	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
In	O
a	O
multicenter	O
randomized	O
clinical	O
trial	O
,	O
436	O
children	O
and	O
adults	O
with	O
type	O
1	O
diabetes	O
were	O
randomized	O
to	O
a	O
treatment	O
group	O
that	O
used	O
CGM	O
(	O
N	O
=	O
224	O
)	O
,	O
or	O
a	O
control	O
group	O
that	O
used	O
standard	O
home	O
blood	O
glucose	O
monitoring	O
(	O
N	O
=	O
212	O
)	O
and	O
completed	O
12	O
months	O
of	O
follow-up	O
.	O

After	O
6	O
months	O
,	O
the	O
original	O
control	O
group	O
initiated	O
CGM	O
while	O
the	O
treatment	O
group	O
continued	O
use	O
of	O
CGM	O
for	O
6	O
months	O
.	O

Baseline	O
risk	O
factors	O
for	O
SH	O
were	O
evaluated	O
over	O
12	O
months	O
of	O
follow-up	O
using	O
proportional	O
hazards	O
regression	O
.	O

CGM-derived	Physical
indices	Physical
of	Physical
hypoglycemia	Physical
were	O
used	O
to	O
predict	O
episodes	O
of	O
SH	O
over	O
a	O
24-h	O
time	O
horizon	O
.	O

RESULTS	O
The	O
SH	Physical
rate	Physical
was	O
17.9	O
per	O
100	O
person-years	O
,	O
and	O
a	O
higher	O
rate	O
was	O
associated	O
with	O
the	O
occurrence	O
of	O
SH	Physical
in	O
the	O
prior	O
6	O
months	O
and	O
female	O
sex	O
.	O

SH	Physical
frequency	Physical
increased	O
eightfold	O
when	O
30	O
%	O
of	O
CGM	Physical
values	Physical
were	O
?	O
70	O
mg/dL	O
on	O
the	O
prior	O
day	O
(	O
4.5	O
vs.	O
0.5	O
%	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
the	O
positive	O
predictive	O
value	O
(	O
PPV	O
)	O
was	O
low	O
(	O
<	O
5	O
%	O
)	O
.	O

Results	O
were	O
similar	O
for	O
hypoglycemic	O
area	O
under	O
the	O
curve	O
and	O
the	O
low	O
blood	O
glucose	O
index	O
calculated	O
by	O
CGM	O
.	O

CONCLUSIONS	O
SH	O
in	O
the	O
6	O
months	O
prior	O
to	O
the	O
study	O
was	O
the	O
strongest	O
predictor	O
of	O
SH	O
during	O
the	O
study	O
.	O

CGM-measured	O
hypoglycemia	O
over	O
a	O
24-h	O
span	O
is	O
highly	O
associated	O
with	O
SH	O
the	O
following	O
day	O
(	O
P	O
<	O
0.001	O
)	O
,	O
but	O
the	O
PPV	O
is	O
low	O
.	O

Perioperative	Physical
fever	O
and	O
outcome	O
in	O
surgical	O
patients	O
with	O
aneurysmal	O
subarachnoid	O
hemorrhage	O
.	O

OBJECTIVE	O
We	O
examined	O
the	O
incidence	O
of	O
perioperative	O
fever	O
and	O
its	O
relationship	O
to	O
outcome	O
among	O
patients	O
enrolled	O
in	O
the	O
Intraoperative	O
Hypothermia	O
for	O
Aneurysm	O
Surgery	O
Trial	O
.	O

METHODS	O
One	O
thousand	O
patients	O
with	O
initial	O
World	O
Federation	O
of	O
Neurological	O
Surgeons	O
grades	O
of	O
I	O
to	O
III	O
undergoing	O
clipping	O
of	O
intracranial	O
aneurysms	O
after	O
subarachnoid	O
hemorrhage	O
were	O
randomized	O
to	O
intraoperative	O
normothermia	O
(	O
36	O
degrees	O
C-37	O
degrees	O
C	O
)	O
or	O
hypothermia	O
(	O
32.5	O
degrees	O
C-33.5	O
degrees	O
C	O
)	O
.	O

Fever	Physical
(	O
>	O
or	O
=38.5	O
degrees	O
C	O
)	O
and	O
other	Physical
complications	Adverseeffect
(	Adverseeffect
including	Adverseeffect
infections	Adverseeffect
)	Adverseeffect
occurring	Physical
between	Physical
admission	Physical
and	Physical
discharge	Physical
(	Physical
or	Physical
death	Adverseeffect
)	Physical
were	O
recorded	O
.	O

Functional	Physical
and	Physical
neuropsychologic	Mental
outcomes	Mental
were	O
assessed	O
3	O
months	O
postoperatively	O
.	O

The	O
primary	O
outcome	O
variable	O
for	O
the	O
trial	O
was	O
dichotomized	Physical
Glasgow	Physical
Outcome	Physical
Scale	Physical
(	Physical
good	Physical
outcome	Physical
versus	Physical
all	Physical
others	Physical
)	Physical
.	Physical

RESULTS	O
Fever	Physical
was	O
reported	O
in	O
41	O
%	O
of	O
patients	O
.	O

In	O
97	O
%	O
of	O
these	O
,	O
fever	Physical
occurred	O
in	O
the	O
postoperative	O
period	O
.	O

The	O
median	Physical
time	Physical
from	Physical
surgery	Physical
to	Physical
first	Physical
fever	Physical
was	O
3	O
days	O
.	O

All	O
measures	O
of	O
outcome	O
were	O
worse	O
in	O
patients	O
who	O
developed	O
fever	O
,	O
even	O
in	O
those	O
without	O
infections	Adverseeffect
or	O
who	O
were	O
World	O
Federation	O
of	O
Neurological	O
Surgeons	O
grade	O
I.	O
Logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
adjust	O
for	O
differences	O
in	O
preoperative	O
factors	O
(	O
e.g.	O
,	O
age	O
,	O
Fisher	O
grade	O
,	O
initial	O
neurological	O
status	O
)	O
.	O

This	O
demonstrated	O
that	O
fever	Physical
continued	O
to	O
be	O
significantly	O
associated	O
with	O
most	O
outcome	O
measures	O
,	O
even	O
when	O
infection	Adverseeffect
was	O
added	O
to	O
the	O
model	O
.	O

An	O
alternative	O
stepwise	O
model	O
selection	O
process	O
including	O
all	O
fever-related	Physical
measures	O
from	O
the	O
preoperative	O
and	O
intraoperative	O
period	O
(	O
e.g.	O
,	O
hydrocephalus	O
,	O
duration	O
of	O
surgery	O
,	O
intraoperative	O
blood	O
loss	O
)	O
resulted	O
in	O
the	O
loss	O
of	O
significance	O
for	O
dichotomized	O
Glasgow	O
Outcome	O
Scale	O
,	O
but	O
significant	O
associations	O
between	O
fever	Physical
and	O
several	O
other	O
outcome	O
measures	O
remained	O
.	O

After	O
adding	O
postoperative	O
delayed	Physical
ischemic	Physical
neurological	Physical
deficits	Physical
to	O
the	O
model	O
,	O
only	O
worsened	O
National	Physical
Institutes	Physical
of	Physical
Health	Physical
Stroke	Physical
Scale	Physical
score	Physical
,	O
Barthel	Physical
Activities	Physical
of	Physical
Daily	Physical
Living	Physical
index	Physical
,	O
and	O
discharge	Others
destination	Others
(	O
home	O
versus	O
other	O
)	O
remained	O
independently	O
associated	O
with	O
fever	O
.	O

CONCLUSION	O
These	O
findings	O
suggest	O
that	O
fever	Physical
is	O
associated	O
with	O
worsened	O
outcome	O
in	O
surgical	O
subarachnoid	O
hemorrhage	O
patients	O
,	O
although	O
,	O
because	O
the	O
association	O
between	O
fever	Physical
and	O
the	O
primary	O
outcome	O
measure	O
for	O
the	O
trial	O
is	O
dependent	O
on	O
the	O
covariates	O
used	O
in	O
the	O
analysis	O
(	O
particularly	O
operative	O
events	O
and	O
delayed	Physical
ischemic	Physical
neurological	Physical
deficits	Physical
)	Physical
,	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
fever	Physical
is	O
a	O
marker	O
for	O
other	O
events	O
.	O

Only	O
a	O
formal	O
trial	O
of	O
fever	Physical
treatment	O
or	O
prevention	O
can	O
address	O
this	O
issue	O
.	O

Observer	O
variation	O
in	O
the	O
assessment	Others
of	Others
outcome	Others
in	O
traumatic	O
brain	O
injury	O
:	O
experience	O
from	O
a	O
multicenter	O
,	O
international	O
randomized	O
clinical	O
trial	O
.	O

OBJECTIVE	O
Accurate	O
and	O
consistent	O
outcome	Others
assessment	Others
is	O
essential	O
to	O
randomized	O
clinical	O
trials	O
.	O

We	O
aimed	O
to	O
explore	O
observer	O
variation	O
in	O
the	O
assessment	Others
of	Others
outcome	Others
in	O
a	O
recently	O
completed	O
trial	O
of	O
dexanabinol	O
in	O
head	O
injury	O
and	O
to	O
consider	O
steps	O
to	O
reduce	O
such	O
variation	O
.	O

METHODS	O
Eight	O
hundred	O
sixty-one	O
patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
who	O
were	O
admitted	O
to	O
86	O
centers	O
were	O
included	O
in	O
a	O
multicenter	O
,	O
placebo-controlled	O
,	O
Phase	O
III	O
trial	O
.	O

Outcome	O
was	O
assessed	O
at	O
3	O
and	O
6	O
months	O
postinjury	O
using	O
the	O
extended	Physical
Glasgow	Physical
Outcome	Physical
Scale	Physical
;	Others
standardized	O
assessment	O
was	O
facilitated	O
by	O
the	O
use	O
of	O
a	O
structured	O
interview	O
.	O

Before	O
initiation	O
of	O
trial	O
centers	O
,	O
outcome	Others
ratings	Others
were	O
obtained	O
for	O
sample	O
cases	O
to	O
establish	O
initial	O
levels	O
of	O
agreement	O
.	O

Training	O
sessions	O
in	O
outcome	O
assessment	O
were	O
held	O
,	O
and	O
problems	O
in	O
assigning	O
outcome	O
were	O
investigated	O
.	O

During	O
the	O
trial	O
,	O
a	O
process	O
of	O
central	O
review	O
was	O
established	O
to	O
monitor	O
performance	O
.	O

Interobserver	O
variation	O
was	O
analyzed	O
using	O
the	O
kappa	O
statistic	O
.	O

RESULTS	O
Substantial	Others
observer	Others
variation	Others
was	O
found	O
in	O
the	O
rating	O
of	O
sample	O
cases	O
(	O
weighted	O
kappa	O
,	O
0.72	O
;	O
confidence	O
interval	O
,	O
0.68-0.75	O
)	O
and	O
in	O
assigning	O
outcome	Others
based	O
on	O
completed	O
structured	O
interviews	O
(	O
weighted	O
kappa	O
,	O
0.61	O
;	O
confidence	O
interval	O
,	O
0.57-0.64	O
)	O
.	O

In	O
the	O
early	O
stages	O
of	O
the	O
trial	O
,	O
a	O
relatively	O
large	O
number	O
of	O
discrepancies	Others
(	O
29-37	O
%	O
)	O
were	O
identified	O
on	O
central	O
review	O
.	O

This	O
number	O
declined	O
as	O
the	O
trial	O
progressed	O
and	O
coincided	O
with	O
investigator	O
training	O
and	O
feedback	O
from	O
central	O
review	O
.	O

Centers	O
with	O
higher	O
enrollment	O
rates	O
showed	O
better	O
performance	O
.	O

CONCLUSION	O
Observer	Others
variation	Others
in	O
outcome	Others
assessment	Others
is	O
a	O
significant	O
problem	O
for	O
head	O
injury	O
trials	O
.	O

Consistency	Others
can	O
be	O
improved	O
by	O
standardizing	O
procedures	O
,	O
training	O
assessors	O
,	O
and	O
monitoring	O
the	O
quality	O
of	O
assessments	O
and	O
providing	O
feedback	O
to	O
interviewers	O
.	O

Endometrial	O
cytodiagnosis	O
using	O
a	O
new	O
softcyte	O
versus	O
a	O
conventional	O
endocyte	O
.	O

A	O
new	O
endometrial	O
cytologic	O
sampling	O
device	O
,	O
softcyte	O
,	O
was	O
used	O
in	O
cytological	O
screening	O
for	O
endometrial	O
cancer	O
,	O
and	O
was	O
compared	O
with	O
the	O
endocyte	O
with	O
regard	O
to	O
manipulability	O
,	O
adverse	O
effects	O
(	O
including	O
pain	O
and	O
hemorrhage	O
)	O
,	O
and	O
cellular	O
findings	O
(	O
including	O
the	O
quantity	O
of	O
cells	O
collected	O
,	O
the	O
success	O
rate	O
,	O
cell	O
freshness	O
,	O
and	O
cellular	O
clumping	O
)	O
.	O

A	O
total	O
of	O
315	O
women	O
(	O
premenopause	O
251	O
,	O
postmenopause	O
64	O
)	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
who	O
underwent	O
the	O
endometrial	O
cytological	O
screening	O
with	O
either	O
the	O
softcyte	O
or	O
the	O
endocyte	O
.	O

To	O
assess	O
the	O
value	O
of	O
the	O
softcyte	O
we	O
compared	O
it	O
with	O
the	O
endocyte	O
.	O

Endometrial	O
cytology	O
using	O
a	O
softcyte	O
or	O
an	O
endocyte	O
achieved	O
high	O
correct	Others
diagnosis	Others
rate	Others
for	Others
cancer	Others
,	O
and	O
both	O
instruments	O
are	O
valuable	O
as	O
endometrial	O
cytologic	O
sample	O
devices	O
.	O

The	O
softcyte	O
causes	O
only	O
mild	Pain
pain	Pain
on	Physical
introduction	Physical
and	Physical
during	Physical
collection	Physical
,	O
and	O
a	O
large	O
quantity	Physical
of	Physical
cells	Physical
could	O
be	O
harvested	O
.	O

These	O
results	O
suggest	O
that	O
the	O
softcyte	O
is	O
a	O
useful	O
cytologic	O
sampling	O
device	O
in	O
screening	O
for	O
endometrial	O
cancer	O
.	O

A	O
comparison	O
of	O
intermittent	O
vaginal	O
administration	O
of	O
misoprostol	O
with	O
continuous	O
dinoprostone	O
for	O
cervical	Physical
ripening	Physical
and	Physical
labor	Physical
induction	Physical
.	Physical

OBJECTIVE	O
Our	O
purpose	O
was	O
to	O
compare	O
the	O
effect	O
of	O
vaginal	O
administration	O
of	O
misoprostol	O
(	O
Cytotec	O
)	O
with	O
that	O
of	O
dinoprostone	O
(	O
Cervidil	O
)	O
on	O
cervical	Physical
ripening	Physical
and	Physical
labor	Physical
induction	Physical
.	Physical

STUDY	O
DESIGN	O
Two	O
hundred	O
patients	O
with	O
indications	O
for	O
induction	O
of	O
labor	O
and	O
unfavorable	O
cervical	O
examinations	O
were	O
randomly	O
assigned	O
to	O
receive	O
vaginally	O
administered	O
misoprostol	O
(	O
prostaglandin	O
E1	O
)	O
or	O
the	O
dinoprostone	O
(	O
prostaglandin	O
E2	O
)	O
vaginal	O
insert	O
.	O

Twenty-five	O
microgram	O
tablets	O
of	O
misoprostol	O
were	O
placed	O
in	O
the	O
posterior	O
vaginal	O
fornix	O
every	O
4	O
hours	O
for	O
a	O
maximum	O
of	O
six	O
doses	O
.	O

Additional	O
misoprostol	O
was	O
not	O
given	O
after	O
either	O
spontaneous	O
rupture	O
of	O
membranes	O
,	O
adequate	O
cervical	O
ripening	O
(	O
Bishop	O
score	O
of	O
>	O
or	O
=	O
8	O
or	O
cervical	O
dilatation	O
of	O
>	O
or	O
=	O
3	O
cm	O
)	O
,	O
or	O
beginning	O
of	O
active	O
labor	O
.	O

The	O
vaginal	O
insert	O
,	O
Cervidil	O
,	O
containing	O
10	O
mg	O
of	O
dinoprostone	O
in	O
a	O
timed-release	O
preparation	O
was	O
placed	O
in	O
the	O
posterior	O
vaginal	O
formix	O
for	O
a	O
maximum	O
period	O
of	O
24	O
hours	O
.	O

The	O
vaginal	O
insert	O
was	O
removed	O
for	O
spontaneous	O
rupture	O
of	O
membranes	O
,	O
entry	O
into	O
active	O
labor	O
,	O
adequate	O
cervical	O
ripening	O
,	O
or	O
abnormality	O
of	O
uterine	O
contractile	O
pattern	O
or	O
fetal	O
cardiac	O
activity	O
.	O

RESULTS	O
Of	O
the	O
200	O
patients	O
enrolled	O
,	O
99	O
were	O
randomized	O
to	O
misoprostol	O
and	O
101	O
to	O
dinoprostone	O
.	O

The	O
average	Physical
interval	Physical
from	Physical
start	Physical
of	Physical
induction	Physical
to	Physical
vaginal	Physical
delivery	Physical
was	O
1	O
hour	O
shorter	O
in	O
the	O
misoprostol	O
group	O
(	O
1296.7	O
+/-	O
722.1	O
minutes	O
)	O
than	O
in	O
the	O
dinoprostone	O
group	O
(	O
1360.0	O
+/-	O
792.0	O
minutes	O
)	O
,	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.97	O
)	O
.	O

Oxytocin	Others
augmentation	Others
of	Others
labor	Others
was	O
used	O
in	O
50	O
(	O
50.5	O
%	O
)	O
misoprostol-treated	O
patients	O
and	O
43	O
(	O
43.5	O
%	O
)	O
dinoprostone-treated	O
patients	O
(	O
relative	O
risk	O
1.14	O
,	O
95	O
%	O
confidence	O
interval	O
0.86	O
to	O
1.51	O
,	O
p	O
=	O
0.35	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
routes	Others
of	Others
delivery	Others
with	O
misoprostol	O
or	O
dinoprostone	O
.	O

Overall	O
,	O
38	O
patients	O
(	O
19.3	O
%	O
)	O
had	O
cesarean	O
deliveries	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
prevalence	O
of	O
tachysystole	Physical
(	O
six	O
or	O
more	O
uterine	O
contractions	O
in	O
a	O
10-minute	O
window	O
for	O
two	O
consecutive	O
10-minute	O
periods	O
)	O
in	O
the	O
misoprostol	O
group	O
(	O
7.1	O
%	O
)	O
than	O
in	O
the	O
dinoprostone	O
group	O
(	O
18.4	O
%	O
)	O
(	O
relative	O
risk	O
0.52	O
,	O
95	O
%	O
confidence	O
interval	O
0.31	O
to	O
0.89	O
,	O
p	O
=	O
0.02	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
frequency	Physical
of	Physical
uterine	Physical
hyperstimulation	Physical
or	Physical
hypertonus	Physical
.	Physical

Abnormal	Physical
fetal	Physical
heart	Physical
rate	Physical
tracings	Physical
were	O
found	O
in	O
23	O
(	O
23.2	O
%	O
)	O
of	O
misoprostol-treated	O
patients	O
and	O
35	O
(	O
35.7	O
%	O
)	O
of	O
dinoprostone-treated	O
patients	O
(	O
relative	O
risk	O
0.73	O
,	O
95	O
%	O
confidence	O
interval	O
0.52	O
to	O
1.01	O
,	O
p	O
=	O
0.0546	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
meconium	Physical
passage	Physical
,	O
1-	O
or	O
5-minute	O
Apgar	Physical
scores	Physical
<	O
7	O
,	O
neonatal	Physical
resuscitations	Physical
,	Physical
or	Physical
admissions	Others
to	Others
the	Others
neonatal	Others
intensive	Others
care	Others
unit	Others
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
Vaginally	O
administered	O
misoprostol	O
is	O
as	O
effective	Others
as	O
dinoprostone	O
for	O
cervical	Physical
ripening	Physical
and	Physical
the	Physical
induction	Physical
of	Physical
labor	Physical
.	Physical

Mean	Others
time	Others
intervals	Others
to	Others
delivery	Others
,	O
need	Others
for	Others
oxytocin	Others
augmentation	Others
,	O
and	O
routes	Others
of	Others
delivery	Others
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Incidence	O
of	O
uterine	Physical
tachysystole	Physical
with	O
misoprostol	O
every	O
4	O
hours	O
was	O
significantly	O
less	O
than	O
with	O
dinoprostone	O
.	O

Effects	O
of	O
weight-bearing	O
versus	O
nonweight-bearing	O
exercise	O
on	O
function	Physical
,	O
walking	Physical
speed	Physical
,	O
and	O
position	Physical
sense	Physical
in	O
participants	O
with	O
knee	O
osteoarthritis	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
weight-bearing	O
(	O
WB	O
)	O
exercise	O
enhances	O
functional	Physical
capacity	Physical
to	O
a	O
greater	O
extent	O
than	O
nonweight-bearing	O
(	O
NWB	O
)	O
exercise	O
in	O
participants	O
with	O
knee	O
osteoarthritis	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Kinesiology	O
laboratory	O
.	O

PARTICIPANTS	O
Participants	O
(	O
N=106	O
)	O
were	O
randomly	O
assigned	O
to	O
WB	O
exercise	O
,	O
NWB	O
exercise	O
,	O
or	O
a	O
control	O
group	O
(	O
no	O
exercise	O
)	O
.	O

INTERVENTION	O
WB	O
exercise	O
and	O
NWB	O
exercise	O
groups	O
underwent	O
an	O
8-week	O
knee	O
extension-flexion	O
exercise	O
program	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Western	Physical
Ontario	Physical
and	Physical
McMaster	Physical
Universities	Physical
Osteoarthritis	Physical
Index	Physical
(	Physical
WOMAC	Physical
)	Physical
function	Physical
scale	Physical
,	O
walking	Physical
speed	Physical
,	O
muscle	Physical
torque	Physical
,	O
and	O
knee	Physical
reposition	Physical
error	Physical
were	O
assessed	O
before	O
and	O
after	O
intervention	O
.	O

RESULTS	O
Equally	O
significant	O
improvements	O
were	O
apparent	O
for	O
all	O
outcomes	O
after	O
WB	O
exercise	O
and	O
NWB	O
exercise	O
,	O
except	O
for	O
reposition	Physical
error	Physical
,	O
for	O
which	O
improvement	O
was	O
greater	O
in	O
the	O
WB	O
exercise	O
group	O
.	O

In	O
contrast	O
,	O
there	O
were	O
no	O
improvements	O
in	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
Simple	O
knee	O
flexion	O
and	O
extension	O
exercises	O
(	O
WB	O
and	O
NWB	O
)	O
performed	O
over	O
8	O
weeks	O
resulted	O
in	O
significant	O
improvement	O
in	O
the	O
WOMAC	Physical
function	Physical
scale	Physical
and	O
knee	O
strength	O
compared	O
with	O
the	O
control	O
group	O
.	O

NWB	O
exercise	O
alone	O
may	O
be	O
sufficient	O
enough	O
to	O
improve	O
function	Physical
and	O
muscle	Physical
strength	Physical
.	O

The	O
additional	O
benefit	O
of	O
WB	O
exercise	O
was	O
improved	O
position	Physical
sense	Physical
,	O
which	O
may	O
enhance	O
complex	Physical
walking	Physical
tasks	Physical
(	O
walking	O
on	O
figure	O
of	O
8	O
route	O
and	O
spongy	O
surface	O
)	O
.	O

VLDL	Physical
,	Physical
apolipoproteins	Physical
B	Physical
,	Physical
CIII	Physical
,	Physical
and	Physical
E	Physical
,	O
and	O
risk	O
of	O
recurrent	Physical
coronary	Physical
events	Physical
in	O
the	O
Cholesterol	O
and	O
Recurrent	O
Events	O
(	O
CARE	O
)	O
trial	O
.	O

BACKGROUND	O
Plasma	O
triglyceride	O
concentration	O
has	O
been	O
an	O
inconsistent	O
independent	O
risk	O
factor	O
for	O
coronary	O
heart	O
disease	O
,	O
perhaps	O
because	O
of	O
the	O
metabolic	O
heterogeneity	O
among	O
VLDL	O
particles	O
,	O
the	O
main	O
carriers	O
of	O
triglycerides	O
in	O
plasma	O
.	O

METHODS	O
AND	O
RESULTS	O
We	O
conducted	O
a	O
prospective	O
,	O
nested	O
case-control	O
study	O
in	O
the	O
Cholesterol	O
and	O
Recurrent	O
Events	O
(	O
CARE	O
)	O
trial	O
,	O
a	O
randomized	O
placebo-controlled	O
trial	O
of	O
pravastatin	O
in	O
4159	O
patients	O
with	O
myocardial	O
infarction	O
and	O
average	O
LDL	O
concentrations	O
at	O
baseline	O
(	O
115	O
to	O
174	O
mg/dL	O
,	O
mean	O
139	O
mg/dL	O
)	O
.	O

Baseline	O
concentrations	O
of	O
VLDL-apolipoprotein	Physical
(	O
apo	O
)	O
B	Physical
(	Physical
the	Physical
VLDL	Physical
particle	Physical
concentration	Physical
)	Physical
,	Physical
VLDL	Physical
lipids	Physical
,	O
and	O
apoCIII	Physical
and	Physical
apoE	Physical
in	Physical
VLDL+LDL	Physical
and	Physical
in	Physical
HDL	Physical
were	O
compared	O
in	O
patients	O
who	O
had	O
either	O
a	O
myocardial	O
infarction	O
or	O
coronary	O
death	O
(	O
cases	O
,	O
n=418	O
)	O
with	O
those	O
in	O
patients	O
who	O
did	O
not	O
have	O
a	O
cardiovascular	O
event	O
(	O
control	O
subjects	O
,	O
n=370	O
)	O
in	O
5	O
years	O
of	O
follow-up	O
.	O

VLDL-cholesterol	Physical
,	O
VLDL-triglyceride	Physical
,	O
VLDL-apoB	Physical
,	Physical
apoCIII	Physical
and	O
apoE	Physical
in	Physical
VLDL+LDL	Physical
and	O
apoE	Physical
in	Physical
HDL	Physical
were	O
all	O
interrelated	O
,	O
and	O
each	O
was	O
a	O
univariate	O
predictor	O
of	O
subsequent	O
coronary	O
events	O
.	O

The	O
significant	O
independent	O
predictors	O
were	O
VLDL-apoB	Physical
(	O
relative	O
risk	O
[	O
RR	O
]	O
3.2	O
for	O
highest	O
to	O
lowest	O
quintiles	O
,	O
P	O
:	O
=0.04	O
)	O
,	O
apoCIII	Physical
in	Physical
VLDL+LDL	Physical
(	O
RR	O
2.3	O
,	O
P	O
:	O
=0.04	O
)	O
,	O
and	O
apoE	Physical
in	Physical
HDL	Physical
(	O
RR	O
1.8	O
,	O
P	O
:	O
=0.02	O
)	O
.	O

Plasma	Physical
triglycerides	Physical
,	O
a	O
univariate	O
predictor	O
of	O
coronary	Physical
events	Physical
(	O
RR	O
1.6	O
,	O
P	O
:	O
=0.03	O
)	O
,	O
was	O
not	O
related	O
to	O
coronary	Physical
events	Physical
(	O
RR	O
1.3	O
,	O
P	O
:	O
=0.6	O
)	O
when	O
apoCIII	Physical
in	Physical
VLDL+LDL	Physical
was	O
included	O
in	O
the	O
model	O
,	O
whereas	O
apoCIII	Physical
remained	O
significant	O
.	O

Adjustment	O
for	O
LDL-	Physical
and	Physical
HDL-cholesterol	Physical
did	O
not	O
affect	O
these	O
results	O
.	O

CONCLUSIONS	O
The	O
plasma	O
concentrations	O
of	O
VLDL	Physical
particles	Physical
and	O
apoCIII	Physical
in	Physical
VLDL	Physical
and	Physical
LDL	Physical
are	O
more	O
specific	O
measures	O
of	O
coronary	O
heart	O
disease	O
risk	O
than	O
plasma	O
triglycerides	O
perhaps	O
because	O
their	O
known	O
metabolic	O
properties	O
link	O
them	O
more	O
closely	O
to	O
atherosclerosis	O
.	O

Morphological	O
onset	O
and	O
early	O
diagnosis	O
in	O
apical	O
hypertrophic	O
cardiomyopathy	O
:	O
a	O
long	O
term	O
analysis	O
with	O
nuclear	O
magnetic	O
resonance	O
imaging	O
.	O

OBJECTIVES	O
A	O
long-term	O
follow-up	O
study	O
with	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
imaging	O
was	O
undertaken	O
to	O
detect	O
the	O
morphological	O
onset	O
and	O
to	O
establish	O
the	O
early	O
diagnosis	O
in	O
apical	O
hypertrophic	O
cardiomyopathy	O
(	O
HCM	O
)	O
.	O

BACKGROUND	O
A	O
spadelike	O
configuration	O
on	O
left	Physical
ventriculogram	Physical
(	Physical
LVG	Physical
)	Physical
is	O
regarded	O
as	O
a	O
diagnostic	O
criterion	O
for	O
the	O
classical	O
apical	O
HCM	O
.	O

There	O
also	O
exists	O
a	O
segmented	O
hypertrophy	O
at	O
the	O
apical	O
level	O
without	O
indicating	O
the	O
spadelike	O
features	O
(	O
a	O
nonspade	O
configuration	O
)	O
.	O

To	O
detect	O
the	O
hypertrophied	O
myocardium	O
of	O
the	O
nonspade	O
configuration	O
,	O
circumferential	O
scrutiny	O
of	O
the	O
apex	O
is	O
required	O
.	O

Although	O
both	O
configurations	O
can	O
be	O
underlying	O
causes	O
of	O
giant	O
negative	O
T	O
waves	O
,	O
etiological	O
relationship	O
between	O
the	O
two	O
is	O
not	O
clarified	O
.	O

METHODS	O
The	O
criteria	O
for	O
the	O
spadelike	O
configuration	O
defined	O
on	O
left	O
ventricular	O
short-axis	O
NMR	O
images	O
were	O
as	O
follows	O
:	O
(	O
apical	O
maximal	O
thickness	O
>	O
or	O
=	O
15	O
mm	O
)	O
,	O
(	O
apical	O
anterior	O
thickness	O
over	O
basal	O
anterior	O
thickness	O
>	O
or	O
=	O
1.3	O
)	O
and	O
(	O
apical	O
posterior	O
thickness	O
over	O
basal	O
posterior	O
thickness	O
>	O
or	O
=1.3	O
)	O
.	O

Thirteen	O
patients	O
who	O
had	O
predominant	O
hypertrophy	O
(	O
>	O
or	O
=	O
15	O
mm	O
)	O
at	O
the	O
apical	O
level	O
without	O
the	O
spadelike	O
configuration	O
underwent	O
NMR	O
imaging	O
twice	O
before	O
and	O
after	O
54+/-10	O
months	O
'	O
follow-up	O
.	O

RESULTS	O
Apical	Physical
hypertrophy	Physical
that	O
had	O
been	O
confined	O
to	O
the	O
lateral	O
wall	O
in	O
four	O
,	O
the	O
anterior-lateral	O
wall	O
in	O
two	O
,	O
and	O
the	O
septal-anterior	O
wall	O
in	O
one	O
developed	O
to	O
become	O
circumferential	Physical
hypertrophy	Physical
that	O
fulfilled	O
the	O
criteria	O
for	O
the	O
spadelike	O
configuration	O
after	O
the	O
follow-up	O
period	O
.	O

CONCLUSIONS	O
The	O
spadelike	O
configuration	O
can	O
begin	O
with	O
the	O
nonspade	O
configuration	O
and	O
therefore	O
,	O
both	O
can	O
constitute	O
a	O
single	O
disease	O
entity	O
of	O
apical	O
HCM	O
.	O

The	O
early	O
diagnosis	O
of	O
apical	Physical
HCM	Physical
can	O
be	O
achieved	O
by	O
identifying	O
the	O
hypertrophy	Physical
frequently	O
confined	O
to	O
the	O
lateral	O
wall	O
at	O
the	O
apical	O
level	O
.	O

Oral	O
health	O
impacts	O
on	O
daily	O
living	O
related	O
to	O
four	O
different	O
treatment	O
protocols	O
for	O
chronic	O
periodontitis	O
.	O

BACKGROUND	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
the	O
oral	O
health	O
impacts	O
perceived	O
by	O
patients	O
submitted	O
to	O
different	O
treatments	O
of	O
chronic	O
periodontitis	O
and	O
their	O
association	O
with	O
clinical	O
parameters	O
.	O

METHODS	O
Sixty	O
patients	O
were	O
assigned	O
to	O
one	O
of	O
the	O
following	O
therapeutic	O
groups	O
:	O
control	O
,	O
treated	O
with	O
full-mouth	O
scaling	O
and	O
root	O
planing	O
(	O
SRP	O
)	O
;	O
test	O
1	O
,	O
treated	O
with	O
SRP	O
and	O
400	O
mg	O
systemically	O
administered	O
metronidazole	O
(	O
MET	O
)	O
three	O
times	O
per	O
day	O
for	O
10	O
days	O
;	O
test	O
2	O
,	O
treated	O
with	O
SRP	O
and	O
professional	O
supragingival	O
plaque	O
removal	O
(	O
PP	O
)	O
every	O
week	O
for	O
3	O
months	O
;	O
and	O
test	O
3	O
,	O
treated	O
with	O
SRP	O
and	O
MET	O
plus	O
PP	O
.	O

Clinical	O
periodontal	O
measurements	O
and	O
data	O
regarding	O
patients	O
'	O
oral	Physical
health	Physical
impacts	Physical
(	Physical
perceived	Physical
impacts	Physical
on	Physical
bleeding	Physical
gums	Physical
,	Physical
gingival	Physical
recession	Physical
,	Physical
sensitivity	Physical
to	Physical
cold	Physical
,	Physical
packing	Physical
foods	Physical
,	Physical
aesthetics	Physical
,	Physical
bad	Physical
breath	Physical
,	Physical
and	Physical
tooth	Physical
mobility	Physical
)	Physical
were	O
collected	O
at	O
baseline	O
and	O
3	O
months	O
after	O
therapy	O
.	O

RESULTS	O
All	O
groups	O
presented	O
significant	O
improvement	O
in	O
oral	Physical
health	Physical
perceived	Physical
impacts	Physical
.	Physical

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
improvement	O
of	O
oral	Physical
health	Physical
impacts	Physical
among	O
groups	O
subjected	O
to	O
different	O
treatments	O
.	O

The	O
clinical	O
data	O
of	O
percentage	O
of	O
deep	Physical
probing	Physical
depth	Physical
,	Physical
deep	Physical
clinical	Physical
attachment	Physical
level	Physical
,	Physical
and	Physical
bleeding	Physical
on	Physical
probing	Physical
were	O
found	O
to	O
be	O
correlated	O
significantly	O
with	O
oral	O
health	O
impacts	O
.	O

CONCLUSIONS	O
Periodontal	O
treatment	O
leads	O
to	O
a	O
significant	O
reduction	O
of	O
self-perceived	Physical
impacts	Physical
regardless	O
of	O
the	O
non-surgical	O
treatment	O
protocol	O
employed	O
.	O

Most	O
of	O
the	O
clinical	O
data	O
were	O
associated	O
with	O
oral	O
health	O
impacts	O
.	O

Recombinant	O
human	O
erythropoietin	O
therapy	O
for	O
anemic	O
cancer	O
patients	O
on	O
combination	O
chemotherapy	O
.	O

BACKGROUND	O
Patients	O
with	O
advanced	O
cancer	O
frequently	O
experience	O
clinically	Physical
significant	Physical
anemia	Physical
,	O
which	O
is	O
often	O
exacerbated	O
by	O
myelosuppressive	O
chemotherapy	O
.	O

Consistent	O
with	O
the	O
anemia	O
of	O
chronic	O
disease	O
,	O
studies	O
have	O
documented	O
serum	O
erythropoietin	O
levels	O
that	O
are	O
inappropriately	O
low	O
for	O
the	O
degree	O
of	O
anemia	O
in	O
cancer	O
patients	O
.	O

Myelosuppressive	O
chemotherapy	O
impairs	O
erythropoiesis	O
,	O
which	O
may	O
not	O
fully	O
recover	O
between	O
treatment	O
cycles	O
.	O

Recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
has	O
been	O
used	O
safely	O
and	O
effectively	O
to	O
treat	O
anemia	O
in	O
AIDS	O
patients	O
receiving	O
zidovudine	O
(	O
AZT	O
)	O
and	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
.	O

PURPOSE	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
clinical	O
role	O
of	O
rHuEPO	O
in	O
reducing	O
symptomatic	Physical
anemia	Physical
in	O
patients	O
with	O
advanced	O
cancer	O
who	O
were	O
receiving	O
myelosuppressive	O
chemotherapy	O
(	O
excluding	O
cisplatin	O
)	O
.	O

METHODS	O
We	O
studied	O
153	O
anemic	O
cancer	O
patients	O
receiving	O
cyclic	O
combination	O
chemotherapy	O
in	O
a	O
prospective	O
multicenter	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
rHuEPO	O
(	O
150	O
U/kg	O
)	O
or	O
placebo	O
subcutaneously	O
three	O
times	O
a	O
week	O
for	O
a	O
maximum	O
of	O
12	O
weeks	O
or	O
until	O
the	O
hematocrit	Physical
level	Physical
increased	O
to	O
38	O
%	O
-40	O
%	O
.	O

If	O
the	O
hematocrit	Physical
reached	O
this	O
target	O
level	O
before	O
12	O
weeks	O
,	O
the	O
rHuEPO	O
dose	O
could	O
be	O
reduced	O
to	O
maintain	O
the	O
hematocrit	O
at	O
that	O
level	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Response	O
to	O
rHuEPO	O
therapy	O
was	O
assessed	O
by	O
measuring	O
changes	Physical
in	Physical
hematocrit	Physical
level	Physical
,	O
transfusion	Others
requirements	Others
,	O
and	O
quality	Others
of	Others
life	Others
.	O

Quality-of-life	Others
assessment	O
was	O
based	O
on	O
patients	O
'	O
responses	O
to	O
questionnaires	O
before	O
and	O
after	O
the	O
courses	O
of	O
therapy	O
.	O

RESULTS	O
The	O
increase	O
in	O
hematocrit	Physical
in	O
the	O
rHuEPO-treated	O
group	O
compared	O
with	O
hematocrit	Physical
in	O
the	O
placebo-treated	O
group	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
.0001	O
)	O
as	O
measured	O
by	O
percentage	O
point	O
of	O
change	O
from	O
baseline	O
to	O
final	O
evaluation	O
,	O
by	O
an	O
increase	O
in	O
hematocrit	Physical
level	O
of	O
six	O
percentage	O
points	O
or	O
more	O
unrelated	O
to	O
transfusion	O
,	O
and	O
by	O
a	O
rise	O
in	O
hematocrit	Physical
level	Physical
to	O
38	O
%	O
or	O
more	O
unrelated	O
to	O
transfusion	O
.	O

There	O
was	O
a	O
trend	O
toward	O
the	O
reduction	O
in	O
mean	Others
units	Others
of	Others
blood	Others
transfused	Others
per	Others
patient	Others
during	O
months	O
2	O
and	O
3	O
of	O
therapy	O
combined	O
in	O
rHuEPO-treated	O
patients	O
compared	O
with	O
placebo-treated	O
patients	O
(	O
0.91	O
U	O
versus	O
1.65	O
U	O
;	O
P	O
=	O
.056	O
)	O
.	O

In	O
addition	O
,	O
rHuEPO-treated	O
patients	O
experienced	O
a	O
statistically	O
significant	O
improvement	O
in	O
energy	Others
level	Others
and	O
ability	Others
to	Others
perform	Others
daily	Others
activities	Others
(	O
P	O
<	O
or	O
=	O
.05	O
)	O
.	O

The	O
two	O
treatment	O
groups	O
showed	O
no	O
statistically	O
significant	O
differences	O
in	O
toxic	Adverseeffect
effects	Adverseeffect
except	O
for	O
increased	O
incidence	O
of	O
diaphoresis	Adverseeffect
(	O
P	O
<	O
.05	O
)	O
and	O
diarrhea	Adverseeffect
(	O
P	O
=	O
.05	O
)	O
in	O
the	O
rHuEPO-treated	O
group	O
.	O

CONCLUSIONS	O
We	O
conclude	O
that	O
rHuEPO	O
is	O
safe	O
and	O
effective	O
for	O
reversing	O
anemia	Physical
related	O
to	O
advanced	O
cancer	O
or	O
to	O
chemotherapy	O
for	O
cancer	O
.	O

Allogeneic	O
marrow	O
transplantation	O
in	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
in	O
the	O
chronic	O
phase	O
:	O
a	O
randomized	O
trial	O
of	O
two	O
irradiation	O
regimens	O
.	O

A	O
randomized	O
trial	O
was	O
performed	O
to	O
compare	O
two	O
regimens	O
of	O
total	O
body	O
irradiation	O
in	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
treated	O
by	O
allogeneic	O
marrow	O
transplantation	O
while	O
in	O
the	O
chronic	O
phase	O
.	O

All	O
patients	O
received	O
cyclophosphamide	O
120	O
mg/kg	O
followed	O
by	O
total	O
body	O
irradiation	O
and	O
marrow	O
from	O
HLA-identical	O
siblings	O
.	O

Cyclosporine	O
and	O
methotrexate	O
were	O
used	O
for	O
prophylaxis	O
against	O
acute	O
graft-versus-host	O
disease	O
.	O

Fifty-seven	O
patients	O
were	O
randomized	O
to	O
receive	O
2.0	O
Gy	O
fractions	O
of	O
irradiation	O
daily	O
for	O
6	O
days	O
and	O
59	O
were	O
randomized	O
to	O
receive	O
2.25	O
Gy	O
fractions	O
daily	O
for	O
7	O
days	O
.	O

The	O
probabilities	Physical
of	Physical
relapse	Physical
at	O
4	O
years	O
were	O
0.25	O
for	O
the	O
12.0	O
Gy	O
group	O
and	O
0.00	O
for	O
the	O
15.75	O
Gy	O
group	O
(	O
P	O
=	O
.008	O
)	O
.	O

The	O
actuarial	Mortality
probabilities	Mortality
of	Mortality
survival	Mortality
and	O
relapse-free	Mortality
survival	Mortality
at	O
4	O
years	O
were	O
0.60	O
and	O
0.58	O
among	O
the	O
patients	O
who	O
received	O
12.0	O
Gy	O
compared	O
with	O
0.66	O
and	O
0.66	O
for	O
those	O
who	O
received	O
15.75	O
Gy	O
.	O

The	O
4-year	O
probabilities	Mortality
of	Mortality
transplant-related	Mortality
mortality	Mortality
were	O
0.24	O
and	O
0.34	O
respectively	O
(	O
P	O
=	O
.13	O
)	O
while	O
the	O
probability	Others
of	Others
moderate	Others
to	Others
severe	Others
acute	Others
graft-versus-host	Others
disease	Others
was	O
0.33	O
for	O
the	O
12.0	O
Gy	O
group	O
and	O
0.44	O
for	O
the	O
15.75	O
Gy	O
group	O
(	O
P	O
=	O
.15	O
)	O
.	O

The	O
lower	O
relapse	Physical
probability	Physical
in	O
the	O
patients	O
receiving	O
the	O
higher	O
dose	O
of	O
total	O
body	O
irradiation	O
did	O
not	O
result	O
in	O
improved	Physical
survival	Mortality
because	O
mortality	O
from	O
causes	O
other	O
than	O
relapse	O
was	O
increased	O
.	O

Effects	O
of	O
20	O
mg	O
rosuvastatin	O
on	O
VLDL1-	O
,	O
VLDL2-	O
,	O
IDL-	O
and	O
LDL-ApoB	O
kinetics	O
in	O
type	O
2	O
diabetes	O
.	O

AIMS/HYPOTHESIS	O
In	O
addition	O
to	O
its	O
efficacy	O
in	O
reducing	O
LDL-cholesterol	Physical
,	O
rosuvastatin	O
has	O
been	O
shown	O
to	O
significantly	O
decrease	O
plasma	Physical
triacylglycerol	Physical
.	O

The	O
use	O
of	O
rosuvastatin	O
may	O
be	O
beneficial	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
,	O
who	O
usually	O
have	O
increased	O
triacylglycerol	Physical
levels	Physical
.	O

However	O
,	O
its	O
effects	O
on	O
the	O
metabolism	O
of	O
triacylglycerol-rich	O
lipoproteins	O
in	O
type	O
2	O
diabetic	O
patients	O
remains	O
unknown	O
.	O

METHODS	O
We	O
performed	O
a	O
randomised	O
double-blind	O
crossover	O
trial	O
of	O
6-week	O
treatment	O
with	O
placebo	O
or	O
rosuvastatin	O
20	O
mg	O
in	O
eight	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
were	O
being	O
treated	O
with	O
oral	O
glucose-lowering	O
agents	O
.	O

In	O
each	O
patient	O
,	O
an	O
in	O
vivo	O
kinetic	O
study	O
of	O
apolipoprotein	O
B	O
(	O
ApoB	O
)	O
-containing	O
lipoproteins	O
with	O
[	O
13C	O
]	O
leucine	O
was	O
performed	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
.	O

A	O
central	O
randomisation	O
centre	O
used	O
computer-generated	O
tables	O
to	O
allocate	O
treatments	O
.	O

Participants	O
,	O
caregivers	O
and	O
those	O
assessing	O
the	O
outcomes	O
were	O
blinded	O
to	O
group	O
assignment	O
.	O

RESULTS	O
Rosuvastatin	O
20	O
mg	O
significantly	O
reduced	O
plasma	Physical
LDL-cholesterol	Physical
,	O
triacylglycerol	Physical
and	O
total	Physical
ApoB	Physical
.	O

It	O
also	O
significantly	O
reduced	O
ApoB	O
pool	O
sizes	O
of	O
larger	O
triacylglycerol-rich	O
VLDL	O
particles	O
(	O
VLDL1	O
;	O
p	O
=	O
0.011	O
)	O
,	O
smaller	Physical
VLDL	Physical
particles	Physical
(	O
VLDL2	O
;	O
p	O
=	O
0.011	O
)	O
,	O
intermediate	Physical
density	Physical
lipoprotein	Physical
(	O
IDL	O
;	O
p	O
=	O
0.011	O
)	O
and	O
LDL	O
(	O
p	O
=	O
0.011	O
)	O
.	O

This	O
reduction	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
the	O
total	Physical
fractional	Physical
catabolic	Physical
rate	Physical
of	Physical
VLDL1-ApoB	Physical
(	O
6.70	O
+/-	O
3.24	O
vs	O
4.52	O
+/-	O
2.34	O
pool/day	O
,	O
p	O
=	O
0.049	O
)	O
,	O
VLDL2-ApoB	O
(	O
8.72	O
+/-	O
3.37	O
vs	O
5.36	O
+/-	O
2.64	O
,	O
p	O
=	O
0.011	O
)	O
,	O
IDL-ApoB	O
(	O
7.06	O
+/-	O
1.68	O
vs	O
4.21	O
+/-	O
1.51	O
,	O
p	O
=	O
0.011	O
)	O
and	O
LDL-ApoB	O
(	O
1.02	O
+/-	O
0.27	O
vs	O
0.59	O
+/-	O
0.13	O
,	O
p	O
=	O
0.011	O
)	O
.	O

Rosuvastatin	O
did	O
not	O
change	O
the	O
production	Physical
rates	Physical
of	Physical
VLDL2-	Physical
,	Physical
IDL-	Physical
or	Physical
LDL-	Physical
,	O
but	O
did	O
reduce	O
VLDL1-ApoB	Physical
production	Physical
rate	Physical
(	O
12.4	O
+/-	O
4.5	O
vs	O
19.5	O
+/-	O
8.4	O
mg	O
kg	O
(	O
-1	O
)	O
day	O
(	O
-1	O
)	O
,	O
p	O
=	O
0.035	O
)	O
.	O

No	O
side	Adverseeffect
effects	Adverseeffect
of	O
rosuvastatin	O
were	O
observed	O
during	O
the	O
study	O
.	O

CONCLUSIONS/INTERPRETATION	O
In	O
type	O
2	O
diabetic	O
patients	O
rosuvastatin	O
20	O
mg	O
not	O
only	O
induces	O
a	O
significant	O
increase	O
of	O
LDL-ApoB	Physical
catabolism	Physical
(	O
73	O
%	O
)	O
,	O
but	O
also	O
has	O
favourable	O
effects	O
on	O
the	O
catabolism	Physical
of	Physical
triacylglycerol-rich	Physical
lipoproteins	Physical
,	O
e.g	O
.	O

a	O
significant	O
increase	O
in	O
the	O
catabolism	Physical
of	Physical
VLDL1-ApoB	Physical
(	O
48	O
%	O
)	O
,	O
VLDL2-ApoB	Physical
(	O
63	O
%	O
)	O
and	O
IDL-ApoB	Physical
(	O
68	O
%	O
)	O
,	O
and	O
a	O
reduction	O
in	O
the	O
production	O
rate	O
of	O
VLDL1-ApoB	Physical
(	O
-36	O
%	O
)	O
.	O

The	O
effects	O
of	O
rosuvastatin	O
on	O
the	O
metabolism	O
of	O
triacylglycerol-rich	O
lipoproteins	O
may	O
be	O
beneficial	O
for	O
prevention	O
of	O
atherosclerosis	O
in	O
type	O
2	O
diabetic	O
patients	O
.	O

Enhancing	O
the	O
self-esteem	Mental
of	O
inpatient	O
alcoholics	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
pairing	O
inpatient	O
alcoholics	O
with	O
nursing	O
home	O
residents	O
(	O
NHRs	O
)	O
on	O
the	O
alcoholics	Mental
'	Mental
self-esteem	Mental
.	O

In	O
this	O
PALS	O
program	O
,	O
the	O
alcoholic	O
inpatients	O
assumed	O
a	O
helping-companion	O
relationship	O
with	O
the	O
NHRs	O
for	O
2	O
hr	O
per	O
day	O
during	O
their	O
last	O
2	O
weeks	O
of	O
treatment	O
.	O

Fifty	O
alcoholic	O
inpatients	O
were	O
randomly	O
assigned	O
to	O
the	O
PALS	O
program	O
(	O
n	O
=	O
25	O
)	O
or	O
to	O
the	O
library	O
for	O
free	O
reading	O
time	O
(	O
n	O
=	O
25	O
)	O
.	O

The	O
Tennessee	Mental
Self-Concept	Mental
Scale	Mental
(	Mental
TSCS	Mental
)	Mental
was	O
administered	O
to	O
all	O
subjects	O
in	O
both	O
groups	O
before	O
and	O
after	O
the	O
interventions	O
.	O

Of	O
the	O
nine	O
TSCS	Mental
scales	Mental
,	O
the	O
improvement	O
on	O
the	O
Moral-Ethical	Mental
scale	Mental
was	O
significantly	O
greater	O
in	O
the	O
PALS	O
group	O
.	O

Because	O
the	O
alcoholic	O
inpatients	O
in	O
the	O
PALS	O
group	O
engaged	O
in	O
altruistic	Mental
(	Mental
moral	Mental
)	Mental
behavior	Mental
,	O
this	O
study	O
provides	O
a	O
logical	O
link	O
between	O
the	O
intervention	O
and	O
the	O
outcome	O
,	O
which	O
has	O
been	O
a	O
prevalent	O
weakness	O
in	O
previous	O
studies	O
of	O
self-esteem	O
in	O
alcoholics	O
.	O

Cytokine	Physical
levels	Physical
and	O
systemic	Adverseeffect
toxicity	Adverseeffect
in	O
patients	O
undergoing	O
isolated	O
limb	O
perfusion	O
with	O
high-dose	O
tumor	O
necrosis	O
factor	O
,	O
interferon	O
gamma	O
,	O
and	O
melphalan	O
.	O

PURPOSE	O
Isolated	O
limb	O
perfusion	O
(	O
ILP	O
)	O
with	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
interferon	O
gamma	O
,	O
and	O
melphalan	O
(	O
M	O
)	O
has	O
been	O
reported	O
to	O
result	O
in	O
high	O
response	Physical
rates	Physical
for	O
extremity	O
melanoma	O
and	O
sarcoma	O
.	O

We	O
have	O
evaluated	O
the	O
relationship	O
of	O
systemic	O
TNF	O
exposure	O
to	O
induction	O
of	O
several	O
secondary	Physical
mediators	Physical
and	O
incidence	O
of	O
systemic	Adverseeffect
toxicity	Adverseeffect
.	O

PATIENTS	O
AND	O
METHODS	O
Nineteen	O
patients	O
with	O
extremity	O
melanoma	O
(	O
n	O
=	O
16	O
)	O
or	O
sarcoma	O
(	O
n	O
=	O
3	O
)	O
,	O
underwent	O
90-minute	O
ILP	O
with	O
TNF-alpha	O
,	O
interferon	O
gamma	O
(	O
0.2	O
mg	O
)	O
,	O
and	O
M	O
(	O
10	O
to	O
13	O
mg/L	O
of	O
limb	O
volume	O
)	O
(	O
TNF/IFN/M	O
)	O
(	O
n	O
=	O
12	O
)	O
,	O
or	O
M	O
alone	O
(	O
n	O
=	O
7	O
)	O
.	O

Continuous	O
intraoperative	O
monitoring	O
(	O
CIM	O
)	O
for	O
systemic	O
leak	O
from	O
the	O
perfusion	O
circuit	O
was	O
performed	O
using	O
radioactive	O
iodine-131	O
albumin	O
.	O

Cytokine	O
levels	O
in	O
the	O
perfusate	O
and	O
systemic	O
circulation	O
during	O
and	O
after	O
ILP	O
were	O
measured	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
Systemic	O
leaks	O
>	O
or	O
=	O
1	O
%	O
from	O
the	O
perfusion	O
circuit	O
occurred	O
in	O
six	O
patients	O
who	O
received	O
TNF/IFN/M	O
and	O
in	O
four	O
who	O
received	O
M	O
alone	O
.	O

Hypotension	Adverseeffect
that	Adverseeffect
required	Adverseeffect
vasopressor	Adverseeffect
support	Adverseeffect
occurred	O
in	O
six	O
of	O
six	O
patients	O
with	O
evidence	O
of	O
a	O
leak	O
(	O
>	O
or	O
=	O
1	O
%	O
)	O
and	O
zero	O
of	O
six	O
patients	O
without	O
a	O
leak	O
(	O
<	O
1	O
%	O
)	O
.	O

These	O
six	O
patients	O
had	O
significantly	O
higher	O
peak	Physical
systemic	Physical
TNF	Physical
levels	Physical
during	O
and	O
after	O
perfusion	O
than	O
patients	O
without	O
a	O
leak	O
(	O
2.8	O
and	O
8.2	O
ng/mL	O
v	O
0.7	O
and	O
2.0	O
ng/mL	O
,	O
respectively	O
;	O
P	O
<	O
.05	O
)	O
.	O

All	O
patients	O
who	O
received	O
TNF/IFN/M	O
had	O
significantly	O
greater	O
increases	O
in	O
systemic	Physical
interleukin-6	Physical
(	Physical
IL-6	Physical
)	Physical
levels	Physical
than	O
in	O
patients	O
with	O
M	O
alone	O
(	O
12,395	O
+/-	O
10,374	O
pg/mL	O
v	O
79.4	O
+/-	O
7.2	O
pg/mL	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
.	O

Intracellular	Physical
adhesion	Physical
molecule	Physical
(	Physical
ICAM	Physical
)	Physical
,	Physical
IL-8	Physical
,	Physical
and	Physical
TNF-R	Physical
levels	Physical
were	O
also	O
increased	O
after	O
ILP	O
with	O
TNF/IFN/M	O
.	O

CONCLUSION	O
ILP	O
with	O
TNF/IFN/M	O
can	O
be	O
safely	O
performed	O
,	O
as	O
I131	O
albumin	O
provides	O
a	O
sensitive	O
measure	O
of	O
systemic	O
leakage	O
from	O
the	O
perfusion	O
circuit	O
.	O

Patients	O
with	O
a	O
measured	O
leak	O
of	O
>	O
or	O
=	O
1	O
%	O
develop	O
mild	O
and	O
transient	O
postoperative	O
hypotension	O
with	O
significantly	O
higher	O
systemic	O
TNF	O
levels	O
and	O
lower	O
perfusate	O
TNF	O
levels	O
than	O
in	O
patients	O
without	O
leaks	O
.	O

A	O
randomized	O
controlled	O
study	O
of	O
parent-assisted	O
Children	O
's	O
Friendship	O
Training	O
with	O
children	O
having	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
evaluated	O
Children	O
's	O
Friendship	O
Training	O
(	O
CFT	O
)	O
,	O
a	O
manualized	O
parent-assisted	O
intervention	O
to	O
improve	O
social	O
skills	O
among	O
second	O
to	O
fifth	O
grade	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Comparison	O
was	O
made	O
with	O
a	O
delayed	O
treatment	O
control	O
group	O
(	O
DTC	O
)	O
.	O

Targeted	O
skills	O
included	O
conversational	Mental
skills	Mental
,	O
peer	Mental
entry	Mental
skills	Mental
,	O
developing	O
friendship	Mental
networks	O
,	O
good	Mental
sportsmanship	Mental
,	O
good	Mental
host	Mental
behavior	Mental
during	Mental
play	Mental
dates	Mental
,	O
and	O
handling	Mental
teasing	Mental
.	O

At	O
post-testing	O
,	O
the	O
CFT	O
group	O
was	O
superior	O
to	O
the	O
DTC	O
group	O
on	O
parent	O
measures	O
of	O
social	Mental
skill	Mental
and	O
play	Mental
date	Mental
behavior	Mental
,	O
and	O
child	O
measures	O
of	O
popularity	Mental
and	Mental
loneliness	Mental
,	O
At	O
3-month	O
follow-up	O
,	O
parent	O
measures	O
showed	O
significant	O
improvement	O
from	O
baseline	O
.	O

Post-hoc	O
analysis	O
indicated	O
more	O
than	O
87	O
%	O
of	O
children	O
receiving	O
CFT	O
showed	O
reliable	O
change	O
on	O
at	O
least	O
one	O
measure	O
at	O
post-test	O
and	O
66.7	O
%	O
after	O
3	O
months	O
follow-up	O
.	O

Memantine	O
add-on	O
to	O
risperidone	O
for	O
treatment	O
of	O
negative	O
symptoms	O
in	O
patients	O
with	O
stable	O
schizophrenia	O
:	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
memantine	O
add-on	O
in	O
the	O
treatment	O
of	O
primary	O
negative	O
symptoms	O
of	O
patients	O
with	O
stable	O
schizophrenia	O
.	O

In	O
a	O
double-blind	O
placebo-controlled	O
clinical	O
trial	O
,	O
40	O
patients	O
with	O
schizophrenia	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
)	O
who	O
were	O
stabilized	O
on	O
risperidone	O
for	O
a	O
minimum	O
of	O
8	O
weeks	O
were	O
randomized	O
to	O
either	O
memantine	O
(	O
20	O
mg	O
)	O
or	O
placebo	O
in	O
addition	O
to	O
risperidone	O
,	O
6	O
mg/d	O
,	O
for	O
eight	O
weeks	O
.	O

Assessment	O
was	O
done	O
using	O
the	O
Positive	Mental
and	Mental
Negative	Mental
Syndrome	Mental
Scale	Mental
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
.	O

The	O
Hamilton	Mental
Depression	Mental
Rating	Mental
Scale	Mental
and	O
the	O
Extrapyramidal	Mental
Symptom	Mental
Rating	Mental
Scale	Mental
at	O
baseline	O
and	O
week	O
8	O
were	O
used	O
to	O
assess	O
depression	O
and	O
extrapyramidal	O
symptoms	O
,	O
respectively	O
.	O

All	O
40	O
patients	O
had	O
at	O
least	O
one	O
postbaseline	O
measurement	O
,	O
and	O
38	O
patients	O
completed	O
the	O
trial	O
.	O

Patients	O
in	O
the	O
memantine	O
group	O
showed	O
a	O
significantly	Mental
greater	Mental
improvement	Mental
on	Mental
negative	Mental
subscale	Mental
than	O
the	O
placebo	O
group	O
at	O
end	O
point	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
same	Physical
effect	Physical
was	O
observed	O
for	O
the	O
total	O
score	O
(	O
P	O
<	O
0.001	O
)	O
and	O
the	O
general	O
psychopathology	O
subscale	O
score	O
(	O
P	O
=	O
0.002	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
reduction	O
of	O
positive	O
symptoms	O
score	O
between	O
the	O
2	O
groups	O
(	O
P	O
=	O
0.757	O
)	O
.	O

Changes	O
in	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Extrapyramidal	O
Symptom	O
Rating	O
Scale	O
scores	O
and	O
frequency	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
effects	Adverseeffect
did	O
not	O
differ	O
between	O
the	O
2	O
groups	O
.	O

Our	O
study	O
showed	O
that	O
memantine	O
is	O
a	O
tolerable	O
and	O
efficacious	O
add-on	O
treatment	O
for	O
primary	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

Effects	O
of	O
bifidobacterium	O
breve	O
supplementation	O
on	O
intestinal	O
flora	O
of	O
low	O
birth	O
weight	O
infants	O
.	O

BACKGROUND	O
It	O
is	O
known	O
that	O
the	O
bifidobacteria	O
flora	O
play	O
important	O
roles	O
in	O
mucosal	O
host	O
defense	O
and	O
can	O
prevent	O
infectious	O
diseases	O
.	O

Because	O
bacterial	O
populations	O
develop	O
during	O
the	O
first	O
day	O
of	O
life	O
,	O
the	O
authors	O
examined	O
whether	O
the	O
early	O
administration	O
of	O
bifidobacteria	O
has	O
a	O
positive	O
effect	Physical
on	Physical
the	Physical
health	Physical
of	O
low	O
birth	O
weight	O
infants	O
.	O

METHODS	O
The	O
effects	O
of	O
oral	O
administration	O
of	O
Bifidobacterium	O
breve	O
(	O
B.	O
breve	O
)	O
supplements	O
were	O
studied	O
in	O
a	O
controlled	O
trial	O
with	O
low	O
birth	O
weight	O
infants	O
(	O
average	O
birth	O
weight	O
1489	O
g	O
)	O
.	O

The	O
infants	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Group	O
A	O
and	O
B	O
received	O
a	O
dose	O
of	O
1.6	O
x	O
10	O
(	O
8	O
)	O
cells	O
of	O
B.	O
breve	O
supplement	O
twice	O
a	O
day	O
,	O
commencing	O
either	O
from	O
several	O
hours	O
after	O
birth	O
(	O
group	O
A	O
)	O
or	O
24	O
h	O
after	O
birth	O
(	O
group	O
B	O
)	O
.	O

Group	O
C	O
,	O
the	O
control	O
group	O
,	O
received	O
no	O
supplement	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
birth	Physical
weight	Physical
,	O
treatment	Physical
with	Physical
antibiotics	Physical
,	O
and	O
the	O
starting	Physical
time	Physical
of	Physical
breast-feeding	Physical
among	O
the	O
three	O
groups	O
.	O

A	O
Bifidobacterium-predominant	O
flora	O
was	O
formed	O
at	O
an	O
average	O
of	O
2	O
weeks	O
after	O
birth	O
in	O
group	O
A	O
and	O
at	O
an	O
average	O
of	O
4	O
weeks	O
after	O
birth	O
in	O
group	O
B	O
,	O
while	O
no	O
Bifidobacterium	O
was	O
isolated	O
in	O
eight	O
out	O
of	O
10	O
infants	O
in	O
group	O
C	O
during	O
the	O
observation	O
period	O
of	O
7	O
weeks	O
.	O

In	O
comparison	O
between	O
group	O
A	O
and	O
B	O
,	O
Bifidobacterium	O
was	O
detected	O
significantly	O
earlier	O
in	O
group	O
A	O
,	O
and	O
the	O
number	O
of	O
Enterobacteriaceae	O
present	O
in	O
the	O
infants	O
at	O
2	O
weeks	O
after	O
birth	O
was	O
significantly	O
lower	O
in	O
group	O
A	O
.	O

CONCLUSION	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
very	O
early	O
administration	O
of	O
B.	O
breve	O
to	O
low	O
birth	O
weight	O
infants	O
is	O
useful	O
in	O
promoting	O
the	O
colonization	O
of	O
the	O
Bifidobacterium	O
and	O
the	O
formation	O
of	O
a	O
normal	O
intestinal	O
flora	O
.	O

Effect	O
of	O
four	O
intermediate	O
layer	O
treatments	O
on	O
microleakage	O
of	O
Class	O
II	O
composite	O
restorations	O
.	O

This	O
in	O
vitro	O
study	O
examines	O
the	O
marginal	O
sealing	O
ability	O
of	O
four	O
different	O
intermediate	O
materials	O
applied	O
before	O
placement	O
of	O
a	O
condensable	O
composite	O
.	O

Class	O
II	O
preparations	O
were	O
made	O
with	O
gingival	O
margins	O
placed	O
1.0	O
mm	O
apical	O
to	O
the	O
cementoenamel	O
junction	O
of	O
60	O
extracted	O
teeth	O
,	O
randomly	O
assigned	O
to	O
five	O
groups	O
of	O
12	O
.	O

Following	O
restoration	O
,	O
teeth	O
were	O
thermocycled	O
,	O
soaked	O
in	O
0.5	O
%	O
basic	O
fuchsin	O
,	O
and	O
sectioned	O
longitudinally	O
.	O

The	O
resin-modified	O
glass	O
ionomer	O
cement	O
demonstrated	O
significantly	O
less	O
microleakage	Physical
than	O
the	O
use	O
of	O
a	O
dentin	O
bonding	O
agent	O
alone	O
or	O
in	O
combination	O
with	O
flowable	O
composite	O
,	O
flowable	O
compomer	O
,	O
or	O
autoploymerizing	O
composite	O
(	O
p	O
<	O
0.05	O
,	O
Dunn	O
's	O
test	O
)	O
.	O

This	O
study	O
supports	O
the	O
use	O
of	O
the	O
glass	O
ionomer	O
open	O
sandwich	O
technique	O
in	O
deep	O
Class	O
II	O
direct	O
composite	O
restorations	O
.	O

The	O
additional	O
value	O
of	O
a	O
night	O
splint	O
to	O
eccentric	O
exercises	O
in	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

AIM	O
To	O
assess	O
whether	O
the	O
use	O
of	O
a	O
night	O
splint	O
is	O
of	O
added	O
benefit	O
on	O
functional	O
outcome	O
in	O
treating	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
.	O

METHODS	O
This	O
was	O
a	O
single-blind	O
,	O
prospective	O
,	O
single	O
centre	O
,	O
randomised	O
controlled	O
trial	O
set	O
in	O
the	O
Sports	O
Medical	O
Department	O
,	O
The	O
Hague	O
Medical	O
Centre	O
,	O
The	O
Netherlands	O
.	O

Inclusion	O
criteria	O
were	O
:	O
age	O
18-70	O
years	O
,	O
active	O
participation	O
in	O
sports	O
,	O
and	O
tendon	O
pain	O
localised	O
at	O
2-7	O
cm	O
from	O
distal	O
insertion	O
.	O

Exclusion	O
criteria	O
were	O
:	O
insertional	O
disorders	O
,	O
partial	O
or	O
complete	O
ruptures	O
,	O
or	O
systemic	O
illness	O
.	O

70	O
tendons	O
were	O
included	O
and	O
randomised	O
into	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
eccentric	O
exercises	O
with	O
a	O
night	O
splint	O
(	O
night	O
splint	O
group	O
,	O
n	O
=	O
36	O
)	O
or	O
eccentric	O
exercises	O
only	O
(	O
eccentric	O
group	O
,	O
n	O
=	O
34	O
)	O
.	O

INTERVENTIONS	O
Both	O
groups	O
completed	O
a	O
12-week	O
heavy-load	O
eccentric	O
training	O
programme	O
.	O

One	O
group	O
received	O
a	O
night	O
splint	O
in	O
addition	O
to	O
eccentric	O
exercises	O
.	O

At	O
baseline	O
and	O
follow-up	O
at	O
12	O
weeks	O
,	O
patient	Others
satisfaction	Others
,	O
Victorian	Physical
Institute	Physical
of	Physical
Sport	Physical
Assessment-Achilles	Physical
questionnaire	Physical
(	Physical
VISA-A	Physical
)	Physical
score	Physical
and	O
reported	Others
compliance	Others
were	O
recorded	O
by	O
a	O
single-blind	O
trained	O
researcher	O
who	O
was	O
blinded	O
to	O
the	O
treatment	O
.	O

RESULTS	O
After	O
12	O
weeks	O
,	O
patient	Others
satisfaction	Others
in	O
the	O
eccentric	O
group	O
was	O
63	O
%	O
compared	O
with	O
48	O
%	O
in	O
the	O
night	O
splint	O
group	O
.	O

The	O
VISA-A	Physical
score	Physical
significantly	O
improved	O
in	O
both	O
groups	O
;	O
in	O
the	O
eccentric	O
group	O
from	O
50.1	O
to	O
68.8	O
(	O
p	O
=	O
0.001	O
)	O
and	O
in	O
the	O
night	O
splint	O
group	O
from	O
49.4	O
to	O
67.0	O
(	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
in	O
VISA-A	Physical
score	Physical
(	O
p	O
=	O
0.815	O
)	O
and	O
patient	Others
satisfaction	Others
(	O
p	O
=	O
0.261	O
)	O
.	O

CONCLUSION	O
A	O
night	O
splint	O
is	O
not	O
beneficial	O
in	O
addition	O
to	O
eccentric	O
exercises	O
in	O
the	O
treatment	O
of	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
.	O

Randomized	O
trial	O
of	O
fenretinide	O
in	O
superficial	O
bladder	O
cancer	O
using	O
DNA	O
flow	O
cytometry	O
as	O
an	O
intermediate	O
end	O
point	O
.	O

Retinoids	O
have	O
shown	O
a	O
potential	O
activity	O
in	O
preventing	O
tumor	O
recurrence	O
in	O
superficial	O
bladder	O
cancer	O
.	O

We	O
assessed	O
the	O
activity	O
of	O
the	O
synthetic	O
retinoid	O
fenretinide	O
in	O
superficial	O
bladder	O
cancer	O
using	O
DNA	O
flow	O
cytometry	O
and	O
conventional	O
cytology	O
as	O
surrogate	O
biomarkers	O
.	O

A	O
total	O
of	O
99	O
subjects	O
with	O
resected	O
superficial	O
bladder	O
cancer	O
(	O
pTa	O
,	O
pT1	O
)	O
were	O
randomized	O
to	O
either	O
fenretinide	O
(	O
200	O
mg	O
day	O
p.o	O
.	O

for	O
24	O
months	O
)	O
or	O
no	O
intervention	O
.	O

Cystoscopy	O
and	O
bladder	O
washing	O
for	O
DNA	O
flow	O
cytometry	O
end	O
points	O
(	O
proportion	O
of	O
DNA	O
aneuploid	O
histograms	O
,	O
hyperdiploid	O
fraction	O
,	O
and	O
percentage	O
of	O
apoptotic	O
cells	O
)	O
and	O
proportion	O
of	O
abnormal	Physical
cytological	Physical
examinations	Physical
were	O
repeated	O
every	O
4	O
months	O
for	O
up	O
to	O
36	O
months	O
.	O

The	O
primary	O
study	O
end	O
point	O
was	O
the	O
proportion	Physical
of	Physical
DNA	Physical
aneuploid	Physical
histograms	Physical
after	O
12	O
months	O
.	O

This	O
figure	O
was	O
48.9	O
%	O
in	O
the	O
fenretinide	O
arm	O
and	O
41.9	O
%	O
in	O
the	O
control	O
arm	O
(	O
odds	O
ratio	O
,	O
1.16	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.44-3.07	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
any	O
other	O
response	Physical
biomarker	Physical
between	O
the	O
two	O
groups	O
up	O
to	O
36	O
months	O
,	O
nor	O
was	O
any	O
biomarker	O
able	O
to	O
predict	O
recurrence	O
risk	O
.	O

Recurrence-free	Mortality
survival	Mortality
was	O
comparable	O
between	O
the	O
arms	O
(	O
27	O
events	O
in	O
the	O
fenretinide	O
arm	O
versus	O
21	O
in	O
the	O
control	O
arm	O
;	O
P	O
=	O
0.36	O
)	O
.	O

Twelve	O
subjects	O
in	O
the	O
fenretinide	O
arm	O
complained	O
of	O
diminished	O
dark	Adverseeffect
adaptability	Adverseeffect
,	O
and	O
nine	O
subjects	O
in	O
the	O
fenretinide	O
arm	O
versus	O
one	O
control	O
subject	O
had	O
mild	Physical
dermatological	Physical
alterations	Physical
.	O

We	O
conclude	O
that	O
fenretinide	O
showed	O
a	O
lack	O
of	O
effect	O
on	O
the	O
DNA	O
content	Physical
distribution	Physical
and	O
the	O
morphology	Physical
of	Physical
urothelial	Physical
cells	Physical
obtained	O
in	O
serial	O
bladder	O
washings	O
.	O

Recurrence-free	Mortality
survival	Mortality
was	O
comparable	O
between	O
groups	O
.	O

Because	O
our	O
data	O
are	O
hampered	O
by	O
the	O
lack	O
of	O
predictivity	O
of	O
the	O
selected	O
biomarkers	O
,	O
additional	O
studies	O
are	O
necessary	O
to	O
assess	O
the	O
activity	O
of	O
fenretinide	O
in	O
preventing	O
bladder	O
cancer	O
.	O

Effect	Physical
of	O
hydrochlorothiazide	O
therapy	O
on	O
cardiac	Physical
arrhythmias	Physical
in	O
African-American	O
men	O
with	O
systemic	O
hypertension	O
and	O
moderate	O
to	O
severe	O
left	O
ventricular	O
hypertrophy	O
.	O

The	O
effect	O
of	O
hydrochlorothiazide	O
therapy	O
on	O
ventricular	Physical
arrhythmias	Physical
was	O
studied	O
in	O
45	O
hypertensive	O
African-American	O
men	O
with	O
moderate	O
to	O
severe	O
left	O
ventricular	O
(	O
LV	O
)	O
hypertrophy	O
.	O

After	O
medication	O
washout	O
,	O
patients	O
were	O
treated	O
with	O
placebo	O
followed	O
by	O
hydrochlorothiazide	O
.	O

Clinical	Physical
,	O
biochemical	Physical
,	O
and	O
48-hour	Physical
ambulatory	Physical
electrocardiographic	Physical
data	Physical
was	O
collected	O
after	O
each	O
treatment	O
phase	O
.	O

Signal-averaged	Physical
electrocardiograms	Physical
were	O
recorded	O
in	O
a	O
subgroup	O
of	O
24	O
patients	O
.	O

Average	Physical
LV	Physical
posterior	Physical
wall	Physical
thickness	Physical
was	O
15	O
+/-	O
1.1	O
mm	O
,	O
septum	O
16	O
+/-	O
2	O
mm	O
,	O
LV	O
mass	O
420	O
+/-	O
90	O
g	O
,	O
and	O
LV	O
mass	O
index	O
212	O
=	O
51	O
g/m2	O
.	O

Systolic	Physical
blood	Physical
pressure	Physical
(	Physical
BP	Physical
)	Physical
was	O
168	O
+/-	O
18	O
mm	O
Hg	O
after	O
the	O
placebo	O
phase	O
and	O
146	O
+/-	O
15	O
mm	O
Hg	O
after	O
hydrochlorothiazide	O
;	O
diastolic	O
BP	O
was	O
103	O
+/-	O
6	O
mm	O
Hg	O
and	O
89	O
+/-	O
9	O
mm	O
Hg	O
,	O
respectively	O
.	O

Serum	Physical
potassium	Physical
decreased	O
significantly	O
from	O
4.2	O
+/-	O
0.4	O
mmol/L	O
to	O
3.7	O
+/-	O
0.6	O
mmol/L	O
after	O
hydrochlorothiazide	O
therapy	O
.	O

The	O
average	O
hourly	O
incidence	O
of	O
ventricular	Physical
premature	Physical
contractions	Physical
was	O
22	O
with	O
placebo	O
and	O
25	O
with	O
hydrochlorothiazide	O
.	O

There	O
were	O
3	O
and	O
1	O
couplets	O
and	O
0.2	O
and	O
0.2	O
runs	O
of	O
ventricular	Physical
tachycardia	Physical
per	O
patient	O
per	O
hour	O
,	O
respectively	O
.	O

Variables	O
of	O
signal-averaged	Physical
electrocardiography	Physical
did	O
not	O
differ	O
between	O
the	O
2	O
treatments	O
.	O

Thus	O
,	O
in	O
hypertensive	O
African-American	O
men	O
with	O
moderate	O
to	O
severe	O
LV	O
hypertrophy	O
,	O
hydrochlorothiazide	O
does	O
not	O
worsen	O
ventricular	Physical
arrhythmias	Physical
or	O
signal-averaged	Physical
electrocardiographic	Physical
variables	Physical
.	O

How	O
does	O
Cash	O
and	O
Counseling	O
affect	O
costs	O
?	O
OBJECTIVE	O
To	O
test	O
the	O
effect	O
of	O
a	O
consumer-directed	O
model	O
(	O
Cash	O
and	O
Counseling	O
)	O
of	O
Medicaid	O
personal	O
care	O
services	O
(	O
PCS	O
)	O
or	O
home-	O
and	O
community-based	O
waiver	O
services	O
(	O
HCBS	O
)	O
on	O
the	O
cost	O
of	O
Medicaid	O
services	O
.	O

DATA	O
SOURCES/STUDY	O
SETTING	O
Medicaid	O
claims	O
data	O
were	O
collected	O
for	O
all	O
enrollees	O
in	O
the	O
Cash	O
and	O
Counseling	O
demonstration	O
.	O

Demonstration	O
enrollees	O
included	O
those	O
eligible	O
for	O
PCS	O
(	O
in	O
Arkansas	O
)	O
,	O
those	O
assessed	O
to	O
receive	O
such	O
services	O
(	O
in	O
New	O
Jersey	O
)	O
,	O
and	O
recipients	O
of	O
Medicaid	O
HCBS	O
(	O
in	O
Florida	O
)	O
.	O

Enrollment	O
occurred	O
from	O
December	O
1998	O
through	O
April	O
2001	O
.	O

The	O
follow-up	O
period	O
covered	O
up	O
to	O
24	O
months	O
after	O
enrollment	O
.	O

STUDY	O
DESIGN	O
Demonstration	O
volunteers	O
were	O
randomly	O
assigned	O
to	O
have	O
the	O
option	O
to	O
participate	O
in	O
Cash	O
and	O
Counseling	O
(	O
the	O
treatment	O
group	O
)	O
,	O
or	O
to	O
receive	O
Medicaid	O
services	O
as	O
usual	O
from	O
an	O
agency	O
(	O
the	O
control	O
group	O
)	O
.	O

Ordinary	O
least	O
squares	O
regressions	O
were	O
used	O
to	O
estimate	O
the	O
effect	O
of	O
the	O
program	O
on	O
costs	Others
for	Others
Medicaid	Others
PCS/waiver	Others
services	Others
and	O
other	O
Medicaid	Others
services	Others
,	O
while	O
controlling	O
for	O
consumers	O
'	O
preenrollment	O
characteristics	O
and	O
preenrollment	O
Medicaid	O
spending	O
.	O

Models	O
were	O
estimated	O
separately	O
for	O
nonelderly	O
and	O
elderly	O
adults	O
in	O
each	O
state	O
and	O
for	O
children	O
in	O
Florida	O
.	O

DATA	O
EXTRACTION	O
METHODS	O
Each	O
state	O
supplied	O
claims	O
data	O
for	O
demonstration	O
enrollees	O
.	O

PRINCIPAL	O
FINDINGS	O
Largely	O
because	O
the	O
program	O
increased	O
consumers	O
'	O
ability	O
to	O
get	O
the	O
authorized	O
amount	O
of	O
paid	O
care	O
,	O
expenditures	Others
for	Others
personal	Others
care/waiver	Others
services	Others
were	O
higher	O
for	O
the	O
treatment	O
group	O
than	O
for	O
the	O
control	O
group	O
in	O
each	O
state	O
and	O
age	O
group	O
,	O
except	O
among	O
the	O
elderly	O
in	O
Florida	O
.	O

Higher	O
costs	Others
for	Others
personal	Others
care/waiver	Others
services	Others
were	O
partially	O
offset	O
by	O
savings	O
in	O
other	O
Medicaid	O
services	O
,	O
particularly	O
those	O
related	O
to	O
long-term	O
care	O
.	O

During	O
year	O
1	O
,	O
total	Others
Medicaid	Others
costs	Others
were	O
generally	O
higher	O
for	O
the	O
treatment	O
group	O
than	O
for	O
the	O
control	O
group	O
,	O
with	O
treatment-control	O
cost	O
differences	O
ranging	O
from	O
1	O
percent	O
(	O
and	O
statistically	O
insignificant	O
)	O
for	O
the	O
elderly	O
in	O
Florida	O
to	O
17	O
percent	O
for	O
the	O
elderly	O
in	O
Arkansas	O
.	O

In	O
year	O
2	O
,	O
these	O
cost	Others
differences	Others
were	O
generally	O
greater	O
than	O
in	O
year	O
1	O
.	O

Only	O
in	O
Arkansas	O
did	O
the	O
treatment-control	O
difference	O
in	O
total	O
cost	Others
shrink	Others
over	Others
time-to	Others
less	O
than	O
5	O
percent	O
(	O
and	O
statistically	O
insignificant	O
)	O
in	O
year	O
2	O
.	O

CONCLUSIONS	O
Medicaid	Others
costs	Others
were	O
generally	O
higher	O
under	O
Cash	O
and	O
Counseling	O
because	O
those	O
in	O
the	O
traditional	O
system	O
did	O
not	O
get	O
the	O
services	O
they	O
were	O
entitled	O
to	O
.	O

Compared	O
with	O
the	O
treatment	O
group	O
,	O
(	O
1	O
)	O
control	O
group	O
members	O
were	O
less	O
likely	O
to	O
receive	Others
any	Others
services	Others
at	O
all	O
(	O
despite	O
being	O
authorized	O
for	O
them	O
)	O
,	O
and	O
(	O
2	O
)	O
service	O
recipients	O
received	O
a	O
lower	Others
proportion	Others
of	Others
the	Others
amount	Others
of	Others
care	Others
that	O
was	O
authorized	O
.	O

In	O
addition	O
,	O
a	O
flaw	O
in	O
Florida	O
's	O
reassessment	O
procedures	O
led	O
to	O
treatment	O
group	O
members	O
receiving	O
more	O
generous	O
benefit	O
amounts	O
than	O
control	O
group	O
members	O
.	O

To	O
keep	O
total	O
Medicaid	O
costs	O
per	O
recipient	O
at	O
the	O
level	O
incurred	O
under	O
the	O
traditional	O
system	O
,	O
consumer-directed	O
programs	O
need	O
to	O
be	O
carefully	O
designed	O
and	O
closely	O
monitored	O
.	O

Migration	O
of	O
the	O
acetabular	O
component	O
:	O
effect	Physical
of	Physical
cement	Physical
pressurization	Physical
and	O
significance	Physical
of	Physical
early	Physical
radiolucency	Physical
:	O
a	O
randomized	O
5-year	O
study	O
using	O
radiostereometry	O
.	O

BACKGROUND	O
Cementing	O
technique	O
is	O
a	O
crucial	O
factor	O
in	O
prosthesis	O
fixation	O
.	O

No	O
randomized	O
studies	O
have	O
been	O
published	O
,	O
however	O
,	O
comparing	O
the	O
outcome	O
of	O
conventional	O
fingerpacking	O
with	O
the	O
outcome	O
of	O
pressurization	O
of	O
the	O
cement	O
prior	O
to	O
cup	O
insertion	O
.	O

PATIENTS	O
AND	O
METHODS	O
We	O
randomized	O
50	O
THAs	O
to	O
either	O
fingerpacking	O
or	O
sequential	O
pressurization	O
(	O
including	O
individual	O
pressurization	O
of	O
each	O
anchorage	O
hole	O
)	O
and	O
followed	O
the	O
patients	O
with	O
RSA	O
for	O
5	O
years	O
.	O

The	O
penetration	O
of	O
cement	O
into	O
the	O
anchorage	O
holes	O
was	O
measured	O
on	O
digital	O
radiographs	O
.	O

Postoperative	O
radiolucent	Physical
lines	Physical
around	O
the	O
cup	O
were	O
correlated	O
to	O
later	O
RSA	O
results	O
.	O

For	O
clinical	O
evaluation	O
,	O
we	O
used	O
SF-36	O
and	O
HHS	O
.	O

RESULTS	O
The	O
pressurized	O
group	O
of	O
THAs	O
was	O
more	O
stable	O
regarding	O
changes	O
in	O
inclination	O
.	O

We	O
found	O
no	O
other	O
difference	O
in	O
the	O
migratory	O
behavior	O
.	O

The	O
cement	O
penetration	O
into	O
the	O
anchorage	O
holes	O
was	O
deeper	O
with	O
the	O
pressurization	O
technique	O
than	O
with	O
fingerpacking	O
.	O

For	O
the	O
whole	O
group	O
taken	O
together	O
,	O
there	O
was	O
a	O
strong	O
relation	O
between	O
the	O
presence	O
of	O
radiolucent	O
lines	O
as	O
measured	O
on	O
the	O
postoperative	O
radiograph	O
and	O
later	O
migration	O
observed	O
by	O
RSA	O
at	O
2	O
and	O
5	O
years	O
.	O

INTERPRETATION	O
Pressurization	O
of	O
the	O
cement	O
produced	O
better	O
cement	O
penetration	O
and	O
increased	O
the	O
cup	O
stability	O
in	O
terms	O
of	O
changes	O
in	O
inclination	O
.	O

Early	O
findings	O
of	O
radiolucent	O
lines	O
can	O
predict	O
later	O
unfavorable	O
cup	O
migration	O
.	O

[	O
Clinical	O
observation	O
on	O
different	O
acupuncture	O
and	O
moxibustion	O
therapies	O
for	O
treatment	O
of	O
postsurgical	O
gastroparesis	O
syndrome	O
]	O
.	O

OBJECTIVE	O
To	O
optimize	O
therapy	O
of	O
acupuncture	O
and	O
moxibustion	O
for	O
postsurgical	O
gastroparesis	O
syndrome	O
(	O
PGS	O
)	O
.	O

METHODS	O
Forty-one	O
cases	O
of	O
PGS	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
in	O
order	O
of	O
visiting	O
.	O

Group	O
A	O
(	O
n	O
=	O
17	O
)	O
were	O
treated	O
by	O
warming	O
needle	O
moxibustion	O
,	O
group	O
B	O
(	O
n	O
=	O
12	O
)	O
by	O
acupuncture	O
plus	O
auricular	O
point	O
sticking	O
,	O
and	O
group	O
C	O
(	O
n	O
=	O
12	O
)	O
by	O
routine	O
acupuncture	O
.	O

Changes	O
of	O
gastric	Physical
drainage	Physical
volume	Physical
,	O
therapeutic	Physical
times	Physical
and	Physical
cured	Physical
rate	Physical
were	O
investigated	O
in	O
the	O
3	O
groups	O
.	O

RESULTS	O
All	O
the	O
3	O
therapeutic	O
methods	O
could	O
significantly	O
decrease	O
gastric	Physical
drainage	Physical
volume	Physical
.	O

The	O
cured	Physical
rate	Physical
was	O
100.0	O
%	O
and	O
the	O
therapeutic	Physical
times	Physical
was	O
(	O
7.24	O
+/-	O
3.87	O
)	O
in	O
the	O
group	O
A	O
,	O
66.7	O
%	O
,	O
(	O
9.83	O
+/-	O
4.60	O
)	O
times	O
in	O
the	O
group	O
B	O
and	O
75.0	O
%	O
,	O
(	O
15.25	O
+/-	O
3.81	O
)	O
times	O
in	O
the	O
group	O
C	O
,	O
with	O
significant	O
differences	O
in	O
the	O
cured	Physical
rate	Physical
and	Others
the	Others
therapeutic	Physical
times	Physical
among	O
the	O
3	O
groups	O
(	O
P	O
<	O
0.05	O
,	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
The	O
warming	O
needle	O
moxibustion	O
is	O
the	O
best	O
method	O
for	O
PGS	O
,	O
with	O
less	O
therapeutic	Physical
times	Physical
,	O
high	O
cured	Physical
rate	Physical
and	O
rapid	O
effect	O
.	O

Partial	O
depletion	Physical
of	Physical
tissue	Physical
factor	Physical
pathway	Physical
inhibitor	Physical
during	O
subcutaneous	O
administration	O
of	O
unfractionated	O
heparin	O
,	O
but	O
not	O
with	O
two	O
low	O
molecular	O
weight	O
heparins	O
.	O

Tissue	O
factor	O
pathway	O
inhibitor	O
(	O
TFPI	O
)	O
is	O
released	O
to	O
circulating	O
blood	O
after	O
intravenous	O
(	O
i.v	O
.	O

)	O
and	O
subcutaneous	O
(	O
s.c.	O
)	O
injections	O
of	O
heparins	O
,	O
and	O
may	O
thus	O
contribute	O
to	O
the	O
antithrombotic	O
effect	O
of	O
heparins	O
.	O

We	O
have	O
recently	O
shown	O
that	O
total	O
TFPI	Physical
activity	Physical
,	Others
plasma	Physical
free	Physical
TFPI	Physical
antigen	Physical
,	O
and	O
heparin	Physical
releasable	Physical
TFPI	Physical
were	O
partially	O
depleted	O
during	O
repeated	O
and	O
continuous	O
i.v	O
.	O

infusion	O
of	O
unfractionated	O
heparin	O
(	O
UFH	O
)	O
,	O
but	O
not	O
during	O
s.c.	O
treatment	O
with	O
a	O
low	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
.	O

The	O
difference	O
may	O
be	O
attributed	O
to	O
a	O
different	O
mode	O
of	O
action	O
or	O
the	O
different	O
mode	O
of	O
administration	O
.	O

In	O
the	O
present	O
randomized	O
cross-over	O
study	O
,	O
s.c.	O
administration	O
of	O
therapeutic	O
doses	O
of	O
UFH	O
was	O
compared	O
with	O
s.c.	O
administration	O
of	O
two	O
LMWHs	O
.	O

12	O
healthy	O
male	O
volunteers	O
were	O
treated	O
for	O
3	O
d	O
with	O
UFH	O
,	O
250	O
U/kg	O
twice	O
daily	O
,	O
dalteparin	O
,	O
200	O
U/kg	O
once	O
daily	O
,	O
and	O
enoxaparin	O
,	O
1.5	O
mg/kg	O
once	O
daily	O
.	O

Six	O
participants	O
were	O
also	O
treated	O
with	O
UFH	O
,	O
300	O
U/kg	O
once	O
daily	O
.	O

On	O
day	O
5	O
a	O
single	O
dose	O
of	O
either	O
drug	O
was	O
given	O
.	O

Peak	Physical
levels	Physical
of	Physical
total	Physical
TFPI	Physical
activity	Physical
and	Others
free	Physical
TFPI	Physical
antigen	Physical
were	O
detected	O
1	O
h	O
after	O
injection	O
,	O
whereas	O
maximal	Physical
prolongation	Physical
of	Physical
activated	Physical
partial	Physical
thromboplastin	Physical
time	Physical
(	Physical
APTT	Physical
)	Physical
and	Others
peak	Physical
levels	Physical
of	Physical
anti-factor	Physical
Xa	Physical
activity	Physical
and	Physical
anti-factor	Physical
IIa	Physical
activity	Physical
were	O
detected	O
after	O
4	O
h.	O
On	O
UFH	O
administered	O
twice	O
daily	O
,	O
free	Physical
TFPI	Physical
antigen	Physical
decreased	O
by	O
44	O
%	O
from	O
baseline	O
level	O
before	O
the	O
first	O
injection	O
on	O
day	O
1	O
to	O
pre-injection	O
level	O
on	O
day	O
5	O
.	O

On	O
UFH	O
administered	O
once	O
daily	O
,	O
basal	Physical
free	Physical
TFPI	Physical
antigen	Physical
decreased	O
by	O
50	O
%	O
,	O
56	O
%	O
and	O
27	O
%	O
on	O
day	O
2	O
,	O
3	O
and	O
5	O
respectively	O
,	O
compared	O
with	O
day	O
1	O
.	O

Minimal	Physical
depletion	Physical
of	Physical
TFPI	Physical
was	O
detected	O
during	O
treatment	O
with	O
LMWHs	O
.	O

The	O
study	O
demonstrates	O
the	O
different	O
modes	O
of	O
action	O
of	O
LMWHs	O
and	O
UFH	O
and	O
may	O
help	O
to	O
explain	O
the	O
superior	O
antithrombotic	O
efficacy	O
of	O
LMWHs	O
.	O

Epirubicin	O
and	O
cyclophosphamide	O
versus	O
epirubicin	O
and	O
docetaxel	O
as	O
first-line	O
therapy	O
for	O
women	O
with	O
metastatic	O
breast	O
cancer	O
:	O
final	O
results	O
of	O
a	O
randomised	O
phase	O
III	O
trial	O
.	O

BACKGROUND	O
This	O
randomised	O
phase	O
III	O
trial	O
was	O
carried	O
out	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
epirubicin	O
and	O
cyclophosphamide	O
(	O
EC	O
)	O
with	O
epirubicin	O
and	O
docetaxel	O
(	O
Taxotere	O
)	O
(	O
ED	O
)	O
as	O
first-line	O
chemotherapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
(	O
n	O
=	O
240	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
ED	O
(	O
epirubicin	O
75	O
mg/m	O
(	O
2	O
)	O
and	O
docetaxel	O
75	O
mg/m	O
(	O
2	O
)	O
)	O
or	O
EC	O
(	O
epirubicin	O
90	O
mg/m	O
(	O
2	O
)	O
and	O
cyclophosphamide	O
600	O
mg/m	O
(	O
2	O
)	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
objective	Physical
response	Physical
rate	Physical
(	Physical
ORR	Physical
)	Physical
.	O

Secondary	O
end	O
points	O
were	O
progression-free	Mortality
survival	Mortality
(	Mortality
PFS	Mortality
)	Mortality
,	O
overall	Mortality
survival	Mortality
(	Mortality
OS	Mortality
)	Mortality
,	O
and	O
safety	Mortality
.	O

RESULTS	O
ORR	Physical
for	O
patients	O
randomly	O
assigned	O
to	O
receive	O
EC	O
and	O
ED	O
were	O
42	O
%	O
and	O
47	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.63	O
)	O
.	O

Median	Mortality
PFS	Mortality
[	O
10.1	O
versus	O
10.3	O
months	O
;	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.98	O
;	O
log-rank	O
P	O
=	O
0.38	O
]	O
and	O
OS	Mortality
(	O
19.9	O
versus	O
30.0	O
months	O
;	O
HR	O
0.663	O
;	O
log-rank	O
P	O
=	O
0.21	O
)	O
were	O
comparable	O
in	O
both	O
arms	O
.	O

Although	O
grade	Physical
3/4	Physical
leucopenia	Physical
occurred	O
more	O
frequently	O
with	O
ED	O
(	O
81	O
%	O
versus	O
73	O
%	O
;	O
P	O
=	O
0.01	O
)	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
incidence	O
of	O
febrile	Physical
neutropenia	Physical
and	Physical
grade	Physical
3/4	Physical
infections	Physical
.	O

Grade	Adverseeffect
3/4	Adverseeffect
non-haematologic	Adverseeffect
toxicity	Adverseeffect
was	O
infrequent	O
in	O
both	O
arms	O
.	O

Congestive	Physical
heart	Physical
failure	Physical
was	O
observed	O
in	O
one	O
patient	O
in	O
each	O
arm	O
.	O

CONCLUSION	O
In	O
this	O
randomised	O
trial	O
,	O
no	O
differences	O
in	O
the	O
efficacy	O
study	O
end	O
points	O
were	O
observed	O
between	O
the	O
two	O
treatment	O
arms	O
.	O

Comparison	O
of	O
the	O
in	Others
vitro	Others
and	Others
in	Others
vivo	Others
release	Others
of	Others
digoxin	Others
from	O
four	O
different	O
soft	O
gelatin	O
capsule	O
formulations	O
.	O

A	O
blinded	O
,	O
four-treatment	O
crossover	O
study	O
in	O
16	O
normal	O
adult	O
male	O
volunteers	O
compared	O
plasma	O
concentrations	O
and	O
urinary	Others
excretion	Others
of	Others
digoxin	Others
,	O
measured	O
by	O
radioimmunoassay	O
,	O
after	O
oral	O
administration	O
of	O
soft	O
gelatin	O
capsule	O
formulations	O
of	O
digoxin	O
.	O

Four	O
0.4-mg	O
formulations	O
with	O
different	O
in	O
vitro	O
burst	O
times	O
and	O
dissolution	O
rates	O
were	O
administered	O
,	O
with	O
2-week	O
intervals	O
between	O
treatments	O
.	O

The	O
two	O
capsules	O
with	O
lowest	O
in	O
vitro	O
burst	O
times	O
(	O
2.9	O
and	O
16	O
min	O
)	O
gave	O
comparable	O
in	O
vivo	O
results	O
.	O

The	O
other	O
two	O
capsules	O
,	O
with	O
in	O
vitro	O
burst	O
times	O
of	O
62	O
and	O
229	O
min	O
,	O
produced	O
significant	O
delays	O
in	O
digoxin	O
absorption	O
.	O

In	O
vitro-in	O
vivo	O
correlations	O
were	O
obtained	O
by	O
comparing	O
the	O
logarithm	O
of	O
the	O
in	O
vitro	O
burst	O
time	O
with	O
time	O
to	O
peak	Others
plasma	Others
level	Others
and	O
the	O
time	O
to	O
the	O
first	O
measurable	O
plasma	Others
level	Others
(	O
>	O
or	O
=	O
0	O
.	O

05	O
ng/ml	O
)	O
.	O

Also	O
,	O
the	O
mean	O
time	O
to	O
peak	Others
plasma	Others
level	Others
correlated	O
with	O
the	O
logarithm	O
of	O
the	O
time	O
required	O
to	O
release	O
either	O
50	O
%	O
or	O
85	O
%	O
of	O
the	O
digoxin	O
in	O
vitro	O
.	O

No	O
significant	O
changes	O
were	O
found	O
in	O
the	O
amount	O
of	O
digoxin	O
absorbed	O
from	O
each	O
capsule	O
as	O
determined	O
by	O
urinary	O
excretion	O
or	O
AUC0-infinity	O
.	O

The	O
influence	O
of	O
breast	O
size	O
on	O
late	O
radiation	O
effects	O
and	O
association	O
with	O
radiotherapy	O
dose	O
inhomogeneity	O
.	O

A	O
prospective	O
assessment	O
of	O
late	O
changes	O
in	O
breast	O
appearance	O
in	O
559	O
patients	O
after	O
tumour	O
excision	O
and	O
radiotherapy	O
for	O
early	O
breast	O
cancer	O
noted	O
a	O
strong	O
association	O
with	O
breast	O
size	O
.	O

Only	O
3/48	O
(	O
6	O
%	O
)	O
patients	O
with	O
small	O
breasts	O
developed	O
moderate	O
or	O
severe	O
late	O
changes	O
compared	O
with	O
94/423	O
(	O
22	O
%	O
)	O
with	O
medium	O
sized	O
breasts	O
and	O
34/88	O
(	O
39	O
%	O
)	O
patients	O
with	O
large	O
breasts	O
(	O
p	O
<	O
0.001	O
)	O
.	O

One	O
possibility	O
is	O
that	O
greater	O
radiation	O
changes	O
are	O
related	O
to	O
greater	O
dose	O
inhomogeneity	O
in	O
women	O
with	O
large	O
breasts	O
.	O

To	O
explore	O
this	O
hypothesis	O
,	O
radiation	O
dose	O
distributions	O
were	O
assessed	O
in	O
a	O
separate	O
group	O
of	O
37	O
women	O
in	O
whom	O
three-level	O
transverse	O
computer	O
tomographic	O
images	O
of	O
the	O
breast	O
in	O
the	O
treatment	O
position	O
were	O
available	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
breast	O
size	O
and	O
dose	O
inhomogeneity	O
which	O
may	O
account	O
for	O
the	O
marked	O
changes	O
in	O
breast	O
appearance	O
reported	O
in	O
women	O
with	O
large	O
breasts	O
.	O

Cyclosporin	O
versus	O
cyclophosphamide	O
for	O
patients	O
with	O
steroid-dependent	O
and	O
frequently	O
relapsing	O
idiopathic	O
nephrotic	O
syndrome	O
:	O
a	O
multicentre	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	Others
(	Others
maintenance	Others
of	Others
remission	Others
)	Others
,	O
safety	Others
and	O
tolerability	Others
of	O
cyclosporin	O
(	O
CsA	O
)	O
with	O
those	O
of	O
cyclophosphamide	O
in	O
patients	O
with	O
steroid-dependent	O
or	O
frequently	O
relapsing	O
nephrotic	O
syndrome	O
(	O
NS	O
)	O
.	O

DESIGN	O
Open	O
,	O
prospective	O
,	O
randomized	O
,	O
multicentre	O
,	O
controlled	O
study	O
for	O
parallel	O
groups	O
,	O
stratified	O
for	O
adults	O
and	O
children	O
.	O

The	O
setting	O
was	O
in	O
nephrological	O
departments	O
in	O
Italy	O
.	O

SUBJECTS	O
AND	O
INTERVENTIONS	O
Seventy-three	O
patients	O
with	O
steroid-sensitive	O
idiopathic	O
NS	O
admitted	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
cyclophosphamide	O
(	O
2.5	O
mg/kg/day	O
)	O
for	O
8	O
weeks	O
or	O
CsA	O
(	O
5	O
mg/kg/day	O
in	O
adults	O
,	O
6	O
mg/kg/day	O
in	O
children	O
)	O
for	O
9	O
months	O
,	O
tapered	O
off	O
by	O
25	O
%	O
every	O
month	O
until	O
complete	O
discontinuation	O
at	O
month	O
12	O
.	O

Seven	O
patients	O
lost	O
to	O
follow	O
up	O
were	O
not	O
considered	O
in	O
the	O
analysis	O
.	O

The	O
remaining	O
66	O
patients	O
were	O
followed	O
up	O
for	O
3-24	O
months	O
after	O
randomization	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Relapse-free	Mortality
survival	Mortality
;	O
number	Physical
of	Physical
N.S	Physical
.	Physical

relapses/patient/year	Physical
;	O
cumulative	Others
dose	Others
of	Others
prednisone/patient	Others
;	O
laboratory	Physical
investigations	Physical
(	Physical
kidney	Physical
and	Physical
liver	Physical
functions	Physical
,	Physical
haematological	Physical
parameters	Physical
)	Physical
;	O
incidence	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
.	O

RESULTS	O
At	O
month	O
9	O
,	O
26	O
of	O
35	O
CsA-treated	O
patients	O
were	O
still	O
in	O
complete	Physical
remission	Physical
and	O
a	O
further	O
five	O
patients	O
were	O
in	O
partial	Physical
remission	Physical
;	O
18	O
of	O
28	O
cyclophosphamide-treated	O
patients	O
were	O
in	O
complete	Physical
remission	Physical
,	O
and	O
one	O
in	O
partial	Physical
remission	Physical
(	O
P	O
=	O
NS	O
)	O
.	O

No	O
difference	O
between	O
adults	O
and	O
children	O
was	O
seen	O
with	O
either	O
treatment	O
.	O

The	O
risk	Physical
of	Physical
relapse	Physical
was	O
similar	O
between	O
frequent	O
relapsers	O
(	O
19	O
of	O
22	O
)	O
and	O
steroid-dependent	O
patients	O
(	O
8	O
of	O
14	O
)	O
given	O
CsA	O
,	O
and	O
those	O
given	O
cyclophosphamide	O
(	O
5	O
of	O
15	O
and	O
6	O
of	O
15	O
)	O
.	O

The	O
mean	Physical
number	Physical
of	Physical
relapses	Physical
per	Physical
year	Physical
and	O
the	O
mean	O
dose	Others
of	Others
prednisone	Others
per	Others
year	Others
were	O
significantly	O
less	O
(	O
P	O
<	O
0.001	O
)	O
in	O
both	O
groups	O
for	O
the	O
experimental	O
year	O
than	O
for	O
the	O
year	O
before	O
randomization	O
.	O

At	O
2	O
years	O
,	O
25	O
%	O
of	O
the	O
patients	O
given	O
CsA	O
(	O
50	O
%	O
adults	O
and	O
20	O
%	O
children	O
)	O
and	O
63	O
%	O
of	O
those	O
given	O
cyclophosphamide	O
(	O
40	O
%	O
adults	O
and	O
68	O
%	O
children	O
)	O
had	O
not	O
had	O
any	O
relapse	Physical
of	Physical
NS	Physical
.	Others

Tolerance	Others
to	O
the	O
two	O
drugs	O
was	O
generally	O
good	O
.	O

The	O
CsA-related	Adverseeffect
side-effects	Adverseeffect
were	O
mild	O
and	O
disappeared	O
after	O
drug	O
discontinuation	O
.	O

CONCLUSIONS	O
This	O
study	O
shows	O
that	O
both	O
treatments	O
are	O
effective	O
and	O
well	O
tolerated	O
;	O
more	O
patients	O
given	O
cyclophosphamide	O
had	O
stable	Physical
remissions	Physical
.	Others

Failure	O
of	O
naltrexone	O
hydrochloride	O
to	O
reduce	O
self-injurious	O
and	O
autistic	O
behavior	O
in	O
mentally	O
retarded	O
adults	O
.	O

Double-blind	O
placebo-controlled	O
studies	O
.	O

BACKGROUND	O
It	O
is	O
hypothesized	O
that	O
self-injurious	O
behavior	O
(	O
SIB	O
)	O
and	O
symptoms	O
of	O
autism	O
may	O
be	O
due	O
to	O
overactivity	O
in	O
some	O
opioid	O
systems	O
in	O
the	O
brain	O
.	O

We	O
examined	O
the	O
efficacy	Others
and	O
safety	Others
of	O
naltrexone	O
hydrochloride	O
,	O
an	O
opioid	O
antagonist	O
,	O
in	O
the	O
treatment	O
of	O
SIB	O
and	O
autism	O
in	O
mentally	O
retarded	O
adults	O
.	O

METHOD	O
Thirty-three	O
mentally	O
retarded	O
adults	O
with	O
autism	O
and/or	O
SIB	O
participated	O
in	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
studies	O
.	O

Active	O
treatment	O
was	O
first	O
a	O
single	O
100-mg	O
dose	O
of	O
naltrexone	O
hydrochloride	O
.	O

Subsequently	O
,	O
19	O
subjects	O
were	O
treated	O
with	O
50	O
mg/d	O
and	O
14	O
with	O
150	O
mg/d	O
of	O
naltrexone	O
hydrochloride	O
for	O
4	O
weeks	O
.	O

The	O
outcome	O
was	O
assessed	O
by	O
means	O
of	O
direct	O
observations	O
(	O
n	O
=	O
11	O
)	O
and	O
on	O
the	O
basis	O
of	O
scores	O
on	O
a	O
list	Mental
of	Mental
target	Mental
behaviors	Mental
,	O
the	Mental
Aberrant	Mental
Behavior	Mental
Checklist	Mental
,	O
and	O
the	O
Clinical	Mental
Global	Mental
Impression	Mental
Scale	Mental
.	O

RESULTS	O
Thirty-two	O
subjects	O
(	O
seven	O
with	O
autism	O
,	O
16	O
with	O
autism	O
and	O
SIB	O
,	O
and	O
nine	O
with	O
SIB	O
)	O
completed	O
the	O
trial	O
.	O

Naltrexone	O
treatment	O
failed	O
to	O
have	O
therapeutic	O
effects	O
on	O
SIB	O
and	O
autism	O
.	O

On	O
the	O
contrary	O
,	O
naltrexone	O
increased	O
the	O
incidence	Mental
of	Mental
stereotypic	Mental
behavior	Mental
on	O
the	O
Aberrant	Mental
Behavior	Mental
Checklist	Mental
,	O
and	O
the	O
care	O
staff	O
evaluated	O
the	O
effect	O
of	O
the	O
50-mg/d	O
treatment	O
as	O
being	O
significantly	O
worse	O
than	O
that	O
of	O
the	O
placebo	O
treatment	O
as	O
measured	O
by	O
the	O
Clinical	Mental
Global	Mental
Impression	Mental
Scale	Mental
.	O

CONCLUSION	O
Our	O
findings	O
suggest	O
that	O
naltrexone	O
has	O
no	O
clinical	O
value	O
for	O
a	O
broad	O
group	O
of	O
mentally	O
retarded	O
subjects	O
with	O
SIB	O
and/or	O
autism	O
.	O

The	O
acute	O
effects	O
of	O
fluid	O
intake	O
on	O
urine	O
specific	O
gravity	O
and	O
fluid	O
retention	O
in	O
a	O
mildly	O
dehydrated	O
state	O
.	O

Many	O
athletes	O
arrive	O
at	O
training	O
sessions	O
and	O
competitions	O
in	O
a	O
mildly	O
hypohydrated	O
(	O
HYPO	O
)	O
state	O
and	O
are	O
instructed	O
to	O
drink	O
fluids	O
before	O
exercise	O
to	O
reach	O
a	O
euhydrated	O
(	O
HYD	O
)	O
state	O
.	O

Ten	O
recreational	O
athletes	O
(	O
6	O
women	O
,	O
4	O
men	O
;	O
71.9	O
?	O
4.6	O
kg	O
,	O
25.2	O
?	O
0.9	O
years	O
)	O
participated	O
in	O
the	O
studies	O
to	O
examine	O
(	O
a	O
)	O
the	O
day-to-day	O
variability	O
of	O
morning	O
urine	O
specific	O
gravity	O
(	O
USG	O
)	O
,	O
(	O
b	O
)	O
the	O
effects	O
of	O
consuming	O
600	O
ml	O
of	O
water	O
on	O
the	O
hydration	O
status	O
of	O
HYD	O
and	O
HYPO	O
(	O
USG	O
>	O
1.020	O
)	O
subjects	O
,	O
and	O
(	O
c	O
)	O
the	O
effects	O
of	O
consuming	O
water	O
(	O
W	O
)	O
,	O
salt-water	O
(	O
SW	O
,	O
40	O
mM	O
Na	O
)	O
,	O
a	O
carbohydrate-electrolyte	O
solution	O
with	O
3	O
%	O
or	O
light	O
carbohydrate	O
(	O
CES-L	O
,	O
20	O
mM	O
Na	O
)	O
or	O
a	O
CES	O
with	O
6	O
%	O
carbohydrate	O
(	O
CES	O
,	O
20	O
mM	O
Na	O
)	O
on	O
the	O
hydration	O
status	O
of	O
HYPO	O
subjects	O
.	O

The	O
hydration	O
status	O
was	O
assessed	O
with	O
USG	O
and	O
body	O
mass	O
measures	O
and	O
urine	O
volume	O
collections	O
.	O

The	O
day-to-day	O
variability	O
in	O
morning	O
USG	O
(	O
coefficient	O
of	O
variation	O
=	O
0.2	O
?	O
0.1	O
%	O
)	O
was	O
low	O
and	O
the	O
responses	O
to	O
600	O
ml	O
of	O
W	O
ingestion	O
were	O
repeatable	O
.	O

Pretrial	O
USG	O
was	O
1.022	O
?	O
0.001	O
in	O
the	O
HYPO	O
trial	O
and	O
decreased	O
<	O
1.020	O
by	O
45	O
minutes	O
(	O
1.013	O
?	O
0.003	O
)	O
.	O

In	O
the	O
CES	O
study	O
,	O
HYPO	O
subjects	O
reached	O
HYD	O
status	O
at	O
45	O
minutes	O
in	O
all	O
conditions	O
(	O
W	O
1.013	O
?	O
0.003	O
,	O
SW	O
1.013	O
?	O
0.003	O
,	O
CES-L	O
1.011	O
?	O
0.003	O
,	O
CES	O
1.017	O
?	O
0.004	O
)	O
because	O
salt	O
or	O
CES	O
ingestion	O
did	O
not	O
affect	O
fluid	Physical
retention	Physical
(	O
W	O
68	O
%	O
,	O
SW	O
72	O
%	O
,	O
CES-L	O
68	O
%	O
,	O
CES	O
76	O
%	O
)	O
.	O

This	O
study	O
demonstrated	O
that	O
mildly	O
HYPO	O
subjects	O
could	O
reach	O
euhydration	O
within	O
45	O
minutes	O
of	O
the	O
ingestion	O
of	O
600	O
ml	O
of	O
W	O
or	O
a	O
combination	O
of	O
salt	O
and	O
CES	O
solutions	O
.	O

Following	O
this	O
practice	O
will	O
minimize	O
the	O
incidence	O
of	O
starting	O
a	O
practice	O
or	O
competition	O
hypohydrated	O
.	O

Glibenclamide	O
vs	O
gliclazide	O
in	O
reducing	O
oxidative	Physical
stress	Physical
in	O
patients	O
of	O
noninsulin	O
dependent	O
diabetes	O
mellitus	O
--	O
a	O
double	O
blind	O
randomized	O
study	O
.	O

OBJECTIVE	O
Parameters	O
of	O
oxidative	Physical
stress	Physical
were	O
quantitated	O
in	O
50	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
in	O
uncontrolled	O
state	O
and	O
after	O
control	O
using	O
oral	O
glibenclamide	O
or	O
gliclazide	O
.	O

The	O
estimates	O
were	O
further	O
compared	O
between	O
the	O
two	O
groups	O
irrespective	O
of	O
drug	O
used	O
to	O
evaluate	O
the	O
difference	O
,	O
if	O
any	O
.	O

METHODS	O
The	O
study	O
was	O
a	O
double	O
blind	O
,	O
uncontrolled	O
,	O
noncrossover	O
and	O
randomized	O
trial	O
.	O

Fifty	O
patients	O
of	O
uncontrolled	O
type	O
2	O
diabetes	O
were	O
divided	O
in	O
to	O
two	O
groups	O
.	O

Group	O
I	O
(	O
25	O
patients	O
)	O
received	O
capsule	O
A	O
(	O
glibenclamide	O
)	O
while	O
Group	O
II	O
(	O
25	O
patients	O
)	O
received	O
capsule	O
B	O
(	O
gliclazide	O
)	O
.	O

The	O
parameters	O
studied	O
were	O
Superoxide	Physical
dismutase	Physical
(	Physical
SOD	Physical
)	Physical
,	O
malonyl-dialdehyde	Physical
(	Physical
MDA	Physical
)	Physical
and	O
reduced	Physical
glutathione	Physical
(	Physical
GSH	Physical
)	Physical
.	O

They	O
were	O
done	O
at	O
(	O
a	O
)	O
uncontrolled	O
stage	O
(	O
FBS	O
--	O
165	O
+/-	O
16.7	O
mg/dl	O
,	O
PP	O
--	O
240	O
+/-	O
30.1	O
mg/dl	O
and	O
HbA1	O
--	O
10.5	O
+/-	O
0.9	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
150	O
+/-	O
15.8	O
mg/dl	O
,	O
PP	O
--	O
246	O
+/-	O
29.1	O
mg/dl	O
HbA1	O
10.6	O
+/-	O
0.8	O
%	O
in	O
group	O
II	O
)	O
and	O
during	O
controlled	O
stage	O
at	O
12	O
weeks	O
(	O
FBS	O
--	O
120	O
+/-	O
18.5	O
mg/dl	O
,	O
PP	O
--	O
180	O
+/-	O
19.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.4	O
+/-	O
0.29	O
%	O
in	O
group	O
I	O
and	O
FBS	O
--	O
118	O
+/-	O
17.6	O
mg/dl	O
,	O
PP	O
--	O
176	O
+/-	O
20.1	O
mg/dl	O
and	O
HbA1	O
--	O
8.5	O
+/-	O
0.39	O
%	O
in	O
group	O
II	O
patients	O
)	O
.	O

RESULTS	O
The	O
significantly	O
raised	O
levels	Physical
of	Physical
MDA	Physical
and	Others
SOD	Physical
,	O
and	O
decreased	O
levels	Physical
of	Physical
reduced	Physical
glutathione	Physical
(	Physical
GSH	Physical
)	Physical
during	O
uncontrolled	O
stage	O
of	O
diabetes	O
indicated	O
free	O
radical	O
stress	O
induced	O
lipid	O
peroxidation	O
.	O

The	O
significant	O
fall	Physical
of	Physical
MDA	Physical
and	Physical
SOD	Physical
and	O
increased	Physical
levels	Physical
of	Physical
GSH	Physical
in	O
blood	O
in	O
both	O
groups	O
after	O
control	O
revealed	O
beneficial	O
effects	O
of	O
glycemic	O
control	O
on	O
oxidative	Physical
stress	Physical
.	Physical

The	O
levels	O
were	O
not	O
normalized	O
and	O
stayed	O
higher	O
than	O
those	O
in	O
controls	O
.	O

On	O
intergroup	O
comparison	O
;	O
the	O
control	O
of	O
diabetes	O
with	O
gliclazide	O
(	O
group	O
II	O
)	O
showed	O
improvement	O
in	O
oxidative	Physical
stress	Physical
(	Physical
MDA	Physical
,	Physical
GSH	Physical
)	Physical
better	O
(	O
p	O
<	O
0.001	O
)	O
than	O
glibenclamide	O
(	O
group	O
I	O
)	O
.	O

CONCLUSION	O
Oxidative	Physical
stress	Physical
in	O
uncontrolled	O
diabetes	O
is	O
decreased	O
with	O
glycemic	O
control	O
.	O

The	O
control	O
of	O
diabetes	O
with	O
gliclazide	O
reduced	O
oxidative	Physical
stress	Physical
more	O
than	O
glibenclamide	O
,	O
indicating	O
higher	O
antioxidant	O
properties	O
of	O
gliclazide	O
.	O

Normalization	O
of	O
oxidative	Physical
stress	Physical
was	O
not	O
achieved	O
.	O

Further	O
studies	O
are	O
required	O
to	O
see	O
long-term	O
effect	O
of	O
drug	O
therapy	O
in	O
combating	O
oxidative	Physical
stress	Physical
after	O
achieving	O
acceptable	O
control	O
of	O
diabetes	O
.	O

The	O
effect	O
of	O
body	O
positioning	O
upon	O
maximal	O
oxygenation	O
of	O
patients	O
with	O
unilateral	O
lung	O
pathology	O
.	O

A	O
quasi-experimental	O
,	O
repeated-measures	O
cross-over	O
design	O
study	O
on	O
the	O
effect	O
of	O
body	O
position	O
on	O
oxygenation	O
(	O
SaO2	O
)	O
blood	O
pressure	O
,	O
respiration	O
and	O
pulse	O
in	O
patients	O
with	O
unilateral	O
lung	O
pathology	O
was	O
conducted	O
.	O

Previous	O
research	O
strongly	O
suggests	O
that	O
positioning	O
with	O
the	O
healthy	O
(	O
unaffected	O
)	O
lung	O
in	O
the	O
dependent	O
lateral	O
(	O
down	O
)	O
position	O
is	O
related	O
to	O
improved	O
oxygenation	O
,	O
but	O
knowledge	O
about	O
whether	O
this	O
effect	O
is	O
maintained	O
over	O
time	O
is	O
lacking	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
:	O
(	O
1	O
)	O
Is	O
positioning	O
with	O
the	O
unaffected	O
lung	O
in	O
the	O
dependent	O
lateral	O
position	O
related	O
to	O
increased	O
arterial	O
blood	O
saturation	O
levels	O
and	O
decreased	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
?	O
(	O
2	O
)	O
What	O
is	O
the	O
relationship	O
between	O
the	O
dependent	O
variables	O
--	O
oxygenation	O
saturation	O
levels	O
,	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
--	O
and	O
the	O
independent	O
variables	O
--	O
body	O
position	O
and	O
time	O
in	O
the	O
position	O
?	O
Thirty-nine	O
patients	O
with	O
unilateral	O
lung	O
pathology	O
were	O
positioned	O
on	O
their	O
sides	O
with	O
the	O
unaffected	O
lung	O
down	O
,	O
on	O
their	O
sides	O
with	O
the	O
affected	O
lung	O
down	O
,	O
and	O
also	O
in	O
semi-Fowler	O
's	O
position	O
.	O

Arterial	Physical
(	Physical
SaO2	Physical
)	Physical
blood	Physical
saturation	Physical
and	Physical
vital	Physical
signs	Physical
were	O
measured	O
at	O
baseline	O
0	O
,	O
15	O
and	O
30	O
minutes	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
relationship	O
between	O
oxygenation	Physical
level	Physical
or	Physical
systolic	Physical
blood	Physical
pressure	Physical
.	Physical

Diastolic	Physical
blood	Physical
pressure	Physical
,	Physical
respiration	Physical
and	Physical
pulse	Physical
did	O
vary	O
significantly	O
with	O
position	O
.	O

Double-blind	O
comparison	O
of	O
the	O
efficacy	Others
and	Others
safety	Others
of	O
trandolapril	O
2	O
mg	O
and	O
hydrochlorothiazide	O
25	O
mg	O
in	O
patients	O
with	O
mild-to-moderate	O
essential	O
hypertension	O
.	O

Investigator	O
Study	O
Group	O
.	O

This	O
multicenter	O
international	O
trial	O
recruited	O
205	O
patients	O
from	O
16	O
investigators	O
.	O

After	O
a	O
4-week	O
,	O
single-blind	O
placebo	O
run-in	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
16	O
weeks	O
of	O
trandolapril	O
2	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
hydrochlorothiazide	O
(	O
HCTZ	O
)	O
25	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
or	O
the	O
combination	O
(	O
69	O
patients	O
)	O
.	O

Morning	Physical
predosing	Physical
supine	Physical
diastolic	Physical
blood	Physical
pressure	Physical
(	Physical
DBP	Physical
)	Physical
was	O
the	O
primary	O
efficacy	O
measurement	O
.	O

Intention-to-treat	O
analysis	O
showed	O
significant	O
decreases	O
in	O
all	O
three	O
groups	O
in	O
mean	O
(	O
+/-	O
SEM	O
)	O
supine	Physical
DBP	Physical
throughout	O
the	O
study	O
,	O
with	O
no	O
significant	O
differences	O
at	O
week	O
16	O
between	O
trandolapril	O
(	O
-10.6	O
+/-	O
1.3	O
mm	O
Hg	O
)	O
and	O
HCTZ	O
(	O
-10.9	O
+/-	O
1.3	O
mm	O
Hg	O
)	O
.	O

The	O
combination	O
gave	O
a	O
significantly	O
greater	O
reduction	O
than	O
either	O
drug	O
alone	O
(	O
-15.1	O
+/-	O
1.13	O
mm	O
Hg	O
)	O
.	O

Blood	Physical
pressure	Physical
was	O
normalized	O
in	O
the	O
combination	O
group	O
in	O
67	O
%	O
of	O
patients	O
,	O
a	O
significantly	O
higher	O
proportion	O
than	O
either	O
trandolapril	O
(	O
63	O
%	O
)	O
or	O
HCTZ	O
(	O
60	O
%	O
;	O
p	O
=	O
0.04	O
)	O
.	O

Each	O
treatment	O
was	O
well	O
tolerated	O
.	O

The	O
incidence	O
of	O
adverse	Adverseeffect
events	Adverseeffect
was	O
similar	O
in	O
all	O
three	O
groups	O
.	O

Trandolapril	O
2	O
mg	O
once	O
daily	O
is	O
an	O
effective	O
antihypertensive	O
agent	O
,	O
comparable	O
to	O
HCTZ	O
.	O

Furthermore	O
,	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
was	O
shown	O
to	O
enhance	O
the	O
antihypertensive	Physical
effect	Physical
of	O
the	O
two	O
compounds	O
alone	O
.	O

Parents	O
'	O
state	O
and	O
trait	O
anxiety	O
:	O
relationships	O
with	O
anxiety	Mental
severity	Mental
and	O
treatment	O
response	O
in	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Comorbid	O
anxiety	O
is	O
common	O
among	O
children	O
with	O
Autism	O
Spectrum	O
Disorder	O
(	O
ASD	O
)	O
,	O
and	O
parents	O
of	O
children	O
with	O
ASD	O
are	O
more	O
likely	O
to	O
have	O
anxiety	O
disorders	O
.	O

This	O
study	O
investigated	O
the	O
relationship	O
between	O
parents	O
'	O
state	Mental
and	O
trait	Mental
anxiety	Mental
and	O
parent-reported	O
internalizing	O
and	O
externalizing	O
symptoms	O
among	O
adolescents	O
(	O
n	O
=	O
30	O
)	O
with	O
ASD	O
,	O
as	O
well	O
as	O
the	O
relationship	O
of	O
parents	O
'	O
anxiety	O
symptoms	O
and	O
adolescent	O
treatment	O
response	O
in	O
the	O
context	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

Parental	O
state	O
anxiety	O
correlated	O
with	O
severity	O
of	O
adolescent	O
anxiety	O
,	O
and	O
trait	O
anxiety	O
in	O
parents	O
correlated	O
with	O
parent-reported	O
adolescent	O
internalizing	O
and	O
externalizing	O
symptoms	O
.	O

Also	O
,	O
parents	O
of	O
adolescent	O
treatment	O
responders	O
experienced	O
a	O
decrease	O
in	O
their	O
own	O
trait	O
anxiety	O
.	O

Findings	O
highlight	O
the	O
importance	O
of	O
considering	O
parental	O
anxiety	O
when	O
targeting	O
anxiety	O
among	O
youth	O
with	O
ASD	O
.	O

